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Abstract   
___________________________________________________________________________        
                                                                                                                            
Although a number of studies have focused on the role of neuropilin-2 (NRP2) in early 
embryological development and in various cancer cells, very little is known about the 
biological roles of NRP2 in microvascular endothelial cells (ECs). Here, we show that siRNA 
depletion of NRP2 decreases fibronectin (FN)-dependent migration, adhesion and focal 
adhesion assembly and disassembly in murine lung microvascular endothelial cells (ECs). 
Compared to control cells, NRP2-depleted cells exhibit elevated levels of total cellular 
integrin-α5 (ITGA5 - the main FN receptor in ECs), but this increase does not translate to the 
cell surface. MS analysis identified the major FN receptors α5β1 as NRP2 binding partners. 
However, ITGA5 internalization and recycling assays revealed that NRP2 knockdown 
suppress ITGA5 recycling to the cell surface and a direct interaction between NRP2 and 
ITGA5 is observed by co-immunoprecipitation. This suggests that NRP2 controls 
microvascular EC behaviour on FN by regulating ITGA5 function. 
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Chapter 1: Introduction 
___________________________________________________________________________ 
 
1.1 Circulatory system 
The circulatory systems of vertebrates and invertebrates differ according to the presence of a 
true endothelium, which is a continuous layer of adluminal epithelial cells connected by a 
specialised junctional complex. The circulatory system is responsible for the transport and 
exchange of fluids containing gases, nutrients and metabolic waste products to and from each 
cell in the body (Muñoz‐Chápuli, Carmona et al. 2005). In diploblastic animals, such as 
jellyfish, the circulatory system is open to the environment, whereas in triploblastic animals 
(from flat worms to humans), the circulatory fluids travel through either the body cavity or a 
complex network of vessels, sinuses and the central macular pump (Monahan‐Earley, Dvorak 
et al. 2013). Acoelomates are small animals, such as flat worms, that lack a body cavity 
(coelom) and a blood vascular system in which the space between the ectoderm and 
endoderm is filled with a meshwork of parenchyma, which allows them to obtain food and 
oxygen by simple diffusion across the skin and gut. Small coelomates are animals, such as 
sea stars, that possess a coelomic circulatory system in which the body cavity provides a 
connective flow of gas, food and waste products, thus allowing the organ to move freely. 
Large coelomates, including mice and humans, possess a vascular system that circulates both 
blood and lymph throughout the body (Monahan‐Earley, Dvorak et al. 2013). In large 
coelomates, fluid flows through two circulatory systems: 1) the cardiovascular system, which 
circulates blood that is mainly composed of plasma, erythrocytes (red blood cells), leukocytes 
(white blood cells), and thrombocytes (platelets); 2) lymphatic circulation, which collects 
lymph that is derived from the interstitial fluid and returns it to the blood circulation (Pugsley 
and Tabrizchi 2000).  
In the cardiovascular system, which is also called systemic circulation, the blood is circulated 
in a “closed loop” through two circulatory systems: systemic circulation and pulmonary 
circulation. In systemic circulation, oxygenated blood is circulated from the heart through 
arteries that branch into arterioles until it reaches the arterial capillaries. Because the 
hydrostatic pressure within these capillaries is greater, the blood is diffused from these 
capillaries to the interstitial tissues that take up the oxygen and nutrients. Simultaneously, the 
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waste products, including carbon dioxide, that are secreted by these surrounding tissues, are 
diffused back to the venial capillaries because of the greater osmatic pressure within these 
capillaries. The deoxygenated blood then is circulated through venules and large veins back 
to the heart. In pulmonary circulation, the deoxygenated blood in the heart is pumped to the 
lung capillaries. Because the oxygen partial pressure (OPP) of CO2 in the lungs is lower than 
that within the capillaries, the CO2 is diffused into the lungs. Simultaneously, the greater OPP 
of oxygen in the lungs leads to the diffusion of oxygen from the lungs to the capillaries where 
it is bound by haemoglobins. The oxygenated blood then returns into the heart where it is 
pumped again throughout the body to supply oxygen to the tissues. 
In contrast, the lymphatic system is an ‘open’ and one-way transport system. The purpose of 
this system is to collect the excess interstitial fluid, proteins, white blood cells and 
microorganisms from the interstitial space via lymphatic capillaries and circulate it as lymph. 
The lymphatic capillaries merge with large lymphatic vessels called lymphatic ducts, which 
recycle lymph via the lymph nodes back into the cardiovascular circulation. (Riley and 
Cournand 1951), (Pugsley and Tabrizchi 2000), (Swartz 2001), (Monahan‐Earley, Dvorak et 
al. 2013)  
1.1.1 Blood vessel function and architecture 
In vertebrates, the blood vessels are the conduits of the cardiovascular system, which allows 
the movement of the blood. Based on their diameters, blood vessels are categorised into five 
classes that are connected in series: artery, arteriole, capillary, venule and vein (Figure 1.1). 
The smallest blood vessels (capillaries) consist of only one layer, tunica interna (intima), 
whereas all the larger blood vessels are composed of three layers: tunica interna, tunica 
media and tunica externa (adventitia). The tunica interna is made up of a single layer of 
endothelial cells surrounded by a basement membrane (BM) that lines the entire circulatory 
system from the heart to the capillaries. The tunica media is located between the innermost 
and the outermost layer, and it is made up of vascular smooth muscles (vSMC) and elastic 
fibres. The tunica externa is the outermost layer, which is made up of fibro-elastic connective 
tissues that anchor the vessels to the surrounding tissue.  
The function and architecture of the arteries differ from those of veins (see Figure 1.1). The 
arteries transport the oxygenated blood away from the heart (except in the pulmonary artery), 
whereas veins carry the deoxygenated blood toward the heart (except in the pulmonary vein). 
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Arteries have narrow lumens and a greater number of muscles and elastic fibres, which allow 
them to transport the blood under high pressure, whereas veins have wider and fewer muscles 
and elastic fibres for transporting blood under low pressure. Finally, the arteries do not 
contain valves (except the semilunar valves of the aorta and the pulmonary artery), whereas 
veins possess valves that prevent the backflow of the blood. (Pugsley and Tabrizchi 2000), 
(McConnell 2013), (Potente and Mäkinen 2017)  
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Figure 1.1 The basic structure of the blood vessels and the direction of the blood flow. The capillaries consist of only 
tunica intema, whereas the large blood vessels (arteries, arterioles, veins and venules) consist of tunica intema, tunica media 
and tunica externa. The oxygenated blood flows from the heart into arteries that branch off into arterioles until it reaches the 
capillaries where the oxygen is diffused. The deoxygenated blood then flows back to the heart after passing through the 
venules and veins in that order (McConnell 2013). 
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1.1.2 Endothelium  
The endothelium consists of a monolayer of cells that line the blood vessels (vascular 
endothelial cells) and lymphatic vessels (lymphatic endothelial cells), allowing them to 
interact not only with the circulating blood/lymph but also with the cells in the vessel walls. 
(Félétou 2011), (Cahill and Redmond 2016). These interactions are achieved because of the 
presence of three surfaces in the endothelial cells (ECs): cohesive, adhesive and luminal. 
Cohesive surfaces consist of intracellular gap, tight and adherent junctions that connect ECs 
to one another and promote crosstalk between adjacent cells. The function of adhesive 
surfaces is to adhere the endothelium to a sheet-like structure called the basement membrane 
(BM). Luminal surfaces contain specific binding proteins that regulate the trafficking of the 
circulating blood cells (Favero, Paganelli et al. 2014).  
Although the cells in the endothelium share many common characteristics, they vary in size 
and shape across the blood vessel network (Setyawati, Tay et al. 2015). Because of these 
differences, the endothelium is remarkably heterogeneous in structure and function not only 
in different organs but also within the same organ (e.g. the kidney). The heterogeneity of the 
endothelium is the most notable at the morphological level, where it can be classified into 
three types: continuous nonfenestrated, continuous fenestrated, and discontinuous 
endothelium (Setyawati, Tay et al. 2015) (Figure 1.2 A). In the continuous nonfenestrated 
endothelium, the ECs are joined to one another by intracellular junctions to form a sheet of 
continuous ECs surrounded by an uninterrupted BM that allows only the passage of small 
molecules (e.g. water and ions). The plasmalemma also contains a distinct invaginations 
called caveolae (see Figure 1.2 A). This type of endothelium lines the interior surface of 
arteries, veins and capillaries in the brain, lungs, skin and heart. In continuous fenestrated 
endothelium, the EC sheet contains ~70nm pores (fenestra), which are sealed by a thin 5–6 
nm non-membranous diaphragm and are surrounded by a continuous BM, thus allowing the 
filtration and transport of certain sizes of solutes. This fenestrated endothelium is found in 
organs that are involved in filtration or secretion, such as the capillaries of the exocrine and 
endocrine glands, gastric and intestinal mucosa, choroids plexus, glomeruli and renal tubules. 
The discontinuous endothelium possesses fenestrations with larger diameters (100–200 nm) 
that lack a diaphragm but contain pores or “gaps” within individual ECs and an absent or 
partially formed underlying BM such as that present in the liver. (Cleaver and Melton 2003), 
(Favero, Paganelli et al. 2014), (Setyawati, Tay et al. 2015), (Kim, Faix et al. 2017). This 
heterogeneity allows ECs to play central roles in many physiological functions, including 
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thrombosis, fibrinolysis, inflammation, white cell trafficking, vascular tone, vascular 
permeability, vascular smooth muscle proliferation, metabolism and angiogenesis (Galley 
and Webster 2004), (Aird 2007), (Aird 2012), (Setyawati, Tay et al. 2015) 
ECs adhere to one another through intracellular junctions (tight, adherent and gap) (Figure 
1.2 B) formed by transmembrane junctional adhesive proteins, which are linked to the actin 
cytoskeletal through intracellular signalling proteins. These proteins not only stabilise the 
junctions but also regulate permeability, haemostasis and apoptosis as well as maintaining 
their shape and polarity (Dejana 2004), (Bazzoni and Dejana 2004). Some junctional 
adhesive proteins are specifically expressed in ECs (e.g. VE-cadherins, claudins-5), while 
others are also expressed in epithelial cells, such as occludin, junctional adhesion molecules 
(JAM)-A, CD99, and melanoma cell-associated molecules (MCAM), which are also known 
as (S-endo-1/CD146) or VE-caderin-2 (Wallez and Huber 2008). Tight junctions (TJ) act as 
either para-cellular passage “gates” for selected ions, water and various macromolecules or 
“fences” that maintain cell polarity between the luminal side and the outer side of ECs (e.g. 
claudins and ocludins) (Galley and Webster 2004). The adherens junction (AJ) is mainly 
mediated by vascular endothelial cadherins (VE-cadherins), which interact with several 
signalling partners to inhibit growth and decrease permeability (Dejana 2004), (Evans, De 
Vuyst et al. 2006). Nectin is involved in the organisation of both TJ and AJ (Wallez and 
Huber 2008). The gap junction (GJ) directly connects the cytoplasm of two adjacent cells, 
mediating cell-to-cell communication through the assembly of connexin hemichannel 
proteins (connexons), which act as bi-directional channels for the intracellular passage of 
small molecular weight molecules and ions (Bazzoni and Dejana 2004), (Evans, De Vuyst et 
al. 2006). Other proteins, such as Platelet endothelial cell adhesion molecule-1 (PECAM-1, 
CD31), cluster of differentiation (CD99), surface glycoprotein MUC18 (MCAM) and 
protocadherin-12, also connect adjacent ECs independently of the intracellular junctions 
(Wallez and Huber 2008). In contrast to epithelial cells, the organisation of endothelial 
junctions is less defined because the TJs are mingled with the AJs, and the junctional 
compositions are varied along the vascular tree in different organs (Bazzoni and Dejana 
2004), (Wallez and Huber 2008). 
The blood flow within the small vascular vessels (arterioles, venules and capillaries in 
particular) is not only controlled by the ECs and the surrounding BM but also by contractile 
small cells called pericytes (Figure 1.3 A), which are embedded in the BM and communicate 
with the ECs through both direct physical interactions and paracrine signalling. For example, 
 17 
ions and small molecules are exchanged directly between the cytoplasm of the pericytes and 
the ECs through gap junctions in the peg-socket junctional complex, while the adhesion 
plaques serve to anchor pericytes to the ECs (Figure 1.3 B) (Rucker, Wynder et al. 2000), 
(Gerhardt and Betsholtz 2003), (Bergers and Song 2005), (Armulik, Genové et al. 2011), 
(Munde, Khandekar et al. 2014), (Yang, Jin et al. 2017). 
1.1.3. Extracellular matrix 
ECs are embedded in a collection of non-cellular three dimensional macromolecules called 
the extracellular matrix (ECM), which can be classified into two distinct compartments: the 
BM (or basal lamina) and the interstitial matrix (Iivanainen, Kähäri et al. 2003), (Theocharis, 
Skandalis et al. 2016). These two compartments are not isolated from one another; instead, 
they are interconnected by a series of anchoring fibrils (Figure 1.3 C) (Akalu and Brooks 
2005). The BMs are large insoluble molecules secreted by the ECs in a sheet-like structure 
50–100 nm in thickness, including type IV collagen, laminin, heparan sulphate proteoglycans 
(HSPGs) and nidogen/entactin (Raghu 2003), (Iivanainen, Kähäri et al. 2003). The difference 
between the two compartments is that the BM is always in direct contact with the monolayer 
of the endothelium, lining up the blood vessels to provide structural support and prevent them 
from ripping apart, whereas the interstitial matrix is found in the interstitial space between the 
cells and mainly consists of fibrillar collagens and glycoproteins such as fibronectin (FN) 
(Iivanainen, Kähäri et al. 2003), (Theocharis, Skandalis et al. 2016). The compartments in the 
ECM not only provide the scaffolded architecture of the ECs but also exhibit dynamic 
interactions with endothelial receptors (e.g. integrins), as well as initiating intercellular 
signalling cascades in response to binding to specific ECM molecules (Iivanainen, Kähäri et 
al. 2003), (Theocharis, Skandalis et al. 2016). Because of these dynamic interactions, the 
ECM is continually remodelled either enzymatically or non-enzymatically (Streuli 1999), 
(Frantz, Stewart et al. 2010) (Figure 1.3 D), and thus regulates many cellular processes, 
including proliferation, migration, differentiation, survival, invasion, morphogenesis and 
angiogenesis (Iivanainen, Kähäri et al. 2003) (Akalu and Brooks 2005), (Theocharis, 
Skandalis et al. 2016). For example, during angiogenesis, the matrix metalloproteases 
(MMPs) degrade the BMs, allowing direct interactions between endothelial receptors and the 
interstitial matrix molecules, which results in the invasion of ECs through the interstitial 
matrix until new blood vessels are formed with BM surrounding the endothelium (Senger and 
Davis 2011). 
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A) 
.  
B) 
 
Figure 1.2 Endothelial morphology and transmembrane junctional adhesive proteins between adjacent ECs. A) 
Schematic representation showing the three major types of endothelium. (Kim, Faix et al. 2017) B) Tight junction is 
mediated by claudins, occludin, JAMs, ESAM and nectin, while the adherens junction is mediated by VE-cadherin and 
nectin. Tight junctions are formed by hemichannel connexins, whereas PECAM, CD99, protocadherin-12 and S-endo are 
located outside the intracellular junctions (Wallez and Huber 2008). 
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A)                                                                      B)  
  
C) 
 
D) 
 
Figure 1.3 Pericyte interactions with endothelium along small blood vessels. A) All vessels contain a single layer of ECs 
surrounded by a BM. In contrast to arteries that contain multi layers of vSMCs, the endothelium of arterioles and 
precapillary arterioles are entirely surrounded by a single layer of vSMCs and pericytes, while capillaries are covered only 
by pericytes with primary cytoplasmic extensions along the endothelium. On the postcapillaries, the pericytes are flattened, 
and they produce many slender and secondary branches. The venules are covered by relatively large vSMCs with many 
branches, and they do not entirely surround the endothelium. B) ECs and pericytes are separated by a BM, but they interact 
with each other at holes in the BM. The number of contacts between a single endothelial cell and pericyte can reach 1,000. 
These contacts are found at the peg-socket junctional complex and the adhesion plaques that link the actin filaments in the 
pericyte’s cytoplasm to the cytoplasm in the endothelial cell. Figures in A-B are adapted from (Armulik, Genové et al. 
2011). C) Schematic representation showing ECM organisation and compositions. D) Mechanisms by which ECM 
modifications can alter cellular behaviour (Akalu and Brooks 2005). 
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1.2. Blood vessel development/formation 
Blood vessels are the first functional organ to be developed in the vertebrate embryo (Risau 
and Flamme 1995). Blood vessels are generally developed through two different processes: 
vasculogenesis and angiogenesis (Figure 1.4 A). In embryonic development, these processes 
complement each other to eventually form the mature circulatory system. Vasculogenesis 
refers to the de novo formation of primitive blood vessels from vascular progenitor cells, 
while angiogenesis refers to the formation of new blood vessels by primary and secondary 
extensions from existing capillaries (Vailhé, Vittet et al. 2001), (Demir, Yaba et al. 2010). 
Although the formation of the postnatal neovasculature was believed to occur only by 
angiogenesis, some research suggests that vasculogenesis continues to play an essential role 
in adults (Asahara, Masuda et al. 1999), (Gehling, Ergün et al. 2000), (Reyes, Dudek et al. 
2002), (Balaji, King et al. 2013). For example, endothelial progenitor cells (EPCs), which are 
derived from bone marrow, circulate in the blood and mobilise to sites of neovascularisation 
in response to tissue ischaemia, where they differentiate in situ into mature ECs to promote 
tissue repair (Figure 1.4 B) (Isner and Asahara 1999). 
1.2.1 Vasculogensesis  
During vasculogenesis, primitive blood vessel development is established following the 
gastrulation process when mesenchymal cell aggregations, known as blood islands, are 
formed within the mesoderm adjacent to the extra-embryonic yolk sac. These pluripotent 
mesenchymal cells proliferate and differentiate to multipotent hemangiogenic stem cells 
(hemangioblasts). The hemangioblasts further proliferate and differentiate into 
haematopoietic progenitor cells, which give rise to all blood cell types, and angioblastic 
progenitor cells (angioblasts), which give rise to blood vessels, including endothelial cells 
and smooth muscle cells (SMC) (Figure 1.4 C) (Risau and Flamme 1995), (Conway, Collen 
et al. 2001), (Kubis and Levy 2003), (Demir, Kayisli et al. 2006), (Failla, Carbo et al. 2018). 
Therefore, in embryonic development, vasculogenesis is responsible for the formation of the 
first blood vessels, including the dorsal aorta (Cox and Poole 2000), (Helker, Schuermann et 
al. 2015), (Jin, Zhu et al. 2017). 
 
 
 
 21 
A)                                                           
 
B)                                                                                                          C)  
                             
Figure 1.4 Development of blood vessels through vasculogenesis and angiogenesis processes. A) The schematic 
representation shows the complementary step-by-step route of vasculogenesis and angiogenesis to develop a mature vascular 
network from the mesenchymal cells in the yolk sac during embryonic development (Demir, Kayisli et al. 2006). B) The 
schematic representation shows the complementarity of vasculogenesis and angiogenesis to develop neovasculature in 
adults. Adapted from (Isner and Asahara 1999). C) A schematic representation showing the de novo formation of the 
primitive blood vessels from the vascular progenitor cells through vasculogenesis. Adapted from (de Oliveira, Hamm et al. 
2011).  
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1.2.2. Angiogenesis 
The formation of new blood vessels from already existing vessels (angiogenesis) is achieved 
by either the migration of endothelial cells from a pre-existing vessel until it eventually forms 
a mature blood vessel (sprouting angiogenesis) (Figure 1.5 A) or by the insertion of the 
tissue pillar mechanism, which eventually leads to the extension and subdivision of a pre-
existing vessel into two mature vessels (intussusceptive or non-sprouting angiogenesis) 
(Figure 1.5 B) (Vailhé, Vittet et al. 2001), (Adams and Alitalo 2007), (Kim, Faix et al. 2017). 
The main goal of the two types of angiogenesis is to supply blood to newly forming tissue 
(Demir, Yaba et al. 2010). Angiogenesis normally occurs during embryonic development 
after the de novo formation of the primitive blood vessels by vasculogenesis (see Figure 1.4), 
but it rarely occurs in adults because most blood vessels are quiescent except in wound or 
fracture healing after an injury, in females during endometrial growth and corpus luteum 
formation, and in specific diseases (e.g. diabetic retinopathy and tumour growth) (Klagsbrun 
and Moses 1999), (Demir, Yaba et al. 2010).  
1.2.2.1. Mechanism of sprouting angiogenesis 
Sprouting angiogenesis is a complex process of sequential stages that employ many cellular 
proteins and growth factors secreted by different cell types. In a healthy adult, quiescent ECs 
are interconnected through junctional molecules (see Figure 1.2 B) and ensheathed by 
pericytes, which stabilise ECs and suppress EC proliferation and release cell survival growth 
factors, such as vascular endothelial growth factor (VEGF) and angiopietin 2 (ANG-2). 
Because ECs are in direct contact with the blood flow, they are equipped with oxygen 
sensors, such as prolyl hydroxylase domain 2 (PHD2) and hypoxia-inducible factor-2α (HIF-
2α), to optimise blood flow within vessels, and re-adjusting their shape accordingly. In a 
resting state, ECs and pericytes form the BM. However, when these quiescent ECs sense pro-
angiogenetic growth factors, such as VEGF, angiopietin 2 (ANG-2), basic fibroblast growth 
factor (bFGF), placental growth factor (PlGF, PLGF or PGF), chemokines, or tumour 
necrosis factor alpha (TNFa) (Ferrara, Gerber et al. 2003), the pericytes are first removed 
from the vessel walls, mainly in response to ANG-2. The ECs are thereby liberated from the 
BM, increasing permeability and vasodilation in the vessel by proteolytic enzymes, such as 
MMPs, which degrade the surrounding BM and allow the interstitial provisional matrix 
components, such as FN, vitronectin and type I collagen, to directly interact and activate the 
ECs signalling through their cell surface anchors (integrins). Following the disruption of the 
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intracellular junctions, the ECs are liberated and thereby proliferate, migrate and invade the 
ECM toward the angiogenic stimuli site. The initial formation of a new blood vessel from a 
pre-existing one is initiated by the selection of one endothelial cell, known as the tip cell, 
which leads the growing sprout in response to the secreted growth factor (e.g. binding of 
VEGF isoforms to their VEGF receptors (VEGFRs) and neuropilins by extending filopodia to 
explore signals that are present in the tissue environment. Notch receptors and their ligands 
(e.g. delta like ligand 4 (DLL4) and Jagged1) have also been shown to be essential in 
sprouting growth during development. At this stage, as well as during other steps in sprouting 
angiogenesis, changes in the balance between pro- or anti-angiogenic factors may result in 
pruning the formation of the new vessel. Cells behind the tip cells (known as stalk-cells), 
divide to elongate the sprout toward the angiogenic stimulus until lumen formation within the 
endothelial sprout is established, ultimately forming loops by the anastomoses of sprouts to 
connect blood flow. For the vessel to be functionally mature, ECs first have to regain their 
BM and intercellular junctions, a process initiated by protease inhibitors called tissue 
inhibitors of metalloproteinases (TIMPs) and plasminogen activator inhibitor-1 (PAI-1). 
Finally, mural cells (pericytes and vSMCs) are then recruited, mainly by platelet-derived 
growth factor-B (PDGF-B) and ANG-1, to stabilise ECs, which then resume their quiescent 
phalanx state. The blood flow increases oxygen delivery and thus reduces pro-angiogenic 
attractants (see Figure 1.5 A) (Raghu 2003), (Adams and Alitalo 2007), (Demir, Yaba et al. 
2010), (Senger and Davis 2011), (Elpek 2015). 
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A) 
 
 
B) 
 
Figure 1.5 Mechanisms of formation of new blood vessel from a pre-existing vessel. A) Sprouting angiogenesis. In 
response to angiogenic factors, the following sequential changes occur during sprouting angiogenesis: 1) de-attachment of 
pericytes from a blood vessel walls (in response to ANG-2); 2) degradation of BM by enzymatic degradation (e.g. MMPs) as 
well as disruption of intracellular junctions, which results in increasing vessels permeability and vasodilation; 3) selection of 
a tip cell (regulated by DLL4 and NOTCH signalling); 4) proliferation of the stalk-cells behind the tip cell; 5) migration of 
the tip cell toward the source of the angiogenic (guidance) signals, which is mediated by adhesion of integrins to ECM; 6) 
encountering the tip cell with the tip cell of the adjacent blood vessel; 7) strong EC-EC junctional interactions are stablished 
at this joining point; 8) re-establishing BM and intracellular junctions and deposition of ECM protein into the sub-
endothelial BM; 9) stabilising ECs by pericyte attachment to resume ECs quiescent phalanx state; 10) Flowing of blood to 
adjacent blood vessel improves oxygen delivery and thus reduces pro-angiogenic signals. B) Intussusceptive (Non-sprouting 
angiogenesis). Little is known about the function and regulation of this mechanism but it is believable that it involves ECM 
degradation, EC proliferation and new ECM deposition (Raghu 2003). Adapted from (Adams and Alitalo 2007), (Carmeliet 
and Jain 2011).  
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1.2.2.2. The VEGF family and their receptors  
VEGFs are disulphide bond-linked soluble secretary glycoproteins. In mammals, five subtype 
members of the family are designated as VEGF-A (also known as VEGF) to VEGF-D (also 
known as FIGF) and the placenta growth factor (PLGF), which are characterised by the 
presence of eight conserved cysteine residues that form a cystine knot structure (Muller, Li et 
al. 1997), (Holmes and Zachary 2005), (Shibuya 2011), (Iyer and Acharya 2011). Virus-
encoded VEGF-E (Meyer, Clauss et al. 1999) and snake venom-derived VEGF-F (Yamazaki, 
Matsunaga et al. 2009) have also been identified (Iyer and Acharya 2011). The VEGF family 
regulates the physiological and pathological development of blood and lymph vessels through 
binding to their transmembrane type III receptor tyrosine kinases (RTKs) (Figure 1.6) as well 
as non-tyrosine kinase receptors (neuropilins), which will be discussed in section 1.2.3.1 (see 
Figure 1.9 B) (Duffy, Bouchier-Hayes et al. 2004), (Demir, Kayisli et al. 2006), (Smith, 
Fearnley et al. 2015). Following the binding of VEGFs and the dimerisation of VEGFRs, 
auto-phosphorylation occurs, generating a series of VEGF-associated downstream signals 
that change and regulate many cellular functions (Arroyo and Winn 2008), (Mesquita, 
Castro-de-Sousa et al. 2018). 
The VEGF/VEGFR-associated signalling pathways play an essential role in orchestrating EC 
behaviour during the angiogenic process (Harry and Paleolog 2003), (Carmeliet 2003), (Kim, 
Faix et al. 2017). Three VEGF tyrosine kinase receptor subtypes, which are similar to 
platelet-derived growth factor receptors (PDGFRs), have been identified: VEGFR1 (flt-1), 
VEGFR2 (flk-1) and VEGFR3 (flt-4). (Arroyo and Winn 2008), (Peach, Mignone et al. 
2018). Both VEGFR1 and VEGFR2 have an extracellular region that consists of seven 
immunoglobulin-like domains. VEGFR3 has the same composition except in its extracellular 
region, which consists of only six Ig-homology domains (Ferrara, Gerber et al. 2003), 
(Shibuya 2011). In the embryos of gene-targeted mice, the knockout of any VEGFR is lethal 
because of dramatic blood vessel phenotypes. However, in adults, VEGFR3 expression 
becomes restricted to lymphatic ECs and certain fenestrated blood vessels (Kaipainen, 
Korhonen et al. 1995), (Partanen, Arola et al. 2000), (Tammela, Enholm et al. 2005). It is 
noteworthy mentioning that VEGFR1 and VEGFR2 can also exist as soluble secreted forms 
sVEGFR1 and sVEGFR2, respectively (Arroyo and Winn 2008), (Lal, Puri et al. 2018), 
(Collet, Lamerant-Fayel et al. 2013). 
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VEGFR1 and VEGFR2 are predominantly expressed by vascular ECs (Costache, Ioana et al. 
2015), whereas (as mentioned above) VEGFR3 expression is limited largely to lymphatic 
ECs. Among the three subtypes in the family of VEGFRs, VEGFR2 is the major mediator of 
angiogenic, mitogenic and permeability pathways via its interactions with  VEGF-A (Achen, 
Jeltsch et al. 1998), (Costache, Ioana et al. 2015). VEGF-A binds to VEGFR1 with an affinity 
that is 10-fold higher than its binding to VEGFR2, but binding to VEGFR2 promotes more 
potent angiogenic responses than VEGFR1 (Sawano, Takahashi et al. 1996). VEGFR1 is also 
a receptor for VEGF-B and PLGF, while both VEGFR2 and VEGFR3 are receptors for 
VEGF-C and VEGF-D (Lal, Puri et al. 2018). The alternative splicing of VEGF-A, VEGF-B 
and PLGF can form different isoforms, whereas VEGF-C and VEGF-D isoforms are formed 
through proteolytic processing (Tammela, Enholm et al. 2005). 
VEGF-B (also called VEGF-related factor/VRF) and PLGF bind to and activate only 
VEGFR1 (Lal, Puri et al. 2018). Both VEGF-B-NULL mice and PLGF-NULL mice are 
viable and develop with no significant angiogenic defects, suggesting that the genes of these 
two growth factors are dispensable for embryogenesis (Takahashi and Shibuya 2005), 
(Shibuya 2011). However, some studies showed that these mice do develop mild phenotypes,  
such as smaller hearts and slower myocardial recovery following ischema (Bellomo, 
Headrick et al. 2000), (Li, Tjwa et al. 2008), (Sun, Jin et al. 2004). Although VEGF-B has a 
wide tissue distribution, it is highly expressed in the heart, skeletal muscles and pancreas 
(Lal, Chiu et al. 2017), (Mesquita, Castro-de-Sousa et al. 2018). Because VEGF-B is highly 
related to VEGF-A, it can compete with VEGF-A for VEGFR1 and form heterodimers with 
VEGF-A to increase its bioavailability (Iyer and Acharya 2011). PLGF is highly expressed in 
the placenta and other organs, such as heart, lung and ovary (Tammela, Enholm et al. 2005). 
Although PIGF is known to bind only to VEGFR1, it can also form a heterodimer with 
VEGF-A and then bind to VEGFR2 (Autiero, Luttun et al. 2003) 
VEGF-C and VEGF-D are not essential for blood vessel formation. Instead, they are 
implicated in lymphatic vessel formation (lymphangiogenesis) (Tammela, Enholm et al. 
2005). VEGF-C is expressed during embryonic development, whereas VEGF-D is expressed 
after birth (Shibuya 2011). Both growth factors are secreted as pro-proteins with long C and 
N terminals. They do not bind to VEGFR2 or VEGFR3 until they are cleaved by proteolytic 
processing (Lal, Puri et al. 2018). VEGF-C and its receptor, VEGFR3, are expressed in 
regions where lymph vessels sprout from blood vessels, and then their expression is 
decreased in most tissues except in the lymph nodes where expression remains high 
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(Kaipainen, Korhonen et al. 1995), (Iyer and Acharya 2011). Mouse embryos missing both 
alleles of VEGF-C, but not of VEGF-D (Baldwin, Halford et al. 2005), die due to a failure in 
the development of lymphatic vasculature (e.g. lymphedema) (Karkkainen, Haiko et al. 
2004), whereas the overexpression of VEGF-C leads to enlarged lymphatic vessels (Shibuya 
2011). In adult humans, VEGF-D is localised in smooth muscle cells in many tissues, 
indicating that it may play an important role in vessel repair after tissue damage (Rutanen, 
Leppänen et al. 2003). Furthermore, in mice, VEGF-D binds to only VEGFR3, suggesting 
that it may play a different role in this species (Baldwin, Catimel et al. 2001). 
Because of the dominant and overwhelming role of VEGF-A and its main receptor 
(VEGFR2) in angiogenesis, in this thesis, we focus on these two molecules.  
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Figure 1.6 Structure of VEGF receptors and their ligands. Schematic representation shows VEGFR-1 (flt-1), VEGFR-2 
(flk-1) and VEGFR-3 (flt-4). These receptors have the same compositions of the intracellular regions. However, the 
extracellular regions of VEGFR1 and VEGFR2 consist of seven immunoglobulin (Ig)-like domains, while VEGFR3 consists 
of six Ig-homology domains. Different isoforms of VEGF recognise different VEGFRs. Adapted from (Zachary, Frankel et 
al. 2009) 
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1.2.2.2.1. VEGF 
VEGF, which is also known as vascular permeability factor (VPF) or (VEGF-A), was first 
described in 1989 as an endothelial cell-specific mitogen (Leung, Cachianes et al. 1989), 
(Demir, Kayisli et al. 2006). Subsequent studies showed that non-endothelial cells also 
expressed VEGF, such as fibroblast, macrophages (Nissen, Polverini et al. 1998), smooth 
muscle cells (Brogi, Wu et al. 1994) platelets (Banks, Forbes et al. 1998), neutrophils 
(Gaudry, Brégerie et al. 1997), and about 60% of all tumours (Mesquita, Castro-de-Sousa et 
al. 2018). VEGF is considered the most active and powerful modulator of angiogenic 
processes that increase the leakage of other proteins and molecules from blood vessels to 
promote EC proliferation, migration, sprouting, and tube formation (Woolard, Bevan et al. 
2009), (Iyer and Acharya 2011), (Dehghanian, Hojati et al. 2014), (Costache, Ioana et al. 
2015). For example, among all the pro-angiogenetic factors that are upregulated in response 
to hypoxia, VEGF is released as much as 30 fold within minutes to increase the permeability 
of ECs (Carmeliet 2003). However, VEGF expression is also stimulated by other factors even 
in the presence of oxygen (Iyer and Acharya 2011). Additionally, VEGF expression increases 
the production of nitric oxide (NO), which promotes vasodilation and facilitates blood flow 
(Hood, Meininger et al. 1998), fibroblast growth factor (FGF) for EC proliferation, and 
ICAM/VECAM/metalloproteases for EC migration and adhesion, all of which contribute to 
the formation of new blood vessels (Mesquita, Castro-de-Sousa et al. 2018). After birth, 
VEGF-A is downregulated (Breier, Albrecht et al. 1992), and it is upregulated during 
physiological (e.g. injury) or pathological angiogenesis (e.g. tumour growth) (Ferrara, Gerber 
et al. 2003). Therefore, VEGF has become a target in many anticancer therapies. For 
example, in 2004, bevacizumab (Avastin
®
), an anti-VEGF monoclonal antibody, was 
approved for the treatment of cancer (Mesquita, Castro-de-Sousa et al. 2018). 
During mouse development, VEGF is first expressed in the anterior portion of the embryo to 
direct the tissue migration through VEGFR1 and VEGFR2 (Hiratsuka, Kataoka et al. 2005), 
(Tammela, Enholm et al. 2005). It is essential for the chemotaxis and differentiation of the 
endothelial progenitor cells (EPCs; angioblasts). It eventually directs ECs to form a vascular 
structure (vasculogenesis) and angiogenic remodelling (angiogenesis) (Adams and Alitalo 
2007). The inactivation of a single VEGF allele in mice causes severe defects and 
abnormalities in the development of the cardiovascular system, which leads to death between 
E10 and E12 (Carmeliet, Ferreira et al. 1996), (Shibuya 2011). 
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The alternative splicing of VEGF can generate 16 distinct isoforms, which are distinguished 
by their number of amino acids (Woolard, Bevan et al. 2009), (Gu, Li et al. 2013), 
(Eswarappa, Potdar et al. 2014), (Peach, Mignone et al. 2018). These isoforms are divided 
into two groups: pro-angiogeneic, termed VEGFxxx, and anti-angiogenic, termed VEGFxxxb 
(Figure 1.7 A-B). The most frequently studied VEGF isoforms are VEGF111, VEGF121, 
VEGF145, VEGF165, VEGF189, and VEGF206 (Mesquita, Castro-de-Sousa et al. 2018); 
however, VEGF165 and VEGF121 were proposed to be the most abundant isoforms (Soker, 
Takashima et al. 1998). These isoforms differ in the presence or absence of exons 6 and 7, 
which encode the heparin binding domain that is responsible for the binding affinity to the 
heparin/heparan sulphate proteoglycan proteins either on the EC’s surface or in the 
surrounding ECM proteins. (Pan, Chathery et al. 2007), (Shibuya 2011), (Iyer and Acharya 
2011). Although all VEGF isoforms can bind to VEGFR2, VEGF165 (in mice known as 
VEGF164) (Stalmans, Ng et al. 2002), is the most VEGFR2-driven signal and therefore is 
considered the most potent and essential stimulator of angiogenesis (Sun, Liu et al. 2011), 
(Peach, Mignone et al. 2018), possibly because amongst all VEGF-A isoforms it induces the 
highest level of the phosphorylation of VEGFR2, extracellular-signal-regulated kinase (ERK) 
and Protein kinase B ( PKB, Akt)(Fearnley, Smith et al. 2016). 
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A) 
 
B) 
 
Figure 1.7 VEGF-A pre-mRNA isoforms. A) A schematic representation shows the gene structure of human VEGF, which 
consists of 8 exons (16,272 bp). The protein structure of all VEGF-A isoforms contain binding sites for VEGFR1 (encoded 
by exon 3), VEGFR2 (encoded by exon 4) and heparin (encoded by exon 6a/b and exon 7b). B) A schematic representation 
shows that VEGF-A pre-mRNA undergoes alternative splicing into the pro-angiogenic isoform subfamily, of which 
members are generated by proximal splice site (PSS) selection of exon 8 and anti-angiogenic isoforms, which are generated 
from exon 8 distal splice site (DSS) choices. These alternative splicing isoforms differ by their extreme carboxy-terminal six 
amino acids. The six amino acids encoded at exon 8a generate pro-angiogenic VEGF-Axxx isoforms, while those encoded at 
exon 8b generates anti-angiogenic VEGF-Axxxb isoforms. Adapted from (Bates 2011), (Hilmi and Guyot 2012) 
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1.2.2.2.2. VEGFR2  
VEGFR2, which is also known as the kinase-insert domain receptor (KDR) in humans, 
consists of 1,356 amino acids in humans and 1,345 amino acids in mice. It is separated into 
four regions: the extracellular-binding domain, the transmembrane domain, the tyrosine 
kinase region and the carboxyl-terminal region (Guo, Colbert et al. 2010). Its molecular 
weight is approximately 210–230 kilodalton (kDa). VEGFR2 binds to its cognate angiogenic 
growth factor (VEGF) with a binding affinity between 75–125pM (Ferrara, Gerber et al. 
2003), (Koch and Claesson-Welsh 2012). VEGFR2 is expressed by a range of non-
endothelial cells (e.g. megakaryocytes, pancreatic duct cells, osteoblasts, retinal progenitor 
cells and neurons) but at a lower level than in vascular ECs (Ho and Kuo 2007). VEGFR2 
expression increases during embryonic development (vasculogenesis and angiogenesis) as 
well as during physiological and pathological neovasculogenesis (Koch and Claesson-Welsh 
2012), (Zhang, Wang et al. 2018). For example, the mRNA level of VEGFR2 increases 
during the reproductive period from the middle to the late stage of the luteal phase during the 
oestrus cycle within the uterus (Tasaki, Nishimura et al. 2010). Similar to VEGF-NULL 
mice, VEGFR2-NULL mice die in utero between 8.5 and 9.5 days because of an early defect 
in the development of haematopoietic progenitor and endothelial cells (Shalaby, Rossant et 
al. 1995). The VEGF/VEGFR-associated signalling pathway is the most prominent 
ligand/receptor complex that orchestrates EC functions during angiogenesis (Harry and 
Paleolog 2003), (Carmeliet 2003), (Abhinand, Raju et al. 2016), (Kim, Faix et al. 2017). This 
complex association can occur in cis- or trans-binding fashion (e.g. via HSPGs), forming 
homo- or hetero-dimerisation with other receptors on adjacent cells (Plein, Fantin et al. 
2014). Unlike other tyrosine kinase receptors which use the Ras pathway to activate ERK, 
VEGFR2 uses mainly the phospholipase Cγ (PLCγ)-protein kinase C (PKC) pathway 
(Takahashi, Yamaguchi et al. 2001), (Shibuya 2006), (Koch and Claesson-Welsh 2012). 
Upon VEGF binding, VEGFR2 can internalise within 15–20 minutes, and then it is recycled 
back to the plasma membrane or is subjected to lysosomal degradation. VEGFR2 endocytosis 
has been reported to be essential in ERK activation (Gourlaouen, Welti et al. 2013), (Peach, 
Mignone et al. 2018).  
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1.2.2.2.2.1. VEGF and VEGFR2 during early stage of angiogenesis 
VE-cadherin stabilises EC interactions by activating TGF-β receptor signalling, which then 
inhibits VEGFR2 activation (Lampugnani, Zanetti et al. 2003), (Carmeliet and Jain 2011). 
Additionally, VE-cadherin alone can prevent VEGFR2 internalisation and proliferative 
signalling by forming a direct multiprotein complex with VEGFR2 (Lampugnani, Orsenigo et 
al. 2006). However, in response to VEGF and other growth factors, EC permeability in 
addition to the production of proteases are increased because of the loss of VE-cadherin and 
other junctional adhesions between adjacent ECs via rapid VE-cadherin endocytosis, which 
leads to the formation of fenestrated BM, through which small molecules can pass (Roberts 
and Palade 1997), (Gavard and Gutkind 2006), (Dejana, Orsenigo et al. 2008), (Koch and 
Claesson-Welsh 2012). Simultaneously, VE-cadherin in the tip cell that is localised at the 
filopodia initiates new outreach contacts to establish sprouting (Carmeliet and Jain 2011). 
HSPGs, which are present in the assembled BM can sequester growth factors, such as VEGF 
and basic epidermal growth factor (bEGF), and prevent them from playing a pro-angiogenic 
role. However, when MMP9 is released in response to VEGF stimulation, it effectively 
degrades type VI collagen in the BM, which results in the disruption of the assembled BM, 
including HSPG and perlecan, leading to the release of BM-bound VEGF (Kalluri 2003). 
Protolytic release (e.g. MMP12 and heparanase) has also been shown to increase VEGF–
VEGFR2 associations on ECs (Vempati, Popel et al. 2014). Heparin and heparan sulphate 
proteoglycans (e.g. syndecan) have been also been shown to enhance VEGF–VEGFR2 
binding and subsequent downstream signalling through the co-activation of integrins (e.g. 
α5β1 on FN and αvβ3 on vitronectin) (Jakobsson, Kreuger et al. 2006), (Purushothaman, 
Uyama et al. 2010), (Wijelath, Murray et al. 2002), (Mahabeleshwar, Feng et al. 2007), 
(Koch and Claesson-Welsh 2012), (Vempati, Popel et al. 2014). 
VEGF orchestrates the sprouting of quiescent ECs in the parent vessel by binding to 
VEGFR2 and other accessory co-receptors (e.g. neuropilin and integrins) on the selected tip 
cell and one or more adjacent proliferative stalk cells via DLL4-Notch signalling. The 
VEGF–VEGFR2 interaction upregulates DLL4 expression in the tip cell, which results in the 
activation of NOTCH signalling in the trailing stalk-cells. Jagged1 is another protein that is 
expressed by the stalk cells acting with the NOTCH receptor to promote the selection of tip 
cell. This action supresses VEGFR2 expression but increases VEGFR1 signalling (e.g. 
through PIGF) in the stalk cells, thus preventing the stalk cells from sprouting and allowing 
the tip cell to lead the sprout in the direction of VEGF cues. The tip cells and the trailing stalk 
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cells can be dynamically re-assigned based on the direction of the gradient of VEGF cues. 
Previous research showed that reductions in DLL4 or the blocking of Notch signalling caused 
significant angiogenic sprouting of ECs during mouse development (Adams and Alitalo 
2007), (Jakobsson, Bentley et al. 2009), (Phng and Gerhardt 2009), (Benedito, Roca et al. 
2009), (Carmeliet and Jain 2011), (Blanco and Gerhardt 2012). To restrain VEGFR2 
production as well as the VEGF-VEGFR2 signalling pathway, VEGFR3 expression is 
essentially enhanced in the tip EC, which prevents the excessive permeability of vascular ECs 
(Heinolainen, Karaman et al. 2017), (Zhang, Wang et al. 2018). Furthermore, soluble 
inhibitor factors (e.g. VEGF165b) prevent VEGFR2 dimerisation and the subsequent 
downstream signalling from being established in the tip cell (Woolard, Wang et al. 2004), 
(Vempati, Popel et al. 2014). 
1.2.2.2.2.2. VEGF/VEGFR2 signalling mechanism  
VEGF/VEGR2 signalling is essential in four main biological functions of ECs during 
angiogenesis: EC permeability, proliferation, migration and survival (Guo, Colbert et al. 
2010), (Dellinger and Brekken 2011). In a recent study, a comprehensive VEGF/VEGFR2 
signalling map was developed to depict all the proteins and pathways involved in ECs during 
angiogenesis. Briefly, the study identified 70 proteins that are involved in cell proliferation, 
103 proteins that participate in cell migration function, 95 proteins that are implicated in cell 
survival, and 31 proteins that engage in the internalisation and recycling of receptors 
[reviewed by  (Abhinand, Raju et al. 2016)]. A change in any of these proteins would change 
the signalling output and therefore affect EC function during angiogenesis.  
Mechanistically, VEGF binds to the 2 and 3 Ig-like domains of VEGFR2, leading to 
conformational changes in the extracellular region of VEGFR2, which subsequently results in 
the rotation of the transmembrane helices (Fuh, Li et al. 1998), (Dell'Era Dosch and Ballmer-
Hofer 2010), (Koch and Claesson-Welsh 2012). Conformational changes in the intracellular 
regions of VEGFR2 then occur, leading to VEGFR2 dimerisation through tyrosine auto-
phosphorylation at five major tyrosine (Tyr) sites: Tyr 951 (in the kinase-insert domain), Tyr 
1054 and Tyr 1059 (in the kinase domain), and Tyr1175 and Tyr1214 (in the carboxyl-
terminal domain) (Takahashi, Yamaguchi et al. 2001), (Matsumoto, Bohman et al. 2005). 
Other phosphorylation positions have also been identified, including 801, 1223, 1305, 1309 
and 1319 (Matsumoto, Bohman et al. 2005), (Koch and Claesson-Welsh 2012). All these 
phosphorylated tyrosines then recruit the cytoplasmic adaptor proteins to bind the VEGFR2 
 35 
cytoplasmic tail and initiate the complex downstream signalling pathways required for 
angiogenesis (Figure 1.8).  
For example, Tyr951 phosphorylation serves as a binding site for the T-cell-specific-adaptor 
molecule (TSAd) (Matsumoto, Bohman et al. 2005), which is also known as the VEGF 
receptor associated protein (VRAP) (Wu, Mayo et al. 2000), thus activating Src. The 
substrates of Src, including the SHB adaptor domain, then activate phosphatidylinositol 3-
kinase (PI3-kinase)/Akt pathway required for actin reorganisation and migration (Koch and 
Claesson-Welsh 2012). Tyr 1175 phosphorylation recruits SHB (Holmqvist, Cross et al. 
2004), which activates focal adhesion kinase (FAK) and PI3-kinase for cell attachment and 
migration (Holmqvist, Cross et al. 2004). Additionally, the recruitment of the nucleotide-
exchange factor Son of sevenless (SOS) to the phosphorylated VEGFR2 at Tyr 1175 is 
mediated by either Src homology collagen homology (SHC) or growth factor receptor-bound 
protein 2 (GRB2) (Warner, Lopez-dee et al. 2000). Subsequently, the phosphorylated Tyr 
1175 binds to PLCγ, which releases Ca2+ from the smooth endoplasmic reticulum (ER). 
Then, the Ca
2+ 
activates protein kinase C (PKC) and the subsequent downstream signalling 
ERK. This signalling cascade is believed to be an important pathway leading to cell 
proliferation during angiogenesis (Takahashi, Yamaguchi et al. 2001), (Koch and Claesson-
Welsh 2012). When PLCγ is phosphorylated, it hydrolyses the membrane phospholipid 
phosphatidylinositol (4, 5)-bisphosphate (PIP2), resulting in production of two products, 
which act as second messengers, diacylglycerol (DAG) and inositol 1,4,5-triphosphate (IP3). 
Subsequently, DAG remains on the cell membrane and activates PKC, which sequentially 
activates other cytosolic proteins by phosphorylating them, while IP3 binds to the IP3 
receptors on the smooth ER and opens calcium channels and release Ca
2+
, which in turn 
activates other protein signalling cascades (see Figure 1.8).Tyr 1214 phosphorylation creates 
a direct binding site to the cytoplasmic adaptor protein NCK, which then forms a complex 
with FYN (Lamalice, Houle et al. 2006). This complex then phosphorylates p21-activated 
protein kinase-2 (PAK2) and the subsequent sequential activation of cell division cycle 42 
(CDC42), P38 mitogen-activated protein kinases (p38 MAPK, p38), MAPK-activated protein 
kinase 2 (MAPKAPK2) and Heat shock protein 27 (HSP27) for cell migration regulation 
(Lamalice, Houle et al. 2004), (Koch and Claesson-Welsh 2012) (see Figure 1.8). It was 
reported that Tyr1059 phosphorylation binds to Src, and the complex can then phosphorylate 
the Tyr 1175 as well as other downstream signalling, such as IQGAP1 (IQ-motif containing 
GTPase-activating protein 1), which regulates cell–cell adhesion, proliferation and migration 
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(Yamaoka-Tojo, Tojo et al. 2006), (Meyer, Sacks et al. 2008), (Koch and Claesson-Welsh 
2012). Additionally, in response to VEGF induction, the p85 subunit of the phosphoinositide 
3-kinase (PI3K) enzyme is activated through binding to GAP1. The activated PI3K then 
catalyses the production of phosphatidylinositol-3,4,5-trisphosphate (PIP3) (Cantley 2002), 
which then activates the small GTPase Rac for the membrane ruffle and cell motility (Cain 
and Ridley 2009). EC survival during VEGF/VEGFR2 signalling is also regulated by the 
PI3K pathway. The activated PI3K can activate Akt through two kinase proteins: PDK 
(phosphoinositide-dependent kinase)-1 and PDK-2. Consequently, Akt can inhibit cell 
apoptosis by phosphorylating cysteine-aspartic proteases-9 (caspase-9) and BAD [Bcl (Bcell 
lymphoma)-2-associated death promoter] (Cardone, Roy et al. 1998), (Koch and Claesson-
Welsh 2012). The VEGF-induced activation of VEGFR2 promotes EC permeability through 
NO generation via endothelial NO synthase (eNOS) activation, which can be activated by 
either PLCγ-dependent Ca2 release or Akt phosphorylation (Fukumura, Gohongi et al. 2001), 
(Dimmeler, Fleming et al. 1999), (Koch and Claesson-Welsh 2012) (see Figure 1.8). It is 
worth noting that angiogenesis is regulated not only by the binding of the secreted growth 
factors to their receptors; EC adhesion mediated by the interaction of integrins with ECM 
ligands can also regulate angiogenesis (Dietrich, Onderka et al. 2007). 
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Figure 1.8 VEGFR2 downstream signalling via its tyrosine phosphorylation sites. Upon VEGF-A isoform binding to the 
extracellular Ig-like domains 2 and 3 of VEGFR2, the cytoplasmic tyrosine sites (indicated by numbers) of VEGFR2 are 
phosphorylated, in which each site recognises specific signalling molecules and then recruits other downstream signalling 
molecules needed for controlling ECs proliferation, migration, survival and permeability during vascular development and 
angiogenesis. See the main text for details. Cell division cycle 42 (CDC42); diacylglycerol (DAG); inositol 1,4,5-
trisphosphate (IP3); MAPK/ERK kinase (MEK); phosphatidylinositol 4,5-bisphosphate (PIP2); Son of sevenless (SOS) 
(Koch and Claesson-Welsh 2012). 
 
 
  
 38 
1.2.3. Additional molecular players in angiogenesis  
1.2.3.1 Neuropilin 
1.2.3.1.1 History of neuropilin 
In 1987, the antigen A5 was first identified in the nervous system of Xenopus embryos by 
using a monoclonal antibody (MAb-AS) against the optic tectum of Xenopus laevis tadpoles 
as an axonal adhesion protein (Takagi, Tsuji et al. 1987). In 1991, the deduced amino acid 
sequence of A5 protein revealed that the structure of this protein was a novel neuronal cell 
surface protein with at least five different extracellular domains (Takagi, Hirata et al. 1991). 
The A5 protein was then found to be expressed in vertebrates, including chicken and mouse. 
Specifically, the A5 protein is expressed in a particular neuron circuit at particular 
developmental stage when axonal growth is active, which was subsequently named 
neuropilin (NRP) (Fujisawa, Takagi et al. 1995). NRP was found to regulate axon guidance 
through its binding to class III semaphorin family members (Sema-3). Subsequent studies 
found that ECs also express NRP; here it plays an essential role in sprouting angiogenesis 
through the selective binding to members of the VEGF family (Soker, Takashima et al. 
1998), (Miao, Soker et al. 1999). Furthermore, early studies in this field discovered that NRP 
has a very small cytoplasmic tail, which lacks any known catalytic activities (Fujisawa, 
Kitsukawa et al. 1997), suggesting that NRP is unlikely to be able to transduce intracellular 
signalling on its own (Fujisawa, Kitsukawa et al. 1997), (Gluzman-Poltorak, Cohen et al. 
2000). Instead, neuronal Sema-3 and endothelial VEGF-induced intracellular signalling 
require the formation of a NRP/ligand complex with other receptors, such as plexins or 
VEGFRs, in neurons or ECs, respectively. It has become widely accepted that the endothelial 
NRP1, the first NRP to be discovered, binds to VEGF165 with high affinity (Soker, 
Takashima et al. 1998), (Miao, Soker et al. 1999). This complex then binds to VEGFR2 to 
enhance the VEGF165-induced activation of many intracellular pathways, including ERK 
signalling (Prahst, Héroult et al. 2008). However, subsequent studies in this field found that 
the function of NRPs extend beyond augmenting VEGF-signalling. For example, it was 
revealed that NRPs (NRP1 and NRP2) play important roles independently of VEGFRs 
(Wang, Zeng et al. 2003), (Wang, Mukhopadhyay et al. 2006), (Guo and Vander Kooi 2015), 
(Ou, Wei et al. 2015) . Subsequent studies found that endothelial NRPs can also bind and 
control many other cell surface receptors, including transforming growth factor-β1 (TGF-β1), 
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hepatocyte growth factor (HGF), FGF, Placental growth factor-B (PGF-B), platelet-derived 
growth factor (PDGF) etc. (Parker, Guo et al. 2012), (Djordjevic and Driscoll 2013). 
Furthermore, NRP’s expression was shown to extend beyond ECs and neuron cells. Many 
other cells were shown to express NRPs, including immune (Delgoffe, Woo et al. 2013) and 
tumour cells (Guo and Vander Kooi 2015). To exacerbate the complexity of these receptors, 
ECs were reported to express different members of the neuronal Sema-3 family, which 
function with NRPs as competitors for VEGFs and therefore inhibit angiogenic signalling 
(Miao, Soker et al. 1999). In addition to the regulation of the plexin and VEGF receptors, 
NRPs can also regulate integrin functions and influence cell adhesion, migration and 
permeability in physical and pathological conditions (Fukasawa, Matsushita et al. 2007), 
(Valdembri, Caswell et al. 2009), (Ellison, Atkinson et al. 2015). Because accumulating 
studies have been found that NRPs participate in many cellular functions depending on the 
type of cells that express these receptors, the publications in this field defined NRPs as 
multifunctional and versatile cell surface receptors (Neufeld, Cohen et al. 2002), (Parker, Guo 
et al. 2012), (Prud'homme and Glinka 2012), (Li, Parker et al. 2014), (Guo and Vander Kooi 
2015). 
1.2.3.1.2. NRP structure 
NRP, which is also known as Nrp, Npn or Np, is a single multifunctional non-tyrosine kinase 
receptor belonging to type I transmembrane glycoprotein receptor of about 130–140 kDa 
(Soker, Takashima et al. 1998). To date, only two NRPs have been identified in vertebrates, 
NRP1 and NRP2, which are composed of 923 and 926 amino acids, respectively. NRP2 
shares a very similar domain structure and an overall 44% amino acid identity with NRP1 
(Figure 1.9 A) (Pellet-Many, Frankel et al. 2008), (Zachary 2014). Both NRPs are comprised 
of a large single extracellular region consisting of five domains: two complement C1r/C1s, 
Uegf, Bmp1 (CUB) domains, two coagulation factor V/VIII homology domains, and one 
meprin, A-5 protein domain, and a receptor protein-tyrosine phosphatase mu (MAM) domain 
of 170 amino acids. This extracellular region is connected to a single helical transmembrane 
domain (TMD) and a short cytoplasmic tail of 44 amino acids in NRP1 and 43 amino acids in 
NRP2 (Nakamura, Tanaka et al. 1998), (Pellet-Many, Frankel et al. 2008), (Zachary 2014). 
The CUB domains (a1 and a2) serve as binding sites for the Sema-3 family, while the V/VIII 
domains (b1 and b2) serve as binding sites for certain isoforms of the VEGF family (Figure 
1.9 B) and heparins. It was reported that the b2 domain is required for both Sema-3 binding 
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and glycosaminoglycan (GAG) binding. The MAM domain is similar to other MAM domains 
that are present in many proteins. Its function is believed to be required for both receptor 
dimerisation and homophilic interaction with other receptors (Schwarz and Ruhrberg 2010), 
(Zachary 2014), (Plein, Fantin et al. 2014). The short cytoplasmic domain contains three 
conserved amino acids at the carboxyl-terminal (SEA-COOH) of NRP1 and NRP2a, forming 
a consensus PDZ domain binding motif that can bind to the cytoplasmic adaptor protein 
RGS-GAIP interacting protein C-terminus (GIPC), which is also called neuropilin-interacting 
protein-1 (NIP-1) or synectin, a molecule that modulates endocytic trafficking (De Vries, Lou 
et al. 1998), (Cai and Reed 1999), (Ballmer-Hofer, Andersson et al. 2011), (Lanahan, Zhang 
et al. 2013), (Zachary 2014). 
Although both NRPs are glycoproteins, their glycosylation differs depending on the cell type 
(Shintani, Takashima et al. 2006), (Zachary 2014). In addition to the normal molecular 
weight of NRP1 (130kDa), some tumours, vSMCs and cultured ECs express high 
glycosylated molecular weights of NRP1 (> 250 kDa) (Shintani, Takashima et al. 2006), 
(Frankel, Pellet‐Many et al. 2008), (Pellet-Many, Frankel et al. 2011). The modification of 
NRP1 occurs in the linker region between the V/VIII (b2) domain and the MAM domain at 
Ser 612 by the addition of an O-linked heparan sulphate and/or chondroitin sulphate GAGs 
(Zachary 2014). NRP1 also exists in a soluble form (sNRP1) because the truncation that 
occurs in the linker region between the second V/VIII (b2) domain and MAM domain, 
ending with the 3 amino acids GlyIsoLys (GIK) (Rossignol, Gagnon et al. 2000), (Mamluk, 
Klagsbrun et al. 2005), (Neufeld, Shraga-Heled et al. 2007), (Zachary 2014). In contrast, no 
highly glycosylated, high molecular weight isoform of NRP2 has been identified. NRP2 is 
divided into the two major forms NRP2a and NRP2b, but NRP2a has received the most 
attention in research because it possesses the SEA domain. In mice, NRP2a can have three 
variants, which are generated by the insertion of 5, 7 or 22 amino acids at position 809. 
However, only one isoform has been identified in humans, which is generated by the 
insertion of 7 amino acids at position 808. In mice, NRP2b is missing the SEA domain, and it 
can exist in two isoforms that differ in the sequence of the transmembrane and the 
intracellular region starting from position 809 (Gluzman-Poltorak, Cohen et al. 2000). 
Soluble NRP2 (sNRP2) has also been identified (Rossignol, Gagnon et al. 2000), (Neufeld, 
Shraga-Heled et al. 2007).  
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A) 
 
B) 
 
Figure 1.9 Neuropilin structure and ligand interactions. A) NRP1 and NRP2 consist of two CUB domains that are 45% 
homologous, two FV/FVIII domains that are 48% homologous, a single MAM domain that is 35% homologous, and a 
cytoplasmic tail that is 55% homologous. B) Schematic representation showing that neuropilins can transduce signalling of 
two distinct classes of growth factors (Sema-3 and VEGFs) by forming a complex with plexin-A or VEGFRs, respectively. 
In neuron cells, neuropilins bind to major receptors (Plexin A1 and A2) and transduce signalling of different isoforms of 
Sema-3 to promote growth cone collapse and sensory axonal guidance. NRP1 transduces the signalling of Sema-3A, Sema-
3B. Sema-3C, Sema-3E And Sema-3F, while NRP2 transduces the signalling of Sema-3B, Sema-3C, Sema-3F and Sema-
3G. In endothelial cells, neuropilins bind to major receptors (VEGFR1, VEGFR2 and VEGFR3) and transduce the signalling 
of different isoforms of VEGF to promote vascular maturation/branching, cardiac development or lymphogenesis. Adapted 
from (Zachary, Frankel et al. 2009), (Gaur, Bielenberg et al. 2009), (Lange, Storkebaum et al. 2016) 
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1.2.3.1.3. Neuropilins in embryonic development 
During mouse embryonic development, NRP1 is predominantly expressed on the ECs of 
arteries and capillaries as well as in the mouse embryo hindbrain. NRP2 is mainly expressed 
in venous and lymphatic vessels (Plein, Fantin et al. 2014). Transgenic mouse studies 
revealed that NRP1-NULL mice die between E10.5 and E13.5, as a result of an impairment 
in the heart outflow tract as well as severe defects in the yolk sac and neuronal vacuolisation, 
especially in the brain and spinal cord (Kawasaki, Kitsukawa et al. 1999), (Gu, Rodriguez et 
al. 2003), (Jones, Yuan et al. 2008). The overexpression of NRP1 leads to hyper-
vascularisation in the growth of capillaries and blood vessels, which were leaky and 
haemorrhagic (Klagsbrun, Takashima et al. 2002), (Kitsukawa, Shimono et al. 1995). 
Transgenic mice lacking the short intracellular domain of NRP1 survive, but the mutation 
impairs arteriogenesis, a process that involves the growth of the luminal vessels (Fantin, 
Schwarz et al. 2011), (Lanahan, Zhang et al. 2013). Another study reported that targeting 
NRP1 only in ECs, but not other cell types, caused severe disruption of vascular development 
(Gu, Rodriguez et al. 2003). The same study also reported that the disruption of the CUB 
domain, which is essential for Sema binding, did not affect general vascular development, but 
there was a bilateral atrial enlargment in the heart, suggesting that both VEGF-NRP1 and 
Sema-3A-NRP1 signalling in endothelial cells are essential in the development of the heart 
(Gu, Rodriguez et al. 2003). The results of another study indicated that the phenotypic defects 
seen in vascular development upon NRP1 deletion occurred because of the disruption of EC 
migration, not EC proliferation (Jones, Yuan et al. 2008). These previous studies confirmed 
that NRP1 plays critical roles in embryonic vascular development.  
On the other hand, studies on NRP2 revealed that NRP2-NULL mice are viable with normal 
arterial development; however, the animals exhibit markedly small veins and lymphatic 
vessels in addition to abnormalities of sensory axons in the spinal cord, hippocampal and 
olfactory bulb (Chen, Bagri et al. 2000), (Yuan, Moyon et al. 2002). The double knockout of 
both NRPs is lethal, and mice die in utero earlier than NRP1 knockout mice at E8.5 
(Takashima, Kitakaze et al. 2002). Transgenic mice with the targeted deletion in one NRP 
while the other one was heterozygous died at E10 to E10.5 (Takashima, Kitakaze et al. 2002). 
Interestingly, mice lacking the NRP2 gene and containing only one functional NRP1 gene 
exhibited more severe defects in vascular development than those reported in mice lacking 
both NRP1 alleles (Takashima, Kitakaze et al. 2002). Another study compared the expression 
of both NRPs during embryonic vascular development of chicks and showed both NRPs are 
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expressed in the blood islands of 24-hours old chick embryos. However, between 48 and 72 
hours, the expression of NRP1 was restricted to the arteries as well as the smaller branches of 
these arteries, whereas NRP2 was preferentially expressed in veins as well as in the smaller 
venous branches that merged with the arteries (Herzog, Kalcheim et al. 2001). Overall, these 
results indicate that the expressions of both NRPs are required in the early development of 
embryonic vessels (Takashima, Kitakaze et al. 2002).  
1.2.3.1.4 Post-embryonic Neuropilin expression 
NRP expression is not only resected to nerve cells and ECs. Their expression and function 
has been implicated in many other cells, including immune cells, epithelial cells, osteoblasts, 
and tumour cells (Bielenberg, Hida et al. 2004). 
1.2.3.1.4.1. Neuropilins in nerve cells 
Semaphorins are a large family of transmembrane and secreted proteins characterised by the 
expression of conserved 500 amino acids called the Sema domain. Semaphorins are grouped 
into eight major subclasses in which classes 1 and 2 are expressed in invertebrates, and 
classes 3 to 7 are expressed in vertebrates. Semaphorin class 8 was also identified, but it is 
only encoded by a virus. Transmembrane semaphorin proteins are in classes 1 and 4–7, 
whereas secreted semaphorin proteins are in classes 2, 3 and 8 (Raper 2000), (Suzuki, 
Kumanogoh et al. 2008). Although semaphorins are expressed by other cells, their functions 
are best illustrated in the nerve cells where they guide the growing exons to the target and 
simultaneously deflect or repel them from an inappropriate target (Yazdani and Terman 
2006). Transmembrane and viral semaphorin signalling occur through binding with the plexin 
family of transmembrane proteins, whereas secreted semaphorins, specifically Sema-3 family 
members, transduce signalling through complex formations with plexins and NRPs, which 
act as co-receptors to enhance signalling (Tamagnone, Artigiani et al. 1999).  
It was believed that only the Sema-3 subfamily binds and utilises NRPs to transduce 
signalling, but subsequent studies reported that Sema-4A can also signal through NRP1 
expressed by the regulatory T-cells (Treg cells) (Delgoffe, Woo et al. 2013), (Guo and 
Vander Kooi 2015). Seven Sema-3 members are designated from Sema-3A to Sema-3G, all 
of which require NRP binding to mediate repulsive signals during neuronal axon guidance 
with the exception of Sema-3E, which has been reported to signal through plexin D1 
independently of NRPs (Gu, Yoshida et al. 2005), (Serini, Bussolino et al. 2013). The CUB 
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(a1/a2) domains of NRPs selectively bind different members of the secreted Sema-3 family, 
in which NRP1 binds to Sema-3A, Sema-3B, Sema-3C and Sema-3F, while NRP2 binds to 
Sema-3B, Sema-3C, Sema-3D and Sema-3F (Neufeld, Cohen et al. 2002), (Djordjevic and 
Driscoll 2013). However, Sema-3A binds to NRP1 with the highest affinity, while Sema-3F 
is the best characterised ligand for NRP2 binding (Zachary 2014).  
1.2.3.1.4.2. Neuropilins in ECs 
Based on early transgenic mouse studies in this field (see above), it was speculated that NRP1 
is mainly expressed in arteries, arterioles and capillaries, whereas NRP2 is expressed in veins, 
venules and lymphatic vessels (Herzog, Kalcheim et al. 2001), (Yuan, Moyon et al. 2002). 
However, subsequent studies revealed that both NRPs are expressed in normal blood and 
lymphatic endothelial cells, and both play essential roles in forming blood and lymphatic 
vasculature networks (Jurisic, Maby-El Hajjami et al. 2012), (Bouvrée, Brunet et al. 2012), 
(Mucka, Levonyak et al. 2016). Additionally, both EC types express the soluble Sema-3 
subfamily, which signal through NRPs, thus adding another layer to the complexity of NRP 
functions in ECs (Jurisic, Maby-El Hajjami et al. 2012). With regard to angiogenesis, both 
NRPs were described to act as co-receptors for selective forms of VEGFs to enhance VEGFR 
phosphorylation (Fuh, Garcia et al. 2000), (Gluzman-Poltorak, Cohen et al. 2001), 
(Kärpänen, Heckman et al. 2006), (Xu, Yuan et al. 2010), (Ballmer-Hofer, Andersson et al. 
2011), (Fearnley, Smith et al. 2016), (Fuh, Garcia et al. 2000), (Herzog, Pellet-Many et al. 
2011), (Tiwari, Jung et al. 2012). There is also evidence that NRPs can mediate ligand 
signalling independently of VEGFRs (Wang, Zeng et al. 2003), (Favier, Alam et al. 2006). 
Furthermore, there is strong evidence that NRPs can regulate VEGFRs independently of 
VEGF binding (Fantin, Schwarz et al. 2011), (Fantin, Herzog et al. 2014). In another group 
of studies, NRP functions were implicated in EC adhesion and migration independently of 
both VEGF and VEGFR by modulating other transmembrane receptors (e.g. integrins) 
(Murga, Fernandez-Capetillo et al. 2005), (Valdembri, Caswell et al. 2009), (Raimondi, 
Fantin et al. 2014), which also play critical roles in modulating the biological function of ECs 
during angiogenesis.  
Understanding the different mechanisms by which NRPs are implicated in angiogenesis is 
required to improve therapeutic inhibitors in cancer treatment. In the following sections, we 
will discuss the different functions of NRPs in endothelial cells and cancer cells.  
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1.2.3.1.4.2.1 NRP1 
In 1996, an immunoprecipitation experiment revealed for the first time that NRP1 protein is a 
receptor of VEGF165 but not of the soluble VEGF121 because it lacks the exon 6 and 7-
encoded domains (Soker, Fidder et al. 1996), (Soker, Takashima et al. 1998), which contain 
HSPG- and NRP1-binding regions (Tiwari, Jung et al. 2012), (Vempati, Popel et al. 2014). 
Ten years later, studies demonstrated that VEGF121 binds directly to NRP1 and regulates both 
EC migration and sprouting, but unlike VEGF165, VEGF121 does not form a NRP1-VEGF121-
VEGFR2 complex (Pan, Chathery et al. 2007), (Shraga-Heled, Kessler et al. 2007). Not all 
VEGF-A isoforms can bind to NRP1; for example, VEGF165b (Suarez, Pieren et al. 2006) and 
VEGF145 do not bind to NRP1, whereas VEGF189 (Tillo, Erskine et al. 2015) can bind to 
NRP1, but VEGF165 is believed to be the only VEGF-A isoform that can form a 
heterocomplex with VRGFR2 and NRP1 and increase VEGFR2 signalling and recycling. 
VEGF165b acts negatively through binding to VEGFR2 and preventing NRP1 from binding to 
VEGFR2, thus leading to VEGFR2 degradation (Ballmer-Hofer, Andersson et al. 2011), 
(Fearnley, Smith et al. 2016). In particular, Ballmer et. el showed that in response to 
VEGF165, NRP1 is essential in mediating VEGFR2 internalisation, phosphorylation and 
recycling back to the plasma membrane through the Rab11 vesicles, whereas VEGF165b, 
which lacks NRP1-binding, inactivated VEGFR2 and rapidly promoted the accumulation of 
VEGFR2 in Rab7 vesicles (not in Rab11 vesicles) and trafficking to lysosomes for 
degradation because of the absence of NRP1 (Ballmer-Hofer, Andersson et al. 2011). 
Therefore, because of this key role, VEGFR2 signalling driven by VEGF165 is the most potent 
angiogeneic factor function during angiogenesis (Sun, Liu et al. 2011), (Peach, Mignone et al. 
2018). 
An in vitro binding analysis showed that the extracellular domain of NRP1 does not interact 
directly with VEGFR2, but the density of NRP1 on the cell membrane increases the 
interaction between VEGF165 and VEGFR2 (Fuh, Garcia et al. 2000). Additionally, targeting 
the Tyr297 residue within the extracellular b1 domain of NRP1 prevented the VEGF165-
induced complex formation between VEGFR2 and NRP1 (Herzog, Pellet-Many et al. 2011), 
suggesting that the VEGF165–VEGFR2 complex is dependent on NRP1 (Fuh, Garcia et al. 
2000), (Herzog, Pellet-Many et al. 2011), (Tiwari, Jung et al. 2012). Furthermore, another 
study showed that NRP1 and VEGFR2 are highly expressed in the tip cell during sprouting 
angiogenesis (Fantin, Vieira et al. 2013), which supports a mechanism whereby VEGF165-
induced angiogenic signalling occurs through binding to NRP1 and its main receptor 
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(VEGFR2) in the tip cell. This mechanism requires the formation of the VEGF-NRP1 pre-
complex (Soker, Fidder et al. 1996) to enhance VEGF binding to VEGFR2, and thus 
potentiate VEGFR2-mediated ECs signalling, migration and permeability during 
angiogenesis (Pan, Chathery et al. 2007). This mechanism was validated using an antibody 
that blocks the extracellular (b1/b2) domains within NRP1, which resulted in a significant 
reduction in: (1) VEGF-induced VEGFR2 complex formation; (2) migration; (3) in vitro 
sprouting; (4) and in vivo neovasciologenesis (Pan, Chanthery et al. 2007). Another study 
used RNA interference silencing of NRP1 or VEGFR2 to show that NRP1 and VEGFR2 are 
required for VEGF-induced signalling as well as for the proliferation and migration of ECs 
(Murga, Fernandez-Capetillo et al. 2005). Consistent with these findings, NRP1-siRNA 
knockdown (Fearnley, Odell et al. 2014), (Raimondi, Fantin et al. 2014) or NRP1 inhibition 
(Becker, Waltenberger et al. 2005) reduce VEGF165-induced phosphorylation of  VEGFR2, 
ERK1/2, and p38. Another study also strongly supported this mechanism, indicating that 
VEGF165-VEGFR2-NRP1 complex formation induces angiogenic sprouting and EC 
organisation in vitro and in vivo through the activation of VEGFR2, ERK1/2, Akt and p38, 
whereas VEGF121 failed to activate p38 (Kawamura, Li et al. 2008) (Figure 1.10). It is worth 
noting that HSPGs can also enhance VEGF165-VEGFR2-NRP1 complex formation and 
ERK1/2 phosphorylation (Kawamura, Li et al. 2008), (Teran and Nugent 2015). Many other 
proteins are also upregulated in response to hypoxia, and they are involved directly or 
indirectly in angiogenesis (e.g. VEGFR1, NRP2, Ang-2, eNOs, TGF-β1 and PDGF-BB), thus 
adding another layer of complexity to VEGF-VEGFR2 signalling (Conway, Collen et al. 
2001). In brief, the extracellular region of NRP1 does not directly bind to VEGFR2, and the 
complex formation of VEGF165-VEGFR2 is, at least partially, dependent on NRP1.  
Although the extracellular region of NRP1 has become a model for mediating the VEGF165-
VEGFR2 complex, another group of studies provided strong evidence that the short 
intracellular region of NRP1 is also required for VEGF165–VEGFR2 downstream signalling, 
and it can even regulates EC migration, adhesion and the functions of other cell membrane 
receptors, including VEGFR2, independently of VEGF-stimulation (Wang, Zeng et al. 2003). 
In fact, this suggestion was published only three years after the discovery of NRP1 by Cai 
and Reed, who isolated the cytoplasmic-bound adaptor GIPC from the C-terminal PDZ-
binding domain of NRP1, suggesting that GIPC-NRP1 may participate in membrane 
trafficking machinery (Cai and Reed 1999). This suggestion was supported by a study 
showing that PLCγ phosphorylation, one of the downstream signals directly activated by 
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VEGFR2, was decreased when the cytoplasmic C-terminal PDZ domain-binding SEA motif 
of NRP1 was mutanted, suggesting that one or more sites in the NRP1 cytoplasmic tail play 
an essential regulatory role in PLCγ-1 phosphorylation (Ballmer-Hofer, Andersson et al. 
2011). Interestingly, the same study also found that p38, a required molecule in vascular 
sprouting (Kawamura, Li et al. 2008), phosphorylation was diminished when the entire NRP1 
cytoplasmic tail, including the last three amino acids (SEA), was missing, indicating that not 
only the SEA motif in NRP1 mediates signalling but the entire cytoplasmic tail is also 
required in VEGF165-VEGFR2 signalling (Ballmer-Hofer, Andersson et al. 2011). Another 
study showed that binding β3-integrin subunit (ITGB3) to NRP1 via its cytoplasmic PDZ-
binding domain limited the interaction between NRP1-VEGFR2 and the subsequent 
VEGF165-VEGFR2 downstream signalling, thereby significantly reducing the number of 
microvessel sprouting in ex vivo aortic ring assays (Robinson, Reynolds et al. 2009).  
The cytoplasmic tail of NRP1 can also regulate EC functions independently of VEGF-
induction. This statement is supported by two studies. Veldambri et al. showed that silencing 
NRP1 with siRNA in human umbilical artery ECs (HUAECs) reduced ECs adhesion to FN 
and impaired endogenous soluble FN (sFN) incorporation into a dense fibrillar network 
(Valdembri, Caswell et al. 2009). By transfecting the NRP1-siRNA depleted ECs with 
retrovirus carrying full-length mouse NRP1 (mNRP1) or lacking either the C-terminal SEA 
amino acids (mNrp1dSEA) or the whole cytoplasmic domain (mNrp1dCy), the authors found 
that, in comparison to full-length mNRP1, cytoplasmic deletion constructs of mouse NRP1 
failed to rescue the adhesion and fibrilogenesis defects seen in NRP1-siRNA depleted ECs, 
suggesting that NRP1 through its cytoplasmic tail promotes EC adhesion to FN and FN 
matrix formation. Importantly, NRP1-siRNA blocked VEGF165-induced human EC adhesion 
to FN stimulation, but all the three constructs (mNRP1, mNrp1dSEA and mNrp1dCy) 
rescued the adhesion of NRP1-siRNA depleted EC in response to VEGF165 stimulation with 
similar efficiency, suggesting that the NRP1 cytoplasmic tail regulates EC adhesion to FN 
independently of VEGF165 (Valdembri, Caswell et al. 2009). Fantin et al. showed that 
targeting the Tyr 297A within the extracellular b1 domain of NRP1, which is a required site 
for VEGF binding and NRP1VEGFR2 complex formation, resulted in no severe embryonic 
defects in full or endothelial-specific NRP1 knockout, but these mice displayed significant 
impairment in arterial morphogenesis during development and in adulthood, suggesting that 
VEGF binding to NRP1 is not essential for embryonic angiogenic development. Therefore, 
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NRP1 must have a VEGF-independent role, which is likely through its cytoplasmic tail 
(Fantin, Herzog et al. 2014).  
NRP1 interacts with VEGFR2 not only in a cis-binding fashion but also in trans, mediating 
interactions between adjacent cells. For example, the investigations of the effects of NRP1 on 
VEGFR2 function in cis- and trans-binding showed results that were consistent with previous 
observations. The study found that VEGF-induced rapid VEGFR2-NRP1 complex formation 
and internalisation when the receptors were expressed in the same cell. However, when 
NRP1 was expressed by adjacent cells (e.g. tumour cells), it showed distinct effects on 
VEGFR2 function by causing a delay in complex formation and a reduction in ERK1 
phosphorylation, while the prolonged expression of PLCγ-1 and ERK2 resulted in preventing 
and reducing sprouting angiogenesis (Figure 1.11) (Koch, van Meeteren et al. 2014).  
A group of other studies demonstrated that NRP1 regulated EC function and extracellular 
remodelling independently of VEGFR2. For example, transducing EGNRP-1, a chimeric 
receptor generated by fusing the extracellular region of the epidermal growth factor receptor 
(EGFR) to the transmembrane/intracellular domains of NRP1, promoted HUVEC migration 
in response to EGF when VEGFR2 was mutated, indicating that the cytoplasmic tail of NRP1 
alone could mediate ligand-dependent ECs migration, but not proliferation, independently of 
VEGFR2 (Wang, Zeng et al. 2003). Murga et al. showed that VEGFR2-siRNA displayed no 
significant effect on HUVEC adhesion on FN, laminin or gelatin, whereas NRP1-siRNA 
significantly impaired HUVEC adhesion on these matrices. Additionally, the pattern of 
filamentous actin (F-actin) over 24 hours incubation in VEGFR2-siRNA depleted HUVECs 
were not different compared to control HUVECs, whereas NRP1-siRNA depleted HUVECs 
displayed a significant reduction in F-actin organisation over 48 hours of incubation. Only 
after this time did NRP1-siRNA depleted HUVECs display F-actin organisation similar to 
control cells, suggesting that NRP1 controls endothelial cell adhesion independently of 
VEGFR-2 (Murga, Fernandez-Capetillo et al. 2005). Four years later, this finding was 
strongly supported by another study showing that NRP1, independently of VEGF165 and 
SEMA-3A signalling, promotes α5β1 integrin-mediated EC adhesion to FN via the 
interaction of the SEA domain at the C-terminal of NRP1 with the endocytic adaptor protein 
GIPC. Specifically, the interaction of NRP1-GIPC with the active form of α5β1 is mediated 
by another associated molecule called motor myosin VI (Myo-6), which then promotes active 
α5β1 integrin endocytosis and EC adhesion to FN. This study suggested that vascular 
phenotypes resulting from the loss of the NRP1 gene or its cytoplasmic tail could be due to 
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the role of NRP1 in mediating EC adhesion to ECM. (Valdembri, Caswell et al. 2009). 
Consistent with these results, another study showed that NRP1 regulates angiogenesis 
independently of VEGF-VEGFR2 system by regulating FN matrix remodelling and 
phosphorylation of paxillin, a focal adhesion multifunctional adaptor molecule that links the 
cell surface protein-ECM to the actin cytoskeleton during cell migration, activation and actin 
remodelling (Raimondi, Fantin et al. 2014). In contrast to earlier studies, which showed that 
NRP1 depletion decreased HUVEC adhesion to FN (Murga, Fernandez-Capetillo et al. 2005), 
(Valdembri, Caswell et al. 2009), Raimondi and Fantin reported that NRP1-siRNA-depletion 
did not affect EC adhesion to FN substrates in either HUVECs or HDMECs. However, 
NRP1-silencing reduced the migration of these ECs on FN. NRP1 knockdown led to 
abnormal cytoskeletal morphology with abundant cortical actin as well as a significant 
reduction in paxillin phosphorylation, when cells were plated on FN.  In contrast, control 
siRNA-treated or VEGFR2-siRNA treated ECs exhibited normal elongated stress fibres with 
paxillin localised to focal adhesion (FAs) at the end of the actin filament fibres stimulated 
with VEGF165. Additionally, VEGF165-induced paxillin phosphorylation was not changed in 
NRP1-dpleted ECs compare to control siRNA ECs, whereas NRP1 knockdown showed a 
downregulation of paxillin phosphorylation in FN-stimulated ECs. Interestingly, the co-
immunoprecipitation experiment showed that NRP1 formed a complex with paxillin as well 
as ABL1 (Raimondi, Fantin et al. 2014), a non-receptor tyrosine kinase whose activity and 
recruitment from the nucleus to FAs is regulated by integrins (Lewis, Baskaran et al. 1996), 
(Lewis and Schwartz 1998), (Cui, Chen et al. 2009). These findings showed that NRP1 
regulates FN-dependent actin remodelling, cell migration, and paxillin activation via ABL1 
independently of VEGF–VEGFR signalling (Raimondi, Fantin et al. 2014). 
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Figure 1.10 Contribution of NRP1 function in VEGF-A165/VEGFR2 vs VEGF-A121/VEGFR2 signalling in ECs. 
Schematic representation showing that the complex formation of NRP1-VEGFR2 as well as HSPG enhance VEGFR2 
binding to VEGF165 and transduce the downstream signalling activation of ERK1/2, Akt and p38 MAPK, which results in 
angiogenic sprouting/branching, whereas VEGF-A121 does not induce stable complex formation between NRP1 and 
VEGFR2 and thus fails to transduce the downstream signalling activation of p38 MAPK and endothelial angiogenic 
sprouting/branching. The P symbol in yellow indicates VEGFR2 phosphorylation. Note that NRP1 interacts directly with 
VEGFR2, but for better visualisation, they are shown separately. Adapted from (Kawamura, Li et al. 2008). 
------------------------------------------------------------------------------------------------------------- 
 
Figure 1.11 Differential VEGFR2 activation driven by NRP1-binding in cis- vs. trans. The schematic representation 
shows that the complex formation of NRP1-VEGFR2 in response to VEGF in the same cell (cis-binding) promotes rapid 
VEGFR2 activation, internalisation and angiogenic sprouting/branching; whereas a trans-binding formation between non-
endothelial (e.g. tumour cells) NRP1 and endothelial VEGFR2 in response to VEGF results in a delay of NRP1-VEGFR2 
complex formation, arrests internalisation and prevents angiogenic sprouting/branching (Koch, van Meeteren et al. 2014).  
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1.2.3.1.4.2.2 NRP2 
A role for NRP2 in regulating neuron cells axon guidance was discovered only one year after 
the discovery that NRP1 regulates this same process. NRP2’s domain structure is highly 
similar to NRP1 (Chen, Chédotal et al. 1997); however, studies on neuropilins were mainly 
focused on NRP1 (Zachary 2014), (Wittmann, Grubinger et al. 2015). This focus was 
possibly due to the observations of early transgenic mice studies in which NRP1-NULL mice 
were embryonically lethal (Kawasaki, Kitsukawa et al. 1999), whereas NRP2-NULL mice 
were viable with only small defects in venous/lymphatic vessels and the minor brain defects 
described above (Giger, Cloutier et al. 2000), (Chen, Bagri et al. 2000), (Yuan, Moyon et al. 
2002). To date, there are only a few studies that have examined the role of NRP2 in ECs; 
these will be summarised below. A few more studies have focused on NRP2 function in 
cancer cells perhaps because its upregulation is consistent with cancer progression (e.g. 
neuroblastomas (Fakhari, Pullirsch et al. 2002), nonsmall cell lung carcinoma [NSCLC] 
(Kawakami, Tokunaga et al. 2002), human prostate carcinoma, melanoma (Bielenberg, Hida 
et al. 2004), lung cancer (Tomizawa, Sekido et al. 2001), (Kawakami, Tokunaga et al. 2002), 
(Lantuéjoul, Constantin et al. 2003), myeloid leukaemia (Vales, Kondo et al. 2007), breast 
cancer (Bachelder, Crago et al. 2001) and pancreatic cancer (Fukahi, Fukasawa et al. 2004)). 
Perhaps it is not surprising that NRP2 has become a biomarker for some cancers, including 
endocrine pancreatic (Cohen, Herzog et al. 2002) and bladder cancer progression (Sanchez-
Carbayo, Socci et al. 2003), or a prognostic indicator in osteosarcoma (Handa, Tokunaga et 
al. 2000). 
In 2000, NRP2 expression was reported for the first time in HUVECs, suggesting that it may 
play a role in cardiovascular biology (Gluzman-Poltorak, Cohen et al. 2000). Interestingly, 
this study reported two important findings: 1) Similar to NRP1, NRP2 binds to VEGF165 and 
PIGF-2 with high affinity; 2) VEGF145, which lacks exon 7, but contains exon 6 (Poltorak, 
Cohen et al. 1997), is able to bind only to NRP2, not to NRP1; however, the affinity between 
NRP2 and VEGF145 is five-fold lower than that between NRP2 and VEGF165. This initial 
study concluded that NRP2 may initiate signal transduction through VEGF receptors in ECs 
(Gluzman-Poltorak, Cohen et al. 2000). A study conducted the following year supported this 
hypothesis by showing that NRP2 binds to VEGF165. The disruption of the cytoplasmic tail of 
NRP2 by inserting myc-epitope in frame after the conserved SEA domain of NRP2 caused 
NRP2 to lose most of its binding affinity with VEGF165 but not with Sema-3F, indicating that 
the cytoplasmic tail of NRP2 is required for VEGF165 but not for Sema-3F signalling 
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(Gluzman-Poltorak, Cohen et al. 2001). This study also reported that both NRP1 and NRP2 
form a complex with VEGFR1 (Fuh, Garcia et al. 2000), and this interaction allows NRPs to 
bind to VEGF121 (Gluzman-Poltorak, Cohen et al. 2001).  
NRP2 has also been implicated in lymphogenesis, by forming a complex with VEGFR3, 
which is exclusively expressed in lymphatic ECs (Kärpänen, Heckman et al. 2006). This 
study reported several important findings: 1) NRP2 is expressed in both human lymphatic 
dermal microvascular endothelial cells (HLDMVECs) and in human blood dermal 
microvascular endothelial cells (HBDMVECs), indicating directly that NRP2 may play roles 
in both lymphatic and blood ECs; 2) Human embryonic kidney 293 cells expressing the SV40 
large T antigen (HEK293 cells) transfected with plasmids encoding human VEGF-C or 
VEGF-D and NRP1 or NRP2 showed that VEGFC could interact with NRP2 and that this 
interaction was slightly enhanced with the addition of HSPGs, while the interaction of 
VEGFC with NRP1 was entirely dependent on HSPGs. VEGF-D could also bind to both 
NRP1 and NRP2, but both interactions were dependent on HSPGs; 3) Sema-3F, whose 
binding was believed to be restricted to NRP2 (Bielenberg, Hida et al. 2004), binds to NRP1 
and NRP2 and competes with VEGF-C in binding to both NRPs, indicating that these 
different ligands interact with NRPs through overlapping binding sites; 4) HEK293 cells 
transfected with a plasmid encoding NRP2 and then stimulated with VEGF-C did not induce 
NRP2 internalisation. However, if the cells were additionally transfected with VEGFR3, 
NRP2 was internalised, indicating that NRP2 internalisation is dependent on the presence of 
both VEGFR3 and VEGF-C; 5) endogenous NRP2 binds directly to VEGFR3 in a ligand-
independent manner, but VEGF-C or VEGF-D is required for NRP2-VEGFR3 complex to 
co-internalise and co-localise in endocytic vesicles (Kärpänen, Heckman et al. 2006). 
Another study published in the same year examined HEK293 cells transfected with NRP2-
flag and HA-VEGFR2 or HA-VEGFR3. Immunoprecipitation studies showed that NRP2 
interacts with not only VEGFR3 but also VEGFR2. Interestingly, stimulation with VEGF-A 
or VEGF-C increased the association of flag-NRP2/VEGFR2, while flag-NRP2/VEGFR3 
was increased only in the presence of VEGF-C, indicating that NRP2 binds to VEGFR2 or 
VEGFR3 in both ligand-dependent and -independent fashions (Favier, Alam et al. 2006).  By 
using porcine aortic endothelial cells (PAEC), the authors also showed that VEGFR2 
phosphorylation was increased when the cells were transfected with human pCDNA hygro–
NRP2 and stimulated with either VEGF-A or VEGF-C compared to low VEGFR2 
phosphorylation in the absence of NRP2. This observation was confirmed by NRP2-siRNA 
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silencing experiments in human microvascular endothelial cells (hMVECs). VEGF-C or 
VEGF-D induced phosphorylation of VEGFR2 was inhibited upon NRP2 knockdown. 
Interestingly, the overexpression of NRP2 in hMVECs increased cell survival induced by 
either VEGF-A or VEGF-C compared to cells transfected with an empty vector (Favier, 
Alam et al. 2006), whereas NRP2 knockdown significantly inhibited VEGF-A- and VEGF-C-
induced migration (Favier, Alam et al. 2006), supporting the hypothesis that NRP2 
knockdown might help in cancer therapy. Consistent with this concept, another report studied 
the effect NRP2 inhibition in three different lymphogenesis models of adult mice, where the 
injection of a function-blocking anti-NRP2 antibody resulted in a significant reduction in the 
number of: 1) superficial dermal tail lymphatic network; 2) lymphatic villi with lacteals in the 
small intestinal; and 3) epicardial lymphatic branch points in the heart. Interestingly, NRP2 
was also shown to be highly expressed in lymphatic tip cells, but not in stalk cells. Moreover, 
blocking the VEGF-C binding to NRP2 with anti-NRP2 antibody inhibited the sprouting of 
the lymphatic endothelial tip cells, indicating that NRP2-VEGF-C plays a critical role in 
inducing filopodia extension in this system. The same study also showed that LECs, 
including tip cells, expressed both VEGFR2 and VEGFR3, but the lymphatic vessels 
sprouting in the double-heterozygous NRP2
+/-
 VEGFR2
+/-
 mice developed normally without 
detectable defects, whereas in the double-heterozygous NRP2
+/-
VEGFR3
+/-
 mice, lymphatic 
sprouting was reduced in the three lymphogenesis models. The authors concluded that the 
NRP2-VEGFR3 interaction induced by VEGF-C in the tip cells mediates the sprouting of 
lymphatic vessels during lymphogenesis (Xu, Yuan et al. 2010).  
In contrast to the findings of the above studies, a recent study showed that the siRNA-
mediated depletion of NRP2 in HUVEC resulted in a ~1.5-fold increase in both cell 
migration and invasion, and the overexpression of NRP2 reduced HUVEC migration and 
invasion. Similarly, EC infiltration into a matrigel implant plug treated with NRP2-siRNA 
was increased compared to an implant containing control siRNA (German, Mammoto et al. 
2014). Furthermore, this study showed that VEGF alone or soluble tumour-driven factors 
induces cell migration and micro-vessel sprouting by decreasing the expression levels of 
NRP2 and paxillin, (German, Mammoto et al. 2014). This observation is inconsistent with 
many other studies that show VEGF, NRP2, and paxillin (Jagadeeswaran, Surawska et al. 
2008), (Mackinnon, Tretiakova et al. 2010), (Deakin, Pignatelli et al. 2012), (Sen, De Castro 
et al. 2012) are all highly expressed in tumours and their expression is correlated with cancer 
progression. Nevertheless, the same study reported that the deletion of paxillin resulted in a 
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50% reduction in both NRP2 protein and mRNA, indicating that NRP2-paxillin signalling 
plays a significant role in cell migration, but how is still under investigation. The findings of 
this study suggested that the amino-terminus (N-terminus) of paxillin binds to NRP2 
indirectly through other adaptor proteins, including vinculin, to regulate cell migration 
(German, Mammoto et al. 2014).  
1.2.3.1.4.2.2.1. NRP2’s function in cancer  
Similar to NRP1 expression, NRP2 expression has been implicated in cancer progression. A 
previous study showed that the NRP2-VEGF-C complex is required to promote the survival 
of prostate cancer cells (PC3 cells) by activating Akt signalling and preventing these cells 
from oxidative stress-induced cell death. The study found that by increasing the concentration 
of VEGF-C in the presence of oxidative stress hydrogen peroxidase (H2O2), Akt 
phosphorylation as well as the phosphorylation of its downstream signalling proteins 
Forkhead box protein O1 (FOXO1) and Glycogen synthase kinase 3 beta (GSK-3β) were 
increased compared to unstimulated cells. NRP2 knockdown inhibited the VEGF-C-induced 
phosphorylation of these proteins, indicating that VEGF-C promotes cell survival through 
binding to NRP2 (Muders, Zhang et al. 2009). To further understand the potential mechanism 
involved in VEGF-C-induced survival, three years later, the same group conducted a 
microarray study and identified two molecules that were consistently upregulated when 
VEGF-C or NRP2 were separately knocked down in PC3 cells: 1) WD Repeat and FYVE 
domain containing 1 (WDFY1), a vesicle trafficking protein; 2) Lysosome-associated 
membrane protein 2 (LAMP2), a lysosomal membrane protein that functions as a 
downstream effector of WDFY1 and facilitates the fusion of autophagosomes to the late 
endosomes during autophagy. Additionally, the deletion of VEGF-C or NRP2 decreased 
autolysosomal turnover and thus inhibited autophagy trafficking in PC3 cells. Furthermore, 
the overexpression of VEGF-C in other prostate cancer cell lines (LNCaP C4-2B and LNCaP 
C4-2) that contain high levels of NRP2 enhanced autophagy and thus prevented cell death, 
whereas the overexpression of VEGF-C in VEGF-C-depleted PC3s increased cell survival. 
Interestingly, the depletion of VEGF-C or NRP2 in cancer cells after treatment with 
chemotherapy enhanced cell death compared to the untreated cells, suggesting that VEGF-C 
and NRP2 depletion in cancer cells could ameliorate the resistance to cancer treatment. 
Overall, this study showed that the upregulation of VEGF-C and NRP2 in prostate cancer 
cells reduce the expression of WDFY1 and LAMP2, which resulted in the activation of 
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autophagy and therefore enhanced cancer cell survival. These two studies indicated that 
VEGF-C-NRP2 can regulate both autophagic pathways and antiapoptotic pathways (Stanton, 
Dutta et al. 2012). Because VEGF-C-NRP2 was shown to induce autophagic and anti-
apoptotic signalling pathways, a follow-up longitudinal study analysed the prognostic effects 
of NRP2 and VEGF-C expression in 247 bladder cancer patients over a period of 15 years. 
When NRP2 was highly expressed, the cancer-specific survival (CSS) rate dropped from 166 
months to 85 months. When VEGF-C was highly expressed, the CSS rate dropped from 170 
months to 88 months, suggesting that NRP2 alone or in combination with VEGF-C 
expression is a prognostic marker that can predict outcomes before transurethral resection 
(TURBT) and radio-chemotherapy (RCT). Their expression can also be used as a biomarker 
to predict the response to therapy for bladder cancer or other cancer types (Keck, Wach et al. 
2015). Another study provided a molecular mechanism by which NRP2 regulated WDFY1 
synthesis in prostate cancer. In this study, NRP2 knockdown did not alter the protein stability 
of WDFY1 in PC3 prostate cancer cells, but it did increase the transcriptional activity of 
WDFY1 as well as both mRNA and protein levels of WDFY1. Similar to the NRP2 
knockdown effect, the deletion of foetal ALZ50-reactive clone 1 (FAC1), a transcriptional 
repressor protein that presents in the cytosol and in the nucleus of PC3 cells, also increased 
the mRNA level of WDFY1. Interestingly, NRP2 knockdown shifts the localisation of FAC1 
from the nucleus to the cytosol and thus reduces the recruitment of FAC1 to bind and supress 
WDFY1 transcription in the nucleus, which results in the continual transcription of WDFY1, 
indicating that NRP2 inhibits the transcription of WDFY1 by controlling the subcellular 
localisation of FAC1 repressor protein (Dutta, Roy et al. 2016). Another study identified a 
correlation between the elevation of NRP2 expression in aggressive prostate cancer cells, 
including PC3 cells, and the hindrance of the tumour suppressor protein phosphatase and 
tensin homolog (PTEN). The findings also revealed a novel molecular mechanism by which 
NRP2 suppresses PTEN function. These aggressive prostate cancer cells also exhibited high 
levels of VEGF protein, polycomb complex protein (Bmi-1), c-Jun N-terminal kinases 
(JNKs), and focal adhesion kinase (FAK) phosphorylation but downregulation of Insulin-like 
growth factor-1 receptor (IGF-1R). Silencing any of these proteins serves to rescue the IGF-
1R and BTEN expression, which then inhibits NRP2 expression as well as other molecules 
implicated in prostate cancer cells (Goel, Chang et al. 2012).  
NRP2 also has been implicated in many other cancers. For example, NRP2 is highly 
expressed in breast cancer, and its expression is correlated with aggressiveness (Yasuoka, 
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Kodama et al. 2009). In this study, the NRP2 immunostaining of breast cancer tissues showed 
that the NRP2 protein is expressed not only in the vascular ECs of cancer tissue but also in 
the cytoplasm of the cancer cells. This study showed that NRP2 expression tended to be co-
localised or adjacent to endogenous VEGF-C expression on cell surface, whereas the 
cytoplasmic NRP2 was co-localised to chemokine receptor 4 (CXCR4), which was 
previously shown to promote lymph node metastasis. Interestingly, anti-NRP2 antibody 
inhibited both cytoplasmic CXCR4 expression and CXCR4-endogenous VEGF-C-induced 
migration, suggesting that there is a correlation between NRP2-VEGF-C-CXCR4 expression 
in breast cancer (Yasuoka, Kodama et al. 2009). Another study correlated the upregulation of 
NRP2 levels in lung cancer with TGF-β-mediated epithelial mesenchymal transition (EMT), 
a process by which cells lose their cell–cell interaction allowing tumour cells to migrate and 
invade. Mechanistically, TGF-β induced NRP2 upregulation through activation of the zinc 
finger E-box-binding homeobox-1 (ZEB-1) transcription repressor, which inhibits SEMA-3F 
and downregulates E-cadherin. Consequently, this caused tumour progression, migration and 
invasion through activating the downstream signalling of TGFR-β, including the ERK and 
Akt pathways. Interestingly, blocking the canonical TGF-β signalling (e.g. SNAIL protein) 
by mothers against decapentaplegic homolog 7 (Smad7) antagonist did not change NRP2 
expression at the protein or mRNA levels, while inhibiting non-canonical TGF-β signalling 
(e.g. ERK or Akt) by U0126 or MKK-2206 inhibitors, respectively, reduced NRP2 levels, 
indicating that NRP2 upregulation in lung cancers is mediated by non-canonical TGF-β 
signalling (Nasarre, Gemmill et al. 2013). A similar mechanism was also observed in 
hepatocellular carcinoma (HCC), in which NRP2 upregulation in HCC enhanced both cell 
migration and invasion, whereas NRP2 knockdown reduced cell migration and invasion, but 
not proliferation. However, this study showed that NRP2 is upregulated in the HCC that 
undergo EMT induced by the canonical Smad2/3-Smad4 signalling cascade, indicating that 
TGF-β induces NRP2 expression in a Smad-dependent fashion. The authors concluded that 
NRP2 could be used as a biomarker for cancer progression in patients with HCC (Wittmann, 
Grubinger et al. 2015). Furthermore, NRP2 was also overexpressed in a human pancreatic 
adenocarcinoma cell line. The depletion of NRP2 in these cells reduced VEGFR1 
phosphorylation as well as Akt phosphorylation, indicating that NRP2 knockdown inhibited 
the survival signalling pathway. Additionally, NRP2 knockdown also reduced pancreatic 
cancer cell migration and invasion in vitro, but not proliferation. However, in a cross-
sectional analysis, an in vivo study showed that NRP2 depletion significantly reduced the 
number of proliferative nuclei evaluated by cell nuclear staining and smaller blood vessels. 
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Interestingly, this study also showed that NRP2 depletion decreased tumour volume and 
altered the tumour vasculature. To further understand the effects observed in the development 
of tumour vasculature, the study investigated the protein level of several angiogenic 
mediators, including VEGF, VEGF-C, DLL4 and Jagged-1. Only Jagged-1, a cell surface 
protein that functions in Notch signalling to control tip cell selection, was significantly 
reduced by NRP2 knockdown. The overall findings of this study suggested that NRP2 
expression may serve as a therapeutic target for pancreatic cancer (Dallas, Gray et al. 2008). 
As in pancreatic cancer, NRP2 is also overexpressed in human colorectal tumours. NRP2 
depletion also resulted in reductions in VEGFR1 phosphorylation, Akt phosphorylation, 
invasiveness and tumour volume, but not proliferation. In addition, NRP2 knockdown 
resulted in less metastasis and increased apoptosis compared to the control cells. The overall 
findings of this study suggested that NRP2 expression may serve as a potential therapeutic 
target for colorectal cancer (Gray, Van Buren et al. 2008). Recently, another study 
demonstrated that NRP2 overexpression acts as a mediator in VEGF-C/VEGFR3 activation 
to promote aggressive oral squamous cell carcinoma (OSCC) (Ong, Gokavarapu et al. 2017). 
The immunofluorescence experiments performed in this study revealed that NRP2 was co-
localised with VEGF-C expression and that it was associated with regional lymph node 
metastasis, whereas Sema-3F was not detected in these cancer cells. Interestingly, the NRP2 
knockdown reduced cell proliferation, migration and invasion, whereas the overexpression of 
VEGFR3 with VEGF-C supplementation did not ‘rescue’ these cellular behaviours when 
NRP2 was depleted, indicating that NRP2 overexpression plays a central role in aggressive 
cellular biological behaviour and tumour progression. In this study, it was also concluded that 
the overexpression of NRP2 may be used as a biomarker for predicting lymph node regional 
metastasis in patients with OSCC (Ong, Gokavarapu et al. 2017). 
Because NRP1 was shown to interact with integrins (Fukasawa, Matsushita et al. 2007), 
(Valdembri, Caswell et al. 2009), (Robinson, Reynolds et al. 2009) another group of studies 
demonstrated that NRP2 can also play a role in cancer through its interaction with integrins. 
For example, in line with previous studies showing that the NRP2 (Yasuoka, Kodama et al. 
2009) and α6β1 integrin (Friedrichs, Ruiz et al. 1995), (Wewer, Shaw et al. 1997) are 
implicated in aggressive breast cancer, a subsequent study also found that aggressive breast 
cancers express high levels of both NRP2 and α6β1 integrin. This study led to the discovery 
of a potential mechanism whereby NRP2 regulates α6β1 signalling to promote the association 
of α6β1 with laminin  allowing for the formation of stable adhesions required for breast 
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cancer cells to spread (Goel, Pursell et al. 2012). Via co-immunoprecipitation experiments, 
this study revealed a biochemical interaction between NRP2 and α6-integrin subunit 
(ITGA6). Furthermore, immunofluorescence microscopy substantiated the co-localisation of 
the two proteins in FAs, specifically with active FAK at the leading edge on laminin 
containing matrices. Interestingly, the adhesion of the breast cancer cells on laminin was 
reduced by NRP2-siRNA depletion or by blocking ITGA6 function with the anti-ITGA6 
antibody. These findings indicate that these two proteins are important in the adhesion of 
breast cancer cells on laminin. Additionally, the separate depletion of endogenous VEGF or 
NRP2 expression reduced FAK activation. The stimulation of VEGF165-depleted cells by 
exogenous VEGF in the presence of NRP2 restored FAK activation, which led to the 
conclusion that NRP2-VEGF165 signalling is necessary for α6β1 to activate FAK and that this 
activation is crucial for promoting robust FA formations at the leading edge of cells migrating 
on laminin (Goel, Pursell et al. 2012). NRP2 expression is also high in human renal cancer 
cell carcinoma (RCC) and pancreatic adenocarcinoma and its level of expression correlates 
with cancer progression (Cao, Hoeppner et al. 2013). This study revealed a unique 
mechanism through which NRP2 highly expressed on these cancer cells binds with α5-
integrin subunit (ITGA5) expressed on the surface of ECs (in trans binding fashion) to 
promote vascular adhesion, extravasation and tumour metastasis (Cao, Hoeppner et al. 2013). 
Unlike NRP1 (Cao, Wang et al. 2008), NRP2 knockdown did not affect primary tumour 
growth (Cao, Hoeppner et al. 2013). However, metastatic nodules in the lung were much 
fewer in mice subcutaneously injected with shRNA directed against NRP2, compared to mice 
in the control group. Additionally, NRP2 expression at the metastatic site was much greater 
than in the primary tumour. Interestingly, RCCs or pancreatic adenocarcinoma cells injected 
into the pericardium of zebrafish embryos extravasated in the extravascular space (adjacent 
tissues), whereas NRP2-depleted cancer cells remained in the intersegment vessels, indicating 
that NRP2 plays a central role in tumour cell extravasation (Cao, Hoeppner et al. 2013). The 
author showed that NRP-2 blocking antibody impaired cancer cell adhesion to a monolayer 
of ECs. This suggests that NRP2 expressed on cancer cells mediates adhesion through a 
NRP2 trans-interacting partner that is expressed on ECs. Interestingly, NRP2 co-
immunoprecipitation in a co-culture of cancer cells and ECs showed a biochemical 
interaction between NRP2 and the ITGA5 integrin subunit. The pre-treatment of cancer cells 
with function-blocking anti-ITGA5 did not inhibit their adhesion to ECs; whereas the pre-
treatment of ECs with anti-ITGA5 antibody significantly reduced cancer cell adhesion to 
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ECs, suggesting that ITGA5 is a trans-binding partner for NRP-2 to promote vascular 
adhesion, extravasation and metastasis (Cao, Hoeppner et al. 2013).   
1.2.3.2. Integrins 
Integrins were first characterised in 1986 as transmembrane glycoproteins that integrate the 
extracellular matrix with the actin cytoskeleton (Tamkun, DeSimone et al. 1986). Subsequent 
studies discovered that integrins are heterodimeric type I transmembrane glycoprotein 
receptors composed of non-covalent associations between α and β subunits. They function as 
cell adhesion molecules as well as connecting the intracellular environment with the 
extracellular environment. In the 30 years since their first characterisation, thousands of 
integrin studies have been published (Hynes 2002); studies which have defined their essential 
roles in embryonic development (Bouvard, Brakebusch et al. 2001) and increased our 
understanding of how different subunits of these receptors associate in different tissues, how 
they transduce adhesion-mediated signalling events, and how they regulate cellular behaviour 
in both physiological and pathological conditions (Bökel and Brown 2002). Integrins are 
expressed in metazoans, including sponges, cnidarians and mammals (Burke 1999). In 
mammals, at least 18 α and 8 β subunits are associated in 24 different heterodimer receptors, 
in which 12 integrins contain the β1 subunit, five integrins contain the αv subunit, and four 
integrins contain the β2 subunit, which are restricted to white blood cells (Figure 1.12 A-B) 
(Hynes 2002). The assembly of these distinct 24 hetero-dimerisations occur within the 
endoplasmic reticulum in an inactive conformation and then undergo post-translation 
modifications in the Golgi apparatus before they are targeted to the plasma membrane where 
they perform their myriad functions (Paul, Jacquemet et al. 2015). Integrins sense ECM and 
change cell behaviour accordingly (Goel and Mercurio 2012). A characteristic of integrins is 
that they can transduce signalling across the plasma membrane in both directions, either 
inside-out signals or outside-in signals. Therefore, integrins play essential roles in several 
cellular processes, including cell adhesion, proliferation, migration, differentiation, survival, 
apoptosis and shape in certain types of cells (Srichai and Zent 2010), (Pan, Zhao et al. 2016). 
Integrins also promote ECM protein assembly, cytoskeleton organisation and angiogenesis 
(Bökel and Brown 2002). For example, integrins may be found in the following locations: in 
the vascular system, depending on the anatomical origin of vessels; on the abluminal cell 
membranes of ECs in the BM, where they recognise ligands such ECM proteins; on the cell 
membranes of circulating blood cells, where they recognise cell adhesion ligands, including 
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intercellular adhesion molecule 1 (ICAM 1) and vascular cell adhesion molecule 1 (VCAM 
1). Integrins are also involved in guiding circulating blood cells into inflamed tissues by 
subsequent adhesion and transmigration (Plow, Meller et al. 2014). During angiogenesis, 
integrins bind to other transmembrane receptors, including VEGFRs and NRPs, to alter cell 
behaviour (Goel and Mercurio 2012), (Seguin, Desgrosellier et al. 2015).  
1.2.3.2.1. Integrin structure and ligands 
Each integrin is built by the non-covalent association between α-β subunits, each of which is 
composed of: 1) a large extracellular domain ranging between ~80–150 kDa that is divided 
into several subdomains, including the N-terminus (headpiece), which is required for 
extracellular ligand binding and a tailpiece, which function as knee for bending/extension 
(Figure 1.13 A); 2) a single membrane-spanning coiled-coil α helix of ~25–29 amino acids 
which allows for bi-directional signal transmission; 3) a short cytoplasmic tail domain of 
about ~30 to 70 amino acids (with the exception of β4 subunit >1000 amino acids) which acts 
to transmit or receive intracellular signals (see Figure 1.13 A) (Srichai and Zent 2010), 
(Campbell and Humphries 2011), (Pan, Zhao et al. 2016). The cytoplasmic tail of the α 
subunit is generally shorter than the β subunit (Pan, Zhao et al. 2016). The cytoplasmic tails 
of β subunits are similar, whereas the cytoplasmic tails of α subunits are diverse (Srichai and 
Zent 2010). All mammalian cells express integrins. For example, ECs express at least 11 
different integrins (α1β1, α 2β1, α3β1, α4β1, α5β1, α6β1, αvβ1, αvβ3, αvβ5, αvβ8, and 
α6b4), whereas platelets express five integrins (αIIβ3, αvβ3, α2β1, α5β1, and α6β1). Mature 
erythrocytes express very few or no integrins, however their precursor erythroblastoid 
proerythroblast cells do (Plow, Meller et al. 2014).  
Unlike VEGFRs and other growth factor receptors, the cytoplasmic tails of integrin subunits 
lack enzymatic and kinase activity. Instead, they effectively transduce signalling by co-
clustering with protein kinases (e.g. FAK) and adaptor proteins (e.g. tailin, vinculin and 
paxillin) in FA complexes. The extracellular regions of integrins have the ability to bind to a 
wide variety of ligands, including ECM deposition proteins (Srichai and Zent 2010) and cell 
surface adhesion molecules (Hynes 2002), (Campbell and Humphries 2011). The 
extracellular regions of integrins undergo conformational changes to transduce signalling or 
initiate apoptosis (Avraamides, Garmy-Susini et al. 2008). Typically, when a heterodimeric 
ligated integrin exists in an upright and unbent conformation upon ligand binding (active 
state), the transmembrane and cytoplasmic tails are separated between the α-β subunits, and 
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the kinases and adaptor proteins are bound to the cytoplasmic tails, allowing the integrins to 
cluster in transducing signalling pathways. However, when the binding to ligands is lost, 
integrins undergo conformational changes that lead to a close association between the 
transmembrane and the cytoplasmic tails of α-β subunits. Then bending of the extracellular 
regions occurs (in an inactive state), allowing the integrins to initiate apoptosis (Figure 1.13 
B). (Srichai and Zent 2010), (Nevo 2011). 
The number of ligands that are recognised by integrins is extensive, and it depends on the 
different combinations of α-β subunits. For example, integrins can bind to ECM proteins, 
including FN, laminin, collagen and other receptor proteins (Srichai and Zent 2010). Some 
integrins can only bind to a single ligand, such as α5β1, whereas others can bind to multiple 
ligands, such as αvβ3. Many integrins bind to specific sequences presented in the ligands 
(Avraamides, Garmy-Susini et al. 2008). These short peptide sequences can be classified into 
four major types: arginine-glycine-aspartic acid tripeptide (RGD) motif-binding integrins, 
leucine-aspartic acid-valine (LDV) motif-binding integrins, αI-domain containing-integrins, 
and non-αI-domain-containing laminin-binding integrins (Humphries, Byron et al. 2006). For 
example, all five αv integrins (αvβ1, αvβ3, αvβ5, αvβ8, αvb4), two β1 integrins (α5β1, α8β1) 
and αIIβ3 can recognise ligands containing the RGD motif. All β2 integrins (αLβ2, αDβ2, 
αMβ2, αXβ2 as well as α4β1, α4β7, α9β1, αEβ7) can recognise ligands containing the LDV 
motif. Regarding the αI-domain, β1 subunit heterodimers or combine with some α subunits 
that possess the αI-domain to form integrins for laminin/collagen binding (α1β1, α2β1, 
α10β1, α11β1), whereas other integrins lack the αI-domain but have highly selective binding 
to laminin (α3β1, α6β1, α7β1, α6β4) (see Figure 1.12 A-B) (Humphries, Byron et al. 2006). 
Previous studies have also shown that integrins function as receptors for the internalisation of 
bacteria and viruses (Triantafilou and Triantafilou 2001), (Hoffmann, Ohlsen et al. 2011), 
(Hussein, Walker et al. 2015).  
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A) 
 
B) 
 
Figure 1.12 The integrin subfamilies and their ligands. A) The schematic illustration shows 24 α-β forms of integrins 
based on their ligand specificity. Note that only 9 of 18 α subunits contain the αI-domain, such as those in collagen and 
leukocyte receptors, whereas none of the RGD and laminin receptors contain the αI-domain (Nevo 2011). B) The schematic 
illustration shows integrins recognising different short peptide sequences (see the integrins in the key on the right) as well as 
how the multivalent ligands recognise and cluster different integrins (Humphries, Byron et al. 2006).  
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A)  
 
B) 
 
Figure 1.13 Integrin structure and conformational changes to integrin α-β subunits during activation. A) Integrins are 
built of associations between different α-β subunits. Each subunit consists of a large extracellular region, which can be 
divided into a headpiece and a tail piece, a transmembrane helical region and the intracellular domain. Generally, the 
cytoplasmic domain of the β subunit is longer than α subunit. Note that not all α subunits have the αI domain. B) The 
schematic illustration shows the three conformational changes that α-β subunits undergo during integrin activation: closed 
headpiece/bent (inactive); closed headpiece/extended (inactive); and open headpiece/extended (active). It is worth noting 
that the activated integrin requires the clustering of integrins as well as intracellular adaptor proteins to transmit signals (not 
illustrated here). Adapted from (Nevo 2011). 
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1.2.3.2.2. Integrin activation  
Integrins promote cell adhesion, angiogenesis, tumour growth and metastasis by sensing, 
integrating and interspersing outside-in and inside-out signalling between cells and their 
environments (Jia, Choi et al. 2018). Integrin activation occurs through two major regulation 
processes: affinity and avidity. The affinity process involves the conformational changes to 
an individual integrin, which can be further divided into two states: inactive “bent state” and 
the primed “extended or upright state”. In the bent state, the extracellular headpiece of an 
individual integrin points to the plasma membrane with a closed headpiece, and the integrin 
is unable to bind to the extracellular ligands because of the close association between α-β 
subunits (see Figure 1.13 B) (Nevo 2011). It is worth noting, however, that there is some 
evidence that integrins can bind to matrix even when they are in a bent state (e.g. on FN) 
(Adair, Xiong et al. 2005). In the primed state, the headpiece swings away from the plasma 
membrane, which is referred to as a “switchblade motion” and the headpiece is still closed 
with a close association between the α-β subunits, but the headpiece is able to bind to 
extracellular ligands. In contrast, the avidity process involves the disassociation between α-β 
subunits after the clustering interaction of the integrins and other cell surface transmembrane 
receptors. In the affinity process, the α-β subunits are closely associated, whereas in the 
avidity process, the α-β subunits are dissociated (Nevo 2011), (Plow, Meller et al. 2014), (Li 
and Springer 2017). Bi-directionality means that signalling that is generated by the ligands 
binding to the extracellular domain of integrins is transmitted to the intracellular space to 
influence the organisation of the actin cytoskeleton (outside-in signalling) while signalling 
that is generated by binding of the intracellular proteins to the cytoplasmic tails of integrins is 
transmitted to the extracellular environment to influence the interaction of the extracellular 
domain with the ligands (inside-out signalling) (Hu and Luo 2013). As a result of integrin 
activation and depending on the stage of maturation of the integrin, subcellular distribution 
and ECM composition, different types of adhesion complexes can form in the migrated cells: 
nascent adhesions, focal complexes, focal adhesions (FAs) and fibrillar adhesions (Figure 
1.14) (Paul, Jacquemet et al. 2015), (De Pascalis and Etienne-Manneville 2017). 
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Figure 1.14 Anatomical section of a migrating cell adhered to a 2D ECM. Cell migration requires the coordination of a 
complex integrated process involving the integrins, signalling/adapting molecules and actin-binding proteins, which are 
activated temporally and spatially at different locations in the cell to achieve the correct balance in the assembly and 
disassembly of adhesions during cell migration. These adhesions are classified into four groups: nascent adhesion, focal 
complex, focal adhesion and fibrillar adhesion based on the morphology or the way they are formed (Webb, Parsons et al. 
2002). Generally, after a cell defines its polarity, polymerisation of actin then occurs by adding new G-actin to the pre-
existing actin filaments at the leading edge, where the retrograde flow is rapid, of lamellipodium, which results in the 
generation of several protrusions (filopodia). Small adhesions, called nascent adhesions, are initiated through the binding of 
integrins on the cell surface to their ECM ligands at the cell periphery. These small nascent adhesions either disappear within 
60 s or grow in size to 1 µm to form a focal complex at the boundary between the lamellipodium and lamellum. They then 
increase up to 10 µm in mature focal adhesions in the lamellum region, where the retrograde flow and the turnover is slower 
than in nascent adhesions (up to a 20-minutes half-life). At the lamellum, the accumulation of stable focal adhesions 
increases, acting as handgrips to tether the cell front. These focal adhesions are rich in integrins that connect the ECM to the 
actin filaments mediated by intracellular adaptor molecules (e.g. paxillin, tailin, vinculin etc.). At the rear of the cell, the 
interaction of integrins with their ECM ligands via the adapting molecules becomes weak because the elevation of integrin 
turnover. This is resulting in the sliding of these focal adhesions toward the cell body until they disperse and eventually 
move the cell tail forward. Regarding a migrated cell on FN, α5β1 can drive the formation of very long stable fibrillary 
adhesion (longer than 10 µm) (Small, Rottner et al. 1998), (Webb, Parsons et al. 2002), (Li, Guan et al. 2005), (Valdembri 
and Serini 2012), (De Pascalis and Etienne-Manneville 2017). Adapted from (Valdembri and Serini 2012), (De Pascalis and 
Etienne-Manneville 2017). 
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1.2.3.2.2.1. Outside-in signalling 
The outside-in signalling of integrins is similar to the classical activation of growth factor 
receptors by their growth factors, in which the receptors on the plasma membrane transmit 
the extracellular signals into the intracellular space through activating a wide array of 
intracellular signalling pathways. In fact, integrins require the interaction with growth factor 
receptors to enhance signal transduction (Menter and DuBois 2012). Typically, outside-in 
integrin signalling begins when ligands (ECM proteins in the case of basal surfaces or ICAM-
1/VECAM in the case of freely circulating cells) bind to the extracellular domain of integrins 
at the intersection between α-β subunits. Here, the Iα and Iβ subdomains in the headpiece of 
both subunits become involved in the ligand binding process (Plow, Meller et al. 2014). 
However, in α subunits without Iα, the β propeller of the α subunit takes over and triggers the 
conformational changes in the extracellular domains to transform from the bent conformation 
to the upright active state (see Figure 1.13 A-B) (Srichai and Zent 2010). Subsequently, 
ligand–integrin interactions trigger separations between α-β subunits in the membrane-
spanning helix and cytoplasmic tail regions. These conformational changes result in 
clustering of more integrin binding at the integrin adhesion sites and activation of the 
cytoplasmic tails of integrins. Over 150 different intracellular accessory proteins are recruited 
to the cytoplasm tail in order to assemble the small nascent adhesions that may disassemble 
or mature into bigger FAs complex. These FA complexes connect integrins to the 
cytoskeletal actin and mediate the mechanical force needed to transmit the extracellular 
signals and activate multiple intracellular pathways “outside-in”, including proliferation, 
migration, differentiation and survival (Srichai and Zent 2010), (Nevo 2011).  
Three different classes of accessory adaptor proteins are found in FA complexes: 1) structural 
or scaffolding adaptors (e.g. talin, kindlin, filamin and tensin) that bind to F-actin and thus 
link integrin directly to the actin cytoskeleton; 2) catalytic adaptors (e.g. FAK, integrin linked 
kinase [ILK] and Src family kinase [Src]), which substitute for the lack of catalytic activity in 
the integrin cytoplasmic tail; 3) protein phosphatase 2A (PP2A), which propagates the 
transduced signals (Legate and Fässler 2009), (Nevo 2011). Briefly, when the cytoplasmic 
tails of the activated integrins are separated, FAK, a major non-tyrosine receptor kinase 
protein, undergoes phosphorylation at its tyrosine 397, and then it binds directly to the 
cytoplasmic tails of integrins or indirectly through the talin adaptor proteins (Figure 1.15 A). 
FAK contains the FERM domain (F for 4.1 protein, E for ezrin, R for radixin and M for 
moesin) at the N-terminus, and the focal adhesion targeting domain (FAT) at the C-terminal, 
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which functions to localise other intracellular adaptor proteins to FAs. The activated FAK 
then phosphorylates paxillin at tyrosines 31 and 118 which creates binding sites for other 
adaptor proteins, including Src. Phosphorylated paxillin regulates actin contraction by 
activating Rho GTPase protein. Phosphorylated Src interacts with scaffold proteins, such as  
p130 CRK-associated substrate (p130Cas), to enhance the FAK-Src complex. Furthermore, 
phosphorylated FAK transduces extracellular signalling and regulates actin polymerisation 
and organisation (see Figure 1.15 A) (Menter and DuBois 2012).  
1.2.3.2.2.2. Inside-out signalling 
In this type of signalling, integrins are activated by binding the intracellular adaptor proteins 
to the cytoplasmic tail, which drives both the affinity and avidity regulation processes. These 
conformational changes guide the integrin headpiece to open, which then interacts with 
extracellular environmental ligands. Large numbers of intracellular signalling proteins 
participate indirectly in inside-out signalling while others directly bind to the cytoplasmic 
tails of integrins, including α-actinin, talin, filamin, paxillin, kindlin and tensin. However, 
talin and kindlin are thought to be the most important adaptor proteins in α-β subunit 
separation and the subsequent integrin activation (Moser, Nieswandt et al. 2008), (Hu and 
Luo 2013), (Campbell and Humphries 2011), (Pan, Zhao et al. 2016). Typically, talin binds to 
the membrane-proximal NpxY motif of β subunits, whereas kindlin binds to the distal 
membrane motif NxxY (Srichai and Zent 2010). The N-terminus of talin possesses a FERM 
domain, which contains three subdomains (F1, F2, F3) that are essential in integrin 
cytoplasmic tail binding, while its C-terminus has additional binding sites for the adaptor 
protein vinculin and additional cytoplasmic tail binding proteins. F3, which resembles a 
phosphotyrosine binding (PTB) domain, is the subdomain through which talin binds to the 
proximal NpxY motif of integrin β subunit (Campbell and Humphries 2011), (Menter and 
DuBois 2012). Other adaptor proteins can also bind to the NpxY motif, such as tensin and 
docking protein 1 (Dok1). However, only talin promotes the disassociation between α-β 
subunits (Srichai and Zent 2010). Talin is present in the cytoplasm in an inactive state. Its 
activation involves PIP2, a phospholipid component of the cell membrane, which disrupts the 
interaction between the head domain and tail rod domains of talin. It thus exposes the FERM 
domain and its subdomains to allow talin to recognise and bind to the proximal NpxY 
sequence of integrin β subunits (Goksoy, Ma et al. 2008), (Nevo 2011). G protein-coupled 
receptors (GPCRs), such as protease-activated receptors-1 (PAR-1), are involved also in the 
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agonist-induced activation of integrins (Figure 1.15 B). Mechanistically, integrin activation 
begins following stimulation of GPCRs, which results in increased cytosolic levels of Ca
2+
. 
This is followed by recruitment of guanine nucleotide-exchange factors (GEF) combined 
with Ras-proximate-1/Ras-related-protein-1- (Rap1-) GTPase to the GPCRs. Subsequently, 
Rap1 activates the Rap1-GTP-interacting adaptor molecule (RIAM), which recruits talin to 
the cytoplasmic tail of integrins (Menter and DuBois 2012) (Plow, Meller et al. 2014) (see 
Figure 1.15 B). There is evidence that vinculin has a binding site for RIAM, and the 
vinculin-RIAM complex binds to talin to promote integrin activation (Goult, Zacharchenko et 
al. 2013). Similar to talin, kindlin has a FERM domain, and its expression is essential for 
stabilising the activation state of the integrin cytoplasmic tail. The expression of kindlin or 
talin alone is insufficient to drive the separation of α-β subunits and subsequent integrin 
activation (Srichai and Zent 2010), indicating that both adaptor proteins are required for the 
activation of integrins. 
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A) 
 
 
B) 
 
Figure 1.15 The bi-directional signalling of integrins. The schematic illustration shows A) outside-in signalling and B) 
inside-out signalling (See text). Note that both types of signalling require the clustering of integrins and other 
transmembrane receptors (not shown) (Menter and DuBois 2012). 
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1.2.3.2.2.3. Cross talk between integrin and growth factor receptors to 
control downstream signalling pathways during outside-in signalling 
Integrin signalling involves more than transmitting signals bi-directionally to adhere cells to 
extracellular ligands and connect the extracellular environment to the actin cytoskeleton. 
Integrins also cluster with growth factor receptors, including VEGFRs, fibroblast growth 
factor receptor 1 (FGFR1) and transforming growth factor receptor-β (TGFR-β), to activate 
complicated downstream signalling pathways that elicit complex cellular responses, such as 
proliferation, survival and migration (Soldi, Mitola et al. 1999), (Eliceiri 2001), (Reynolds, 
Wyder et al. 2002), (Masson-Gadais, Houle et al. 2003), (Mahabeleshwar, Feng et al. 2006), 
(Mahabeleshwar, Feng et al. 2007) (Strieth, Eichhorn et al. 2006), (Robinson, Reynolds et al. 
2009), (Valdembri, Caswell et al. 2009), (Somanath, Ciocea et al. 2009), (Srichai and Zent 
2010), (Ellison, Atkinson et al. 2015), (Jia, Choi et al. 2018) (Figure 1.16). One of the best-
known examples of cross talk between growth factor receptors and integrins is shown by 
VEGFR2 and αvβ3 integrins (Mahabeleshwar, Feng et al. 2007), (Ravelli, Mitola et al. 2013) 
(Plow, Meller et al. 2014). An early study in this field showed that an antibody directed 
against ITGB3 reduced VEGFR2 phosphorylation induced by VEGF165 in human ECs. This 
direct interaction between ITGB3-VEGFR2 was confirmed by the results of a biochemical 
immunoprecipitation experiment (Soldi, Mitola et al. 1999). Moreover, the anti-ITGB3 
antibody and the anti-VEGFR2 antibody had the same effect of reducing PI-3 kinase 
phosphorylation, an early downstream kinase protein of VEGF-VEGFR2 pathway (see 
Figure 1.16) (Dellinger and Brekken 2011), when cells were VEGF165-stimulated (Soldi, 
Mitola et al. 1999). Furthermore, the anti-ITGB3 antibody significantly reduced EC 
migration and proliferation induced by VEGF165, indicating that the VEGF165-ITGB3-
VEGFR2 complex regulates the downstream signalling required for the biological activities 
in ECs (Soldi, Mitola et al. 1999). A subsequent study demonstrated that the VEGF165-
induced stimulation of HUVECs enhanced the interaction between VEGFR2 and ITGB3 of 
αvβ3, but not αvβ5, αIIbβ3, or αvβ1, integrins and that this cross talk is required for the full 
phosphorylation of VEGFR2, in order to transduce the intracellular signalling pathways 
essential for the adhesion and migration of HUVECs. At the molecular level, this study found 
that the addition of VEGF165 to HUVECs also increased the phosphorylation of two 
downstream signal proteins: stress-activated protein kinase-2/p38 (SAPK2/p38) and FAK. 
Anti-VEGFR2 or anti-ITGB3 inhibited the phosphorylation of both proteins, indicating that 
the VEGF-induced phosphorylation of SAPK2/p38 and FAK requires a synergistic complex 
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interaction between VEGFR2 and αvβ3 (Masson-Gadais, Houle et al. 2003). The biological 
functions and interactions between ITGB3 and VEGFR2 will be discussed in detail in the 
next section. Other studies demonstrated the complex association between αvβ3 and another 
TKR, PDGFR-β and this complex formation is dependent on growth factor stimulation of the 
receptors (Schneller, Vuori et al. 1997), (Woodard, García-Cardeña et al. 1998). In line with 
these previous studies, another study showed that ITGB3, but not ITGB1 or ITGB5, formed a 
complex with VEGFR2 only in the presence of ITGAV, while PDGFR-β did not require 
ITGAV to be co-immunoprecipitated with ITGB3 (Borges, Jan et al. 2000). In contrast to 
previous studies, this study also demonstrated that associations between ITGB3 and VEGFR2 
or PDGFR-β are independent of growth factor stimulation and the phosphorylation of these 
TKRs (Borges, Jan et al. 2000). The binding of fibroblast growth factors-1 (FGF-1) to their 
receptors results in GRB2-SOS complex formation, which activates the Ras/ERK/MERK 
pathway (LaVallee, Prudovsky et al. 1998), (Kwabi-Addo, Ozen et al. 2004) (see Figure 
1.16). Another studys demonstrated the direct interaction between αvβ3 integrins and 
FGFR1. The study showed that compared to control cells, αvβ3-binding to defective FGF 
mutant cells reduced cell proliferation and migration, suggesting that the αvβ3-FGF1 
complex is critical in the late FGF signalling pathway (Mori, Wu et al. 2008), (Yamaji, 
Saegusa et al. 2010). 
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Figure 1.16 Downstream signalling of clustered integrin. The schematic illustration shows the contribution of the 
clustered integrins to transmitting extracellular signals by first recruiting FA complex formation, which promotes actin 
cytoskeleton assembly and activates the downstream signalling pathways essential for cell proliferation, survival and 
migration through cross-talking with growth factor receptors (Srichai and Zent 2010).  
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1.2.3.2.3. Integrins in angiogenesis 
Clustered integrins (see Figure 1.16) can cross talk with VEGFRs and their NRP co-
receptors to transmit VEGF signals and regulate the biological functions of ECs during 
angiogenesis. There is also strong evidence that integrins, through interactions to their ECM 
ligands, are essential angiogenic players in the development of blood vessels during 
embryonic and adult tissue neo-vascularisation and pathological angiogenesis (Serini, 
Valdembri et al. 2006). Integrin expression modulates angiogenic processes in many cell 
types, including, ECs, perivascular cells (pericytes and vSMCs), fibroblasts and bone 
marrow-derived dendritic cells (BMDCs) (Desgrosellier and Cheresh 2010). Several previous 
studies were in agreement that ECs express α1β1, α2β1, α5β1, αvβ3, αvβ5, α6β1 and α6β4, 
and others found that ECs also express α3β1, α4β1, αvβ1, αvβ8, α8β1 and α9β1. (Rüegg and 
Mariotti 2003), (Hodivala-Dilke, Reynolds et al. 2003), (Serini, Valdembri et al. 2006), 
(Zovein, Luque et al. 2010), (Carmeliet and Jain 2011). All these integrins have been 
implicated in angiogenesis. The embryonic vascular phenotypes generated from gene deletion 
in each subunit are summarised in Table 1.1 (Rüegg and Mariotti 2003), (Alghisi and Rüegg 
2006), (Desgrosellier and Cheresh 2010). The major integrins in ECs are αvβ3, α5β1, αvβ5 
and α6β4 (Somanath, Ciocea et al. 2009). For the purpose of this thesis, we will focus on the 
function of the two major endothelial FN receptors αvβ3 and α5β1 (van der Flier, Badu-
Nkansah et al. 2010) and their cooperative interaction with VEGFR2 and NRPs.  
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Table 1.1: Vascular Integrins in Angiogenesis  
Integrin Major ECM 
ligands 
Gene 
deletion 
Vascular phenotype in mice with constitutive gene deletion 
α1β1 CO, LM α1 No defects in vascular development + reduced tumour angiogenesis 
α2β1 CO, LM α2 Defects in vascular development 
α3β1 LM, TSP α3 Perinatal lethality because of defects in kidney, lung, skin but no vascular 
defects 
α4β1 FN α4 Lethal at E11–14 because of placental fusion defect and coronary arteries 
defect 
α5β1 FN, fibrin α5 Lethal at E10 vasculogenesis but no maturation/angiogenesis 
α6β1 LM, CCN1 α6 Lethal at birth but no defects in vascular development 
α8β1 FN, TN-C α8 Partial embryonic lethality but no defects in vascular development 
α9β1 TN-C α9 Lethal at birth because of defects in large lymphatic vessels 
αvβ1 FN, VN β1 Lethal at E5.5 because of the failure to organise the embryonic inner mass 
 
 
αvβ3 
 
FN, VN, LM, FB, 
Fibrin, TSP, TN-
C, vWF, dCO, 
OPN, MMP-2, 
Del-1, BSP, FGF-
2, thrombin, 
CCN1 
 
 
β3 
 
 
No defects in vascular development + enhanced postnatal angiogenesis 
 
αvβ5 VN, Del-1, 
CCN1 
β5 No defects in vascular development 
Enhanced postnatal angiogenesis 
α6β4 LM β4 Lethal at birth but no vascular defects in development 
 
αvβ8 
 
VN 
β8 Lethal at E12—perinatal vascular defects in the placenta and brain 
αv Lethal at E12—perinatal because of vascular defects in the placenta, brain, 
and intestine 
Note. ECs express at least 13 different integrins. Vascular phenotypes are reviewed in (Alghisi and Rüegg 2006). 
Abbreviations: CCN1, cysteine rich protein 61; CO, collagen; Del-1, developmental locus-1; LM, laminin; VN, vitronectin; 
TNC, tenascin-C; TSP, thrombospondin; EL, elastin; FN, fibronectin; OPN, osteopontin; FB, fibrinogen; vWF, von 
Willebrand factor; MMP, matrix metalloproteinase; dCO, denatured collagen; BSP, bone sialo protein. 
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1.2.3.2.3.1. αvβ3 integrin 
αvβ3 is a unique integrin that recognises a wide variety of ECM proteins, including 
vitronectin, FN, laminin, fibrinogin, fibrin, thrombospondin, tenascin-C, von Willebrand 
factor, denatured collagen, osteopontin, matrix metalloproteinase, developmental locus-1, 
bone sialo protein, thrombin, and cysteine rich protein 61. However, vitronectin is considered 
the canonical ECM ligand for αvβ3 (Avraamides, Garmy-Susini et al. 2008), 
(Mahabeleshwar, Chen et al. 2008). In ECs, the ITGAV subunit can pair with the β1, β3, β5 
and β8 subunits, whereas the ITGB3 subunit can only pair with the αv subunit, which means 
that the investigation of endothelial αvβ3 functions in ECs can be best acheived by 
manipulating the ITGB3 subunit (Hynes 2002) (see Figure 1.12 A).  
In ITGAV subunit-deficient mice, the formation of dorsal aortae, primary plexus 
(vasculogenesis) and capillary sprouting (angiogenesis) develop normally without any defects 
until E9.5; ~80% of the embryos die in uterus between E10.5 and E11.5 because of 
pericardial oedema, whereas the surviving embryos die immediately after birth because of 
intracerebral haemorrhage (Bader, Rayburn et al. 1998), (McCarty, Monahan-Earley et al. 
2002). The genetic deletion of Itgb3 did not inhibit angiogenesis and vascular development; 
instead, these knockout mice showed excessive angiogenesis, ostensibly attributed to 
increased EC expression of VEGFR2, which may occur developmentally to compensate for 
the loss of ITGB3 (Reynolds, Wyder et al. 2002), (Reynolds, Reynolds et al. 2004) 
(Mahabeleshwar, Feng et al. 2006), (Mahabeleshwar, Chen et al. 2008).  
In adult mice, αvβ3 expression is upregulated in sprouting capillaries during physiological 
conditions (e.g. wound healing and inflammation) and pathological conditions (e.g. tumours), 
whereas the expression of the integrin is barely detected in quiescent capillaries (Hodivala-
Dilke, Reynolds et al. 2003), (Somanath, Malinin et al. 2009), which indicates that αvβ3 
functions as a pro-angiogenic molecule (Somanath, Malinin et al. 2009). Therefore, αvβ3 
antagonists have been designed to inhibit angiogenesis (Miller, Keenan et al. 2000), (Posey, 
Khazaeli et al. 2001), (Wilder 2002), (Burke, DeNardo et al. 2002), (Marugán, Manthey et al. 
2005), (D'andrea, Del Gatto et al. 2006). For example, vitaxin, also known as LM609, was 
the first monoclonal antibody against αvβ3. Vitaxin functions by blocking ECM ligands from 
interacting with the RGD binding site on the integrin, thus blocking cell adhesion, migration 
and sprouting. Brooks et al. showed that Vitaxin induces apoptosis without affecting pre-
existing quiescent blood vessels in vitro, in in vivo chicken chorioallantoic membrane models 
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(CAM) assays (Brooks, Clark et al. 1994), (Brooks, Montgomery et al. 1994), and in a 
chimeric human/mouse model (Brooks, Strömblad et al. 1995). Vitaxin has entered phase II 
clinical trials for use in the treatment of several cancers and a recent study demonstrated that 
Vitaxin specifically binds to the αvβ3 headpiece region during all integrin conformational 
states, including the bent state. Interestingly, Vitaxin binding does not overlap with the RGD 
ligand-binding pocket, which makes it highly selective for αvβ3 (Borst, James et al. 2017). 
Cilengitide, also known as EMD121974, is a small cyclic peptide that shows highly selective 
inhibition of αvβ3 and αvβ5 binding to vitronectin (Dechantsreiter, Planker et al. 1999). It 
inhibits angiogenesis in in vivo animal models (MacDonald, Taga et al. 2001) as well as in in 
vitro bovine aortic endothelial (BAE) angiogenesis assays (Nisato, Tille et al. 2003). In phase 
I and II clinical trials, Cilengitide showed potential antitumor activity and improved survival 
in patients with glioblastoma. However, in a recent phase III clinical trial, it failed to improve 
overall patient survival when combined with the standard of care (temozolomide 
chemoradiotherapy). Hence, Cilengitide has not been developed further as an anticancer drug 
(Stupp, Hegi et al. 2014). Unexpectedly, Reynolds et al. found evidence in vitro and ex vivo 
experiments that low (nanomolar) concentrations of RGD-mimetic αvβ3 inhibitors, including 
Cilengitide, act as a pro-angiogenic molecule that can promote tumour growth and tumour 
angiogenesis. The results showed that Cilengitide enhanced VEGF-induced phosphorylation, 
internalisation, and the accumulation of VEGFR2 in vesicles at the EC periphery as well as 
the delivery of αvβ3 to FAs at the EC periphery, thereby promoting EC migration (Reynolds, 
Hart et al. 2009).  
1.2.3.2.3.1.1. αvβ3-VEGFR2 complex and NRP1 functions in ECs 
In addition to the studies discussed in the previous sections, which showed the ability of αvβ3 
to immunoprecipitate and cross talk with VEGFR2 to promote downstream signalling 
pathways essential for cellular biological behaviour (Soldi, Mitola et al. 1999), 
(Mahabeleshwar, Feng et al. 2007), (Dellinger and Brekken 2011), many other studies by 
numerous groups have shown that αvβ3 can act as a pro-angiogenic molecule through cross 
talk with VEGFR2. For example, a biochemical interaction was found between ITGB3 and 
VEGFR2, but not between VEGFR1 or VEGFR3. The cross talk between the two molecules 
occurs not only in HUVECs but also in proliferating blood vessels (Mahabeleshwar, Chen et 
al. 2008). Importantly, the complex formation between ITGB3 and VEGFR2 in response to 
the VEGF stimulation does not require the presence of vitronectin, in contrast to previous 
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demonstrations (Soldi, Mitola et al. 1999). A study showed that this complex formation can 
take place in the absence of ECM ligands. Interestingly, this study also showed a ~3 fold 
decrease in VEGFR2 phosphorylation when the ITGB3 subunit, but not the ITGB1 and 
ITGA5 subunits, was silenced by siRNA-mediated knockdown in HUVECs, which led to the 
conclusion that ITGB3 is the major integrin in VEGF-induced angiogenic responses 
(Mahabeleshwar, Chen et al. 2008). Furthermore, knock-in (DiYF) mice, a mutant ITGB3 
that is unable to undergo tyrosine phosphorylation of cytoplasmic domain, disrupted 
VEGFR2-ITGB3 complex formation and reduced VEGFR2 phosphorylation in response to 
VEGF stimulation. As a result, cell adhesion, migration, spreading, capillary tube formation 
of ECs isolated from DiYF mice and vascularization/tumour growth in DiYF mice were 
impaired (Mahabeleshwar, Feng et al. 2006). In contrast to the phenotypes that emerged in 
ITGB3 knockout mice (Reynolds, Wyder et al. 2002), (Reynolds, Reynolds et al. 2004), 
DiYF mice showed normal vascular density, maturation and overall development without 
haemorrhagic conditions in any organs, indicating that ITGB3 tyrosine phosphorylation is 
crucial for angiogenesis but not normal vascularization (Mahabeleshwar, Feng et al. 2006). In 
the following year, the same group supported their ITGB3 knock-in mice findings by 
showing that the ITGB3 cytoplasmic tyrosine phosphorylation of HUVECs induced by 
VEGF is directly mediated by downstream tyrosine protein c-Src and that the activation of c-
Src is required for the complex formation between ITGB3 and VEGFR2, which then recruits 
other downstream signalling molecules to promote adhesion, migration, and the initiation of 
angiogenic programming in ECs (Mahabeleshwar, Feng et al. 2007). Five years later, the 
same group provided additional evidence of the direct interaction between the ITGB3 
cytoplasmic tail and VEGFR2 by identifying the membrane-proximal motif within VEGFR2 
(
801
YLSI
804 
residues) mediates the binding interaction with the phosphorylated tyrosine
747
 
located within NpxY motif of ITGB3 cytoplasmic tail. The disruption of tyrosine
747 
within 
the ITGB3 cytoplasmic tail affected the cross talk between ITGB3 and VEGFR2, which 
suppressed VEGF-induced signalling, endothelial tube formation, and angiogenesis in an 
aortic ring assay (West, Meller et al. 2012). Another study identified the cytoplasmic 
regulatory adaptor protein, Sprouty4 (Spry4), which disrupted theis required for ITGB3-
VEGFR2 interaction (Mahabeleshwar, Feng et al. 2007), thus inhibiting EC adhesion, 
migration, as well as retinal angiogenesis (Gong, Yang et al. 2013). In addition to evidence 
that VEGF induces ITGB3-VEGFR2 complex formation, the non-canonical VEGFR2 ligand 
gremlin was shown to phosphorylate VEGFR2, which resulted in conformational changes in 
the extracellular and transmembrane regions of VEGFR2 to form a complex with ITGB3 
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(Ravelli, Mitola et al. 2013). Overall, these studies provided evidence of the essential role of 
ITGB3 in the activation of VEGFR2 in angiogenesis.  
ITGB3-VEGFR2 interactions have also been implicated in functioning as anti-angiogenic 
signals. This hypothesis emerged in an early study by Reynolds et al. (Reynolds, Wyder et al. 
2002), who showed that in ECs derived from ITGB3-NULL mice, both VEGF and VEGFR2 
were significantly elevated compared to those from WT littermates, indicating that the 
absence of Itgb3 gene enhanced tumour growth and angiogenesis (Reynolds, Wyder et al. 
2002). Two years later, based on the results of in vitro studies, the authors showed that ECs 
isolated from ITGB3-NULL mice exhibited increases in cell migration and proliferation as 
well as higher levels of VEGFR2 and ERK1/2 phosphorylation in response to VEGF 
stimulation compared with WT ECs. Similar results were observed in ex vivo aortic ring 
assays, which showed high number of microvessels sprouts in the rings isolated from ITGB3-
NULL mice compared to WT conditions. They concluded that VEGFR2-ERK1/2 signalling 
in response to VEGF stimuli mediates the elevated tumour growth and angiogenesis seen in 
ITGB3-NULL mice (Reynolds, Reynolds et al. 2004). In a separate study, the same group 
revealed that the upregulation of VEGFR2 and VEGF in ITGB3-NULL mice leads to 
increased VEGF-induced EC permeability. Interestingly, when VEGFR2 was blocked by 
VEGFR2-antibody in ITGB3-NULL mice, VEGF164-induced leakage was abolished. This 
indicates that the loss of ITGB3 enhances EC permeability through the upregulation of 
VEGF-VEGFR2-ERK1/2 signalling (Robinson, Reynolds et al. 2004). To determine whether 
more molecular players are responsible for enhancing angiogenesis in ITGB3-NULL mice, 
the same group implicated Ras-related C3 botulinum toxin substrate 1 (Rac1), a member of 
the family of Rho GTPases downstream signalling, in this mechanism. These authors found 
that Rac1 deletion had no effect on VEGF-mediated angiogenesis in vivo, ex vivo, or on 
tumour growth. However, Rac1 enhanced VEGF-mediated angiogenesis and tumour growth 
in the absence of ITGB3 expression, indicating that the augmentation of angiogenesis 
signalling and permeability in ITGB3-NULL mice is Rac1-dependent (D'Amico, Robinson et 
al. 2010). Recently, we found that ITGB3 expression in ECs acted as anti-angiogenic 
molecule by preventing the extension of microtubules to the peripheral FAs through 
telophase disk protein (Rcc2)-Annexin A2 (Anxa2) molecules in a Rac1-dependent manner 
(see the attached published paper for details) (Atkinson, Gontarczyk et al. 2018). 
Other studies showed interactions and cross talk between the ITGB3 subunit and NRP1 in 
ECs (Robinson, Reynolds et al. 2009), (Ellison, Atkinson et al. 2015). Robinson et al. 
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demonstrated a physical interaction between ITGB3 and NRP1 by biochemical 
immunoprecipitation. Fluorescent confocal microscopy also confirmed the close association 
between the two molecules in whole cells. However, this association was disrupted when the 
cytoplasmic tail of ITGB3 was mutated (Robinson, Reynolds et al. 2009). Similar to the 
upregulation of VEGFR2 seen in ITGB3-NULL mice (Reynolds, Wyder et al. 2002), NRP1 
and ERK1/2, which are known downstream targets of VEGF stimulation (Rousseau, Houle et 
al. 1997), (Takahashi, Ueno et al. 1999), were elevated in ITGB3-NULL ECs compared with 
WT ECs. Similarly, NRP1-VEGFR2 co-immunoprecipitation was more augmented in 
ITGB3-NULL ECs than in WT ECs even in the absence of VEGF treatment. Moreover, the 
same study provided evidence that the VEGF-induced angiogenesis seen in ITGB3-NULL 
mice is not restricted to the constitutive deletion of the Itgb3 gene but also occurs in the WT 
system. Indeed, the knockdown of ITGB3 specifically in WT endothelial cells in an in vitro 
wound closure assay significantly enhanced EC migration, while the deletion of both ITGB3 
and NRP1 suppressed the EC migration. Interestingly, when targeting NRP1 in ITGB3-
NULL mice, VEGF-induced angiogenesis was significantly inhibited but not in WT mice, 
indicating that the elevation of angiogenesis that occurs when ITGB3 is absent is dependent 
on NRP1 (Robinson, Reynolds et al. 2009). This finding was confirmed in two angiogenesis 
models. In vivo sponge implant angiogenesis assays showed that the inhibition of NRP1, 
using a peptide designed to inhibit NRP1-VEGF binding, reduced VEGF-induced vessel 
infiltration in subcutaneously implanted sponges in the flanks of ITGB3-NULL mice to a 
greater extent than in WT mice. This finding was supported by the results of an ex vivo aortic 
ring assay, which showed that the siRNA-mediated knockdown of NRP1 in response to 
VEGF stimulation did not affect the number of aortic rings sprouting from WT mice, but it 
significantly supressed the otherwise enhanced ring sprouting from ITGB3-NULL mice, 
which indicates that VEGF-driven sprouting is dependent on NRP1 only when ITGB3 is 
absent. Overall, this study showed that when ITGB3 is expressed normally, it limits the 
interaction between NRP1 and VEGFR2 and thus NRP1 minimally contributes to VEGF-
induced angiogenesis in in vivo and ex-vivo assays. In contrast, when ITGB3 is absent or 
depleted, VEGF-induced VEGFR2 phosphorylation, angiogenesis and tumour growth 
become NRP1-dependent. These findings suggest that by targeting both ITGB3 and NRP1, 
the efficiency of anti-angiogenic therapy may be significantly increased (Robinson, Reynolds 
et al. 2009). Because the complete loss of the Itgb3 gene results in the elevation of 
angiogenesis (Reynolds, Wyder et al. 2002), (Robinson, Reynolds et al. 2009), the Robinson 
group moved away from the use of ITGB3-NULL mice. They generated ITGB3-heterozyous 
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(HET) mice to (hopefully) overcome the developmental upregulation of VEGFR2 in ITGB3-
NULL mice, while simultaneously maintaining critical interactions between ITGB3 and 
VEGFR2 (Ellison, Atkinson et al. 2015). They found that the EC-specific deletion of NRP1 
in WT mice had no effect on subcutaneous allograft tumour growth, or on aortic ring 
sprouting, but both tumour growth and VEGF-induced sprouting were significantly inhibited 
when endothelial NRP1 was deleted in ITGB3-HET conditions. Similar results were 
observed when the cytoplasmic tail of NRP1 was missing, suggesting that this region of the 
molecule plays a role in angiogenesis only when the expression of ITGB3 is reduced (Ellison, 
Atkinson et al. 2015). As hoped, ITGB3-HET ECs displayed only small increases in 
expression of VEGFR2. Unlike ITGB3-NULL ECs, VEGF-induced association between 
NRP1 and VEGFR2 were not enhanced in HET cells. Nonetheless, ITGB3-HET ECs 
migrated faster than WT ECs, and, in contrast to WT ECs, their migration was dependent on 
NRP1. Interestingly, in WT ECs, NRP1 immunolocalised with ITGB3 at the end of F-actin 
fibres, in both VEGF-stimulated and unstimulated conditions. However, in ITGB3-HET ECs, 
VEGF-stimulation lead to a redistribution of NRP1 away from these sites, suggesting that 
ITGB3 regulates the retention of the NRP1 within mature FAs following an angiogenic 
stimulus. This observation was corroborated by the co-localisation of NRP1 and paxillin, a 
marker of FAs. In WT ECs, NRP1 and paxillin were co-localised in the presence and absence 
of VEGF; however, in HET ECs, NRP1 was co-localised with paxillin only in the absence of 
VEGF (Ellison, Atkinson et al. 2015). The authors went on to show that FA disassembly is 
NRP1 dependent only when ITGB3 expression is suppressed. Overall, the results of this 
study suggested that reduced levels of ITGB3 promoted VEGF-induced pathological 
angiogenesis and EC migration through the activation of NRP1 function within FAs (Ellison, 
Atkinson et al. 2015).  
Overall, the results of these previous studies showed that ITGB3 levels play a critical role in 
VEGF-induced pathological angiogenesis through cross talk with NRP1, raising the 
possibility of co-targeting the two molecules to increase the effectiveness of ITGB3-directed 
anti-angiogenic therapy (Robinson, Reynolds et al. 2009), (Ellison, Atkinson et al. 2015). 
Recently, Jia and Chio et al. generated 40 nm silica nanoparticles (NPs) coated with 
heptapeptide ATWLPPR (ATW peptide) antagonists mixed with cilengitide (RGD peptide) 
antagonists (ATW/RGD-NPs) and showed their ability to inhibit VEGF-induced VEGFR2 
phosphorylation and signalling in human ECs at 0.1nM concentration by co-targeting NRP1 
and αvβ3-integrin (Jia, Choi et al. 2018).  
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It is worth noting that, to date, no studies have addressed the possibility that NRP2 could also 
cross talk with αvβ3-integrin. 
1.2.3.2.3.2. α5β1 integrin 
In 1985, Pytela et al. isolated the ITGA5 subunit in osteosarcoma cells using affinity 
chromatography. It was identified as a membrane-embedded cell surface glycoprotein of 
about 140 kDa, which was directly involved in the initial step of cell adhesion to the RGD 
regions of FN (Pytela, Pierschbacher et al. 1985). The endothelial ITGB1 subunit can pair 
with α (1 to 9) subunits except the α7 subunit, which is restricted to skeletal muscle (Velling, 
Collo et al. 1996).  However, the ITGA5 subunit can only pair with the β1 subunit 
(Avraamides, Garmy-Susini et al. 2008), indicating that α5β1 function can be specifically 
examined by manipulating the ITGA5 subunit.  
The α5β1 integrin plays a crucial role during embryonic development. Unlike the deletion of 
the gene encoding for ITGAV or ITGB3 subunit, the constitutive deletion of the Itgb1 gene 
leads to the loss of 12 members of the integrin family (see Figure 1.12). Consequently, 
ITGB1 knockout mice die in utero shortly after embryo implantation because the inner cell 
mass fails to develop (Fässler and Meyer 1995), (Stephens, Sutherland et al. 1995). However, 
the selective deletion of the ITGB1 subunit in mouse ECs resulted in embryonic lethality 
between E9.5 and E10.5 because of the reduced amounts of vessel sprouting and branching 
compared with controls. It was concluded that the vascular ITGB1 subunit is essential for 
embryonic angiogenesis, and it is indispensable in vasculogenesis (Tanjore, Zeisberg et al. 
2008). In contrast, ITGA5 knockout mice die in utero between E10 and E11 of gestation 
because of the absence of posterior somites and a general defect in the paraxial mesoderm. 
These mutant mice also exhibit defects in blood vessel formation, which results in the 
leakage of a large number of blood cells into the exocoelomic cavity as well as the space 
between the extra-embryonic mesoderm and endoderm, indicating that ITGA5 expression is 
required during the embryonic development of early blood vessels (Yang, Rayburn et al. 
1993). Therefore, it was speculated that amongst integrin knockout mice, ITGA5-deficient 
animals exhibit the most severe vascular defects (Yang, Rayburn et al. 1993), (Bouvard, 
Brakebusch et al. 2001). Similar phenotypes were also observed in FN mutant mice, but they 
were much more severe than those seen in ITGA5 mutant mice (George, Georges-Labouesse 
et al. 1993). Consistent with these findings, a previous study addressed the role of both 
ITGA5 and its major ligand, FN, in embryonic development. The results showed that the 
 82 
ITGA5-NULL embryo exhibit significant decreases in the complexity of blood vessels 
accompanied by decreased FN assembly and organisation in the basement membrane of 
ITGA5-NULL ECs compared with WT, ITGB3-NULL and ITGAV-NULL ECs. These 
findings support a critical role for ITGA5-FN interactions during vascular embryonic 
development, which are not dependent on the αvβ3 integrin (Francis, Goh et al. 2002). 
Surprisingly, Flier et al. reported that endothelial-specific knockout embryos of either ITGA5 
or ITGAV alone were viable and had no obvious vascular phenotypic defects. However, FN 
assembly was defective in ITGA5 (but not ITGAV) knockout endothelial cells in vitro, and 
the fibrillar FN was significantly reduced in ITGA5/ITGAV in double-knockout ECs. 
Additionally, double-knockout EC-specific embryos developed normally until E11.5, but 
then extensive defects emerged in the heart and great blood vessels, which resulted in 
embryonic death at ~E14.5, suggesting genetic interactions between ITGA5 and ITGAV 
during embryonic vascular developmental and/or compensation between these two integrin 
subunits (van der Flier, Badu-Nkansah et al. 2010).  
Similar to αvβ3, α5β1 is poorly expressed on quiescent vascular ECs, but its expression is 
upregulated during tumour angiogenesis in humans and animals (Kim, Bell et al. 2000), 
(Avraamides, Garmy-Susini et al. 2008). Kim et al. were the first to implicate α5β1 
expression in angiogenesis. They found that the expression of both α5β1 and its FN ligands 
were co-ordinately elevated within the same blood vessels in human and mice tumours. Using 
the chick CAM assay, they also found that the upregulation of α5β1 and FN were co-
localised in pre-existing blood vessels upon stimulation with bFGF, TNF-α and IL-8 
angiogenic growth factors, but no change in α5β1 expression upon VEGF stimulation was 
detected (Kim, Bell et al. 2000). Interestingly, three different antagonists (antibody, cyclic 
peptide and non-peptide) of α5β1 significantly inhibited HUVEC adhesion and migration on 
FN, but not on collagen. Additionally, the injection of any of these antagonists intravenously 
into the embryonic chick circulation significantly inhibited bFGF, TNF-α and IL-8, but not 
VEGF, induced angiogenesis. This initial study demonstrated a central role for α5β1 binding 
to FN during angiogenesis (Kim, Bell et al. 2000). In the same year, Kim et al. supported 
their previous findings by confirming that anti-α5β1 antibody significantly inhibited both the 
adhesion and the migration of HUVEC and DMVECs on FN, whereas anti-αvβ3 antibody 
had very little effect on FN. The authors showed that both the anti-α5β1 antibody and the 
anti-αvβ3 antibody inhibited HUVEC and DMVEC migration on vitronectin. The adhesion 
on vitronectin was blocked only by the anti-αvβ3 antibody, which suggests an additional role 
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of α5β1 in affecting αvβ3-mediated endothelial migration on vitronectin, but not αvβ3-
mediated adhesion. As ECs naturally secrete their own FN (i.e. endogenous FN) during 
angiogenesis, the author found similar effects were detected when treating ECs migrating on 
vitronectin with function-blocking antibodies directed against the cell-binding domain of FN, 
suggesting that the ligation of α5β1 by FN enhances αvβ3-dependent migration on vitronectin 
(Kim, Harris et al. 2000). In two separate studies, Kim et al. conducted in vitro and in vivo 
chick assays and showed that anti-α5β1 antibody inhibited αvβ3-mediated FA assembly and 
migration on vitronectin by enhancing Protein Kinase A (PKA) (Kim, Harris et al. 2000). 
They also demonstrated that binding of α5β1 with FN promotes ECs migration and survival 
during angiogenesis by suppressing PKA activity, which then blocked apoptosis by 
suppressing cysteine-aspartic proteases-8 (caspase-8), a central player of programmed cell 
death, (Kim, Bakre et al. 2002). Another group of studies showed that human ECs in culture 
secreted soluble VEGFR1, which is known to act as a negative regulator of VEGF-mediated 
signalling, and that soluble VEGFR1, but not soluble VEGFR2, also functions as an 
extracellular protein to promote cell adhesion, migration and spreading through binding to the 
EC α5β1 integrin, which suggests another role for α5β1 during angiogenesis in addition to 
growth factor binding (Orecchia, Lacal et al. 2003). Subsequent studies implicated the 
upregulation of α5β1 integrin during tumour angiogenesis with the transcription factor Hox 
D3, a homeobox-containing transcription factor that converts ECs from the quiescent to the 
proliferative state, which binds to the ITGA5 subunit promotor and enhances the expression 
of the endothelial ITGA5 subunit in vitro and in vivo. The study also showed that Hox D3 
binds directly to ITGB3 promoter and that it regulates αvβ3 integrin by enhancing ITGB3 
expression (Boudreau and Varner 2004). Another group of studies showed that ITGA5-
NULL embryonic stem (ES) cells resulted in smaller teratocarcinomas with reduced 
proliferation and blood vessel formation but increased apoptosis compared to WT and 
ITGA5-heterozygous (α5HET) controls, suggesting that α5β1 integrin plays an essential role 
in vessel formation both in ES cell cultures and in teratocarcinomas  (Taverna and Hynes 
2001). Other studies provided strong evidence that antagonising α5β1 significantly inhibited 
angiogenesis in in vivo mouse models, such as human xenograft tumours, injured corneal and 
ruptured choroidal angiogenesis assays (Bhaskar, Zhang et al. 2007), (Umeda, Kachi et al. 
2006), (Muether, Dell et al. 2007). With regard to cancer, in a large number of studies, the 
upregulation of α5β1 integrin was implicated in cancer progression, including colon, breast, 
ovarian, lung, glioma and melanoma (Schaffner, Ray et al. 2013). Therefore, the antagonists 
of α5β1 have been under investigation as clinical agents that suppress human tumour 
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angiogenesis, such as volociximab (M200) (Figlin, Kondagunta et al. 2006), (Yazji, 
Bukowski et al. 2007), (Avraamides, Garmy-Susini et al. 2008).  
Another group of studies demonstrated the involvement of α5β1 and αvβ3 as well as the FN 
matrix in adult central nervous system (CNS) angiogenesis (Wang and Milner 2006), (Milner, 
Hung et al. 2008), (Li, Welser et al. 2010), (Li, Welser-Alves et al. 2012). Wang and Milner 
conducted in vitro studies showing FN was the most effective ECM protein in promoting 
brain capillary EC survival and proliferation, which was approximately 2-fold greater than 
any other ECM substrate, mediated through α5β1 and αvβ3 via the activation of the ERK1/2 
signalling pathway (Wang and Milner 2006). Using the cerebral hypoxia chamber, a mouse 
angiogenesis model in which littermates of age 8 to 10 weeks were maintained at either 
normal oxygen (21%) or hypoxia (8%) for up to 14 days, the Milner group demonstrated that 
α5β1 and FN were weakly expressed on cerebral capillaries throughout normoxic CNS 
development, whereas hypoxia strongly upregulated their expression on capillaries 
throughout CNS development, in which ITGA5 and FN expressions reached the highest 
expression at day 4 of hypoxia, then gradually declined to endpoint analyses at 14 days 
(Milner, Hung et al. 2008). Two years later, Li and Welse showed that both α5β1 and αvβ3 
were upregulated and partially co-expressed in the angiogeneic brain capillaries during 
hypoxic conditions compared to normoxic conditions. However, they found that ITGA5 and 
FN expressions were induced more quickly, peaking at day 4, and then declining compared 
with ITGB3 and vitronicin expressions, which peaked after day 7. Interestingly, they 
observed no significant difference in capillary density in the brains of WT and ITGB3-NULL 
mice, but the EC proliferation in the brains of ITGB3-NULL mice were increased at day 4 of 
cerebral hypoxia compared with the WT ECs, which correlated with the increase in ITGA5 
expression on FN at day 4 of hypoxia. This observation was supported by the results of 
culturing ITGB3-NULL brain ECs, which exhibited the upregulation of the ITGA5 subunit 
and increased brain EC proliferation on FN, but not on vitronectin, collagen IV or laminin, 
compared with WT brain ECs. These findings suggest an important role for α5β1, but not 
αvβ3, in early angiogenic responses, at least in the brain (Li, Welser et al. 2010). 
Subsequently, the same author generated endothelial-specific knockout mice of ITGA5 (α5-
EC-KO) and used the same mouse model of cerebral hypoxia to evaluate the function of the 
ITGA5 subunit in brain ECs. In normoxic conditions, no difference was detected in the 
density of cerebral blood vessels between WT and α5-EC-KO mice. However, in hypoxic 
conditions, the density of cerebral vessels in α5-EC-KO mice was significantly less than in 
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WT mice after 14 days of hypoxia, indicating that the loss of the endothelial ITGA5 reduced 
the angiogenic response to cerebral hypoxia. Specifically, the authors found that the 
proliferation of brain ECs after 4 days of hypoxia was significantly reduced in α5-EC-KO 
compared with WT. However, after 7 days of hypoxia, the number of proliferating brain ECs 
in α5-EC-KO was higher than in WT, indicating that the loss of endothelial ITGA5 delayed 
the mitogenic response to cerebral hypoxia. It also indicated an important role for the ITGA5 
subunit in promoting the proliferation of brain ECs in response to cerebral hypoxia (Li, 
Welser-Alves et al. 2012). 
In addition to hem-angiogenesis, the α5β1 integrin has been implicated in regulating lymph-
angiogenesis (Zhang, Groopman et al. 2005), (Dietrich, Onderka et al. 2007). For example, 
by stimulating lymphatic hMVECs with VEGF-C156S, a mutant form of VEGF-C that binds 
only to VEGFR3, VEGFR3 phosphorylation and the proliferation of lymphatic ECs on FN 
were significantly enhanced compared with vitronectin, which showed limited effects. 
Importantly, immunoprecipitation showed a physical interaction between VEGFR3 and α5β1, 
but not αvβ3, in the presence or absence of VEGF-C156S, which suggests the constitutive 
association between VEGFR3 and α5β1. Interestingly, VEGFR3 phosphorylation was 
significantly inhibited by a specific antibody against α5β1, but not anti-αvβ3, indicating that 
FN mediates interactions with α5β1, but not with αvβ3, to promote lymphatic ECs 
proliferation (Zhang, Groopman et al. 2005). Consistent with this finding, Dietrich et al. 
demonstrated that ITGAV and ITGA5 were localised with vitronectin and FN, respectively, 
in the quiescentlymphatic vessels at the limbal arcade of mice eyes and in the proliferating 
lymphatic vessels that invaded experimentally inflammed corneas in vivo. Additionally, 
ITGA5 was co-localised with both VEGFR2 and VEGFR3 in the invading lymphatic vessels 
in the cornea. Immunogold labelling was used to co-localise ITGA5 with ITGAV in the 
proliferating lymphatic vessels. Interestingly, the anti-ITGA5 antibody significantly inhibited 
the proliferation of lymphatic vessels in vivo, which was slightly greater in combination with 
an anti-ITGAV antibody, suggesting that the role of ITGA5 is more important than that of 
ITGAV in pathological lymph-angiogenesis (Dietrich, Onderka et al. 2007). Using JSM8757, 
an antagonist that selectively inhibits α5β1 binding to FN, a previous study showed that 
JSM8757 significantly reduced lymphatic hMVECs proliferation in culture, providing 
additional evidence for the essential role of α5β1 in promoting lymphatic ECs proliferation 
(Okazaki, Ni et al. 2009). The authors supported this observation in vivo by using a mouse 
airway trachea model infected with Mycoplasma pulmonis for 14 days and then treated with 
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the JSM8757 antagonist to investigate the role of α5β1 in lymph-angiogenesis. The number 
of lymphatic sprouts as well as ITGA5 immunoreactivity in the lymphatic sprouts was 
significantly greater in the tracheas of pathogen-infected mice than in the pathogen-free mice. 
However, JSM8757 significantly reduced these effects, indicating the important role of α5β1 
in lymph-angiogenesis during airway inflammation by promoting lymphatic sprouting and 
EC proliferation (Okazaki, Ni et al. 2009). Overall, the results of these studies indicate that 
the α5β1 integrin regulates several aspects of EC functions through interactions with various 
molecules during angiogenesis and/or lymph-angiogenesis. 
1.2.3.2.4. Integrin trafficking  
In 1989, Breastcher was the first to apply the cell surface receptor labelling technique to 
follow integrin receptor trafficking. The results showed that FN receptors (α5β1) (Bretscher 
1989) and later other integrins, including α3β1, α4β1 and α6β4 (Bretscher 1992), were 
internalised at 37°C from the surface of the tested cells and then returned to the plasma 
membrane at the leading edges of migrating cells. Importantly, Breastcher also found that 
α5β1 and α6β4 circulated rapidly, whereas α3β1 and α4β1 circulate much more slowly, 
indicating that the rates of integrin trafficking are not the same (Bretscher 1989), (Bretscher 
1992). Subsequently, Breastcher described the mechanism by which animal cells migrate by 
demonstrating that a migrated cell needs to remove its integrins (feet) from the rear of the 
cell, and these feet can be reused many times by redistributing them in the front of the cell 
while crawling across a relevant substratum (Bretscher and Aguado-Velasco 1998). A 
subsequent study on neutrophils demonstrated that the α5β1 integrin is responsible for the 
immobilisation of Ca
++
 on FN and that α5β1 was internalised from the rear of the cells in 
vesicles and then recycled back to the vesicles in the leading edges of the cells only when the 
intracellular Ca
++ 
concentration increases (Pierini, Lawson et al. 2000). Although this 
mechanism of integrin cycling during cell migration has remained attractive to researchers, 
the model does not apply to all migrating cells. For example, the shuttling of integrins from 
the cell rear to the leading edge was not observed in fibroblasts. Instead, fractions of the 
cytoplasm containing α5β1 remained attached to the FN substratum to allow the cell body to 
move forward (Regen and Horwitz 1992), (Palecek, Schmidt et al. 1996), (Laukaitis, Webb et 
al. 2001). Moreover, the movement of the recycling vesicles from the rear of the cell to its 
leading edge in chinese hamster ovary (CHO) cells was not observed. Instead, α5β1 was 
internalised in vesicles from the cell front to perinuclear region before being shuttled to the 
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leading edge of the membrane protrusion (Laukaitis, Webb et al. 2001). In a recent review, 
three directions of integrin trafficking during cell migration were described: from the cell 
front to the cell rear, from the cell front to the cell front, and from the perinuclear region to 
the cell rear (Paul, Jacquemet et al. 2015). In recent years, it has become apparent that 
integrin trafficking also plays a fundamental role in regulating the function, turnover and 
distribution of integrins in adherent cells during cell adhesion, spreading, migration and 
cancer invasion. The mechanism of trafficking includes the delivery of newly synthesised 
integrins as well as the internalisation and recycling of internalised integrins back to the cell 
surface (Margadant, Monsuur et al. 2011). Most integrins on the cell surface are cleared 
within 30 minutes, but the degradative turnover of integrins is slow (12–24 hours), which 
indicates that the majority of internalised integrins are returned to the cell surface (Paul, 
Jacquemet et al. 2015). 
Integrin internalisation can occur through both clathrin-dependent and clathrin-independent 
(via caveolae or macropinocytosis) mechanisms. Both inactive and active (ligand-bound) 
integrin heterodimers can promote internalisation, and both can regulate cell migration 
through the cycles of adhesion assembly and disassembly (turnover) (Valdembri and Serini 
2012), (Paul, Jacquemet et al. 2015). The mechanism of integrin internalisation is influenced 
by two members of the GTPase family: 1) the Rab GTPase, which recruits effector proteins 
to promote cargo sorting, motor protein binding, tethering, docking and fusion events; 2) the 
ADP-ribosylation factor (Arf) GTPase, which recruits coat proteins to promote vesicle 
budding as well as linking to motor cytoskeletal proteins and regulating phospholipid 
signalling (Figure 1.17) (Paul, Jacquemet et al. 2015). Rab and RAF as well as Ran, Ras, and 
Rho, are five members of the Ras subfamily, all of which are determined by small guanine-
nucleotide–binding (G) proteins that act as switches to regulate protein activity or localisation 
(Gillingham and Munro 2007). Rab GTPase family members are known as central regulators 
and vesicle transporters of intracellular membrane traffic by shuttling between the cytosol 
and membranes. Almost 70 members of these small GTPase have been identified in humans 
(Zhen and Stenmark 2015). Rab GTPase members are localised in different membrane 
compartments within a cell to ensure that the membrane-bound cargoes are transported to 
their correct destinations. Similar to other GTPase members, Rab GTPase members are 
regulated by GEF and GTPase-activating proteins (GAP). The activation of Rab GTPase is 
mediated by GEFs, which exchange the bound GDP with GTP (to switch on), whereas the 
deactivation of Rab GTPase is mediated by GAPs, which hydrolyse GTP into GDP (switch 
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off). When the activation of Rab GTPase occurs, Rab effector proteins are recruited to the 
Rab GTPase to promote cargo sorting, vesicle motor, vesicle tethering, vesicle docking and 
vesicle fusion events between donor and acceptor membrane compartments during trafficking 
(Zhen and Stenmark 2015). In contrast, members of the ARF GTPase family act in the 
endoplasmic reticulum (ER)-Golgi system, endosomal and lysosomal pathways as well as the 
secretory membranes and the plasma membrane. In mammals, six conserved members have 
been identified and classified in three groups based on sequence homology: Class I (ARF1, 
ARF2 and ARF3), Class II (ARF4 and ARF5) and Class III (ARF6). Class I ARFs are highly 
conserved, and they are present in all eukaryotic cells (Zhen and Stenmark 2015). 
Additionally, ARF-like (ARL) proteins and SAR1 proteins are considered members of the 
ARF GTPase family (Gillingham and Munro 2007). An important feature of ARF regulator 
proteins, which distinguishes them from other small G proteins, is that they are all modified 
by myristoylation at the N-terminus, which brings ARF proteins into very close contact with 
the membrane to initiate biological activity (Donaldson and Jackson 2011). Therefore, in 
contrast to the Rab effectors that are located distant from membranes, ARF regulators are 
constrained to localise close to the membrane surface (see Figure 1.17) (Gillingham and 
Munro 2007). Similar to Rab GTPase, RAF GTPase family members are also regulated 
through a cycle of GTP binding (activation) and GTP hydrolysis (inactivation); however, 
unlike Rab effectors, no GDP inhibitors have been identified in ARFs. Following the 
activation of ARFs on the membrane, they recruit large numbers of molecules, including coat 
proteins, lipid-modifying enzymes, tethers and other effector molecules, which regulate 
membrane trafficking and organelle structure. For insistence, ARF1 recruits the cytosolic 
coatomer complex I (COPI) to Golgi membranes, where the cargo proteins are then sorted to 
the COPI-coated vesicles. At the trans-Golgi network (TGN), ARF1 regulators subsequently 
recruit the heterotetrametric clathrin adaptor protein 1 (AP1), AP3 and AP4 as well as other 
required vesicle coating proteins to the newly formed COPI-coated vesicles for transporting 
the cargo proteins to the correct destinations (Donaldson and Jackson 2011). Most integrins 
require adaptor proteins, such as disabled (Dab)-2 and adaptor protein-2 (AP-2), which 
accumulate at or near FAs shortly before integrin disassembly, to recruit them into clathrin-
coated pits where endocytosis occurs (Margadant, Monsuur et al. 2011). Studies showed that 
silencing of clathrin, Dab-2 or AP-2 reduced the FAs disassembly and cell migration 
(Ezratty, Bertaux et al. 2009), (Chao and Kunz 2009), (Teckchandani, Toida et al. 2009). It is 
worth noting that ARF3, ARF4 and ARF5 are also present on Golgi membranes. However, 
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previous studies focused on ARF1 at the Golgi membrane and on ARF6 at the plasma 
membrane (Donaldson and Jackson 2011).   
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Figure 1.17 Structure of Arf and Rab G proteins on the plasma membrane. The schematic illustration shows differences 
between the structures and functions of the Rab family and the Arf family. Members of the Rab family interact with effector 
proteins located ~7–8 nm away from the membrane bilayer, which is not the case in Arf family members (Gillingham and 
Munro 2007). 
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1.2.3.2.4.1. Examples of αvβ3 and α5β1 trafficking 
Following internalisation, the integrins return to the plasma membrane through short-loop 
recycling in a Rab4- or Rab5-dependent manner or through long-loop recycling in a Rab11-
dependent manner (Paul, Jacquemet et al. 2015). For example, Woods et al. demonstrated 
that upon the PDGF stimulation of fibroblasts, the αvβ3 integrin was internalised by 
macropinocytosis from dorsal ruffles by following a rapid recycling route (short-loop 
recycling) from early endosomes (EE) directly to the plasma membrane through Rab4 and 
protein kinase D1 (PKD1), in which PKD1 is associated with the cytoplasmic tail of ITGB3 
at a vesicular compartment that is downstream of the Rab4-dependent transport step (Figure 
1.18 A). The study found that a mutant ITGB3 subunit or the suppression of PKD1 inhibited 
the PDGF-dependent accumulation of PKD1 and αvβ3 integrin at intracellular vesicles. 
Hence, the recycling of αvβ3 heterodimer to form new FAs on plasma membrane was 
blocked during cell spreading (Woods, White et al. 2004). Consistent with this result, another 
study demonstrated that upon the VEGF stimulation of ECs, αvβ3 was internalised to EE and 
then recycled to the cell surface by short-loop recycling through PKD1 in both Rab4- and 
Rab5-dependent manners. The results of co-immunoprecipitation and immunofluorescence 
experiments indicated the direct interaction of PKD1 with αvβ3, but not with α5β1. 
Furthermore, the suppression of PKD1 expression increased the internalisation of αvβ3 and 
reduced recycling to the cell surface, which blocked newly formed FAs and reduced EC 
migration on vitronectin (Di Blasio, Droetto et al. 2010).  
In contrast to αvβ3, α5β1 follows a slow recycling (long-loop recycling) mechanism. It 
travels from EE to the perinuclear recycling compartment (PNRC) through Rab11, Arf6, and 
Akt before recycling to the plasma membrane. For example, an early study on α5β1 
demonstrated that the formation of initial adhesive complexes occurs in a hierarchical 
mechanism in which paxillin enters adhesions early at the base of newly forming protrusions 
and then turns-over rapidly in these regions. When the protrusive activity ceases, α-actinin 
begins to appear along the cell border in the membrane protrusions and in fibrous-like 
structures that slide toward the cell body, but not in the newly forming paxillin adhesions. α-
actinin is followed by co-localisation with ITGA5 to stabilise adhesions and translocate 
paxillin and α-actinin–containing cytoskeletal complexes to the cell rear. This study also 
showed that both ITGA5 and α-actinin were not observed in the paxillin-rich complexes 
(Laukaitis, Webb et al. 2001). Shi and Sottile demonstrated that FN matrix turnover occurs 
through receptor-mediated endocytosis and intracellular degradation undertaken by a process 
 92 
that involves caveolae-1, the major integral protein components of membrane caveolin 
(Sottile and Chandler 2005). Subsequently, the same group showed that α5β1, but not αvβ3, 
was co-localised and internalised into FN containing intracellular vesicles during fibronectin 
turnover, indicating that α5β1, but not αvβ3, is important in FN internalisation. Interestingly, 
by using FN-NULL myofibroblasts, they also showed that α5β1 internalised in the presence 
or absence of FN through caveolae-mediated endocytosis (Shi and Sottile 2008). In the 
following year, three different groups of studies showed that α5β1 internalisation is clathrin-
mediated before entering Rab5 endosomes. Interestingly, the deletion of clathrin or any of its 
adaptor proteins, Dap2 or AP2, inhibited the FA disassembly, which resulted in increasing 
the level of α5β1 on the plasma membrane as well as reducing cell migration (Ezratty, 
Bertaux et al. 2009), (Chao and Kunz 2009), (Teckchandani, Toida et al. 2009). Another 
study demonstrated that during the spread of ECs on FN, independently of both VEGF165 and 
SEMA-3A receptors, NRP1 did not directly mediate interactions with FN. Instead, through 
its extracellular domain, NRP1 was required to interact with the active heterodimeric form of 
α5β1-bound FN. Simultaneously, the cytoplasmic domain of NRP1 interacted with the C-
terminal SDA sequence of the active ITGA5 subunit, which was mediated by GIPC1/Myo6 
to enhance the Rab5/Rab21-dependent endocytosis of active α5β1, ensuring the recycling of 
vesicles containing α5β1 to new adhesion sites on FN and promoting the fibrillogenic 
formation required for the adhesion and spread of ECs on FN (Figure 1.18 B) (Valdembri, 
Caswell et al. 2009).  
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A) 
 B) 
 
Figure 1.18 Trafficking mechanisms of αvβ3 and α5β1 to regulate cell adhesion and migration of adherent cells. A) 
The schematic illustration shows the different recycling mechanisms of αvβ3 and α5β1 in an adherent cell. αvβ3 is 
internalised through Rab5, while α5β1 is internalised through both Rab5 and Rab21. Both integrins are then trafficked into 
early endosome (EE). From EE, αvβ3 follows short-loop recycling in a Rab4-dependent manner, whereas α5β1 follows long-
loop recycling in which α5β1 first trafficks into recycling endosome (RE) in a Rab11-dependent manner or in a Rab25-
dependent manner. Then the repopulation of integrins at the ventral surface occurs to form new FAs during cell migration. 
Alternatively, integrins may be ubiquitinated (Ub) and then trafficked into late endosome/lysosome for degradation. αvβ3 
may also be redistributed to the dorsal ruffles after PDGF stimulation and then trafficked to EE by macropinocytosis (MPS) 
before recycling at the ventral surface to form new FAs (see text) (Margadant, Monsuur et al. 2011). B) The schematic 
illustration shows the mechanism through which NRP1 regulates the active form of α5β1 trafficking on FN. During the 
spread of ECs on FN, the adaptor protein GIPC1 and Myo6 are recruited to the cytoplasmic tail of NRP1, which enhances 
the binding of the NRP1 cytoplasmic tail to the C-terminal SEA sequence in the ITGA5 subunit of active α5β1. It then 
promotes the Rab5/Rab21-dependent endocytosis of the active α5β1. When endocytosis occurs, vesicles carrying α5β1-
NRP1 undergo trafficking before recycling to form adhesion sites on the plasma membrane. Additionally, the internalised 
α5β1-NRP1 may also be recycled to the same cell-ECM contact adhesion site for support. APPL1 is an adaptor protein that 
recruits other adaptor proteins essential for vesicles trafficking. Adapted from (Valdembri, Caswell et al. 2009).  
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1.3 Research Aims and Objectives 
Previous research conducted in our laboratory showed that angiogenic responses are only 
sensitive to NRP1 perturbations when β3-integrin levels are reduced. Because of the 
structural and functional similarities between NRP1 and NRP2, and because the cellular 
functions of NRP2 in endothelial cells is less well understood, we felt it was important to 
investigate a role for this protein during angiogenesis. Therefore, this study was undertaken 
to:  
1. Investigate a potential link between NRP2 and ITGB3 within ECs. 
2. Determine if NRP2 depletion affects signalling, migration, proliferation and adhesion 
on fibronectin in ECs.  
3. Identify NRP2 binding partners, using MS, within ECs. 
4. Determine whether NRP2 plays a role in angiogenesis in vivo.      
 
 
 
 
 
 
 
 
 95 
Chapter 2: Materials and Methods 
___________________________________________________________________________ 
 
2.1. Chemicals, antibodies, restriction enzymes and VEGF164 
All chemicals used in this study were purchased from ThermoFisher Scientific 
(Loughborough, UK) unless otherwise noted. Primary conjugated antibodies, primary 
antibodies and secondary conjugated antibodies were purchased from suppliers as listed in 
(Table 2.1), (Table 2.2) and (Table 2.3), respectively. All restriction enzymes and reaction 
buffers (Table 2.4) were purchased from New England Biolabs (Hitchin, UK). 
VEGF164 was produced by the Robinson lab using the protocol described by Krilleke et al. 
(Krilleke, DeErkenez et al. 2007). Briefly, pPICZαC-VEGF164 construct (kindly provided by 
Professor Dave Shema, UCL, London) was transformed into Pichia pastoris yeast cells. 
Then, transformants were subjected to colony blotting for high secreting colonies. The 
highest secreting yeast transformant of VEGF164 was cultured in 500 mL of BMGY medium 
at 30°C until the culture reached an absorbance of 3 at 600nm. Next, yeast pellets were 
resuspended and grown in 100 mL of BMGY supplemented with 0.01% Antifoam 204 
(Sigma-Aldrich, St Louis, US) at 30°C. Cultures were incubated for an additional 36 hours, 
with methanol added to a final concentration of 1% every 12 hours. Cultures were 
centrifuged and supernatant was equilibrated (via dialysis) in Ni
2+
-nitrilotriacetic acid 
chromatography binding buffer (PBS, pH 7.4, with 2.7 mM KCl, 2 mM KH2PO4, 8 mM 
Na2PO4, 300 mM NaCl) and then incubated with Ni
2+
-nitrilotriacetic acid-agarose (Qiagen) 
for 60 minutes at 4°C. Centrifugation was performed, and the collected beads were washed 
with the binding buffer. The bound VEGF164 proteins were eluted in elution buffer and 
analysed by SDS-PAGE (see subsection 2.9.2 to 2.9.5) and Coomassie blue staining to 
visualize the amount of VEGF164 on an SDS-PAGE gel. 
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Table 2.1: List of primary conjugated antibodies 
PE: Phycoerythrin; FC: Flow cytometry; ARA: Aortic ring assay. 
 
Table 2.2: List of primary antibodies 
Antigen Reactivity  Host Conjucation Application Source Cat. # 
CD31 Mouse Rat (IgG2a, κ) PE FC eBioscience™ 12-0311-81 
ICAM-2 Mouse Rat (IgG2a, κ) Alexa®-488 FC eBioscience™ 53-1021-80 
VE-Cadherin Mouse Rat (IgG1) PE FC eBioscience™ 12-1441-80 
ITGA5 Mouse Hamster (IgG) PE FC eBioscience™ 14-0493-81 
IgG isotype 
control 
Mouse Hamster PE FC eBioscience™ 12-4888-81 
IgG isotype 
control 
Mouse Rat PE FC eBioscience™ M1-14D12 
BS1-lectin Mouse ـــــــــــــــــــــــــــــــــــــــــــــــــ PE FC eBioscience™ L2895 
Antigen Reactivity  Host Application Source Clone / Cat. # 
ICAM-2 Mouse Rat ECS AbD Serotec #MCA2295EL 
VE-Cadherin Mouse Rabbit WB Abcam ab33168 
LYVE-1 Mouse Rabbit WB Abcam ab14917 
Prox-1 Mouse Rabbit WB Abcam ab101851 
HSC-70 Mouse Mouse WB Santa Cruz Biotechnology B-6 / sc-7298 
GAPDH Mouse Mouse WB Abcam ab9484 
GAPDH Mouse Mouse WB Proteintech 60004-1-1g 
NRP1 Mouse Rabbit WB Cell Signalling Technology 3725S 
NRP2 Mouse Rabbit WB, ICC, IP Cell Signalling Technology D39A5 
NRP2 Mouse Rabbit ICC Abcam ab155680 
NRP2 Mouse Goat WB,ICC R&D AF567 
NRP2 Mouse Rabbit WB,ICC Millipore  AB10522 
VEGFR2 Mouse Rabbit WB Cell Signalling Technology 55B11 / #2479 
Phospho VEGFR-2 
(Y1175) 
Mouse Rabbit WB Cell Signalling Technology 19A10 / #2478 
ERK1/2 (p44/42 
MAPK) 
Mouse Rabbit WB Cell Signalling Technology 137F5 / #4695 
Phospho ERK1/2 Mouse Rabbit WB Cell Signalling Technology #9101 
ITGB3 Mouse Rabbit WB Cell Signalling Technology 4702S 
ITGB1 Mouse Rabbit WB Abcam ab179471 
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ECS: Endothelial cell sorting; WB: Western blot; ICC: Immunocytochmestry; IP: Immunoprecipitation.  
 
Table: 2.3: List of secondary conjugated antibodies  
Host / name Anti-  Application  Conjugate  Source  Cat. #  
Rabbit  Goat  ICC  Alexa®-488   Invitrogen  A-21222  
Rabbit  Goat  ICC  Alexa®-594   Invitrogen  A-21223  
Donkey  Rabbit  ICC  Alexa®-488   Invitrogen  A-21206  
Donkey  Sheep ICC  Alexa®-633   Invitrogen  A-21100 
Sheep  Rat  ECS  Dynabeads  Invitrogen  11035 
Goat Rabbit WB HRP Dako® P 0448 
Rabbit Mouse  WB  HRP  Dako® P 0260 
Rabbit Goat  WB  HRP  Dako® P 0449 
HRP: Horseradish peroxidase 
 
Table 2.4: List of restriction enzymes and buffers 
Enzyme Cut site Overhang Working conc. (U/μL) Buffer Plasmid Cat. # 
HpaI 
5’…GTT↓AAC…3’ 
3’…CAA↑TTG…5’ 
Blunt 0.3 CutSmart pSico, pSicoR R0105S 
XhoI 
5’…C↓TCGAG…3’ 
3’…GAGCT↑C…5’ 
5’TCGA 0.4 CutSmart & Buffer 2 pSico, pSicoR R0146S 
SacII 
5’…CCGC↓GG…3’ 
3’…GG↑CGCC…5’ 
3’GC 0.8 Buffer 2 pSico R0157S 
NotI 
5’…GC↓GGCCGC…3' 
3’…CGCCGG↑CG…5’ 
5’GGCC 0.2 Buffer 2 pSico R0189S 
XbaI 
5’…T↓CTAGA…3’ 
3’…AGATC↑T…5’ 
5’CTAG 0.4 Buffer 2 pSicoR R0145S 
“↓” indicates the cut site; “↑” indicates the cut site in the complementary strand. 
ITGA5 Mouse Rabbit WB Cell Signalling Technology 4705S 
ITGA5 Mouse Rabbit ICC Abcam ab150361 
ITGA6 Mouse Rabbit WB Abcam ab181551 
Paxillin Mouse Rabbit ICC Abcam ab32084 
Paxillin Mouse Rabbit WB Cell Signalling Technology 2542S 
Phospho Paxillin 
(Y118) 
Mouse Rabbit WB Cell Signalling Technology 2541 
Biotin  Mouse Mouse IP Jackson Immunoresearch 3D6.6 
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2.2. Lung microvascular ECs isolation  
The Robinson group isolated and immortalised lung ECs as previously described (Reynolds 
and Hodivala-Dilke 2006) (Robinson, Reynolds et al. 2009). Briefly, following the cervical 
dislocation and dissection of adult mice under aseptic conditions, the lungs from 3 mice were 
transferred using a pair of sterile forceps to a 10-cm Petri dish containing fresh Ham’s F12 
from which any fat, blood clots, and connective tissue were removed. The lungs were then 
dipped for 2 seconds in a second 10-cm Petri dish containing 70% ethanol (EtOH) before 
transferring the lungs for extending washing in a third 10-cm Petri dish containing MLEC 
complete medium [1:1 mix of Ham’s F-12:DMEM medium low glucose (Gibco® life 
technology, Carlsbad, USA), 20% foetal bovine serum (FBS) (Gibco
®
 life technology), 100 
units/mL penicillin/streptomycin (P/S) (Gibco
®
 life technology), 2mM glutamax (Gibco
®
 life 
technology), 50 μg/mL heparin (Sigma-Aldrich), and 25 mg of endothelial mitogen (AbD 
Serotec, Kidlington, UK)]. Using scalpel blades, the lungs were then minced on an inverted 
lid of a sterile 10-cm Petri dish for 5 minutes before transferring the paté-like homogenate to 
a 50-mL centrifuged tube containing filtered sterilised 0.1% collagenase I (Gibco
®
 life 
technology) to be digested in a 37°C water bath for 1 hour. Following digestion, the 
collagenase-digested lung solution was transferred to a new sterile 10-cm Petri dish and 
mixed with 10 mL fresh MLEC medium. Using a 20-mL syringe, the digested lung solution 
was extracted and separated by mechanical force through a 19.5-gauge needle back into the 
Petri dish four times before passing the digested lungs through a 70-µm cell strainer into a 
50-mL centrifuged tube for centrifuging at 300 g for 5 minutes. The pellet was resuspended 
carefully in 10 mL fresh MLEC medium and seeded in a T75 flask pre-coated with 0.1% 
gelatin, 30 μg/mL collagen I, and 10 μg/mL FN at 37°C in a 5% CO2 incubator. Twenty-four 
hours later, the cells were washed twice with PBS to remove any red blood cells before 
performing the first positive sorting of the ECs by magnetic activated cell sorting (MACS) 
using ICAM-2 as the biomarker for ECs. The cells were incubated with 5 mL PBS containing 
(1:1000) rat-anti-mouse ICAM-2 antibody for 30 minutes at 4°C. One wash was performed 
with cold PBS to remove the excess antibody before incubating the ECs bound to ICAM-2 
antibody with sheep-anti-rat IgG coated magnetic Dynabeads for another 30 minutes at 4°C. 
Following three washes with ice-cold PBS to wash off the unbound Dynabeads, the cells 
were incubated with pre-warmed 0.25% trypsin-EDTA (Invitrogen) for 2–3 minutes at 37°C 
in a CO2 incubator to detach the cells. The solution was subsequently neutralised with MLEC 
medium, transferred to a 15-mL centrifuged tube, and then placed on a magnet. The 
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supernatant was carefully discarded leaving behind ECs bound to the magnetic, which was 
then resuspended in fresh, pre-warmed MLEC medium and seeded in a T25 flask pre-coated 
with 0.1% gelatin, 30 μg/mL collagen I, and 10 μg/mL FN at 37°C in a 5% CO2 incubator 
until it reached 90% confluency. The second positive sorting of the ECs was then performed 
in a similar manner to enhance the purity of the ECs.  
2.3. Microvascular EC immortalisation 
Prior to immortalisation, a polyoma-middle-T-antigen (PyMT) retrovirus was produced using 
GgP+E cells. Then the conditioned medium containing a PyMT retrovirus was collected from 
the cultured packaging GgP+E cells, filtered through a 0.45 μm filter, and preserved at -80°C 
until needed. For immortalisation, the PyMT retrovirus was thawed and mixed with 8 μg/mL 
polybrene to enhance the transfection efficiency before transfecting the sorted positive lung 
ECs with the PyMT conditioned medium at 37°C in a 5% CO2 incubator for 6 hours. The 
medium containing the PyMT retrovirus was then replaced by fresh complete MLEC medium 
and returned to the incubator. Twenty-four hours later, the same transfection procedure was 
repeated. The cells were maintained for four weeks to ensure their immortalisation, and the 
MLEC medium was then changed to IMMLEC medium, which is similar except it is 
supplemented by only 10% FBS and it excludes endothelial mitogen to facilitate the growth 
and survival of vascular ECs in culture. Flow cytometry for ICAM2, CD31, and VE-Cadherin 
was performed to ensure endothelial identity. The ECs were then expanded and stored for a 
long period, as described below.  
2.4. Freezing and thawing cells 
For cell freezing, confluent ECs grown in a cultural flask were washed with a pre-warmed 
PBS, trypsinised, counted by a Neubauer counting chamber (Hawksley, Lancing), and 
centrifuged at 500 g for 4 minutes before resuspending at 1×10
6 
cells per  mL of a pre-chilled 
medium containing 90% FBS and 10% dimethyl sulfoxide (DMSO) to prevent the formation 
of ice crystal during freezing. Then 1 mL of cell suspension was aliquoted in cryovials before 
placing them in a Mr. Frosty freezing container (ThermoFisher Scientific) at -80°C for short-
term storage or in a liquid nitrogen DryStore™ for long-term storage. For cell thawing, the 1 
mL aliquoted cryovial was thawed in a water bath at 37°C for approximately 20 seconds 
before transferring the 1 mL cell suspension to an ice-cold centrifuge tube containing 9 mL of 
IMMLEC media and then centrifuged at 500 g for 4 minutes. The cell pellet was resuspended 
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with 3 mL of pre-warmed IMMLEC medium and seeded in a T25 flask that was pre-coated 
with 0.1% gelatin at 37°C in a 5% CO2 incubator.  
2.5. Tissue culture 
ECs were grown on tissue cultural flasks (T25, T75, or T175) that were pre-coated with 0.1% 
gelatin for 1 hour at 37°C in a 5% CO2 incubator. When the cell growth reached a confluency 
of 90–95%, the ECs were firstly washed once using pre-warmed PBS to remove the excess 
IMMLEC medium before detaching the adherent ECs using pre-warmed 0.25% trypsin-
EDTA for 2–3 minutes at 37°C in a 5% CO2 incubator. Following trypsinisation, the ECs 
were neutralised with pre-warmed IMMLEC medium to stop trypsin enzymatic activity. 
Then, the cell suspension was transferred to a 50-ml centrifuge tube for centrifuging at 500 g 
for 4 minutes. The cell pellet was gently resuspended in a fresh pre-warmed IMMLEC 
medium and either split 1:3 or expanded in a new tissue cultural flask that was pre-coated 
with 0.1% gelatin. It is worth noting that a T175 tissue cultural flask holds up to 9×10
6 
immortalised ECs, whereas T75 and T25 flasks hold up to 4×10
6
 and 1×10
6 
immortalised 
ECs, respectively. Therefore, in experiments that require more than 9×10
6 
ECs, as in the case 
of the cell surface receptors biotinylation assays, we grew ECs in multiple T175 tissue 
cultural flasks and pooled them before performing the experiment. The EC tissue culture is 
summarised in table 2.5.    
 
Table 2.5: Summarisation of EC tissue culture conditions 
Tissue Cultural Flask Size 25 cm2 (T 25) 75 cm2 (T 75) 175 cm2 (T 175) 
90–95% Confluency Up to 1×10
6 ECs Up to 4×106 ECs Up to 9×106 ECs 
PBS Wash 1 mL 5 mL 10 mL 
0.25% Trypsin-EDTA 0.5-1 mL 1.5-2 mL 3-4 mL 
Neutralisation 1 mL 4 mL 8 mL 
Total Complete Media 3 mL 5 mL 20 mL 
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2.6. Mouse genotyping 
2.6.1. DNA extraction 
The ear of each live mouse was snipped, placed in one well of a 96-well PCR plate 
(ThermoFisher Scientific), and digested with a 100 µL of ear/tail lysis buffer (50mM Tris-
HCl pH 8.5, 10mM EDTA pH 8.0, 100mM NaCl, 0.2% SDS) supplemented with 100 μg/mL 
proteinase K and incubated overnight at 56°C in an incubator. To genotype our immortalised 
lung ECs, the cells were trypsinised and centrifuged as described in section 2.4, and then 
using the ear/tail lysis buffer, the cell pellet was lysed overnight at 56°C. The following day, 
100 µL of isopropanol was added to the wells to precipitate DNA. The plate was then capped 
by lids, inverted a few times to mix the isopropanol with the DNA lysate, and then 
centrifuged at 1400 g for 30 minutes. The supernatant was carefully poured off, and the 
precipitated DNA pellet was dried in an incubator at 37°C for 2 hours. Next, 200 µL of TE 
buffer (1M Tris-HCL pH 8 and 0.5M EDTA pH 8) was added to the wells and incubated 
overnight at 37°C to resuspend the DNA pellet. A Veriti™ 96-well thermal cycler PCR 
machine (ThermoFisher Scientific) was then used to perform the PCR reactions as described 
below.   
2.6.1.1. Itgb3 knockout genotype 
Transgenic mice that expressed a knockout for the β3-integrin (KO-Itgb3) allele were created 
by substituting a 1.4 kb HindIII fragment of the β3 gene including exons I and II with a 1.7 
kb construct containing a Pgk-neomycin (neo)-resistance cassette (see chapter 3; Figure 3.1 
A). The PCR analysis was carried out using the following oligonucleotide primers (Hodivala-
Dilke, McHugh et al. 1999):  
 Forward primer 1 (Binds 5’ upstream of exon1 or Pgk-neo):                                    
5’ – CTTAGACACCTGCTACGGGC – 3’  
 Reverse primer 2 (Binds within Pgk-neo):                                                                    
5’ – CACGAGACTAGTGAGACGTG – 3’  
 Reverse primer 3 (Binds 3’ downstream of exon 1):                                                   
5’ – CCTGCCTGAGGCTGAGTG – 3’ 
In each DNA sample, forward primer 1 was mixed in two separate PCR reactions with 
reverse primer 2 or reverse primer 3. A typical PCR reaction in each DNA sample consisted 
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of 0.4 µL of DNA mixed with 10 µL of MegaMix-Blue cocktail, which contains Taq 
polymerase, reaction buffer, dNTPs, and blue agarose loading dye (Microzone, Haywards 
Heath, UK), and 0.04 µL of primers 1 and 2 in a final concentration of 0.4 µM or 0.1 µL of 
primers 1 and 3 in a final concentration of 1 µM in one well of a 96-well PCR plate. Next, the 
plate was carefully capped with lids and placed in a programmed thermal cycler PCR 
machine. The PCR reaction programme was started in an initialisation step at 95°C for 15 
minutes, followed by 35 amplification cycles repeated in sequential order: denaturation at 
95°C for 30 seconds, annealing at 60°C for 45 seconds, and extension at 72°C for 90 seconds. 
The final cycle was terminated by an elongation step at 72°C for 10 minutes. The amplified 
products generated by the reactions involving primers 1 and 2 corresponded to the Itgb3-
NULL allele, whereas the products generated by the reactions involving primers 1 and 3 
corresponded to the Itgb3-WT allele.  
2.6.1.2. Pdgfb.CreER genotyping 
Transgenic mice that expressed a tamoxifen-inducible pdgfb-iCreERT2 allele in vascular 
endothelial cells were created by substituting the exon 1 of the pdgfb gene by the iCreERT2-
IRES-EGFP-pA sequence. The DNA extracted from the pdgfb.CreER mice was PCR-
analysed using the following oligonucleotide primers (Claxton, Kostourou et al. 2008): 
Forward primer: 5’ – GCCGCCGGGATCACTCTC – 3’  
Reverse primer: 5’ – CCAGCCGCCGTCGCAACT – 3’  
For each PCR reaction, 0.8 µL of DNA was mixed with 10 µL of MegaMix-Blue cocktail 
and 0.08 µL of the forward and reverse primers at a final concentration of 0.8 µM in one well 
of a 96-well PCR plate. The PCR reaction programme was started by an initialisation step at 
94°C for 4 minutes, followed by 34 amplification cycles repeated in sequential order: 
denaturation at 94°C for 30 seconds, annealing at 57.5°C for 45 seconds, and extension at 
72°C for 60 seconds. The final cycle was terminated by an elongation step at 72°C for 10 
minutes. 
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2.6.2. Agarose gel electrophoresis 
2.6.2.1. 8% gel preparation 
In this procedure, 3.6g of agarose was added to a conical flask containing 150 mL distilled 
water (dH2O), and the conical flask was then placed in a microwave for 2–3 minutes. To 
reach the final volume of 200 mL, 46 mL of dH2O and 4 mL of 50X TAE buffer (0.5 M Tris, 
1 M acetic acid, 50 mM EDTA pH 8.0) were added to the conical flask. The gel solution was 
cooled by running the flask under tap water. Then, 7.5 µL of 10 mg/mL ethidium bromide 
solution (ThermoFisher Scientific) was added to the gel solution before it was poured into a 
casting tray (Alpha Laboratories, Eastleigh, UK). A comb was inserted, and the gel solution 
was left to set for 30 minutes. Next, the casting tray containing the gel was submerged in a 
running tank containing 1XTAE buffer. The comb was carefully removed from the gel, and 
the PCR products of each sample as well as 4 μL of HyperLadder™ 1 kB (Bioline, London, 
UK) were then loaded in gel wells. The DNA separation was carried out at 100 V for 75 
minutes, and the DNA bands were imaged under UV transilluminators using a BioDoc-It
™
 
System (UVP-Analytik Jena LLC, Upland, US). In the results of the Itgb3 genotype analysis, 
the PCR product bands of 538 base pairs (bp) corresponded to Itgb3-NULL allele, while the 
PCR product bands of 446-bp corresponded to the WT allele. In the results of the 
pdgfb.CreER genotype analysis, the PCR product band of 443-bp was positive, whereas if no 
PCR product was observed, the animal or cell line was considered to be negative.   
2.7. Endothelial cells Electroporation (Nucleofection) 
EC electroporation was performed as described by the manufacturer’s (Lonza, Slough) 
general protocol with a few changes to obtain high survival rates. DNA plasmid 
concentration was used between 2 to 15µg per reaction, whereas siRNA was resuspended as 
described by the manufacturer (Dharmacon, Cambridge) at a concentration of 40μM, and 5.6 
µl was used per reaction (for a final mass of 3 µg).  
2.7.1. General procedure 
The ECs were washed with pre-warmed PBS, trypsinised with 0.25% trypsin-EDTA and 
counted as described in section 2.4. Then, 1×10
6
 ECs per nucleofection were transferred to a 
50-ml sterile centrifuged tube (for 10 nucleofections, 10×10
6
 ECs were collected). Following 
the centrifugation of ECs at 500 g for 4 minutes, the cell pellet was resuspended at a density 
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of 1×10
6
 ECs per 100 μL (10×106 ECs per 1 mL) of pre-warmed nucleofection buffer (200 
mM Hepes, 137 mM NaCl, 5 mM KCl, 6 mM D-glucose, and 7 mM Na2HPO4 in nuclease-
free water; filter sterilised). Then, 100 μL of the suspended ECs was mixed with siRNA or 
plasmid in a 1.5-mL sterile centrifuged tube before transferring the mixture to an Amaxa-
certified cuvette. Next, the cuvette was placed in the Amaxa™ Nucleofector™ II machine 
(Lonza, Slough). The voltage programme T-005 was used to nucleofect our immortalised 
ECs. Following the EC electroporation, the ECs were very gently transferred to a sterile 
universal tube containing 2 ml of pre-warmed IMMLEC medium and then incubated at 37°C 
for 10–15 minutes in a 5% CO2 incubator to allow them to recover. Finally, the ECs were 
seeded very gently in the required sizes of culture dishes.  
2.8. Reusing cuvettes 
The cuvettes were washed and reused over 30 times without decreasing the efficacy of 
electroporation. Briefly, the cuvettes were rinsed 7 times with dH2O to remove any remaining 
cellular debris. Next, 1 mL of 0.2N HCl was added to each cuvette to denature proteins or 
nucleic acids and the cuvettes were incubated for 10 minutes at room temperature. Finally, 
the cuvettes were washed 7 times with 70% EtOH and then left to air-dry in a sterile 
condition a laminar flow cabinet.  
2.9. Western blot analysis  
2.9.1. Lysate preparation  
The ECs were washed twice with PBS before lysing the cells in high-SDS lysis buffer (3% 
sodium dodecyl sulphate (SDS), 60mM sucrose, 65mM Tris-HCl PH 7.4). The ECs were 
then scraped off using a rubber policeman, and the lysates were transferred to a 1.5-mL safe 
lock Eppendorf tube containing acid-washed glass beads (Sigma-Aldrich). Subsequently, the 
ECs were homogenised for 2 minutes at 50 Hz using a TissueLyser (QIAGEN, Manchester, 
UK) followed by centrifugation at 16,000 g for 10–15 minutes at room temperature to 
dissipate the bubbles generated by the homogenisation process. A BioRad DC™ protein 
assay (BioRad, Hemel Hempstead, UK) was then used as described by the manufacturer to 
quantify the protein concentrations in the lysates. Briefly, 5 µl of each protein sample and 5 
µl of the previously made standard curves were loaded in triplicate in a 96-well plate. Then, 
20 µl of reagent S was mixed with 1 mL of reagent A; 25 µL of the total mixture was then 
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added to each well containing a protein sample or a standard curve. Next, 200 µL of reagent 
B was added to each well, and the 96-well plate was incubated for 15 minutes at room 
temperature. The absorbance was read at 750 nm using a VersaMax™ absorbance microplate 
reader (Molecular Devices, San Jose, US). The protein concentration of each sample was 
determined by liner regression analysis and compared to the standard curve.. 
2.9.2. Preparing SDS-PAGE gels 
To prepare the SDS-PAGE gels, 4X resolving buffer (also called separating or lower buffer) 
(1.5M Tris – HCL 0.4% SDS H20 to 500 ml pH to 8.8) and 4X stacking buffer (also called 
upper buffer) (0.5M Tris-HCL 0.4% SDS H20 to 500 ml pH to 6.8) were made and then 
stored at 4°C until needed. The required percentage (usually 8% or 10%) of the SDS-PAGE 
gels was prepared as shown in Table 2.6 one day before performing the Western blot 
analysis. Briefly, the resolving gel was prepared in a 50-mL centrifuged tube (see table 2.6). 
However, ammonium persulfate (APS) 10% and TEMED (Invitrogen) were added just prior 
to pouring the resolving gel buffer because these two chemicals quickly polymerise 
acrylamide. The resolving gel buffer was then poured in the spacer between the two glass 
plates, leaving about 2 cm for the stacking gel buffer. Immediately, 400 µL of isopropanol 
was added in the spacer to remove any bubbles and then left for 15–20 minutes until the 
resolving gel was completely polymerised. The isopropanol was carefully poured off, and the 
remaining isopropanol was then washed off with dH2O. Similar to the resolving buffer, APS 
10% and TEMED were added just prior to pouring the stacking gel buffer. Immediately after 
pouring, a 10- or 15-well comb was inserted in the spacer and left for 10–15 minutes until the 
stacking gel was completely polymerised. The SDS-PAGE gel was then wrapped in moist 
paper towels and stored overnight at 4°C.  
Table 2.6: Recipes for preparing the resolving and stacking buffer gels 
For Making Lower Gel 7% 7.5% 8% 10% 12% 15% 18% 
dH2O (mL) * 6.2 6 5.8 5 4.2 3 1.8 
Acrylamide (mL) 2.8 3 3.2 4 4.8 6 7.2 
Resolving gel buffer (mL) 3 3 3 3 3 3 3 
APS% (µL) * 72 72 72 72 72 72 72 
TEMED (µL) * 14 14 14 14 14 14 14 
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For Making Upper Gel 1 Gel 2 Gel 
dH2O (mL)  2.43 4.86 
Acrylamide (mL) 0.5 1 
Stacking gel buffer (mL) 1 2 
APS% (µL)  72 144 
TEMED (µL)  7 14 
* Abbreviations: Distal water (dH2O); Ammonium persulfate (APS); Tetramethylethylenediamine (TEMED) 
2.9.3. Electrophoretic separation of proteins and transferring proteins to a 
membrane 
The following day, 20–40 µg protein from each sample was transferred to 1.5-Eppendorf 
tubes and mixed with 4X NuPAGE™ LDS sample buffer (Invitrogen) and 10X NuPAGE™ 
sample reducing (Invitrogen), at a final 1X concentration of each. Then, the protein samples 
were heated on a dry block thermostatat (Grant instrument Ltd, Shepreth, UK) at 95°C for 5 
minutes. Next, following the removal of the comb, the gel was clamped into the apparatus, 
and the tank blotting chamber (BIO RAD) was filled with 1X running buffer. The samples 
and molecular mass protein markers were then carefully loaded into the wells using gel-
loading pipette tips (Star Lab, Hamburg, Germany). The separation of proteins by 
electrophoresis was performed at 100 V for 2 hours. The separated proteins were transferred 
onto a 0.45 µm Amersham Protran
®
 nitrocellulose membrane (GE Healthcare, Amersham) 
using an Xcell surelock blot module (Invitrogen) at 35 V for 160 minutes. The transferred 
proteins on the nitrocellulose membrane were then stained with 0.1% Ponceau S stain in 5% 
acetic acid for 3 minutes at room temperature, followed by two washes with dH2O to remove 
the excess Ponceau S stain. Next, the membrane was cut into strips according to the size of 
the proteins of interest. 
2.9.4. Primary/secondary antibody incubation and chemiluminescence 
detection 
The membrane was blocked with 5% milk powder/PBS plus 0.1% Tween-20 (ThermoFisher 
Scientific) for 30 minutes on a rotatest shaker (Luckham LTD, burgess hill, UK) at room 
temperature, followed by three washes with 0.1% Tween-20 in PBS (PBS/T). The membrane 
strips (blots) were incubated overnight with diluted primary antibodies (1:1000) (see Table 
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2.2) in 5% bovine serum albumin (BSA) in PBS/T on a rotatest shaker at 4°C. Next, the blots 
were washed three times with PBS/T for 5 minutes each and incubated with horseradish 
peroxidase (HRP)-conjugated secondary antibodies (see Table 2.3) for 2 hours on a rotatest 
shaker at room temperature in a dark room. Following three washes with PBS/T for 5 minutes 
each on a rotatest shaker, the blots were incubated with Pierce™ ECL substrate 
(ThermoFisher Scientific) for 3 minutes at room temperature in a dark room. Finally, a 
Fujifilm LAS-3000 darkroom (Fujifilm UK Ltd, Bedford, UK) was used to image the 
chemiluminescence.   
2.9.5. Western blot analysis 
The density of Western blot bands were measured by Image J™ software, and the signal of 
each protein was normalised to the loading control (HSC-70 or GAPDH) of the same sample. 
In the signalling assay, the phosphorylation of VEGFR2 and ERK1/2 were normalised to the 
total levels of VEGFR2 and ERK1/2 in the same sample, respectively.  
2.10. Signalling assays 
To analyse the effects of NRP2 depletion on VEGFR2, ERK1/2, NRP1, and ITGB3 
expression in our immortalised murine lung ECs, cells were first subjected to electroporation 
with control-siRNA (Ctrl-siRNA) and NRP2-siRNA (see chapter 3; Figure 3.2 C-D for 
specific information on siRNAs used) as described in section 2.7. Following EC 
nucleofection, 5×10
5
 ECs were seeded in 6-cm culture dishes pre-coated with 10 µg/mL FN 
in PBS for 48 hours at 37°C in a 5% CO2 incubator. Then, the ECs were washed twice with 
pre-warmed PBS to remove any excess complete medium and replaced by pre-warmed 
serum-free OptiMEM
®
 for 3 hours to starve the cells. Following EC starvation, OptiMEM
®
 
medium was replaced by fresh pre-warmed OptiMEM
®
 medium supplemented by 30 ng/mL 
VEGF164 and then incubated sequentially for 5, 15, 30, 45, or 60 minutes at 37°C in a 5% 
CO2 incubator. To stop the VEGF stimulation, the dishes were quickly placed on ice, which 
was followed by two cold PBS washes. The ECs were then subjected to lysing, protein 
quantification, and protein expression analysis as described in section 2.7.  
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2.11. EC detachment assay 
2.11.1. Trypsin 
ECs were seeded in five 10-cm dishes pre-coated overnight with 10 µg/ml FN for 24 hours at 
37°C in a 5% CO2 incubator. After washing the adherent cells twice with PBS, the cells 
adhered in dish 1 were scraped off using a rubber policeman and then lysed with SDS lysis 
buffer. The ECs adhered in dish 2 were trypsinised, neutralised with pre-warmed IMMLEC 
medium and centrifuged at 500 g for 4 minutes. The cell pellets were subjected to two PBS 
washes and two centrifugations at 500 g for 4 minutes to remove the excess remaining 
medium before lysing the cell pellets with high SDS lysis buffer. The ECs adhered in dishes 
3, 4, and 5 were trypsinised, centrifuged at 500 g for 4 minutes, and then resuspended gently 
in pre-warmed IMMLEC medium. The suspended cells from dishes 3, 4 and 5 were then 
placed in a CO2 incubator at 37°C for 1, 2, or 3 hours, respectively. The suspended cells were 
subjected to centrifugation, PBS washes, and lysing with high-SDS lysis buffer as described 
for dish 2. The supernatant proteins from the lysed ECs in the five 10-cm dishes were 
quantified by DC™ protein assay so that equivalent protein masses (20 µg) from each sample 
could be subjected to Western blot analysis to examine the enzymatic effect of trypsin 
cleavage on the cell surface receptor proteins, including NRP1, NRP2, ITGA5, ITGA6, and 
ITGB3.  
2.11.2. Other cell detachment reagents 
Using the same protocol as described in subsection 2.11.1, Gibco TrypLE (kindly provided 
by Dr Samuel Fountain, UEA, Norwich, UK), Dispase (kindly provided by Dr Ernst Pöschl, 
UEA, Norwich, UK), sodium saline buffer (1.35M potassium chloride and 0.15M sodium 
citrate), and different concentrations of EDTA (5mM, 10mM and 15mM) were also used to 
examine their detaching effect capabilities on our immortalised ECs. 
2.12. Adhesion assay  
ECs were subjected to electroporation with either Ctrl-siRNA or NRP2-siRNA, as described 
in section 2.7. Following EC nucleofection, 1×10
6
 of ECs were seeded in 10-cm dishes pre-
coated with 0.1% gelatin for 48 hours at 37°C in a 5% CO2 incubator. One day before the 
experiment, the 96-well plates were coated overnight with 10 µg/ml FN at 4°C. The adherent 
cells were washed twice with PBS, trypsinised, and centrifuged at 500 g for 4 minutes. The 
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cell pellets were then resuspended in pre-warmed serum-free OptiMEM
®
, and the cells were 
incubated in a suspension state at 37°C for 1 hour to allow cell surface receptor proteins 
cleaved by trypsin to be re-express on the plasma membrane. Simultaneously, the FN coating 
solution was removed from the pre-coated 96-well plates and blocked with 5% BSA for 1 
hour at room temperature. Wells were then washed once with PBS before seeding 40×10
3
 
cells per condition in eight wells of a 96-well plate. After seeding, the plates were incubated 
for 15 minutes, 30 minutes, or 3 hours at 37°C in a 5% CO2 incubator. The 3-hours plate was 
used as a control for the total number of seeded cells in each condition, while the 15 and 30 
minutes plates were used to examine the effect of NRP2 depletion on EC adhesion on FN. 
After the desired incubation time, wells were subjected to three washes with PBS + 1mM 
MgCl2 + 1mM CaCl2 before fixing the cells with 4% paraformaldehyde (PFA) for 10 minutes 
at room temperature. The cells were then stained with methylene blue for 30 minutes at room 
temperature. After the removal of the methylene blue stain, the plates were gently submerged, 
all at once, in a bucket of dH2O until the blue stain disappeared from the negative control 
(i.e., the cells seeded on BSA only). After the removal of any excess dH2O from the wells, 
the plates were air-dried for 30 minutes at room temperature. The dye from the stained 
adhered ECs was extracted by a destain solution (50% ethanol and 50% 0.1M HCL) for 10 
minutes at room temperature before the absorbance of each well was read at 630 nm.  
To analyse the results of the adhesion assay, the relative number of the adhered cells at 15 
minutes or 30 minutes in each well was normalised to the relative number of the total cells 
seeded in the 3-hours plates. 
2.13. Random migration assay  
One day before the experiment was performed, 10-cm dishes were coated overnight with 10 
µg/ml FN at 4°C. The ECs were subjected to electroporation with siRNA (Ctrl-siRNA or 
NRP2-siRNA), as described in the ECs electroporation (see section 2.7), and 1×10
6
 cells 
were seeded in 10-cm dishes pre-coated with 10 µg/ml FN for 48 hours at 37°C in a 5% CO2 
incubator. Twenty-four hours before the cells were trypsinised, a 24-well plate was coated 
overnight with 10 µg/ml FN at 4°C. Next, the ECs were trypsinised, resuspended in serum-
free OptiMEM
®
, and seeded at a concentration of 7×10
4
 cells from each condition in 
triplicate wells on a 24-well plate pre-coated with 10 µg/ml FN for 3 hours at 37°C in a 5% 
CO2 incubator to starve and allow the cells to adhere in the wells. Following starvation, the 
medium in half of the plate was replaced by only fresh serum-free OptiMEM
®
 plus 2% FBS, 
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while the medium in the other half of the plate was replaced by fresh serum-free OptiMEM
®
 
plus 2% FBS supplemented by 30 ng/mL VEGF164. Fixed images of multiple fields/well in 
each condition were taken every 10 minutes for 15 hours at 37°C and 5% CO2 using an 
inverted Axiovert (Carl Zeiss Ltd, Cambridge, UK) microscope with one-phase contrast.  
To analyse the results of random migration assays, individual cells in different fields/well in 
the same condition were manually tracked using the ImageJ
TM
 cell tracking plugin, and the 
migration speed of each individual cell was calculated in μm/hour. 
2.14. Wound healing migration assay 
ECs were nucleofected with siRNA (Ctrl-siRNA or NRP2-siRNA), seeded in 10-cm dishes 
pre-coated with FN as described in the random migration assay and incubated for 24 hours at 
37°C in a 5% CO2 incubator. On day of nucleofection, 6-well plates were coated overnight 
with 10 µg/ml FN at 4°C. Twenty-four hours post nucleofection, the ECs were trypsinised, 
resuspended in IMMLEC medium, and seeded at a high density of 5×10
5
 cells of each 
condition in quadruple wells of the 6-well plates. Then, the plates were incubated for another 
24 hours at 37°C in a 5% CO2 incubator. Forty-eight hours post nucleofection, IMMLEC 
medium was replaced by serum-free OptiMEM
®
 for 3 hours to starve the cells. Following 
starvation, manual scratching of the confluent monolayer of ECs using a P200 pipette tip was 
performed. The serum-free OptiMEM
®
 containing debris caused by scratching in two wells 
of each condition was replaced by only fresh serum-free OptiMEM
®
 plus 2% FBS, while the 
serum-free OptiMEM
®
 in the other two wells of each condition was replaced by fresh serum-
free OptiMEM
®
 plus 2% FBS supplemented by 30 ng/mL VEGF164. Using an axiovert 40/cfl 
inverted microscope (Carl Zeiss Ltd), phase contrast images of scratches were captured on 
the day of scratching (time 0), and the plates were then incubated at 37°C in a 5% CO2 
incubator. Then, phase contrast images of the same scratches were captured every 24 hours. 
Most wounds closed between 48–72 hours post scratching.  
To analyse the wound healing assay, the closure distance of each captured wound was 
calculated by normalising the closure distance after 24 hours or 48 hours to the starting 
wound at time 0. 
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2.15. Proliferation assays 
2.15.1. WST-1 
ECs were treated with siRNAs and seeded in 10-cm dishes for 48 hours at 37°C in a CO2 
incubator. Twenty-four hours before the cells were trypsinised, 96-well plates were coated 
overnight with 10 µg/ml FN at 4°C. Following trypsinisation, 7,000 cells from each condition 
were seeded in a final volume of 100 µl of culture medium in two 96-wells plates.  One plate 
was left for 4 hours (this plate served as a control for the total number of seeded cells in each 
condition). The second plate was left for 24 hours. At the end of each incubation period, 10 
µl of WST-1 was added to each well and the plates were left for an additional 2 hours, then 
the absorbance of each well was measured at 450 nm.  
To analyse the results of the WST-1 proliferation assay, the absorbance of each well at 24 
hours was normalised to the absorbance at 4 hours. 
2.15.2. BrdU 
ECs were treated with siRNA and seeded in 10-cm dishes pre-coated with 0.1% gelatin for 30 
hours at 37°C in a 5% CO2 incubator. One day before the cells were trypsinised, 4 acid-
washed/oven-sterilised glass coverslips were transferred into each well of a 6-well plate. 
Then, the coverslips were coated with 10 µg/ml FN at 4°C. Thirty hours post nucleofection, 
the cells were trypsinised and centrifuged at 500 g for 4 minutes. The cell pellets were 
resuspended in pre-warmed serum-free OptiMEM
® 
and seeded onto the coverslips for 4 hours 
to allow the cells to adhere. In the meantime, 10 µM BrdU 5-bromo-2'-deoxyuridine (Abcam) 
labelling solution was made in a IMMLEC medium and filtered sterilised through a 0.2-um 
filter. Next, the serum-free OptiMEM
®
 was replaced by the 10 µM BrdU labelling solution 
and the cells were incubated for another 12 hours at 37°C in a 5% CO2 incubator. Thereafter, 
the BrdU labelling solution was removed and two washes with PBS (15 seconds each) were 
performed. An additional three PBS washes at 2 minutes each were carried out before the 
cells were fixed with 4% PFA for 10 minutes at room temperature. For staining, the 
coverslips were incubated with 1N HCL for 30 minutes at room temperature to hydrolyse the 
DNA. Then, the cells were permeabilised with PBS + 0.25% Triton X-100 for 10 minutes at 
room temperature. Following permeabilization, the coverslips were blocked in Dako
®
 Protein 
Block Serum-Free for 30 minutes at room temperature. The coverslips were washed once 
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with PBS before incubation in a 60 µL volume of 1:20 sheep anti-BrdU overnight at 4°C in a 
humidified chamber. The following day, unbound primary antibody was washed off three 
times with PBS before the coverslips were incubated with donkey anti-sheep IgG antibody 
conjugated to Alexa 633 for 45 minutes at room temperature in a humidified chamber. 
Unbound secondary antibody was then washed off three times with PBS. The coverslips were 
individually dipped three times in a pocket of dH2O to remove the excess salt and then left to 
dry for 5 minutes at room temperature in a dark room. Next, the coverslips were mounted 
with ProLong™ Gold Antifade Mountant with DAPI (ThermoFisher Scientific) to stain the 
nucleus in blue and then cured in a dark room at room temperature. The coverslips were then 
sealed by nail varnish.  
For BrdU proliferation assay analysis, the percentage of cells in S-phase of the cell cycle was 
determined by dividing the number of the BrdU-labelled cells by the total number of cells (as 
determined by DAPI staining) on the coverslip. 
2.16. Protein and FA turnover assay 
In this assay, 1x10
6
 ECs were double nucleofected with Ctrl-siRNA or NRP2-siRNA and 
GFP-paxillin constructs (3 µg) or ITGA5-GFP constructs (tested 3–8µg) (both kindly 
provided by Dr Maddy Parsons, King’s College, London) and seeded in 10-cm dishes pre-
coated with 10 µg/ml FN for 24 hours at 37°C in a 5% CO2 incubator. After 24 hours, the 
cells were washed with PBS, trypsinised, counted, and seeded at a low density of 4x10
4
 cells 
per condition on acid-washed/oven-sterilised glass coverslips (2 per well in a 6-well plate) 
pre-coated with 10 µg/ml FN for another 24 hours at 37°C in a 5% CO2 incubator. Forty-
eight hours post nucleofection, one coverslip at a time was washed once with pre-warmed 
PBS, fixed carefully in a Ludin chamber (Life Imaging Services GmbH, Basel, Switzerland), 
and live-imaged in OptiMEM
®
 phenol-red free medium supplemented with 2% FBS and P/S 
at 37°C and 5% CO2 using an inverted Axiovert (Carl Zeiss Ltd) microscope in which an 
individual cell was captured every one minute for 30 minutes. 
The focal adhesion assembly and disassembly speeds were analysed by manually tracking the 
number of selected GFP-paxillin-positive focal adhesions using the Image J
TM
 MTrackJ 
plugin software. 
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2.17. Immunocytochemistry  
ECs were treated with siRNA (Ctrl-siRNA or NRP2-siRNA) and seeded on 10-cm dishes 
pre-coated with 10 µg/ml FN at 37°C for 36 hours in a 5% CO2 incubator. The following day, 
acid-washed/oven-sterilised glass coverslips were placed into each well of a 6-well plate (4 
per well) and coated overnight with 10 µg/ml FN at 4°C. Thirty-six hours post nucleofection, 
the cells were washed with pre-warmed PBS, trypsinised, counted, and seeded at low density 
on the aforementioned coverslips for 12 hours. The cells grown on the coverslips were 
carefully washed twice with pre-warmed PBS before performing a fixation step with 4% PFA 
for 10 minutes at room temperature. This step was followed by cell permeabilization with 
0.25% Triton X-100 in PBS for 10 minutes at room temperature. Next, the permeabilised 
cells were blocked by with 5% BSA + 1% goat/donkey serum (depending on the secondary 
antibody used) in PBS in a 6-well plate at room temperature for 30 minutes. The ECs were 
then incubated overnight in a humidified chamber at 4°C with 60 µL of the required primary 
antibodies in PBS: anti-ITGA5 at 1:250; anti-NRP2 (various dilutions tested: 1:100, 1:150 
and 1:200). Two washes with PBS were performed to remove the unreacted primary 
antibody, followed by incubation with fluorescently labelled secondary antibodies in PBS at 
1:500 for 1 hour at room temperature in a dark room. Next, three washes with PBS were 
performed followed by one wash with dH2O before drying the coverslips for 5 minutes at 
room temperature in a dark room. The coverslips then were mounted with ProLong™ Gold 
Antifade Mountant with DAPI. The coverslips were then cured overnight at room 
temperature in a dark room. Finally, the coverslips were sealed with nail varnish around their 
edge and allowed to dry for 1 hour at room temperature. At this stage, the coverslips were 
either stored at 4°C or imaged directly using an Axioplan Epifluorescent microscope (Carl 
Zeiss Ltd) and the AxioCam MRm camera (Carl Zeiss Ltd). 
ITGA5 was analysed by measuring the length of ITGA5 in both siRNA-treated conditions 
using the ImageJ™ software plugin (simple neurite tracer). 
2.18. Immunoprecipitation  
One day before the experiment was performed, 10-cm dishes were coated overnight with 10 
µg/ml FN at 4°C. The ECs were washed with pre-warmed PBS, detached with 0.25% trypsin-
EDTA, neutralised with IMMLEC, and then counted and nucleofected as described in section 
2.7 by either Ctrl-siRNA or NRP2-siRNA and seeded at a density of 2x10
6
 cells per 10-cm 
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dish that had been pre-coated with 10 µg/ml at 37°C in a 5% CO2 incubator. Forty-eight 
hours later, the ECs were placed on ice, washed twice with cold PBS, and then lysed in a cold 
lysis buffer [25mM Tris-HCl (pH 7.6), 100mM NaCl, 0.15% Tween-20, 5% glycerol, 0.5mM 
ethylene glycol tetra acetic acid (EGTA), and Halt
®
 Protease and Phosphatase inhibitor 
cocktail (1:100)] using a rubber policeman. The lysates were transferred to correspondingly 
labelled 1.5-mL Eppendorf tubes, incubated for 20 minutes on ice, and then centrifuged at 
15,000 g for 20 minutes at 4°C. The amount of protein per lysate was quantified using the 
DC™ protein assay as described in section 2.9.1. Protein-G Dynabeads® (Invitrogen) were 
washed once with 200 µL of 0.02% Tween
®
-20/PBS and then coupled to the antibody of 
interest (NRP2 or biotin) in a tube rotator for 10 minutes at room temperature. Next, the tubes 
were placed in the magnet, the supernatant was removed, and the coupled Dynabeads-
antibody complex was washed once with 200 µL of 0.02% Tween
®
-20/PBS. The tubes were 
placed back in the magnet, and the supernatant was discarded before the coupled Dynabeads-
antibody complex was immunoprecipitated with an amount equivalent to 1,200 µg of total 
protein from each sample overnight in a tube rotator at 4°C. The following day, the 
immunoprecipitated samples were washed three times with 200 µL of the lysis buffer, once 
with 100 µL of PBS, and then transferred to new 1.5-mL Eppendorf tubes to avoid the co-
elution of proteins bound to the tube wall. The tubes were placed in the magnet, and the 
supernatant was discarded. To detect the NRP2 co-associated proteins, the 
immunoprecipitated Dynabeads complex was eluted with 1X NuPAGE
®
 sample buffer in 
H2O in a total volume of 20 µL, heated at 95°C for 5 minutes, and separated by SDS-PAGE. 
The proteins were transferred to nitrocellulose, probed with anti-ITGA5, and detected by 
chemiluminescence as described in the subsection 2.9.3 to 2.9.5. For silver staining or mass 
spectrometry, the immunoprecipitated Dynabeads complex was eluted in 20 µL of high-SDS 
lysis buffer.  
2.18.1. Silver staining 
The silver staining assay was performed to confirm the efficiency of NRP2 
coimmunoprecipitation. Briefly, from 20 µL of the eluted Dynabeads complex, 5 µL was 
mixed with 1X NuPAGE
®
 sample buffer, heated at 95°C for 5 minutes and then separated by 
SDS-PAGE. The remaining 15 µL drawn from each coimmunoprecipitated sample were 
stored at -20°C for the mass spectrometry. The SDS-PAGE gel was silver stained as 
described by the manufacturer using Pierce™ Silver Stain (ThermoFisher Scientific). The 
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efficiency of NRP2 coimmunoprecipitation was confirmed by comparing the 
immunoprecipitated samples to 1 µl of total cell lysate (TCL). The SDS-PAGE gel was 
placed in a single clean tray, washed twice at 5 minutes each in ultrapure water and then fixed 
twice at 15 minutes each in a 30% ethanol: 10% acetic acid solution. Following fixation, the 
SDS-PAGE gel was subjected to a series of washes: two washes at 5 minutes each in 10% 
ethanol; two washes in ultrapure water; one wash for 1 minute in a sanitiser working solution; 
and two washes in ultrapure water. The SDS-PAGE gel was then stained for 30 minutes in a 
stain working solution followed by washing twice in ultrapure water at 20 seconds each. 
Next, the stain was developed in a developer working solution until the bands on the gel 
appeared (2–3 minutes). When the density of the bands reached the required degree, the SDS-
PAGE gel was treated with 5% acetic acid for 10 minutes to stop the development of the 
bands.  
2.18.2. Mass spectrometry 
After confirming the efficiency of the coimmunoprecipitation samples in the silver staining 
experiment, 15 µL of the remaining coimmunoprecipitation samples were sent to the 
Fingerprints Proteomics Facility (Dundee University, Dundee, UK), which carried out label-
free quantitative mass spectrometry and peptide identification using the MaxQuant software 
based on the Andromeda peptide database as described by (Schiller, Friedel et al. 2011). Each 
sample was analysed in three technical repeats using a mass spectrometer machine. Non-
statistical analysis was performed to visually represent the data with no assumption about the 
number of repeat. The Log 2 of peptides detected more in the immunoprecipitaed Ctrl-siRNA 
samples than that in NRP2-depleted samples were considered as specific binding partner 
proteins with NRP2, whereas those detected more in the NRP2-depleted samples than that in 
Ctrl-siRNA were considered as non-specific binding partners with NRP2. 
2.19. Flow cytometry (FC) 
ECs were trypsinised, counted, nucleofected with either Ctrl-siRNA or NRP2-siRNA, and 
seeded in 10-cm dishes that had been pre-coated with 10 µg/ml FN for 48 hours at 37°C in a 
5% CO2 incubator. Untreated ECs were also seeded in 10-cm dishes that had been pre-coated 
with 10 µg/ml FN and incubated for 48 hours at 37°C in a 5% CO2 incubator. For the flow 
cytometric analysis, the ECs were detached using a pre-warmed sodium saline buffer (1.35M 
potassium chloride and 0.15M sodium citrate) for 4–5 minutes at 37°C in a 5% CO2 
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incubator. They were then neutralised with IMMLEC medium and centrifuged at 500 g for 4 
minutes. Next, a 1x10
6
 EC pellet from each condition (Ctrl-siRNA, NRP2-siRNA, and 
untreated ECs) was resuspended in 1 mL of fluorescence activated cell sorting (FACS) buffer 
(1% FBS in PBS + 1mM CaCl2 + 1mM MgCl2), transferred to an Eppendorf tube, and then 
centrifuged at 270 g for 4 minutes at 4°C. The supernatant was then removed. A second wash 
with 1 mL FACS buffer and centrifugation at 270 g for 4 minutes at 4°C were performed 
before transferring 100 µL (i.e., 1x10
5
 ECs) from each condition to new Eppendorf tubes. 
Next, the ECs in each Eppendorf tube were incubated for 30 minutes at 4°C with the 
following labelling antibodies (used at 1:200): PE-anti-mouse CD49e (ITGA5); Arm. 
hamster IgG isoform control. The tubes were centrifuged at 270 g for 4 minutes at 4°C. The 
pellet in each tube was then washed and centrifuged twice at 4°C with 500 µL FACS. The 
cell pellet in each tube was then resuspended in 300 µL of cold FACS buffer and transferred 
to a flow cytometric tube (Sarstedt Ltd, Leicester, UK). Finally, the cell surface receptor 
proteins were measured using CytoFLEX flow cytometry (Beckman Coulter, Brea, USA) and 
analysed using FlowJo software
TM
 (FlowJo LLC, Ashland, Oregon).  
2.20. Subcellular protein fractionation assay 
ECs were treated with Ctrl- or NRP2-siRNA as described in section 2.7. Then, the 
nucleofected ECs were seeded in two 10-cm dishes that had been pre-coated with 10 µg/ml 
FN per condition at a density of 2x10
6
/dish for 24 hours at 37°C in a 5% CO2 incubator. The 
cells from each condition were trypsinised, counted, and seeded in a T75 flask that had been 
pre-coated with 10 µg/ml FN at a density of 3x10
6
/flask for 24 hours at 37°C in a 5% CO2 
incubator. The cells were detached with sodium saline buffer, transferred to 50-mL 
centrifuged tubes, centrifuged at 500 g for 4 minutes, washed once with PBS, and then 
transferred to 1.5-mL centrifuged tubes. The supernatants were carefully discarded, and the 
obtained pellets were subjected to the cellular protein fractionation assay as described by the 
manufacturer (ThermoFisher Scientific) to sequentially extract proteins located in five 
different cellular compartments: the cytoplasm, cellular membranes, soluble nucleus, 
chromatin-bound nucleus, and cytoskeleton. The sequential extraction of the proteins was 
based on different extraction buffers and different centrifugation speeds. Briefly, ice-cold 
cytoplasmic extraction buffer (CEB) was added to the cell pellet of each siRNA-treated EC 
(Ctrl-siRNA and NRP2-siRNA), incubated at 4°C for 10 minutes, and centrifuged at 500 g 
for 5 minutes. The supernatant (cytoplasmic extract) was immediately transferred to a new 
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1.5-mL centrifuged tube on ice. Then, ice-cold membrane extraction buffer (MEB) was 
added to the cell pellet, which was incubated at 4°C for 10 minutes and centrifuged at 3,000 g 
for 5 minutes. The supernatant (membrane extract) was immediately transferred to a new 1.5-
mL centrifuged tube on ice. Then, ice-cold nuclear extraction buffer (NEB) was added to the 
cell pellet, incubated at 4°C for 10 minutes, and centrifuged at 5,000 g for 5 minutes. The 
supernatant (soluble nuclear extract) was immediately transferred to a new 1.5-mL 
centrifuged tube on ice. Then, NEB at room temperature was added to the cell pellet, 
incubated at room temperature for 15 minutes, and centrifuged at 16,000 g for 5 minutes. The 
supernatant (chromatin-bound nuclear extract) was immediately transferred to a new 1.5-mL 
centrifuged tube on ice. Next, pellet extraction buffer (PEB) at room temperature was added 
to the cell pellet, incubated at room temperature for 15 minutes, centrifuged at 16,000 g for 5 
minutes. The supernatant (cytoskeletal extract) was immediately transferred to a new 1.5-mL 
centrifuged tube. Finally, the extracted proteins from the five cellular compartments were 
separated by SDS-PAGE, and then a Western blot analysis was performed as described in the 
subsection 2.9.3 to 2.9.5.  
The analysis was performed by normalising the total level of ITGA5 in each compartment to 
the total level of the control protein for that compartment: ERK1/2 for cytoplasmic extract; 
VEGFR2 for cellular membrane extract; vimentin for cytoskeletal extract. 
2.21. Protein stability assay 
ECs were treated with either Ctrl- or NRP2-siRNA as described in section 2.7 and seeded in 
a T75 flask that had been pre-coated with 10 µg/ml FN per condition at a density of 
4x10
6
/flask for 24 hours at 37°C in a 5% CO2 incubator. The cells were trypsinised, counted, 
centrifuged, resuspended in serum-free OptiMEM
®,
 and seeded per condition at a density of 
2x10
6
 cells in two 10-cm dishes that had been pre-coated with 10 µg/ml FN for 12 hours at 
37°C in a 5% CO2 incubator. Then, 10 µg/ml of cycloheximide (Cell Signalling Technology) 
was added to one dish per condition for eight hours as described by (Sampieri, Nuttall et al. 
2008); the second dish was left untreated as the control. Following lysing the cells with high-
SDS lysis buffer, the amount of protein per lysate was quantified by the DC™ protein assay, 
separated by SDS-PAGE, and subjected to a Western blot analysis as described in the 
subsection 2.9.3 to 2.9.5 to determine NRP2 and ITGA5 stability. 
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Using the ImageJ™ software, the ITGA5 densitometry in the samples treated with 
cycloheximide was compared to that in the untreated samples.  
2.22. Protein cell surface internalisation assay 
ECs were treated with either Ctrl-siRNA or NRP2-siRNA, as described in the nucleofection 
protocol (see section 2.7), and seeded at a density of 2x10
6 
cells per 10-cm dish (total of 12 
dishes), which had been pre-coated with 10 µg/ml FN, for 48 hours at 37°C in a 5% CO2 
incubator (see chapter 5; Figure 5.6 A). The cells were washed with pre-warmed PBS to 
remove excess IMMLEC medium and then starved in pre-warmed serum-free OptiMEM
®
 for 
3 hours at 37°C in a 5% CO2 incubator. Following starvation, the dishes were placed on ice 
for 5 minutes, followed by two washes with ice-cold Soerensen buffer (SBS) 7.8 pH 
(14.7mM KH2PO4, 2mM Na2HPO4, and 120mM Sorbitol pH 7.8) (Remacle, Murphy et al. 
2003). Next, the EC cell surface proteins were labelled with 0.3 mg/ml of EZ-Link Sulfo-
NHS-SS-Biotin (TheromFisher Scientific) in SBS 7.8 pH for 30 minutes at 4°C. Then, SBS 
containing biotin solution was poured off, and the unreacted biotin was quenched with 
100mM glycine for 10 minutes at 4°C. Another two washes with ice-cold SBS pH 7.8 were 
conducted to remove excess glycine solution. Next, one dish per siRNA-treated cells (i.e., a 
dish from Ctrl-siRNA and NRP2-siRNA) was incubated in pre-warmed serum-free 
OptiMEM
® 
for 2, 4, 10, and 20 minutes (total of 8 dishes) at 37°C in a 5% CO2 incubator. 
Simultaneously, two dishes per siRNA-treated ECs (total of 4 dishes) were maintained at 4°C 
for use as positive/negative (+/- Mesna) controls (see below). The incubation step was 
performed to allow the labelled cell surface proteins to internalise inside the cells at different 
time points. After each incubation time, the dishes were immediately placed on ice to stop the 
internalisation of the cell surface proteins, which was followed by two washes with ice-cold 
SBS pH 8.2. Next, all 10 dishes were incubated with 100mM Mesna (2-mercaptoethane 
sulfonate Na) (Sigma-Aldrich) to strip the biotin from the cell surfaces in SBS pH 8.2 or Tris 
base buffer (50mM Tris-HCl, pH 8.6; 100mM NaCl) for 75 minutes at 4°C, with the 
exception of two (- Mesna) control dishes (a dish from each siRNA-treated EC) were 
immediately lysed in lysis buffer (25mM Tris-HCl, pH 7.4, 100mM NaCl, 2mM MgCl2, 
1mM Na3VO4, 0.5 mM EGTA, 1% Triton X-100, 5% glycerol, and protease inhibitors) and 
then transferred to 1.5-mL tubes on ice. The (- Mesna) controls were used to determine the 
total biotin-labelled cell surface proteins on the EC plasma membranes. The (+ Mesna) 
controls were used to determine the efficacy of biotin removal from the surface of the EC 
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cells. Following the biotin stripping step, the Mesna solution was poured off, and the excess 
Mesna was quenched with 100mM iodoacetamide (Sigma-Aldrich) for 10 minutes at 4°C. 
The ECs in all dishes were washed twice with SBS pH 8.2 and then lysed. The lysates were 
transferred to 1.5-mL tubes on ice. Then, the lysates were cleared by centrifugation at 12,000 
g for 20 minutes at 4°C. The supernatant proteins were placed in clean 1.5-mL tubes and 
quantified using a DC™ protein assay in the subsection 2.9.1. The equivalent protein 
concentration in each sample was immunoprecipitated with Dynabeads-coupled to mouse 
anti-biotin antibody overnight at 4°C as described in the immunoprecipitation assay (see 
section 2.18). The immunoprecipitated biotin-labelled proteins were separated by SDS-
PAGE and then subjected to a Western bolt analysis. 
The densitometry analysis of the ITGA5 bands was measured using Image J
TM
 software. The 
level of the internalised ITGA5 at each time of incubation was normalised to the (- Mesna) 
control, that is, the total ITGA5 on the plasma membrane.   
2.23. Protein cell surface recycling assay 
ECs were treated with siRNA (Ctrl-siRNA or NRP2-siRNA) and seeded at a density of 2x10
6 
cells per 10-cm dish (total of 20 dishes) pre-coated with 10 µg/ml FN for 48 hours at 37°C in 
a 5% CO2 incubator (see chapter 5; Figure 5.7 A). EC starvation, cell surface protein 
labelling, and biotin quenching were all performed in the same manner as the internalisation 
assay (see section 2.22). Following another two washes with ice-cold SBS pH 7.8 to remove 
any excess of glycine solution, eight dishes per siRNA-treated ECs (total of 16 dishes) were 
incubated in pre-warmed serum-free OptiMEM
® 
for 20 minutes  at 37°C in a 5% CO2 
incubator to allow all biotin-labelled cell surface proteins to internalise in the ECs. Two 
dishes per siRNA-treated ECs (total of 4 dishes) were maintained at 4°C for use as positive 
and negative controls. The rest of dishes were immediately transferred to ice to stop the 
internalisation process, which was followed by two washes with ice-cold SBS pH 8.2. Any 
un-internalised biotin-labelled proteins were then stripped off by treatment with 100mM 
Mesna in Tris buffer for 75 minutes at 4°C. Next, two dishes for each subsequent time point 
(i.e., two dishes of Ctrl-siRNA-treated cells and two dishes of  NRP2-siRNA-treated cells per 
condition) were incubated in pre-warmed serum-free OptiMEM
® 
for 2, 4, 10, and 20 minutes 
(total of 8 dishes per siRNA treatment) at 37°C in a 5% CO2 incubator. This incubation step 
was performed to allow recycling of the already internalised biotin-labelled proteins back to 
the plasma membranes. After each incubation time, the dishes were immediately placed on 
 120 
ice to stop the recycling process, which was followed by two washes with ice-cold SBS pH 
8.2. One dish from each condition was subjected to Mesna incubation for 75 minutes at 4°C 
to strip off the recycled biotin-labelled proteins. The second dish was left at 4°C with no 
Mesna treatment. After the biotin was stripped, the Mesna solution was poured off, and the 
excess Mesna was quenched with 100mM Iodoacetamide for 10 minutes at 4°C. The cell 
lysing, biotin immunoprecipitation, protein separation by SDS-PAGE, and Western blot 
analysis for ITGA5 were performed in the same manner as the internalisation assay (see 
section 2.22).  
The densitometry analysis of the ITGA5 bands was measured using ImageJ
TM
 software. The 
level of the recycled ITGA5 in the EC plasma membranes was determined by normalising the 
amount of ITGA5 in each siRNA-treated cell to the total amount of ITGA5 on the EC plasma 
membranes of the Mesna-untreated cells in the same period of incubation. 
2.24. Building shRNA constructs 
2.24.1. Target sequence selection  
Based on the criteria of the PSICOLIGOMAKER1.5 programme, which were established by 
Ventura et al. (Ventura, Meissner et al. 2004), our target sequences and the shRNA 
oligonucleotides (Oligo) were selected and designed, respectively. Briefly, the mouse NRP2 
gene sequence (ENSMUSG00000025969) was first downloaded from the Ensemble 
Genomes Database Project browser, which was established by Hubbard et el. (Hubbard, 
Barker et al. 2002). The sequence was then pasted in the sequence window displayed in the 
PSICOLIGOMAKER1.5 programme, and a cut-off value (from -2 to 9) was selected before 
clicking “search”. Based on the criteria established by Reynolds et al. (Reynolds, Leake et al. 
2004), all potential 19 oligomers (19-mers) were then listed in the right window in addition to 
a score equal or higher than the cut-off value. Reynolds et al. demonstrated that 19-mers with 
a value higher than 6 exhibited an approximately 90% chance of silencing of the target 
messenger RNA (mRNA). Because no target sequence higher than 7 were listed by the 
programme, only the target sequences containing 19-mers with a score of 7 were selected. 
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2.24.2. Oligomer design 
Using the PSICOLIGOMAKER1.5 programme, the selected target sequences were simply 
pasted in the left “target” window, where both the forward (sense) and reverse (antisense) 
oligos (in the 5' to 3' orientation) were generated by applying the following formulas:  
Sense: 5’-T-(complement sequence of 19-mers)-TTCAAGAGA-(reverse complement 
sequence of 19-mers)-TTTTTTC-3’  
Antisense: 5'-TCGAGAAAAAA-(complement sequence of 19-mers)-TCTCTTGAA-
(reverse complement sequence of 19-mers)-A-3’ 
Following the design of the oligos, 5’phosphorylated oligos were ordered (Invitrogen) and 
resuspended accordingly in nuclease-free water (ThermoFisher Scientific) for 30 minutes at 
room temperature to a final concentration of 100µM. The oligos were then stored at -80°C 
until they were needed. 
2.24.3. Vector digestion and extraction 
The pSico vector (Plasmid for Stable Interference Condition) and the pSico reverse vector 
(pSicoR), which are based on the pLL3.7 lentiviral vector developed by Rubinson et al. 
(Rubinson, Dillon et al. 2003), were ordered from Addgene (Cambridge, US). The pSico or 
the pSicoR vector was then digested with Hpal and Xhol restriction enzymes on a heat block 
at 37°C for 1 hour. The reaction for each digested plasmid was prepared as follows: 10 µg of 
vector; 1 µl of Xho1; 3 µl of Hpa1; 5 µl of CutSmart Buffer (New England Biolabs, Hitchin, 
UK) and nuclease-free water to a total volume of 50 µL. Next, the digested vectors were 
mixed with 6X gel loading dye (New England Biolabs) before being separated in 1% agarose 
gel at 100 V for 90 minutes. Under a long-wave UV light, the DNA bands were cut using a 
scalpel, and the gel blocks were transferred to 1.5-mL tubes. Using the QIAquick Gel 
Extraction Kit (QIAGEN), the digested vectors were extracted and then eluted in 30 µL of 
elution buffer (EB) as described by the manufacturer. Vector concentrations were quantified 
using a NanoDdrop ND-1000 UV/Vis spectrophotometer (NanoDrop Technologies Inc, 
Wilmington, US).  
2.24.4. Oligo annealing 
Following resuspension, the oligos were annealed as suggested by Ventura et al. (Ventura, 
Meissner et al. 2004). Briefly, the annealing reaction for each target sequence was first 
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prepared in one well of a 96-well PCR plate in a total volume reaction of 50 µL as follows: 
23 µL of nuclease-free water; 1 µL of sense oligo; 1 µL of antisense oligo; and 25 µL of 2X 
annealing buffer (200mM potassium acetate, 60mM HEPES-KOH pH 7.4, and 4mM 
magnesium acetate). Next, the PCR plate was placed in a programmed thermal cycler PCR 
machine in which the annealing reaction started with a denaturation step at 95°C for 4 
minutes, followed by annealing step at 70°C for 10 minutes, and finally a slow cooling step at 
4°C.  
2.24.5. Vector-oligo (pconstruct) ligation 
The ligation of each annealed oligo to the digested vector (pSico or pSicoR) was performed 
in a well of a 96-well PCR plate in a total volume reaction of 10 µL ligation reaction, as 
suggested by Ventura et al. (Ventura, Meissner et al. 2004). Briefly, 1 µL of each annealed 
oligo was first diluted in 19 µL of nuclease-free water. Next, 1 µL of the diluted oligo was 
mixed with the following: 100 ng of digested vector; 1 µL of 10X ligation buffer; 1 µL of T4 
DNA ligase (New England Biolabs, Hitchin); and nuclease-free water to a total reaction of 10 
µL. The ligation was performed overnight at 16°C.  
2.24.6. Bacterial transformation and colony selection  
One Shot Stb13 chemically competent E. coli (Invitrogen) was used. The ligated plasmid was 
transferred to E. coli as described by the manufacturer. Briefly, 1 µL from pSico or pSicoR 
plasmid was transferred to a vial of E. coli bacteria, thawed on ice for 30 minutes, heat-
shocked for 45 seconds at 42°C, and then placed on ice for 2 minutes before 250 µl of pre-
warmed SOC medium was added to each bacterial vial. The vials were incubated in an 
Innova
™
 4330 incubator shaker (New Brunswick Scientific, Cambridge, UK) for 1 hour. 
Next, 100 μL of the transformation from each bacterial vial was spread on 1.5% agar 
containing 100 µg/ml ampicillin, and the plates were incubated overnight at 37°C in an 
inverted manner. Using one sterile pipette tip per bacterial colony, 6–10 colonies were 
randomly selected and grown in 25-mL tubes containing 2 mL of sterile lysogeny broth (LB) 
medium supplemented by 100 µg/mL ampicillin in an Innova
™
 4330 incubator shaker 
overnight at 37°C.  
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2.24.7. Plasmid miniprep 
Using EZNA
® 
Plasmid DNA Mini kit (Omega Bio-Tek, Norcross, US), plasmid DNA was 
isolated as described by the manufacturer at room temperature. Briefly, 1 mL of overnight-
cultured bacteria from each selected colony was centrifuged at 10,000 g for 1 minute. The 
generated pellet was then resuspended in 250 µL of buffer containing RNase. This step was 
followed by the addition of 250 µL SDS-based lysis buffer for 2–3 minutes and then 350 µL 
of a precipitation buffer. A centrifugation step at a maximum speed (> 13,000 g) for 10 
minutes was then performed to generate a compact white pellet. The supernatant was 
carefully passed through a HiBind
®
 DNA Mini collection column tube by centrifugation at 
maximum speed for 1 minute, followed by the addition of 350 µL of a high salt washing 
buffer containing isopropanol to the DNA collected in the column tube and centrifugation at 
maximum speed for 1 minute. The collected DNA was then washed twice with 700 µL DNA 
washing buffer containing 100% EtOH, followed by centrifugation at a maximum speed and 
a drying step. The collected DNA was then eluted in a new 0.5-mL centrifuge tube with 30–
50 µL of an EB pre-heated at 70°C. Then, the plasmid concentration was quantified using a 
NanoDdrop spectrophotometer.  
2.24.8. Plasmid digestion and positive clone detection  
The collected pSico or pSicoR plasmid from the plasmid miniprep was subjected to a 
digestion test with restriction enzymes to detect the plasmids containing the target sequences 
(i.e., positive clones). Briefly, 1,000 ng/µl of pSico and pSicoR plasmid was digested with 
SacII-NotI and XhoI-XbaI (New England Biolabs), respectively, in 10X buffer-2 (New 
England Biolabs) and nuclease-free water in a total volume of 20 µL for 1 hour on a heat 
block at 37°C. The activity of the restriction enzymes in buffer-2 was used as suggested by 
the manufacture as follows: Not I (50%); SacII (100%); XhoI (100%); and XbaI (100%). 
Next, the digested plasmids were mixed with 6X gel loading dye before being separated in 
2% agarose gel at 100 V for 90 minutes. The digested pSico plasmid released 701-bp 
(positive cloning) and 646-bp (negative cloning), whereas the digested pSicoR released 374-
bp (positive cloning) and 319-bp (negative cloning) DNA fragments.  
2.24.9. Sequencing and plasmid maxiprep 
The positive clones were sent to Source BioScience Ltd (Cambridge) to carry out Sanger 
sequencing using the following primers (Ventura, Meissner et al. 2004): 
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pSico: 5’-CAAACACAGTGCACACCACGC-3’ 
pSicoR: 5’-TGCAGGGGAAAGAATAGTAGAC-3’ 
Next, the verified positive clone sequence was subjected to EZNA® FastFilter Plasmid DNA 
Maxi Kit (Omega Bio-Tek) to generate high-copy plasmids (yield of 1.5 to 3 mg) as 
described by the manufacturer. Briefly, 100 mL of overnight cultural bacteria was centrifuged 
at 4,000 g for 10 minutes. Similar to the plasmid miniprep, the generated pellet was 
resuspended with a 10 mL buffer containing DNase followed by addition of 10 mL lysis 
buffer. Next, 5 mL of neutralisation buffer was added and gently inverted for 2 minutes. 
When flocculent white precipitates were formed, 8.3 mL of binding buffer was added and 
gently inverted 4 times. Then, the lysates were transferred to the lysate clearance filter 
syringe provided in the kit. The cleared lysate was expelled through a filter into a 50-mL 
centrifuge tube by gently inserting a plunger into the barrel. The cleared supernatant was 
passed through a HiBind
®
 DNA Maxi Column into a 50-mL tube and then centrifuged at 
4,000 g for 3 minutes. As in the plasmid mini prep, the collected plasmid was washed once 
with a 10 mL high slat buffer containing isopropanol and twice with a 10 mL DNA washing 
buffer containing EtOH. Finally, the DNA was then then eluted with 1 mL of EB. 
2.24.10. Lentivirus production  
Lentivirus was generated by co-transfecting HEK293 using the ViraPower™ Packaging Mix 
(a mixture of the optimised pLP1, pLP2, and pLP/VSVG plasmids in TE buffer, pH 8.0) 
(Invitrogen) as described by the manufacturer. Briefly, the HEK293 cells were seeded at a 
density of 5x10
6
 cells per 10-cm dish in high-glucose DMEM medium (10% FBS, 2mM 
GlutaMAX™) overnight at 37°C in a 5% CO2 incubator. On the following day, 9 µg of 
ViraPower™ Packaging Mix was mixed gently with 3 µg of each positive clone plasmid 
(pSico or pSicoR) DNA in a sterile 5-mL tube containing 1.5 mL serum-free OptiMEM
®
 
medium (no P/S). Additionally, 36 µg of Lipofectamine
TM
 2000 (Invitrogen) was gently 
mixed with 1.5 mL serum-free OptiMEM
®
 medium in a separate sterile 5-mL tube for 5 
minutes at room temperature. Next, the solutions in the two tubes were combined and 
incubated for another 20 minutes at room temperature to allow the plasmid construct-
Lipofectamine
TM
 2000 complex to form. During the incubation step, high-glucose DMEM 
medium was removed from the 90–95% confluent overnight-cultured HEK293 and replaced 
by 5 mL serum-free OptiMEM
®
 medium in each dish of cells. After 20-minutes incubation, 
the plasmid construct-Lipofectamine
TM
 2000 complex was added in drops to each dish of 
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cells, rocked back and forth gently, and incubated overnight at 37°C in a 5% CO2 incubator. 
On the following day, the medium containing the plasmid-Lipofectimin
TM
 2000 complex was 
replaced by fresh 10 mL serum-free OptiMEM
®
 medium and the dishes placed back in the 
incubator for another 48 hours before harvesting.  
2.24.11. Concentrating lentivirus   
The lentiviruses were harvested by filtering the cultured medium containing the supernatant 
virus through a 0.45 µm polyether sulfone filter (Sigma-Aldrich) into a sterile 15-mL tube. 
One volume of the Lenti-X concentrator (Takara Bio Inc, Mountain View, US) was added to 
3 volumes of the clarified supernatant, gently mixed by inversion, and the tubes incubated 
overnight at 4°C. Next, the mixture was centrifuged at 1,500 g for 45 minutes at 4°C. The 
supernatant was carefully and safely discarded, and the generated white pellet was then 
resuspended in 1/10 of the original volume by serum-free OptiMEM
®
 medium. Immediately, 
the lentivirus was tittered or stored at -80°C in single-use aliquots.  
2.24.12. Lentivirus titering 
Lentivirus titre estimation by transduction is a tittering technique based on the serial dilution 
of the concentrated virus. This technique was used as previously described (Wollebo, 
Woldemichaele et al. 2013). HEK293 cells were washed with PBS, trypsinsed, counted and 
centrifuged as described above (see section 2.4). Then, the cell pellet was resuspended in a 
high-glucose DMEM medium, seeded at a density of 2x10
4
 cells per well of a 6-well plate 
that had been pre-coated with 0.1% gelatin and incubated overnight at 37°C in a 5% CO2 
incubator. On the following day, the cells in each well were washed once with PBS and then 
incubated with 2 mL of high-glucose DMEM medium containing 8 µg/mL polybrene plus a 
serial dilution of the concentrated virus in each well of the 6-well plate for 48 hours at 37°C 
in a 5% CO2 incubator. The serial dilutions used for titering each concentrated lentivirus were 
1, 2, 4, 8, 32, and 64 µL. For the lentiviral titering and estimating the equivalent amount of 
each lentivirus needed for experimental use, the cells were imaged in a Zeiss axiovert 40/cfl 
inverted microscope and a green channel, and the percentage of GFP-expressing cells was 
calculated for each lentiviral prepared at all the dilutions described above.  
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2.24.13. Plasmid transfection and infection 
2.24.13.1. Immortalised mLMECs transfection with shRNAs constructs  
The mLMECs were nucleofected with pSicoR constructs as described in the nucleofection 
protocol (see section 2.7) and seeded in 6-well plates that had been pre-coated with 0.1% 
gelatin for 48 hours at 37°C in a 5% CO2 incubator. The cells were lysed with high-SDS lysis 
buffer, and the lysates were quantified by the DC™ protein assay, separated by SDS-PAGE, 
and then subjected to Western blot analysis, as described in the subsection 2.9.3 to 2.9.5, to 
determine NRP2 silencing compared to the control conditions. 
2.24.13.2. Primary lung ECs infection with lentivirus 
Lung ECs were isolated from pdgfb-iCreER mice as described in section 2.6.1.2. One day 
before the ECs were trypsinised, a 6-well plate was coated with 0.1% gelatin + 10 µg/mL FN 
+ 10 µg/mL collagen overnight at 4°C. The primary lung ECs were washed with PBS, 
trypsinised, counted, and seeded at a density of 2x10
6
 cells in MLEC medium per well of the 
pre-coated 6-well plate at 37°C in a 5% CO2 incubator. Twenty-four hours later, the MLEC 
medium was replaced by 2 mL of fresh MLEC medium (no P/S). Then, the ECs in each well 
were infected with the generated conditional lentiviruses carrying pSico shRNA constructs 
supplemented with 8 µg/mL of polybrene overnight at 37°C in a 5% CO2 incubator. The 
following day, the MLEC medium containing lentivirus in each well was replaced by 2 mL of 
fresh MLEC medium and placed back in the incubator. Forty-eight hours later, the ECs were 
checked for GFP signals using a Zeiss axiovert 40/cfl inverted microscope and a green 
channel. The ECs then received 2 mL of fresh MLEC medium supplemented by 1 μM of 4-
hydroxytamoxifen (OHT) to activate shRNA expression and then placed back in the 
incubator. Ninety-six hours later, the ECs were lysed with a high-SDS lysis buffer. The 
lysates were quantified by the DC™ protein assay, separated by SDS-PAGE, and then 
subjected to Western blot analysis as described in the subsection 2.9.3 to 2.9.5 to determine 
NRP2 silencing compared to the control condition.  
2.25. ex vivo aortic ring assay 
Thoracic aorta isolation and infection with lentivirus were performed as described by Baker 
et al. (Baker, Robinson et al. 2012). Briefly, thoracic aortas were isolated from 6- to 8-week 
old pdgfb-iCreERT2 mice and transferred to a 10-cm dish containing serum-free OptiMEM
®
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medium supplemented by P/S inside a sterile culture hood. Using a Stemi SV 11 
Stereomicroscopes (Carl Zeiss Ltd) inside a laminar flow cabinet (Labcaire Systems Ltd, 
Clevedon, UK), the thoracic aortas were carefully cleaned of any surrounding fat and 
connective tissues. Using a rounded scalpel, the aortas were then cut into rings approximately 
0.5 mm in width. Then, 20–25 aortic rings from different pooled mice were infected by the 
generated pSico lentivirus in each well of a 24-well plate in 1 mL serum-free OptiMEM
®
 
medium overnight at 37°C in a CO2 incubator. The following day, a sterile collagen 
embedding solution in water [1.2 mg/mL collagen I (Millipore, Watford, UK), 1X DMEM 
medium, and 1N sodium hydroxide (NaOH)] was prepared and mixed in a 50-mL tube on ice 
before adding 50 µL of the embedding solution to each well of a 96-well plate on ice. Using a 
dissection microscope inside a laminar flow hood, each aortic ring was embedded (lumen 
facing upright) in each well of the 96-well plate for 1 hour at 37°C in a 5% CO2 incubator to 
allow collagen polymerisation to occur. Next, the embedded rings were fed with 50 µL of 
serum-free OptiMEM
®
 medium + 2.5% FBS + 1 μM OHT supplemented or not with 30 
ng/mL VEGF every three days. Six days later, the serum-free OptiMEM
®
 growth medium 
was removed carefully, and the intact embedded rings were fixed with 4% PFA for 10 
minutes and then permeabilised with 0.25% Triton-X100/PBS for 30 minutes at room 
temperature. Two washes at 15 minutes each with PBLEC solution (1× PBS + 1mM CaCl2 + 
1mM MgCl2, 0.1mM MnCl2 and 1% Tween-20) were performed in a dark room before the 
blocking step was performed using 2% BSA in PBLEC for 30 minutes at room temperature. 
Next, the aortic rings were stained overnight with 50 µL FITC-conjugated BS-1 lectin 
(1:500) in PBLEC at 4°C in a dark room followed by three washes at 15 minutes each with 
0.1% Triton/PBS. Finally, the micro vessels sprouting from the rings were counted using a 
Zeiss axiovert 40/cfl inverted microscope and a green channel.  
2.26. Graphics and statistical significance analysis  
The graphic illustrations and the analyses to determine statistical significance were generated 
using the GraphPad Prism 6 software and Student’s t-tests, respectively. The bar charts show 
the standard error of the mean (+SEM). The asterisks indicate the statistical significance of P 
values: P > 0.05 = nsd (not significantly different), * P < 0.05, ** P < 0.01, *** P < 0.001 and 
**** P < 0.0001. 
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Chapter 3: An introduction to investigating potential links 
between ITGB3 and NRP2 
___________________________________________________________________________ 
 
It was previously shown that NRP1 in ECs affects VEGF-stimulated responses (migration, 
signaling and tumor growth/angiogenesis) in a ITGB3 dependent manner (Ellison, Atkinson 
et al. 2015). Because NRP1 and NRP2 share a similar domain structure, and an overall 44% 
amino acid homology (Zachary 2014), we thought it is possible that NRP2 function is 
similarly regulated by ITGB3 levels, or that NRP2 may compensate for the loss of NRP1 in 
NRP1-depleted cells. To investigate this, we isolated lung microvascular endothelial cells 
(mLMECs) from both wild-type (WT) and β3HET mice and immortalised them with PyMT 
by retroviral transduction, as described in chapter 2; section 2.2 and 2.3. We employed 
polyoma-middle-T-antigen immortalised ECs because: (1) they are easy and cost-effective to 
maintain in culture; (2) they allow us to reduce the number of experimental animals required 
for large biochemical studies, thus adhering to 3R principles (Russell, Burch et al. 1959), 
(Tannenbaum and Bennett 2015), (Carter and Shieh 2015); and (3) we and others have shown 
they present good models to study angiogenesis (Dong, Bernasconi et al. 1997), (Reynolds 
and Hodivala-Dilke 2006), (Robinson, Reynolds et al. 2009), (Burek, Salvador et al. 2012), 
(Ni, Kumar et al. 2014), (Steri, Ellison et al. 2014), (Ellison, Atkinson et al. 2015) 
3.1. Examining ITGB3 levels across a panel of polyomavirus middle-T-
antigen immortalized ECs. 
DNA was extracted from multiple immortalized lines, as described in the previous chapter, 
and analysed by PCR to confirm their genetic status as either WT or β3HET cells (Figure 3.1 
A-B).  We confirmed the endothelial cell identity of each clone by examining the expression 
of VE-Cadherin, an EC marker (Sivarapatna, Ghaedi et al. 2015), (Ikuno, Masumoto et al. 
2017). We also quantified ITGB3 expression in each cell line (Figure 3.1 C-D) and 
confirmed that β3HET ECs expressed approximately 50% less ITGB3 compared to their WT 
counterpart ECs (Figure 3.1 E). It is worth noting, however, the level of ITGB3 expression 
varied across the independent lines. It will become clear in the subsequent chapter why this is 
important.  
.   
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A)  
 
B)  
 
 
C)                                                                                 D) 
               
 
E)  
 
Figure 3.1 β3-integrin genotyping and expression level analyses of immortalised EC lines. PyMT mLMECs were 
seeded in 10-cm dishes pre-coated with gelatin and incubated overnight at 37°C in a CO2 incubator. After trypsinization, 
cells from each line were split into two tubes, and centrifuged twice at 500 g for 4 minutes. For each cell line, the pellet in 
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tube #1 was subjected to DNA extraction and PCR-based genotyping, whereas the cell pellet in tube #2 was subjected to 
protein extraction and Western blot analyses. A) Schematic diagram of the ITGB3 (WT) and (HET) loci, showing where 
PCR genotyping primers align.  P1 and P3 amplify a wild-type product of 446-bp, whilst P1 and P2 amplify a knockout 
product of 538-bp. B) Agarose gel of P1/P3 and P1/P2 primer products from 9 different immortalised EC lines.  Lines 1-5 
show only a P1/P3 product, and are therefore wild-type (WT) for the ITGB3 locus, whilst lines 6-9 show both a P1/P3 
product, and a P1/P2 product, and are therefore heterozygous (β3HET) for the ITGB3 locus.  C) Western blot analysis of 
VE-Cadherin and ITGB3 expression in the same clones shown in B). HSC70 was used as a loading control. Because the 
antibody used for detection of ITGB3 recognises a non-specific band at approximately (135kDa), a β3-knockout (NULL) 
lysate was included as a control (cell line #10). D) ImageJTM densitometric quantification of the blot shown in C). Levels of 
ITGB3 were normalised against HSC70, and are shown relative to those in cell line #1. E) Average expression of ITGB3 in 
WT versus HET ECs (pooled data from panel D). The asterisks indicate statistical significance: ** P<0.01. Unpaired two-
tailed t-test 
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3.2. Analysis of NRP2 knockdown efficiency in immortalised ECs.  
To evaluate the potential roles of NRP2 in microvascular ECs, we first needed to identify: 1) 
optimised conditions for efficient knockdown of NRP2 in PyMT mLMECs; 2) NRP2 specific 
antibodies; 3) short interference RNAs (siRNA) that were specific to NRP2, but showed no 
cross-reactivity to the closely related transmembrane glycoprotein NRP1. Delivering siRNA 
into eukaryotic cells to knockdown specific genes of interest can be accomplished via viral 
vectors (transduction), or via non-viral vectors (transfection), including both physical and 
chemical delivery systems (Biçeroglu and Memis 2005).  Historically, the Robinson lab has 
only achieved efficient siRNA mediated knockdown in PyMT mLMECs by electroporation 
(e.g. nucleofection via Amaxa Nucleofector II
TM
). Electroporation is defined as an electrical 
field applied to target cells to increase the permeability of the plasma membrane by 
producing very small pores through which DNA/RNA sequences, drug, or chemicals may 
enter (Sharma, Khajuria et al. 2004). Aside from being the only tested method that works in 
these cells, electroporation is fast to deliver, highly efficient, and cheap. However, 
electroporation can irreversibly damage cell membranes, resulting in large numbers of dead 
cells. Therefore, we tested multiple conditions (not shown) and settled on those that gave us 
between 90-95% overall cell survival (Figure 3.2 A). Four different mouse-specific NRP2-
siRNAs were then purchased from Dharmacon (Cat# D-040423-01, 02, 03 and 04). At this 
stage, we randomly chose one of the four siRNA constructs, (NRP2-siRNA 01), and then 
tested three commercially available NRP2 antibodies (Cell Signalling Technology 
Cat#D39A5, R&D System Cat#AF2215 and Milipore Cat#AB10522), to determine which 
would be the best to carry forward in future analyses (Figure 3.2 B). After establishing these 
two parameters, we tested four different NRP2-siRNAs against a non-targeting control 
siRNA (Ctrl-siRNA), NRP2-siRNAs 03 and 04 showed a 90% suppression of NRP2 
expression and NRP1 level remain unchanged (Figure 3.2 C-D). Finally, we wanted to know 
how long the NRP2 knockdown will last for future studies (Figure 3.2 E), and we 
determined that NRP2 knockdown lasted for at least 72 hours from the day of nucleofection.  
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A) 
                 
B)                                                                       C) 
                  
D)                                                                         E) 
                      
Figure 3.2  Establishing optimised NRP2 knockdown and Western blotting conditions. A) 1x106 cells from four 
different WT ECs were immediately seeded on 10-cm dishes pre-coated with gelatin (No nucleofection), or nucleofected 
with a non-targeting siRNA (Ctrl-siRNA) for 48 hours at 37°C in a CO2 incubator. Each plate of cells was lysed with the 
same volume (150µl) of lysis buffer. Lysates were then analysed by BioRad DC protein assay. For each cell line, the “cell 
survival rate” was estimated by dividing the total amount of protein in Ctrl-siRNA sample by the amount of protein in no 
electroporation sample. The bar chart shows the mean percentage of surviving cells; n=4, and (mean +SEM), P=0.14. B) 
1x106 ECs were nucleofected with either Ctrl-siRNA or NRP2-siRNA (#01) and seeded on 10-cm dishes pre-coated with 
gelatin for 48 hours at 37°C in a CO2 incubator. The cells were lysed and the lysates were subjected to the DC protein assay. 
The lysates were analysed by Western blots to determine the best NRP2 antibody to be used in future studies. The antibody 
from Cell Signalling appeared to be the most specific (less background). C) 1x106 ECs were nucleofected with either Ctrl-
siRNA or with one of four different NRP2-specific siRNAs (01, 02, 03 or 04) and seeded on 10-cm dishes pre-coated with 
gelatin for 48 hours at 37°C in a CO2 incubator. The cells were lysed and the lysates were subjected to the DC protein assay 
before being analysed by Western blot using the Cell Signalling antibody shown in B). HSC70 was used as a loading 
control. D) Quantification of NRP2 knockdown was analysed by ImageJTM densitometric analysis of the blot in D). Relative 
levels of NRP2 expression were normalised to HSC70 levels and plotted relative to the Ctrl-siRNA. E) 1x106 ECs were 
nucleofected with either Ctrl-siRNA or NRP2-siRNA (04) and seeded on 10-cm dishes pre-coated with gelatin for the 
indicated time at 37°C for 24, 48, 72 and 96 hours in a CO2 incubator. After lysing the cells, the lysates were subjected to the 
DC protein assay before being analysed by Western blot using the Cell Signalling antibody shown in B.  
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3.3. Discussion 
NRPs are single transmembrane receptor proteins that are expressed in a variety of cells 
including nerve cells, ECs, immune cells, epithelial cells, osteoblasts and tumour cells 
(Zachary 2014), (Bielenberg, Hida et al. 2004). They carry out versatile multi-functional roles 
depending on the type of cells that express them (Neufeld, Cohen et al. 2002), (Parker, Guo et 
al. 2012), (Prud'homme and Glinka 2012), (Li, Parker et al. 2014), (Guo and Vander Kooi 
2015). In ECs, NRPs function as co-receptors with many cell-surface growth-factor receptors, 
including VEGFR, TGF-β1R, hepatocyte growth factor receptor (HGFR), FGFR, PGF-BR 
and PDGFR. They enhance the binding and activation of these growth factor signalling 
pathways (Parker, Guo et al. 2012). NRPs can also function independently of the growth-
factor receptors by regulating the function of integrins, thus influencing cell adhesion, 
migration and permeability during angiogenesis, under both physiological and pathological 
conditions (Fukasawa, Matsushita et al. 2007), (Valdembri, Caswell et al. 2009), (Ellison, 
Atkinson et al. 2015).  
Many previous studies have shown that NRP2 is overexpressed in cancer, and its 
upregulation is linked to cancer progression (Fakhari, Pullirsch et al. 2002), (Kawakami, 
Tokunaga et al. 2002), (Bielenberg, Hida et al. 2004), (Tomizawa, Sekido et al. 2001), 
(Kawakami, Tokunaga et al. 2002), (Lantuéjoul, Constantin et al. 2003), (Vales, Kondo et al. 
2007), (Bachelder, Crago et al. 2001), (Fukahi, Fukasawa et al. 2004). Interestingly, Favier et 
al. showed that the overexpression of NRP2 in hMVECs increased cell survival induced by 
VEGF165 and that NRP2 knockdown significantly inhibited VEGF165-induced migration 
(Favier, Alam et al. 2006). These findings supported the suggestion that NRP2 knockdown 
may help in cancer therapy. Hence, it is important to understand NRP2 biology. 
Regarding the role of NRP2 in the embryo, a previous study on embryonic vascular 
development in chicks showed that NRP2 was expressed in the blood islands of 24-hour-old 
embryos (Herzog, Kalcheim et al. 2001). Subsequent studies showed that mice lacking the 
NRP2 gene and containing only one functional NRP1 allele exhibited more severe defects in 
vascular development than those reported in mice lacking both NRP1 alleles and an intact 
NRP2 gene (Takashima, Kitakaze et al. 2002). The results of these studies indicated the 
contributory role of NRP2 in the early development of embryonic vessels. Another study 
found that NRP2, similar to NRP1, bound to VEGF165 with high affinity in HUVEC, 
suggesting that NRP2 has a role in cardiovascular biology through binding to VEGFR2 
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(Gluzman-Poltorak, Cohen et al. 2000). This finding was supported by Favier et al., who 
showed that NRP2 immunoprecipitated with VEGFR2, and the stimulation of cells with 
VEGF165 increased the association between NRP2 and VEGFR2, indicating that NRP2 binds 
to VEGFR2 in both a ligand-dependent and ligand-independent manner (Favier, Alam et al. 
2006). The author also showed that VEGFR2 phosphorylation was increased when the cells 
were transfected with human pCDNA hygro–NRP-2 and stimulated by VEGF165 compared to 
low VEGFR2 phosphorylation in the absence of NRP2 (Favier, Alam et al. 2006). 
Additionally, Kärpänen et al. found NRP2 expression in human lymphatic dermal 
microvascular ECs was higher than in human blood dermal microvascular ECs, indicating 
that NRP2 must play roles in both types of ECs (Kärpänen, Heckman et al. 2006). 
Furthermore, the results of subsequent studies revealed that both NRP1 and NRP2 are 
expressed in normal blood and lymphatic endothelial cells, and both play essential roles in 
forming blood and lymphatic vasculatures (Jurisic, Maby-El Hajjami et al. 2012), (Bouvrée, 
Brunet et al. 2012), (Mucka, Levonyak et al. 2016).  
Most previous studies on NRPs were focused on NRP1 (Zachary 2014), (Wittmann, 
Grubinger et al. 2015). With regard to NRP2, only two studies addressed the roles of NRP2 
in regulating the function of integrins, one in breast cancer and one in renal cell carcinoma 
(Goel, Pursell et al. 2012), (Cao, Hoeppner et al. 2013). Goel et al.’s study led to the 
discovery of a potential mechanism whereby NRP2 regulates α6β1 signalling to promote the 
association of α6β1 with the extracellular matrix (laminin) and to form stable FAs at the 
leading edge, which is required in the spreading of breast cancer cells (Goel, Pursell et al. 
2012). Cao et al.’s study revealed a unique pathological mechanism through which the NRP2 
expressed on these RCC cancer cells functioned as adhesion molecules to trans-bind with the 
ITGA5 subunit expressed on the surface of the ECs to promote vascular adhesion, 
extravasation and tumour metastasis (Cao, Hoeppner et al. 2013). To the best of our 
knowledge, no previous study has addressed the possibility that NRP2 could cross-talk with 
the integrins within ECs.  
The Robinson laboratory previously showed that NRP1 expression in ECs affected VEGF164-
stimulated responses (migration, signalling and tumour growth/angiogenesis) in an ITGB3 
dependent manner (Ellison, Atkinson et al. 2015). Because NRP2 shares a very similar 
domain structure and overall ~44% of the amino acid level with NRP1 (Zachary 2014) (see 
chapter 1; Figure 1.9 A), we aimed to answer the following question: Does NRP2 also 
regulate the ITGB3 subunit function in ECs?  
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The Robinson group and others have shown that polyoma-middle-T-antigen immortalised 
ECs provide a good model for studying angiogenesis (Dong, Bernasconi et al. 1997), 
(Reynolds and Hodivala-Dilke 2006), (Robinson, Reynolds et al. 2009), (Burek, Salvador et 
al. 2012), (Ni, Kumar et al. 2014), (Steri, Ellison et al. 2014), (Ellison, Atkinson et al. 2015). 
Furthermore, immortalised ECs offer at least three advantages: they are easy, cost-effective 
and adhere to 3R principles (Russell, Burch et al. 1959), (Tannenbaum and Bennett 2015), 
(Carter and Shieh 2015). Therefore, we employed the polyoma-middle-T-antigen to 
immortalise different clones of WT ECs and β3HET ECs, confirming that each clone 
expressed VE-cadherin (an EC marker) and showing that β3HET ECs expressed 
approximately 50% less ITGB3 compared to WT ECs (see Figure 3.1 E). Historically, the 
Robinson laboratory has only achieved efficient siRNA mediated knockdown in PyMT 
mLMECs by electroporation using the Amaxa Nucleofector II
TM
. Under the right 
nucleofection conditions, we were successful in achieving overall cell survival rate of 90–
95% (see Figure 3.2 A). We also tested three commercially available anti-NRP2 antibodies 
and showed that the monoclonal antibody produced by Cell Signalling Technology
®
 was 
more specific to NRP2 than the polyclonal antibodies produced by the R&D system and 
Merck Millipore (see Figure 3.2 B). Finally, we tested four different NRP2-siRNAs and 
identified two specific and effective NRP2-siRNAs (03 and 04), which produced ~90%-
suppression of NRP2 expression (see Figure 3.2 C-D), which lasted for 72 hours from the 
day of nucleofection (see Figure 3.2 E). 
3.4. Conclusion 
In this chapter, we have shown that: 
 The immortalized PyMT mLMECs are expressing VE-Cadherin, a specific 
marker of microvascular ECs. 
 Nucleofection of PyMT mLMECs gave us between 90-95% overall cell survival. 
 NRP2 antibody from Cell Signalling Technology is best to use for Western blot.  
 NRP2-siRNAs 03 and 04 produce an approximate 90% suppression of NRP2 
expression that last for 72 hours. 
 NRP1 levels are not affected by NRP2 knockdown. 
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Chapter 4: Investigating the roles of NRP2 in ECs 
___________________________________________________________________________ 
 
4.1. Upregulation of NRP2 in β3HET cells; ITGB3 depletion upregulates 
the expression of NRP2, similar to what was previously reported with 
NRP1.   
As described earlier, NRP1 and NRP2 share a similarity in many aspects: 1) they have a 
similar domain structure and overall 44% amino acid homology (Zachary 2014); 2) both can 
form a complex with the same receptors, including VEGFRs (Soker, Miao et al. 2002), 
(Favier, Alam et al. 2006), and Plexins (Raper 2000) to transduce signalling through binding 
with the same ligands, including VEGFs (Gluzman-Poltorak, Cohen et al. 2000), (Soker, 
Miao et al. 2002) and Semaphorins (Chen, Bagri et al. 2000); 3) both have been shown to 
immunoprecipitate with ITGA5 integrin subunit in different cell types, and to regulate 
ITGA5 function (Valdembri, Caswell et al. 2009), (Cao, Hoeppner et al. 2013). Despite these 
similarities, most studies have focused on the biological functions of NRP1, including studies 
from our own lab. In fact, it is these very similarities that led us to investigate whether NRP2 
has a role to play in regulating endothelial cell behaviour.  
The Robinson lab previously showed that NRP1 expression is up-regulated in β3HET ECs 
compared to WT ECs.  Moreover,  NRP1 seems to only play a role in angiogenic processes, 
at least post developmentally, when ITGB3 expression is reduced (Ellison, Atkinson et al. 
2015). Given the similarities noted above, and the possibility that NRP2 might play a 
functionally redundant role to NRP1 in ECs, we decided to ask whether NRP2 expression 
and/or function is linked to ITGB3 expression in these cells. We first performed a Western 
blot on protein lysates from WT cell line #4 (see Figure 3.1 C-D), which (of the lines 
employed) has the highest expression of ITGB3, and β3HET cell line #7 (see Figure 3.1 C-
D), which has the lowest expression of ITGB3. Like NRP1, NRP2 expression was elevated in 
β3HET cells (Figure 4.1 A). We also noted increased NRP2 expression upon siRNA-
mediated ITGB3 knockdown in two different WT ECs (cell lines #2 and #4) (Figure 4.1 B), 
suggesting the increased expression of NRP2 in β3HET cells is not a response to long-term 
depletion of ITGB3. We were intrigued by this result, and decided to explore whether NRP2 
has a role to play in VEGF-induced endothelial angiogenic responses and if so, whether that 
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role is linked to ITGB3.  Again, given the similarities between NRP1 and NRP2, we thought 
it was important to demonstrate that (1) our NRP2 siRNA was having no effect on NRP1 in 
VEGF164-induced stimulation and (2) that VEGF stimulation itself did not alter NRP2 
expression. To this end, we knocked-down NRP2 in both WT ECs and β3HET ECs in the 
presence or absence of VEGF164 stimulation. As noted above, both NRP1 and NRP2 were 
elevated in β3HET ECs compared to WT.  Furthermore, NRP2 knockdown had no effect on 
NRP1 expression, and VEGF164-stimulation did not affect NRP1 or NRP2 expression when 
ITGB3 is expressed normally or reduced, at least over this short time course of VEGF 
treatment (Figure 4.1 C). 
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A) 
                                                    
B) 
                           
C)                                
 
Figure 4.1 Upregulation of NRP2 expression in β3HET ECs. A) WT or β3HET ECs were seeded on 10-cm dishes pre-
coated with 10 µg/ml FN and incubated at 37 °C in CO2 overnight. Each plate of cells was washed twice with PBS before 
the cells were lysed. Following a protein quantification analysis using the BioRad DC protein assay, the samples were 
subjected to a Western blot to analyse NRP2 expression in the WT and β3HET ECs (left); NRP2 was quantified by 
ImageJ™ densitometry software (right). The bar charts of means (+SEM) are representative of three repeats. The asterisks 
indicate statistical significance: **** P<0.0001. B) Two different WT ECs were either nucleofected with Ctrl-siRNA or 
ITGB3-siRNA and seeded on 10-cm dishes pre-coated with 10 µg/ml FN and incubated for 48 hours at 37 °C in CO2 
incubator. The cells were lysed and the proteins were quantified in the same manner. The samples were then subjected to a 
Western blot to analyse NRP2 expression in the two genotype ECs (left); NRP2 was quantified by ImageJ™ densitometry 
software (right). C) 1x106 cells from both WT and HET ECs were nucleofected with either Ctrl-siRNA or NRP2-siRNA and 
then seeded on 6-cm dishes pre-coated with 10 µg/ml FN and incubated in CO2 at 37 °C for 48 hours. Following two washes 
with PBS and starving ECs in pre-warmed serum-free OptiMEM® for 3 hours, one dish from each condition was left 
unstimulated, while the rest were stimulated with 30 ng/ml VEGF164 for 5 or 15 minutes. All dishes, including those left 
unstimulated, were immediately placed on ice to stop the stimulation process. The cells were lysed and the proteins were 
quantified in the same manner. The samples were then subjected to a Western blot to analyse NRP1 and NRP2 expression.       
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4.2. There is no link between NRP2 and ITGB3 in response to VEGF164 
stimulation, but NRP2 depletion marginally impairs VEGFR2/ERK 
phosphorylation in response to VEGF-stimulation.  
VEGFR signalling is regulated, to some extent, through interaction with NRPs (Álvarez-
Aznar, Muhl et al. 2017).  In the endothelium, VEGF-A, a major angiogenic factor (Neufeld, 
Cohen et al. 1999),  binds to NRPs (Neufeld, Cohen et al. 2002) and forms a complex with 
VEGFR2 that leads to optimal binding of VEGF-A to its receptor and results in enhanced 
VEGFR2 phosphorylation, intracellular signalling and cell migration (Whitaker, Limberg et 
al. 2001), (Soker, Miao et al. 2002),  (Favier, Alam et al. 2006). Therefore, we next 
investigated whether NRP2 modulates, in mMLECs, VEGF-induced activation of VEGFR2, 
as well as downstream signalling through ERK1/2 (Vellon, Menendez et al. 2006), (Koch and 
Claesson-Welsh 2012), (Tan, Popel et al. 2013), (Almalki and Agrawal 2017), (Park-
Windhol, Ng et al. 2017). 
Because VEGFR2 signalling is also regulated by the ITGB3 subunit (Ravelli, Mitola et al. 
2013), (Somanath, Malinin et al. 2009), (Reynolds, Wyder et al. 2002), we decided to 
investigate whether the VEGFR2-NRP2 interaction is dependent on ITGB3 expression in 
response to VEGF164. As mentioned earlier, because ITGB3 levels varied somewhat across 
cell lines in both WT and β3HET ECs (see Figure 3.1 C-D), we performed signalling assays 
with multiple lines of both genotypes; to minimize any potential cell line specific effects. 
Then, the phosphorylation difference of both VEGFR2 (pVEGFR2) and ERK1/2 (pERK) in 
Ctrl-siRNA versus NRP2-siRNA in WT ECs was compared to the phosphorylation in Ctrl-
siRNA versus NRP2-siRNA in β3HET ECs (Figure 4.2 A-B). For signal quantification, the 
phosphorylation level of each protein was normalized to total levels for that protein. As 
previously reported (Ellison, Atkinson et al. 2015), the phosphorylation patterns of ERK and 
VEGFR2 were slightly greater but not significantly in B3HET compared to WT ECs. 
However, densitometric analysis indicated no significant changes in the overall pERK and 
pVEGFR2 levels when comparing WT to B3HET ECs following NRP2 silencing, suggesting 
no link between ITGB3 and NRP2-dependentVEGF-induced signalling. Nevertheless, NRP2 
knockdown did marginally attenuate the expression of pERK at 15 minutes and pVEGFR2 
expression at 5 and 15 minutes in ECs of both genotypes, though statistical significance was 
not achieved in either case (see Figure 4.2 A-B). 
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To further examine the marginal reduction of pERK and pVEGFR2 upon NRP2 depletion 
seen in Figure 4.2 A-B, we looked at the effect of NRP2 knockdown on VEGFR2 and ERK 
phosphorylation in different WT ECs, again, to minimize any potential cell-line specific 
responses, in longer VEGF-induced stimulation (60 minutes) (Figure 4.2 C-D). ERK 
phosphorylation in NRP2-siRNA treated cells was again marginally impaired at 15 and 30 
minutes compared to Ctrl-siRNA treated cells, whereas VEGFR2 phosphorylation in NRP2-
siRNA treated cells was also marginally reduced at 5, 15 and 30 minutes compared to Ctrl-
siRNA treated cells (see Figure 4.2 C-D). This suggests that NRP2 may regulates VEGF-
VEGFR2 signalling.  
Previous reports showed that NRP2 can regulate VEGF-induced signalling in  lymphatic 
human microvascular ECs cells (Favier, Alam et al. 2006), and human lymphatic ECs (Caunt, 
Mak et al. 2008). In our mMLECs, however, we observed only marginal attenuation of ERK 
and VEGFR2 phosphorylation.  
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C) 
 
D) 
       
Figure 4.2 NRP2 silencing attenuates VEGFR2 phosphorylation in response to VEGF164. A) ECs from both genotype 
cells were nucleofected with either Ctrl-siRNA or NRP2-siRNA, and then seeded at a density of 5×105 cells in 6-cm dishes 
pre-coated with 10 µg/ml FN and then incubated in CO2 for 48 hours at 37°C. Following two washes with PBS, the cells 
were starved in serum-free OptiMEM® for 3 hours. 30 ng/mL VEGF164 was added to dishes with respect to the indicated 
time at 15 and 5 minutes. All dishes, including unstimulated one, immediately placed on ice to stop stimulation process. 
After lysing the cells from both genotype ECs and quantifying the concentration of proteins, the lysates were analysed by 
Western blots to examine any differences in the phosphorylation expression of both VEGFR2 and ERK1/2 in the two 
genotype ECs. The blot is representative of six independent experiments. B) The phosphorylation expression of ERK1/2 and 
VEGFR2 were quantified using ImageJ densitometry software™. The bar charts are representative of six experiments. The 
results of the densitometry analysis are shown in bar charts of mean (+SEM); P> 0.05.  C) As in A) but this time after the 
starvation step, the cells were stimulated with 30 ng/mL. VEGF164 was added to dishes with respect to the indicated time at 
60, 45, 30, 15 and 5 minutes. All dishes, including unstimulated one, immediately placed on ice to stop stimulation process. 
After lysing the cells from both genotype ECs and quantifying the concentration of proteins, the lysates were analysed by 
Western blots. D) The phosphorylation expression of VEGFR2 and ERK1/2 were quantified using ImageJ densitometry 
software™. The bar charts are representative of six independent experiments. The results of the densitometry analysis are 
shown in bar charts of mean (+SEM). The asterisks indicate statistical significance: P> 0.05. Unpaired two-tailed t-test. 
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4.3. NRP2-depletion reduces random migration in ECs, but the effects are 
not linked to ITGB3. 
A previous study on NRP2-dependent migration showed that monoclonal antibodies that 
specifically bind to the coagulation V/VII factor (b1-b2) domains of NRP2 (the two domains 
that are essential for optimal binding of both VEGF-C and VEGF165) inhibited the migration 
of human lymphatic ECs (LECs) in the presence of VEGFC but not VEGF165 (Caunt, Mak et 
al. 2008). Another study showed that knocking down NRP2 in HMVEC inhibited VEGF165-
induced migration (Favier, Alam et al. 2006). In contrast to Favier et al.’s study, NRP2 
knockdown resulted in increasing the migration of HUVECs (German, Mammoto et al. 
2014).  
Previous studies in our lab demonstrated that NRP1 plays a role in mLMEC migration only in 
β3HET ECs (Ellison, Atkinson et al. 2015). These studies showed NRP1-dependent effects 
on cell migration only when ITGB3 levels were reduced. This was shown in both cell random 
motility (CRM) assays and wound healing (WH) assays. Therefore, we decided to test the 
effects of NRP2-depletion in both WT and β3HET ECs in the presence or absence of 
VEGF164. Fourty-eight hours after Ctrl-siRNA or NRP2-siRNA treatment, cells were seeded 
on FN matrix, with or without VEGF stimulation. Fixed images from multiple wells of each 
condition were taken every 10 minutes for 15 hours, creating short videos.  Individual cells 
were then tracked manually to measure random cell migration speed. This type of experiment 
was repeated four-independent times, on four different cell lines from each genotype; the 
results were pooled in a single graph (Figure 4.3). As previously reported (Ellison, Atkinson 
et al. 2015), β3HET ECs migrated faster than WT ECs. Unlike NRP1, however, NRP2 
depletion significantly reduced migration speed independently of ITGB3 levels; the percent 
reduction in migration speed when comparing NRP2-siRNA to Ctrl-siRNA treated cells was 
roughly similar in both unstimulated (76% in WT cells, 68% in β3HET cells) and VEGF-
stimulated (73% in WT cells, 74% in β3HET cells) conditions.  However, in contrast to the 
studies published previously in the lab (Ellison, Atkinson et al. 2015), we were not able to 
demonstrate a VEGF-induced increase in cell migration speed.  One possible explanation for 
this discrepancy is differences in batches of serum used. It is possible that the serum used in 
the migration studies presented here contained inhibitory factors, such as Sempahorins, that 
might, in the long term, negate the effects of VEGF (Vadasz, Haj et al. 2012), (Silverio, Prota 
et al. 2015), (Nakayama, Bruneau et al. 2015). For example, both SEMA-3A and SEMA-3F 
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can act as competitors of VEGF binding to NRP1-VEGFR2 complex and subsequently inhibit 
VEGF-induced EC migration (Miao, Soker et al. 1999), (Kessler, Shraga-Heled et al. 2004).    
We also attempted to perform WH assays, but in my hands these assays were very 
inconsistent, and we were not able to derive any concrete conclusions. Possible explanations 
for this are: 1) the width of the manual scratches were always uneven. This resulted in 
unreliable read outs because the speed of the migrated cells increases just before the wound 
closure of the two borders (Kramer, Walzl et al. 2013); 2) some detached cells, which were 
generated by manual scratches, remained attached to the monolayer cells at the border of the 
scratch, even after washing the cell debris with PBS. These cells were eventually reattached 
to the plate, moved to the wound closure area, and then migrated independently of the 
connecting population, which led to unreliable closure and difficult interpretation (Ascione, 
Vasaturo et al. 2016); 3) the scratching caused cell damage at the border of the closure area, 
which affected the motion of other cells, forcing them to migrate around the obstacle to reach 
the wound closure area (Ashby and Zijlstra 2012); 4) the scratching to generate a wound area 
caused scrapping off the FN from the pre-coated plates so that read-outs generated  were FN 
independent (Kam, Guess et al. 2008). 
Because the CRM assay provides a statistically robust measure of cell motility (Decaestecker, 
Debeir et al. 2007), (Terryn, Bonnomet et al. 2009), (Caserta, Campello et al. 2013), and is 
considered “a gold standard” in cell migration studies (Ascione, Vasaturo et al. 2016), we 
conclude that NRP2 plays a role in EC migration on FN, but this role is independent of 
ITGB3. For this reason, we decided to re-focus our attention on NRP2’s role in regulating 
angiogenic processes, irrespective of a link to ITGB3.  
Unlike NRP1 (Ellison, Atkinson et al. 2015),  we have not seen any link between NRP2 and  
ITGB3, at least with respect to EC migration (see Figure 4.3) or VEGF-induced signalling 
(see 4.2 A-B). The expression data presented at the beginning of this chapter (see Figure 4.1) 
suggests a regulatory crosstalk between NRP2 and ITGB3, but the detail of that crosstalk is 
currently unclear. As mentioned above, we were unable to observe a VEGF-induced increase 
in EC migration in our studies, so we cannot establish a firm connection between NRP2’s 
role in VEGF-induced signalling and migration, though undoubtedly the two are linked 
(Lake, Vassy et al. 2006), (Pan, Chanthery et al. 2007), (Hsieh, Ying et al. 2008), (Lamy, 
Lachambre et al. 2010), (Herzog, Pellet-Many et al. 2011), (Chu, Ramakrishnan et al. 2013), 
(Lamy, Ouanouki et al. 2014), (Xu, Wang et al. 2018). We therefore decided to pursue 
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further NRP2’s involvement in regulating EC migration, independently of VEGF-stimulation, 
as well as independently of ITGB3 expression (the remainder of this chapter, and chapter 5).  
In chapter 6, we will come back to examining NRP2’s role in mediating VEGF-induced 
events; in the final results chapter we will present work in which we attempted to develop and 
test NRP2-shRNA constructs for use in ex vivo aortic ring studies. 
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Figure 4.3 NRP2-siRNA significantly reduces ECs migration in both WT and β3HET ECs. ECs from WT and β3HET  
were nucleofected with either Ctrl-siRNA or NRP2-siRNA; 1×106 cells were seeded in 10-cm dishes pre-coated with 10 
µg/ml FN and incubated at 37 °C in CO2 for 48 hours. The ECs from each condition were subjected to trypsin, re-suspended 
in serum-free OptiMEM® and seeded at a low density of 7×105 cells in triplicate wells of a 24-well plate pre-coated with 10 
µg/ml FN for 3 hours at 37 °C to starve and to allow the cells to adhere in the wells. In half of the plate, the medium was 
replaced by fresh serum-free OptiMEM® plus (2% FBS). The medium in the second half was replaced by fresh serum-free 
OptiMEM® plus (2% FBS) supplemented by 30 ng/mL VEGF164. Fixed images of multiple field/well of each condition were 
taken every 10 minutes for 15 hours at 37 °C and 5% CO2 using an inverted Axiovert (Zeiss) microscope in one-phase 
contrast. Cells were manually tracked using ImageJTM Plugin Manual Tracking, and the migration speed of an individual cell 
was measured in μm/hours: A) Chart bar shows the cell migration speed over 15 hours. The asterisks indicate statistical 
significance: **** P<0.0001. Unpaired two-tailed t-test 
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4.4. NRP2 does not regulate EC proliferation. 
Endothelial cell proliferation, as well as cell migration, plays an important role in angiogenic 
process (Jain 2003), (Suzuki, Montagne et al. 2007), (Contois, Akalu et al. 2009), (Carmeliet 
and Jain 2011), (Park-Windhol, Ng et al. 2017). Therefore, we decided to investigate whether 
proliferation was affected by NRP2 knockdown in our cells. First, we employed WST-1 
assays to assess cell viability.  When the tetrazolium WST-1 is added to cells, it is cleaved to 
formazan dyes by mitochondrion oxidoreductase enzymes (dehydrogenase) present in 
“viable” cells; the absorbance of formazan can be measured spectrophotometrically, and OD 
readings correlated to cell viability. When comparing Ctrl-siRNA to NRP2-siRNA treated 
ECs, we did not see any differences (Figure 4.4 A). We then turned to a more direct 
measurement of proliferation by assaying BrdU incorporation. BrdU is a thymidine analogue 
that is incorporated into replicating DNA during the S phase of the cell cycle.  When 
counting the percentage of BrdU positive cells, no difference in relative rates of proliferation 
were noted when comparing Ctrl-siRNA to NRP2-siRNA treated ECs (Figure 4.4 B).  
A number of studies have suggested NRP2 does not play a role in cell proliferation.  This 
includes studies in human microvascular ECs (Favier, Alam et al. 2006), human lymphatic 
ECs (Caunt, Mak et al. 2008), human breast cancer cells (Goel, Pursell et al. 2012), and 
human renal cell carcinoma cells (Cao, Hoeppner et al. 2013).  Our data suggest this is also 
true in mMLECs. 
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A) 
 
B) 
 
Figure 4.4 NRP2 doesn’t regulate mouse microvascular ECs proliferation. ECs were nucleofected with either Ctrl-
siRNA or NRP2-siRNA and seeded on 10-cm pre-coated with 10 µg/ml FN at 37°C. A) 48 hours later, 7,000 cells were 
seeded into two 96-well plates pre-coated with 10µg/ml FN; one plate was incubated for 4 hours, and the second plate was 
incubated for 24 hours. 10 µl of WST-1 was added to each well and then incubated for 2 hours before the absorbance was 
read at 450 nm versus 650 nm using a multi-well spectrophotometer (ELISA reader). The relative number of metabolically 
active cells was analysed by normalizing the absorbance of cells proliferated after 24 hours of incubation to the absorbance 
of total cells seeded for 4 hours (n= 40). B) After 30 hours of incubation, the cells were trypsinised, re-suspended in pre-
warmed serum-free OptiMEM® and seeded on acid-washed/oven-sterilised glass coverslips at a density of 1x104 cells in a 
well of a 6-well plate, in which each well held 4 coverslips, for 4 hours to allow cells to adhere. The serum-free OptiMEM® 
was then replaced by 10 µM BrdU in complete culture medium; the cells were then incubated for 12 hours at 37°C. 
Following two washes with PBS, the cells were fixed with 4% PFA for 10 minutes before hydrolysing the DNA with 1M 
HCL for 30 minutes at room temperature. The cells were then permeabilised with PBS 0.25% Triton X-100 for 10 minutes at 
room temperature prior to blocking with Dako® Protein Block Serum-Free for 30 minutes. After two washes with PBS, the 
cells were incubated with anti-BrdU at 4°C overnight in a humidified chamber. Following two washes with PBS, the cells 
were incubated with secondary antibody for 45 minutes in a humidified chamber at room temperature. After two washes 
with PBS, the coverslips were mounted and sealed. The percentage of the number of proliferated cells was determined by 
dividing the number of the BrdU-labelled (divided) cells by the number of Dapi-labelled cells; (n = 19 field of view, 
containing on average 50 cells per field); nsd means not significantly different. Unpaired two-tailed t-test.  
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4.5. NRP2 is Trypsin sensitive; and siRNA-mediated depletion of NRP2 
reduces the relative number of ECs adhered on Fibronectin. 
Cell adhesion is a fundamental step required for cells to migrate through binding of integrins 
expressed on the cell surface with ECM ligands. Binding is initiated through the formation of 
nascent adhesions which can either regress, or mature into larger adhesions, called FAs, 
through the recruitment of more integrins to these sites. This results in linking the clustered 
integrins to actin filaments with the help of intracellular adaptor/signalling proteins such as 
paxillin, talin, vinculin, etc. . .  (see chapter 1; Figure 1.16) (Nagano, Hoshino et al. 2012), 
(Small, Rottner et al. 1998), (Knight, Laukaitis et al. 2000), (Webb, Parsons et al. 2002), (Li, 
Guan et al. 2005). Alteration of integrins, or any of the intracellular adaptor proteins, will 
result in disruption of cellular adhesion and, subsequently, migration.  
A variety of studies have linked NRP1 to a number of integrins (Ellison, Atkinson et al. 
2015), (Valdembri, Caswell et al. 2009), (Hirota, Clements et al. 2015), (Maric, Annis et al. 
2015), (Wu, Chen et al. 2014), (Kim, Jung et al. 2017), (Fukasawa, Matsushita et al. 2007), 
(Ruffini, Graziani et al. 2015), while only two studies, so far, have reported a physical 
interaction between NRP2 and integrins. One study showed that NRP2 expressed in human 
breast carcinoma cells is located in FAs through interactions with the integrin ITGA6, and 
this interaction is necessary for FA formation on laminin. The same study also reported that 
shRNA-depletion of NRP2 impaired adhesion of these cancer cells to laminin matrices (Goel, 
Pursell et al. 2012). A second study showed that NRP2 in human renal cell carcinoma 
functions as an adhesion molecule through trans-binding with ITGA5 expressed on HUVEC 
(Cao, Hoeppner et al. 2013). 
Because adhesion of cells to the ECM is a key regulator of cell migration, we sought to 
determine whether the significant migration reduction observed in NRP2-siRNA treated ECs 
(see Figure 4.3) was the consequence of attenuated cell adhesion to FN. For this, we decided 
to examine whether NRP2 is required for the initial attachment of ECs to FN, employing a 
previously published technique (Vlodavsky, Lui et al. 1980), (Vlodavsky and Gospodarowicz 
1981), (Valdembri, Caswell et al. 2009), (Goel, Pursell et al. 2013) in which cells were 
detached with Trypsin and then seeded onto FN-coated substratum for short (15 and 30 
minutes) periods of time. However, a previous study reported that NRP2 expressed in human 
breast carcinoma cells is Trypsin sensitive (Cao, Hoeppner et al. 2013); this means cleavage 
of NRP2 by Trypsin might generate inaccurate read outs of adhesion. Therefore, we wanted 
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to test whether NRP2 expressed in mMLECs is Trypsin sensitive. ECs were seeded into two 
10-cm dishes overnight; ECs in the first dish were trypsinized, centrifuged and then lysed, 
while ECs in the second dish were lysed directly, without Trypsin treatment. We then assayed 
for NRP2 expression by Western blot. We observed a sharp reduction in the total level of 
NRP2 after Trypsin treatment (Figure 4.5 B-C lane 2). For this reason, we decided to test 
different cell-dissociation reagents that have been reported to be less aggressive than Trypsin 
when it comes to cleaving cell surface proteins. We tested Dispase, which was originally used 
for separating epidermis from dermis and epithelial cells from substratum in culture by 
cleaving FN  and Type IV collagen (Stenn, Link et al. 1989), (Chen, Tredget et al. 2009) 
(kindly provided by Dr Ernst Pöschl, UEA, Norwich, UK), as well as different concentrations 
of EDTA (5mmol, 10mmol and 15mmol); none of these treatments were able to detach 
mMLECs from their substrata. We also tested TrypLE, another enzymatic reagent, which, 
according to the manufacturer (ThermoFisher Scientific) is superior to Trypsin in protecting 
cell surface proteins. Similar to Trypsin treatment, NRP2 was also cleaved by TrypLE 
(Figure 4.5 B-C lane 3). Due to this limitation, we decided to try NRP2 recovery after 
detaching ECs with either Trypsin or TrypLE by incubating the detached cells in suspension 
for 1 hour before lysing the cell pellets and performing Western blots (Figure 4.5 A). By 
comparing NRP2 levels in cells treated with Trypsin (Lane 2) or TrypLE (Lane 3) to the 
NRP2 levels in the untreated cells (Lane 1), it was clear that NRP2 is sensitive to both 
Trypsin and TrypLE, though NRP2 seems to be slightly less sensitive to Trypsin. 
Interestingly, incubating cells treated with both Trypsin and TrypLE for 1 hour at 37°C in 
suspension allowed cells to recover NRP2 expression (Figure 4.5 B-C lanes 4 and 5). Since 
Trypsin showed less cleavage effect on NRP2 than TrypLE, we decided to continue with 
Trypsin and increased the incubation time in suspension to 3 hours, hoping to fully recover 
NRP2 expression levels (Figure 4.5 D). We also examined Trypsin’s effect on other 
molecules we were interested in, or have been shown previously to interact with NRP2, 
including ITGA5, ITGA6, ITGB3 and NRP1 (Goel, Pursell et al. 2012), (Cao, Hoeppner et 
al. 2013). Unlike NRP2, NRP1 was not sensitive to Trypsin treatment (see Figure 4.5 D). In 
contrast to previous reports,  ITGA5 was not cleaved from the cell surface with Trypsin (Cao, 
Hoeppner et al. 2013), though we did note a slightly truncation of the molecule, suggesting, 
perhaps, cleavage of a small extracellular fragment. ITGB3 was not sensitive to Trypsin 
treatment.  However, after one hour of incubation in suspension, both ITGA5 and ITGB3 
levels decrease, presumably through intracellular degradation. Like NRP2, ITGA6 was 
Trypsin sensitive. Finally, we tested citric saline buffer, which is most often used to detach 
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cells for flow cytometry analyses (Chang, Thalhofer et al. 2007), (Rauch, Müschenborn et al. 
2007), (Gaur, Showalter et al. 2009). When we used citric saline buffer to detach cells, all 
proteins we examined remained intact (Figure 4.5 E). However, in this buffer, cells detach as 
a sheet of attached cells, rather than individual cells, which made counting cells before 
seeding into downstream studies impossible.  
Given these experimental limitations, we decided to explore the role of NRP2 in mediating 
cell adhesion using Trypsin as a detaching agent, and then incubating ECs in suspension for 1 
hour, which elicits 50-60% recovery of NRP2 expression (see Figure 4.5 C), whereas ITGB3 
and ITGA5 (in spite of the slight truncation of ITGA5), are still expressed at relatively high 
levels. Following this treatment regime, 1x10
4
 cells from each condition were seeded in 96-
well plates pre-coated with FN for 15 or 30 minutes. The relative number of adhered cells in 
NRP2-siRNA conditions compared to Ctrl-siRNA conditions was then measured using a 
colorimetric assay (Goel, Pursell et al. 2012). Under these conditions, NRP2 knockdown 
resulted in a significant reduction in the number of ECs adhered to FN compared to Ctrl-
siRNA treated ECs (Figure 4.5 F). 
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Figure 4.5 NRP2 is Trypsin sensitive, and siRNA-mediated depletion of NRP2 reduces the relative number of 
microvascular ECs adhered on FN. A) Cell surface proteins recovery assay schematic (adapted from (Nagano, Hoshino et 
al. 2012)) :B) The comparison of Trypsin and TrypLE for the cleavage effect on NRP2 before and after incubation for 1 hour 
in a suspension state. NRP2 level was analysed by Western Blot; C) Quantification of NRP2 was analysed by ImageJ™ 
densitometric analysis of the blot in B); Relative levels of NRP2 expression were normalised to HSC70 levels. D) The 
cleavage effect of trypsin on other proteins, including NRP1, NRP2, ITGA5, ITGB3 and ITGA6 before and after 1, 2 and 3 
hours of incubation at 37°C in a suspension state. E) Comparison of the cleavage effect of Trypsin and citric saline buffer on 
the same proteins of interest in which ECs were seeded in three 10-cm dishes overnight at 37°C. Two dishes were treated 
with either Trypsin or citric saline buffer to detach cells; the third dish was lysed directly by scrapping off cells using a 
rubber policeman. The cells treated with the detaching reagents were then centrifuged and lysed. The proteins level in lysates 
were analysed by western blot. F) 1x106 ECs were nucleofected with either Ctrl-siRNA or NRP2-siRNA and seeded in pre-
coated 10-cm dishes for 48 hours at 37°C in a CO2 incubator. The cells were trypsinised, centrifuged at 500 g and then re-
suspended in serum-free OptiMEM® in a suspension sate for 1 hour at 37°C in a CO2 incubator; 40x10
5 cells were seeded 
per well in 96-well plates pre-coated with 10 µg/ml FN and incubated for short (15 and 30 minutes) adhesion. The non-
adhered cells were gently washed off with PBS, and the adhered cells were fixed with 4% PFA for 10 minutes at room 
temperature. The cells were stained by methalyne blue for 30 minutes. Then the plates were submerged in water to remove 
the excess stain and then left to dry for 30 minutes. Destain solution was added to each well for 10 minutes before the 
absorbance was read at 630 nm using a multi-well spectrophotometer (ELISA reader).The relative number of adhered cells 
in each condition was analysed by normalizing the absorbance of cells adhered for 15 and 30 minutes to the absorbance of 
total cells seeded for 4 hours (n= 24). The chart bar of mean (+SEM) shows the cell adhesion assay. It is representative of 
three experiments. The asterisks indicate statistical significance: ** P<0.01, *** P<0.001. Unpaired two-tailed t-test. 
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4.6. NRP2 knockdown slows the rate of focal adhesion turnover 
Cell migration requires the coordination of a complex integrated process involving the 
integrins, signalling/adaptor molecules and actin-binding proteins, which are activated 
temporally and spatially at different locations in the cell to achieve the correct balance in the 
assembly and disassembly of adhesions during cell migration (Webb, Parsons et al. 2002). 
The attachment of clustered integrins to ECM results in stabilizing the formation of FAs, 
which in turn leads to cell spreading at the leading edge whereas the reduction of integrin 
attachment to ECM results in destabilization of FAs, which in turn leads to a spherical, non-
adherent cell phenotype (Webb, Parsons et al. 2002). 
We monitored the kinetics of FA turnover in live mMLECs migrating on FN-coated 
coverslips following transfection with paxillin-GFP (Webb, Parsons et al. 2002). Paxillin is a 
required FA adapter protein that promotes FA turnover during cell migration (Zaidel-Bar, 
Milo et al. 2007), (Pasapera, Schneider et al. 2010) and it can control cell migration 
depending on its location within the cell. At the leading edge it can initiate, with other 
adaptor proteins, adhesions and stabilise FAs  (Nayal, Webb et al. 2006). At the trailing edge 
it disperses to destabilize FAs for the rear of the cell to move forward  (Nishiya, Kiosses et al. 
2005). However, a previous study in HUVEC suggested cross-talk between NRP2 and 
paxillin. This was shown by siRNA depletion of paxillin in HUVEC, which led to 50% 
reduction of NRP2 expression at both RNA and protein level (German, Mammoto et al. 
2014). Therefore, before using paxillin as a biomarker for FAs, we wanted to examine 
whether siRNA-mediated knockdown of NRP2 changes the expression or activation of 
paxillin in our ECs. We noted no change in either parameter when comparing NRP2 
knockdown to control knockdown (Figure 4.6 A). We therefore proceeded to track FAs in 
live cells on an inverted Axiovert (Zeiss) microscope. Cells were double transfected with 
(paxillin-GFP) plus either NRP2-siRNA or Ctrl-siRNA and imaged every minute for 30 
minutes. After defining the direction of migration, the assembly and disassembly speeds of 
single FAs were manually tracked using ImageJ™ software (Figure 4.6 B). As expected, FA 
disassembly was faster than the assembly of FAs; siRNA-mediated knockdown of NRP2 
significantly reduced both the assembly and disassembly of FAs compared to that in control 
cells (Figure 4.6 C). 
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C)                           
 
Figure 4.6 NRP2 regulate FAs turnover. A) 1x106 ECs were nucleofected with either Ctrl-siRNA or NRP2-siRNA and 
seeded in 10-cm dishes pre-coated with 10 µg/ml FN for 48 hours at 37°C in a CO2 incubator. Following two washes with 
PBS, the cell lysates were subjected to a DC protein assay. From each sample, 20 µg/ml were analysed by Western blot to 
examine the expression of both paxillin and phospho-paxillin using ImageJ™ densitometry software. GAPDH was used as a 
loading control. B) 1x106 ECs were double nucleofected with paxillin-GFP construct plus either Ctrl-siRNA or NRP2-
siRNA. The cells were then seeded in 10-cm dishes pre-coated with 10 µg/ml FN overnight at 37°C in a CO2 incubator. The 
following day, 4x104 cells per condition were seeded on three coverslips pre-coated with 10 µg/ml FN. 24 hours later, 
individual cells were then imaged every minute for 30 minutes, using an inverted fluorescence microscope. Each FA 
turnover was analysed by tracking the front of FA (assembly) and the back of FA (disassembly) using the ImageJTM 
MTrackJ plugin. One representative cell per condition is shown here; the arrows indicate the direction of cells movement. C) 
The bar chart shows the speed of FAs (assembly and disassembly) in microns/minute of mean (+SEM); in each bar chart, n > 
100 FAs. The asterisks indicate statistical significance: ** P<0.01. Unpaired two-tailed t-test.  
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4.7. Identifying the potential NRP2 binding partners using Mass 
Spectrometry (MS).  
So far, we have shown that NRP2 plays an essential role in FN-dependent migration, 
adhesion and FA turnover in mLMECs. Though we were mainly interested in the potential 
interactions between NRP2 and integrins that might be responsible for these findings, due to 
the large number of proteins involved in FA formation and turnover, we decided to take an 
unbiased approach to identifying NRP2’s binding partners by using mass spectrometry. We 
transfected three different WT EC lines (Cell Lines 2, 3 and 4) (see Figure 3.1 C-D) with 
either NRP2-siRNA or Ctrl-siRNA and incubated them for 48 hours at 37°C. NRP2 was then 
immunoprecipitated and NRP2-associated proteins were re-suspended in 20 µl lysis buffer. 
NRP2 knockdown was confirmed by Western blotting (Figure 4.7 A). The efficiency of the 
IPs was confirmed in two ways: (1) before sending the samples for MS analysis, 5 µl of each 
sample was subjected to SDS-PAGE separation followed by Silver Staining (Figure 4.7 B) to 
determine sample complexity (we hypothesised that anything immunoprecipitated by anti-
NRP2 antibody in NRP2-siRNA treated cells would be non-specific, and that the sample 
would be less complex), whereas 1µg of total cell lysate was used as a measure of the overall 
immunoprecipitation (IP) efficiency; (2) Ctrl-siRNA and NRP2-siRNA samples from two 
cell lines were sent off for MS analyses, while samples from the third cell line were stored at 
-20°C for further verification of the (MS) analysis (explained later in section 2.9). Peptides in 
each sample were detected using Label-Free quantitative (LFQ) mass spectrometry, as three 
technical repeats, and analysed by Andromeda software integrated in MaxQuant software. 
Each dot in Figure 4.7 C represents a single hit protein, which is the average Log2 of three 
LFQs derived from (Ctrl-siRNA) minus (NRP2-siRNA) in each cell line (one cell line plotted 
on the x-axis, the other plotted on the y-axis). A large number of proteins (1,154 hits) were 
detected in MS. To narrow our focus, we considered proteins detected more in NRP2-siRNA 
IP samples than Ctrl-siRNA as non-specific binding. To further clarify: the single dot at the 
(0,0) point contains (507 hits) detected more in (NRP2-siRNA samples) than (Ctrl-siRNA 
samples) in both cell lines, whereas (195 hits), blotted in the  x-axis, and (365 hits), plotted in 
the  y-axis, were detected more in Ctrl-siRNA samples than NRP2-siRNA samples in cell 
line clones (#1) and (#2), respectively. It is worth pointing out that some of the hits detected 
in only one cell line are probably true NRP2 binding partner proteins (such as ITGB3, 
ITGA6, ITGA3 and others), but we decided to focus only on those proteins (87 hits) detected 
more in (Ctrl-siRNA samples) than (NRP2-siRNA samples) in both cell lines (Table 4.1). 
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Among these hits, four microvascular ECs specific markers were identified as NRP2 binding 
partners: Pecam1, Mcam, Endoglin and Plasmalemma vesicle-associated protein (PLVAP) 
(Adams and Alitalo 2007) (Keuschnigg, Tvorogov et al. 2012) (Herrnberger, Ebner et al. 
2012) (Keuschnigg, Karinen et al. 2013) (Park, Sorenson et al. 2015) (see Figure 4.7 C). 
Interestingly, three fibronectin receptors were identified in both cell lines: ITGA5, ITGAV 
and ITGB1 (see Figure 4.7 C). NRP1, which shares similar domain structure with NRP2, 
was not detected at all, suggesting that the anti-NRP2 antibody is specific, and that NRP2 
does not physically interact with NRP1.  
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A) B)     
           
C)  
. 
Figure 4.7 Mass Spectrophotometry to identify NRP2’s binding partners. 1×106 cells were nucleofected with either Ctrl-
siRNA or NRP2-siRNA and seeded in 10-cm dishes pre-coated with 10 µg/ml FN and incubated at 37 °C in a CO2 incubator. 
48 hours later, the ECs were washed twice with PBS before the cells were lysed with (25 mM Tris-HCl, pH 7.4, 100 mM 
NaCl, 2 mM MgCl2, 1 mM Na3VO4, 0.5 mM EGTA, 1% Triton X-100, 5% glycerol, cocktail protease inhibitors) and then  
transferred to 1.5-ml centrifuged tubes on ice. The tubes were centrifuged at 12,000 g for 20 minutes, and the lysates were 
then analysed by DC proteins assay. A) 20 µg of total cell lysates (TCL) from the three cell line clones were subjected to a 
Western blot analysis of NRP2 knockdown. B) 1,200 µg from all three cell line clones were subjected to NRP2 
immunoprecipitation in a total volume of 1 ml of lysis buffer for overnight incubation with magnetic Dynabeads Protein G 
coupled with NRP2 antibody. After resuspending the NRP2-assosited proteins in 20 µl of lysis buffer, 5 µl from each clone 
(cell line cone #1 and #2) was subjected to SDS-PAGE separation and silver staining, whereas 1 µg of TCL was used as a 
measure of the overall IP efficiency. C) 86 hits of 1,166 proteins were detected as NRP2 binding partner proteins, including 
ITGA5, ITGAV, ITGB1, Mcam and Pecam1. 
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Table (4.1): Label-Free quantitative (LFQ) mass spectrometry results of NRP2 immunoprecipitation in two 
mLMEC clones. 
Gene names Protein names 
Log2 of three (LFQ) derived from                                    
(Ctrl-siRNA) minus (NRP2-siRNA) 
mLMECs (1) mLMECs (2) 
Shank3 SH3 and multiple ankyrin repeat domains protein 3 17.82211 18.26145 
Itgav Integrin alpha-V;Integrin alpha-V heavy chain;Integrin alpha-V light chain 12.75036 17.41807 
Eif3k Eukaryotic translation initiation factor 3 subunit K 16.67751 17.44238 
Ldlr Low-density lipoprotein receptor 16.65608 17.01857 
Ubap2 Ubiquitin-associated protein 2 15.22819 17.27588 
Tfpi Tissue factor pathway inhibitor 15.94133 17.69823 
Lgals8 Galectin-8 14.48788 14.66178 
Ywhag 14-3-3 protein gamma;14-3-3 protein gamma, N-terminally processed 11.42696 15.19255 
Pecam1 Platelet endothelial cell adhesion molecule 21.15972 23.34476 
Actb;Actg1 Actin, cytoplasmic 1;Actin, cytoplasmic 1, N-terminally processed 26.74492 27.96095 
Anxa1 Annexin;Annexin A1 14.97204 16.4172 
Ddx3x;D1Pas1 ATP-dependent RNA helicase DDX3X;Putative ATP-dependent RNA helicase Pl10 16.1337 18.40222 
Eif4e2 Eukaryotic translation initiation factor 4E type 2 14.8525 16.96642 
Cope Coatomer subunit epsilon (COP-l) 12.94733 13.11721 
Fmr1 Fragile X mental retardation protein 1 homolog 12.05212 16.94615 
Sipa1 Signal-induced proliferation-associated protein 1 16.50711 17.93118 
Ctnnb1 Catenin beta-1 14.04132 16.01054 
Cald1 Caldesmon 15.64976 19.31011 
Eps15 Epidermal growth factor receptor substrate 15 13.49852 17.56639 
Eng Endoglin 13.63594 16.6332 
Ahnak2 AHNAK nucleoprotein 2 15.62247 17.44713 
Plvap Plasmalemma vesicle-associated protein 8.196397 15.66909 
Sdcbp Syntenin-1 16.56674 17.01283 
Myadm Myeloid-associated differentiation marker 14.62495 19.32868 
H2-D1;H-2D;H2-L 
H-2 class I histocompatibility antigen, D-B alpha chain;H-2 class I histocompatibility 
antigen, L-D alpha chain 13.2829 16.61588 
Tuba1b;Tuba4a Tubulin alpha-1B chain;Tubulin alpha-4A chain 17.77056 18.55225 
Itgb1 Integrin beta-1 19.58851 20.40907 
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Itga5 Integrin alpha-5;Integrin alpha-5 heavy chain;Integrin alpha-5 light chain 17.63318 19.69024 
Rpl7 60S ribosomal protein L7 22.96149 23.20262 
Ap2a1 AP-2 complex subunit alpha-1 15.59941 16.89696 
Slc2a1 Solute carrier family 2, facilitated glucose transporter member 1 17.6579 16.96909 
Rpl13a 60S ribosomal protein L13a 19.60422 21.64278 
Ctnna1 Catenin alpha-1 14.46956 15.58295 
Pabpc1 Polyadenylate-binding protein;Polyadenylate-binding protein 1 21.00949 21.25427 
Kras;Hras 
GTPase KRas;GTPase KRas, N-terminally processed;GTPase HRas;GTPase HRas, N-
terminally processed 15.3272 16.14503 
Rpl18 60S ribosomal protein L18 21.38325 21.41876 
Sep-02 Septin-2 18.15594 18.91559 
Pura Transcriptional activator protein Pur-alpha 18.42197 17.23809 
Capza2 F-actin-capping protein subunit alpha-2 21.93517 22.74181 
Rpl9 60S ribosomal protein L9 20.84547 21.25882 
Atp6v0d1 V-type proton ATPase subunit d 1 10.89936 16.93522 
Entpd1 Ectonucleoside triphosphate diphosphohydrolase 1 15.66521 18.09918 
Acot8 Acyl-coenzyme A thioesterase 8 15.01396 16.4817 
Eif4a1;Eif4a2 
Eukaryotic initiation factor 4A-I;Eukaryotic initiation factor 4A-II;Eukaryotic initiation 
factor 4A-II, N-terminally processed 13.80137 17.49214 
Actr1a Alpha-centractin (Arp1) 15.16257 15.92509 
Rpl37a 60S ribosomal protein L37a 21.42535 18.72089 
Rps24 40S ribosomal protein S24 16.96428 17.11952 
Rps26 40S ribosomal protein S26 21.66345 18.11942 
Actg1 Actin, cytoplasmic 2;Actin, cytoplasmic 2, N-terminally processed 21.38089 18.84251 
Rala Ras-related protein Ral-A 17.51902 18.64505 
Rpl22 60S ribosomal protein L22 20.79656 20.80591 
Actc1;Acta2;Actg2
;Acta1 
Actin, alpha cardiac muscle 1;Actin, aortic smooth muscle;Actin, gamma-enteric 
smooth muscle;Actin, alpha skeletal muscle 16.71621 20.74104 
Ywhah 14-3-3 protein eta 16.12161 16.34551 
Cct2  T-complex protein 1 subunit beta (TCP1) 17.23135 16.06967 
Tubb5;Tubb2b;Tu
bb2a;Tubb3 
Tubulin beta-5 chain;Tubulin beta-2B chain;Tubulin beta-2A chain;Tubulin beta-
3 chain 16.61827 14.75881 
Rsu1 Ras suppressor protein 1 13.95432 17.09032 
Scamp1 Secretory carrier-associated membrane protein 1 14.12918 16.03603 
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Lrrc59 Leucine-rich repeat-containing protein 59 17.09987 15.07779 
Tmod3 Tropomodulin-3 19.75966 23.26303 
Pdia6 Protein disulfide-isomerase A6 12.67655 17.01683 
Vat1 Synaptic vesicle membrane protein VAT-1 homolog 14.4797 15.24995 
Eif3f Eukaryotic translation initiation factor 3 subunit F 16.42773 17.25752 
Btf3 Transcription factor BTF3 17.55739 16.72103 
Scamp3;Tu52 Secretory carrier-associated membrane protein 3 16.18946 17.89125 
Ddx1 ATP-dependent RNA helicase DDX1 17.0069 13.54432 
Igf2bp2 Insulin-like growth factor 2 mRNA-binding protein 2 16.95587 16.34851 
Cltc Clathrin heavy chain;Clathrin heavy chain 1 15.11689 15.77486 
Fxr2 Fragile X mental retardation syndrome-related protein 2 17.69423 17.33225 
Rpl35 60S ribosomal protein L35 18.36439 20.53602 
Actbl2 Beta-actin-like protein 2 25.99547 27.82845 
Ehd2 EH domain-containing protein 2 (EHD2) 16.04132 14.69171 
Rtn4 Reticulon;Reticulon-4 18.27337 18.64878 
Add3 Gamma-adducin 15.54402 19.90345 
Fbxo30 F-box only protein 30 15.00358 15.07755 
Tollip Toll-interacting protein 5.29768 14.48283 
Add2 Beta-adducin 13.89125 17.71187 
Ralb Ras-related protein Ral-B 17.80305 18.1332 
Mcam Cell surface glycoprotein MUC18 20.20144 21.8063 
Myct1 Myc target protein 1 13.76763 16.90254 
Pdcd10 Programmed cell death protein 10 17.15686 18.14309 
Rps5 40S ribosomal protein S5;40S ribosomal protein S5, N-terminally processed 19.15041 18.0047 
Lamtor1 Ragulator complex protein LAMTOR1 16.09562 16.52925 
Napa Alpha-soluble NSF attachment protein 14.9917 15.09713 
Lsm12 Protein LSM12 homolog 16.51124 15.23132 
Plac8 Placenta-specific gene 8 protein 15.63915 19.11841 
Flii Protein flightless-1 homolog (flightless I actin binding protein) 16.09678 16.73463 
Twf2 Twinfilin-2 (Twinfilin actin binding protein 2) 16.10847 17.78743 
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4.8. SiRNA-mediated knockdown of NRP2 upregulates ITGA5 expression.  
As mentioned previously, some of the MS hits that were only detected in one cell line are 
likely true hits, but were set-aside (these might be followed up in future studies) to help focus 
the studies. ITGB3 happens to be one of these hits, suggesting a link between NRP2 and 
ITGB3, but, as we have shown, this potential link does not seem to play a role in EC 
migration (see Figure 4.3). Therefore, we focused our attention on the other integrin subunits 
that were identified in both cell lines. We decided to ignore (at least at this stage) ITGAV 
subunit because it would be an ITGB3 binding partner (ITGB5 might also be an ITGAV 
binding partner, but this subunit was not detected in the MS). Therefore, we were left with 
ITGA5 and ITGB1 subunits which dimerise to form the fibronectin receptor (α5β1).  
Given that α5β1 heterodimer is known to be the predominant receptor in ECs mediating 
adhesion to FN (Serini, Valdembri et al. 2006), (Hynes 2007), (Valdembri, Caswell et al. 
2009), (Mana, Clapero et al. 2016), we wondered if the reduction in FN-dependent cell 
migration, adhesion and FA turnover was due to the disruption of the α5β1 
heterodimerization in mLMECs. Therefore, we decided to examine whether NRP2 
knockdown regulates the expression level of either subunit. Interestingly, the siRNA-
mediated silencing of NRP2 resulted in the upregulation of ITGA5 subunit expression in four 
different ECs clones, whereas the expression of the ITGB1 subunit did not change (Figure 
4.8 A-B).  
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A) 
 
B) 
                      
Figure 4.8 siRNA-mediated silencing of NRP2 upregulates ITGA5 expression, but not ITGB1. 1×106 cells from four 
different EC clones were nucleofected with either Ctrl-siRNA or NRP2-siRNA and seeded in 10-cm dishes pre-coated with 
10 µg/ml FN and incubated at 37°C in a CO2 incubator. The ECs were then washed twice with PBS before lysing the cells. 
Protein quantification was analysed using DC protein assay, and an equivalent concentration of 20 µg  from each sample was 
subjected to Western blot analysis to determine A) the total expression of both ITGA5 and ITGB1 subunits. B) The bar 
charts of means (+SEM) show the levels of the ITGA5 and ITGB1 subunits normalised against HSC70 using ImageJ™ 
densitometric quantification. The asterisks indicate statistical significance: * P<0.05; nsd means not significantly different. 
Unpaired two-tailed t-test. 
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4.9. ITGA5 subunit interacts with NRP2. 
A previous study has shown that NRP2 can form a complex with ITGA5 when NRP2 is co-
immunoprecipitated from a co-culture of renal cell carcinoma and HUVECs (Cao, Hoeppner 
et al. 2013). Another study has shown that NRP1 co-immunoprecipitated with ITGA5 in 
HUVEC (Valdembri, Caswell et al. 2009). Our MS analyses suggest NRP2 can form a 
complex with ITGA5 in mLMECs.  
To further validate our MS results, samples from the third cell line (as mentioned above) 
were subjected to Western blot analyses (Figure 4.9 A). We confirmed ITGA5 was co-
immunoprecipitaed with NRP2; however, some ITGA5 was also co-immunoprecipitaed with 
NRP2 in NRP2-depleted cell lysates (see Figure 4.9 A), which is likely due to incomplete 
silencing of NRP2. To explore this, we decided to further verify the interaction between 
NRP2 and ITGA5 by reducing the incubation time of NRP2 co-immunoprecipitation to 1 
hour and compare it to overnight incubation, which was our standard immunoprecipitation 
incubation period used in the MS studies (Figure 4.9 C). In this experiment NRP2 was also 
immunoprecipitated from 1200 µg of total cell lysate but this time non-specific IgG was used 
as a negative control. We also included an additional control in which 600 µg from each 
(Ctrl-siRNA sample) and (NRP2-siRNA sample) (see Figure 4.9 C Lane 5) were equally 
mixed to investigate whether the amount of the co-immunoprecipitated ITGA5 would 
increase. Interestingly, ITGA5 was co-immunoprecipitaed with NRP2 in both the short and 
overnight incubations (see Figure 4.9 C). Finally, we also demonstrated the interaction 
between the two proteins by immunoprecitating with anti-ITGA5 and probing for NRP2 
(Figure 4.9 E). We concluded from these studies that there is a physical interaction between 
ITGA5 and NRP2. 
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B)                                                                         C) 
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D)                                                                          E) 
 
Figure 4.9 ITGA5 is a partner binding with NRP2. A) Ctrl-siRNA and NRP2-siRNA from cell line clone #3 were 
subjected to Western blot analysis to verify the direct physical interaction between NRP2 and ITGA5. B-E) 1×106 cells were 
nucleofected with either Ctrl-siRNA or NRP2-siRNA and seeded in 10-cm dishes pre-coated with 10 µg/ml FN and 
incubated at 37 °C for 48 hours. The cells then were lysed on ice, and the lysates were subjected to DC protein quantification 
assay. B & D) 20 µg of total cell lysate was subjected to Western blot analysis to determine the efficiency of NRP2 
silencing. B-C) NRP2 was immunoprecipitated from 1,200 µg of total protein concentration for a short period 
immunoprecipitation (1 hour) or overnight immunoprecipitation at 4 °C before subjecting the sample to Western blot 
analysis to determine B) the efficiency of NRP2 knockdown and C) the presence of ITGA5 in the NRP2 IPed samples. IgG 
was used as a negative control, whereas (Lane 5), which is a mixture of (Lane 3) 600 µg from Ctrl-siRNA plus (Lane 4) 600 
µg from NRP2-siRNA, was used as a positive control. D-E) ITGA5 was immunoprecipitated from 1,200 µg of total protein 
concentration using two different anti-ITGA5 antibodies overnight before subjecting the samples to Western blot analysis to 
determine D) the efficiency of NRP2 knock down and E) the presence of NRP2 in the ITGA5 IPed samples. IgG was used as 
a negative control. 
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4.10. Discussion 
Integrins are the main heterodimeric transmembrane receptor proteins that transduce 
signalling bi-directionally by connecting the ECM deposition proteins to the actin 
cytoskeleton by recruiting intracellular adaptor proteins to the cytoplasmic tails of the 
activated integrins (Menter and DuBois 2012), (Hu and Luo 2013), (Tabatabai and Weller 
2013). Integrins regulate many cellular processes, including cell adhesion, proliferation, 
migration, differentiation, survival, apoptosis, the shapes of certain types of cells, ECM 
protein assembly, cytoskeleton organisation and angiogenesis under physiological and 
pathological conditions (Bökel and Brown 2002) (Srichai and Zent 2010), (Pan, Zhao et al. 
2016), (Jia, Choi et al. 2018). With respect to angiogenesis, integrins modulate the behaviour 
of many cell types, including ECs, perivascular cells, fibroblasts and BMDC (Desgrosellier 
and Cheresh 2010).  
The major integrins in ECs are αvβ3, α5β1, αvβ5 and α6β4 (Somanath, Ciocea et al. 2009). 
During angiogenesis, integrins enhance the signal transduction of VEGFs through 
interactions with VEGFRs and NRPs (Menter and DuBois 2012), (Goel and Mercurio 2012), 
(Seguin, Desgrosellier et al. 2015). Many studies have shown that αvβ3 “cross talked” with 
VEGFR2 (Soldi, Mitola et al. 1999), (Mahabeleshwar, Feng et al. 2006), (Mahabeleshwar, 
Chen et al. 2008), (Mahabeleshwar, Feng et al. 2007), (Dellinger and Brekken 2011), (West, 
Meller et al. 2012). (Gong, Yang et al. 2013), (Ravelli, Mitola et al. 2013), (Reynolds, Wyder 
et al. 2002), (Reynolds, Reynolds et al. 2004), (Robinson, Reynolds et al. 2004), (D'Amico, 
Robinson et al. 2010), (Masson-Gadais, Houle et al. 2003) (see chapter 1; subsection 
1.2.3.2.3.1.1), while others showed “cross-talk” between αvβ3 and NRP1 (Robinson, 
Reynolds et al. 2009), (Ellison, Atkinson et al. 2015). The expression of αvβ3 is upregulated 
in sprouting capillaries under physiological and pathological conditions, whereas its 
expression is rarely detected in quiescent capillaries (Hodivala-Dilke, Reynolds et al. 2003), 
(Somanath, Malinin et al. 2009). In ECs, ITGAV subunits can pair with the β1, β3, β5 and β8 
subunits, whereas the ITGB3 subunit only pairs with the ITGAV subunit, which means that 
the investigation of the functions of endothelial αvβ3 in ECs can be conducted best by 
manipulating the ITGB3 subunit (Hynes 2002).  
Reynolds et al. showed that the genetic depletion of the ITGB3 subunit resulted in the 
upregulation of VEGF, VEGFR2, and ERK1/2 phosphorylation in ECs, indicating that the 
absence of the Itgb3 gene increased VEGF-induced angiogenesis, which resulted in excessive 
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vasculature and enhanced tumour growth (Reynolds, Wyder et al. 2002), (Reynolds, 
Reynolds et al. 2004). Robinson et al. found that the complete loss of Itgb3 gene enhanced 
ECs permeability through the upregulation of VEGF-VEGFR2-ERK1/2 signalling 
(Robinson, Reynolds et al. 2004). In another study, Robinson found that NRP1 and ERK1/2 
were also elevated in ITGB3-NULL ECs. He also showed that NRP1-VEGFR2 co-
immunoprecipitation was augmented in ITGB3-NULL ECs compared with WT ECs even in 
the absence of VEGF treatment. Furthermore, NRP1 knockdown reduced the phosphorylation 
of VEGFR2 and ERK1/2 in the ECs of both WT and ITGB3-NULL ECs. In in vivo and ex 
vivo assays, Robinson showed that targeting NRP1 in ITGB3-NULL mice significantly 
inhibited VEGF-induced angiogenesis to a greater extent than that in WT, indicating that the 
elevation of angiogenesis in the absence of the Itgb3 gene is dependent on NRP1 expression 
(Robinson, Reynolds et al. 2009). This study showed that when ITGB3 subunit is expressed 
normally, through its cytoplasmic tail, it limits the interaction between NRP1 and VEGFR2. 
Hence, NRP1 becomes less substantial through its contribution to VEGF-induced signalling, 
migration, vessel infiltration and sprouting angiogenesis. However, when the Itgb3 gene is 
absent or siRNA-depleted, VEGF induces VEGFR2 phosphorylation, angiogenesis and 
tumour growth, become NRP1-dependent (Robinson, Reynolds et al. 2009).  
Because the complete loss of the Itgb3 gene resulted in the elevation of angiogenesis and 
targeting NRP1 only inhibited the otherwise enhance angiogenesis (Reynolds, Wyder et al. 
2002), (Reynolds, Reynolds et al. 2004), (Robinson, Reynolds et al. 2004), (Robinson, 
Reynolds et al. 2009), the Robinson group ceased using ITGB3-NULL mice and instead 
generated β3HET mice to overcome the developmental upregulation of the VEGFR2, 
ERK1/2 and NRP1 expressions that arose in ITGB3-NULL mice, while maintaining the 50% 
expression of ITGB3, which is critical for full VEGFR2 function (Ellison, Atkinson et al. 
2015). Unlike ITGB3-NULL ECs, VEGFR2 expression was not significantly increased in 
β3HET ECs. Additionally, the VEGF-induced association between NRP1 and VEGFR2 was, 
unlike NULL cells, unchanged. Importantly, though, β3HET ECs migrated faster than WT 
ECs, and, like NULL ECs, retained sensitivity to NRP1 perturbations, unlike their WT 
counterparts (Ellison, Atkinson et al. 2015).  
As mentioned previously, because of the structural and the functional similarity between 
NRP1 and NRP2 (see chapter 1; subsection 1.2.3.1.4.2), and because no study has addressed 
the interaction between NRP2 and integrins within ECs, we investigated the potential link 
between the ITGB3 subunit and NRP2 in mLMECs. Similar to NRP1 (Ellison, Atkinson et 
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al. 2015), we found that NRP2 expression was upregulated in β3HET ECs compared to WT 
ECs. Additionally, the upregulation of NRP2 expression was also observed in ITGB3-
siRNA-depleted WT ECs, indicating that the upregulation of NRP2 expression is not a 
response to a long-term depletion of the Itgb3 gene, as it can be replicated by ITGB3-siRNA 
knockdown (see Figure 4.1 A-B). Furthermore, we showed that NRP2 knockdown did not 
change NRP1 expression in the presence or absence of VEGF164 (see Figure 4.1 C). This 
result suggests that NRP1 does not compensate the loss of NRP2 expression in ECs in short-
term depletion.  
It was previously shown by Robinson et al. that inhibiting NRP1 function with a peptide 
minimally reduced VEGF-induced angiogenesis in WT mice (Robinson, Reynolds et al. 
2009). However, this effect was exacerbated in ITGB3-NULL mice, indicating that ITGB3 
limits the participation of NRP1 in VEGF-driven angiogenesis when ITGB3 is expressed 
normally (Robinson, Reynolds et al. 2009). Additionally, the authors also showed that NRP1 
knockdown significantly reduced VEGFR2 and ERK1/2 phosphorylation in WT and ITGB3-
NULL ECs (Robinson, Reynolds et al. 2009), which supported the finding of other studies 
that NRP1 expression in ECs acted as co-receptor molecule with VEGFR2 to enhance 
VEGF-induce downstream signalling (Prahst, Héroult et al. 2008), (Fuh, Garcia et al. 2000), 
(Gluzman-Poltorak, Cohen et al. 2001), (Kärpänen, Heckman et al. 2006), (Xu, Yuan et al. 
2010), (Ballmer-Hofer, Andersson et al. 2011), (Fearnley, Smith et al. 2016), (Fuh, Garcia et 
al. 2000), (Herzog, Pellet-Many et al. 2011), (Tiwari, Jung et al. 2012). Similarly, this effect 
was also exacerbated in ITGB3-NULL mice compared to WT mice (Robinson, Reynolds et 
al. 2009). Furthermore, Pan et al. found some evidence of the same effect by showing that 
blocking the extracellular domains (b1/b2) of NRP1 with the function-blocking antibodies 
directed against NRP1 marginally, but not significantly, reduced VEGFR2 and ERK1/2 
phosphorylation levels (Pan, Chanthery et al. 2007). A subsequent study showed that 
VEGFR2 phosphorylation was not significantly altered by deleting the NRP1 cytoplasmic tail 
in either WT or β3HET ECs, suggesting that the cytoplasmic tail of NRP1 is not required for 
VEGFR2 phosphorylation in mLMECs. In contrast to VEGFR2 phosphorylation, ERK1/2 
phosphorylation was sensitive to the deletion of the NRP1 cytoplasmic tail (Ellison, Atkinson 
et al. 2015). Unlike the NRP1 knockdown (Robinson, Reynolds et al. 2009), our findings 
showed that NRP2 knockdown produced no significant changes in the overall VEGFR2 and 
ERK phosphorylation when comparing WT and β3HET ECs (see Figure 4.2), thus 
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suggesting the absence of a link between ITGB3 and NRP2-dependent VEGF-induced 
signalling.  
Regarding migration, Pan et al. showed that the inhibition of the NRP1 function by blocking 
its extracellular domain had no effect on the HUVEC migration on FN in the absence of 
VEGF. However, the inhibition of the NRP1 function in the presence of VEGF significantly 
reduced VEGF-induced EC migration, in an in vitro endothelial bead sprouting angiogenesis 
assay, and in an in vivo corneal pocket neovasciologenesis assay (Pan, Chanthery et al. 2007). 
Robinson et al. showed that both ITGB3-NULL ECs and the siRNA-depletion of ITGB3 
expression in WT ECs significantly enhanced ECs migration, whereas targeting both ITGB3 
and NRP1 suppressed the enhancement of EC migration (Robinson, Reynolds et al. 2009). A 
subsequent study showed that the deletion of the cytoplasmic tail of NRP1 did not affect WT 
mLMECs migration on FN in the presence or absence of VEGF164 stimulation (Ellison, 
Atkinson et al. 2015). However, β3HET EC migration was significantly reduced when the 
cytoplasmic tail of NRP1 was deleted, indicating that NRP1 regulates mLMECs migration 
only when ITGB3 expression is reduced (Ellison, Atkinson et al. 2015). Our finding showed 
that NRP2 knockdown significantly reduced mLMECs migration on FN in both WT and 
β3HET ECs (see Figure 4.3). The effects of reduction in both cell types upon NRP2 
knockdown were similar, suggesting that NRP2 regulates ECs migration on FN 
independently of ITGB3.  
The upregulation of NRP2 expression we observed when ITGB3 expression was reduced (see 
Figure 4.1) suggests an, as yet, unclear cross-talk mechanism between NRP2 and ITGB3, 
which needs further investigation. However, because we did not observe any link between 
NRP2 and ITGB3 in VEGF-VEGFR2-ERK1/2 signalling (see Figure 4.2) or EC migration 
(see Figure 4.3), we decided to take the effect of NRP2 knockdown in ECs to the next step 
and investigate how NRP2 regulates EC migration independently of both VEGF-stimulation 
and ITGB3. Therefore, we first investigated whether NRP2 knockdown affected mLMEC 
proliferation. In two different proliferation assays, we found that NRP2 knockdown did not 
affect mLMECs proliferation on FN (see Figure 4.4). This finding supported previous 
findings that suggested that NRP2 does not play a role in the proliferation of lymphatic ECs 
(Favier, Alam et al. 2006), (Caunt, Mak et al. 2008) and cancer cells (Goel, Pursell et al. 
2012), (Cao, Hoeppner et al. 2013).  
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Because cell adhesion is a key regulator during cell migration (Nagano, Hoshino et al. 2012), 
(Small, Rottner et al. 1998), (Knight, Laukaitis et al. 2000), (Webb, Parsons et al. 2002), (Li, 
Guan et al. 2005), we asked whether the reduction of the EC migration upon NRP2 
knockdown was the result of the attenuation of EC adhesion on the FN substratum. 
Interestingly, we found that NRP2-siRNA-treated mLMECs adhered to the FN substratum 
more slowly than the Ctrl-siRNA-treated cells, suggesting that NRP2 plays an essential role 
in the adhesion of mLMECs to FN (see Figure 4.5).  
The FA intracellular adapter protein paxillin is essential during cell migration (Zaidel-Bar, 
Milo et al. 2007), (Pasapera, Schneider et al. 2010). Using a transwell chamber coated with 
1% gelatin and Matrigel to study cell migration and invasion, respectively, German et al. 
showed that paxillin or NRP2 knockdown in the presence of growth factors, including bFGF, 
VEGF, IGF, EGF and 5% serum, exhibited ~2 or ~1.5 fold increases, respectively, in 
HUVEC migration and invasion compared to siRNA-treated cells. Additionally, paxillin 
knockdown exhibited a 50% decrease in NRP2 at both protein and mRNA levels in cultured 
HUVEC. The overexpression of NRP2 prevented the augmentation of HUVEC migration and 
invasion in paxillin-depleted HUVEC, suggesting that paxillin controls angiogenesis by 
altering NRP2 expression (German, Mammoto et al. 2014). Because integrins accumulate at 
the lamellum to form stable FAs that act as “hand grips” in connecting the ECM to the 
intracellular cytoskeleton during the cell migration process (Small, Rottner et al. 1998), 
(Webb, Parsons et al. 2002), (Li, Guan et al. 2005), and the disruption of integrin attachment 
to the ECM substratum or any of the FAs intracellular adaptor proteins, such as paxillin (see 
chapter 1; Figure 1.16), affects cellular adhesion and migration, we sought to determine 
whether NRP2 expression contributed to the assembly and disassembly of FAs. Therefore, 
before using paxillin as a marker of FAs, we first sought to determine whether NRP2 
knockdown in mLMECs changed the expression of paxillin on the FN substratum in the 
absence of VEGF164 stimulation. We found that both the total and phosphorylation protein 
levels of paxillin were unchanged in NRP2-siRNA-treated cells compared to siRNA-Ctrl-
treated cells (see Figure 4.6 A). Interestingly, consistent with the attenuation we observed in 
mLMEC migration and adhesion upon NRP2 knockdown, we found that the NRP2-siRNA-
treated cells exhibited reduced assembly and disassembly (turnover) of FAs on FN (see 
Figure 4.6 B-C).  
We next employed NRP2 co-immunoprecipitation followed by silver staining to confirm the 
uniform efficiency of the immunoprecipitation between the samples, and we used MS to 
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identify potential binding partners of NRP2 (see Figure 4.7). Interestingly, the MS analysis 
did not show NRP1 as a binding partner of NRP2, which supported our findings (see Figure 
3.2 C and 4.1 C), which showed that NRP1 did not compensate the loss of NRP2 expression. 
Our MS analysis identified three FN receptors: ITGA5, ITGAV and ITGB1 (see Figure 4.7 
C). With respect to the ITGAV subunit, it is a binding partner of both ITGB3 and ITGB5. 
However, because we showed the absence of a link between ITGB3 and NRP2 in EC 
migration, and the MS analysis showed that ITGB5 was not a binding partner, we were left 
with the ITGA5 and ITGB1 subunits, the main FN receptor (α5β1) in ECs to mediate the 
adhesion to FN (Serini, Valdembri et al. 2006), (Hynes 2007), (Valdembri, Caswell et al. 
2009), (Mana, Clapero et al. 2016). Therefore, we first examined the effects of NRP2 
knockdown on the total expression of the ITGA5 and ITGB1 subunits. The Western blot 
analysis of four different clones of WT mLMECs revealed that the NRP2-siRNA-depleted 
ECs exhibited the upregulation of the ITGA5 subunit, whereas the ITGB1 subunit was 
unchanged (see Figure 4.8). This potential cross-talk between the NRP2 and ITGA5 subunits 
led us to examine the direct interaction between these two molecules before proceeding 
further. Interestingly, the co-immunoprecipitation experiment revealed that both molecules 
co-immunoprecipitated with one another, indicating a physical interaction between ITGA5 
and NRP2 in mLMECs (see Figure 4.9). 
4.11. Conclusion 
In this chapter, we have shown that: 
 NRP2 expression, similar to NRP1, is upregulated in β3HET ECs compared to 
WT ECs, and that upregulation of NRP2 is not a response to long-term depletion 
of ITGB3. 
 NRP2 knockdown modestly attenuates ERK and VEGFR2 phosphorylation, but 
this is independent of ITGB3 expression.  
 NRP2 knockdown significantly reduces mMLEC random migrations, and, this 
too is not linked to ITGB3. 
 NRP2 does not regulate ECs proliferation.  
 NRP2 knockdown reduced the relative number of mLMECs adhered to FN 
matrix.  
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 NRP2 knockdown slows the rate of FA turnover. 
 siRNA-mediated knockdown of NRP2 upregulates ITGA5 subunit expression, 
but not ITGB1 subunit expression.  
 MS analysis identified the major FN receptors α5β1 as NRP2 binding partners. 
Importantly, NRP2 is not a binding partner with NRP1. 
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Chapter 5: Investigating how NRP2 regulates ITGA5 
function in mouse lung endothelial cells  
___________________________________________________________________________ 
 
In the previous chapter, we reported that siRNA-mediated knockdown of NRP2 resulted in a 
significant reduction in migration, adhesion, FA turnover and the upregulation of ITGA5 
levels. In this chapter, we attempt to understand how NRP2 regulates ITGA5 function. 
5.1. NRP2 knockdown disrupts the structural formation of ITGA5 on FN; 
and attempting to localise NRP2 with ITGA5 in mLMECs. 
The interaction of cells with ECM during cell migration has been described as developing in 
three stages: 1) focal contacts, which represent the short-lived structural interactions of cells 
with ECM through αvβ3 integrins; 2) FAs, which are contacts developed from the clustering 
of both αvβ3 and α5β1 integrins to form a stable adhesion contact with ECM; 3) fibrillar 
adhesions, which are developed exclusively (on fibronectin) when α5β1 integrins translocate 
from FAs along the ECM fibronectin contact (Zaidel-Bar, Ballestrem et al. 2003), (Pankov, 
Cukierman et al. 2000), (McCleverty, Lin et al. 2007). A previous study showed NRP1 
(structurally related to NRP2) in HUAEC promotes cell adhesion to FN. It does not directly 
interact with FN, but instead its cytoplasmic SEA motif first binds to the adaptor protein 
(GIPC1), which in turn binds to the ITGA5 subunit through its C-terminal SDA sequence; 
however, this interaction which stimulates α5β1 integrin endocytosis and trafficking appears 
to be specific for active α5β1 heterodimers. Subsequently, NRP1 guides and promotes the 
internalisation of active α5β1 heterodimers to intracellular vesicles, which are then rapidly 
trafficked and, finally, recycled back to the plasm membrane (Valdembri, Caswell et al. 
2009).   
NRP2 and NRP1 have a similar domain structure (Zachary 2014). However, no previous 
study has addressed a potential biological interaction between NRP2 and ITGA5 in ECs.  
Therefore, we decided to investigate further whether the observed physical interaction 
between NRP2 and ITGA5 (see Figure 4.9) influences ITGA5 biology. Given their similar 
domain structure, and given the upregulation of ITGA5 upon NRP2 knockdown (see Figure 
4.8 A-B), we sought to determine whether NRP2 co-localises with ITGA5 in ECs, and 
whether NRP2 regulates ITGA5 trafficking in ECs.  
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To carry out this investigation, we first tried to visualise ITGA5 movement in living cells by 
transfecting cells with GFP-labelled ITGA5. However, the signal of the ITGA5-GFP 
construct (kindly provided by Dr. Maddy Parsons) was too weak to visualise, at least in our 
hands, using the equipment available to us. Therefore, we visualised endogenous ITGA5 in 
fixed cells treated with Ctrl-siRNA or NRP2-siRNA. Twenty-four hours post siRNA 
treatment, cells were seeded overnight on coverslips pre-coated with FN. The cells were 
fixed, permeabilised, blocked and immuno-labelled for both ITGA5 and NRP2. Whilst 
ITGA5 was readily detected, we were unable to convince ourselves that NRP2 signals were 
specific. Three different anti-NRP2 antibodies (Abcam 155680, Cell Signalling 3366S and 
Millipore AB10522) (see Figure 3.2 B) were tested using different dilutions of these 
antibodies as well as different blocking solutions (BSA or Dako
®
 Protein Block Serum-Free). 
However, no difference in the intensity of NRP2 staining was detected when comparing the 
NRP2-depleted cells to control cells. We therefore examined ITGA5 localisation in isolation.  
Interestingly, compared to control cells, NRP2-siRNA treated ECs exhibited a significant 
disruption of ITGA5 organisation, which appeared in elongated fibrillar structures (Figure 
5.1). Using ImageJ™ software, we measured the overall length of these ITGA5 containing 
structures in both NRP2-depleted and control cells and noted a significant increase in NRP2-
siRNA treated cells (Figure 5.2). 
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A) 
 
B) 
 
Figure 5.1 NRP2 knockdown disrupts the structural formation of ITGA5 subunit on FN. ECs were nucleofected with 
either Ctrl-siRNA or NRP2-siRNA and seeded on 10-cm dishes pre-coated with 10 µg/ml FN and incubated at 37 °C in CO2 
incubator. Thirty-six hours later, the cells were trypsinised and seeded at low density on coverslips pre-coated with 10 µg/ml 
FN and incubated at 37 °C in CO2 incubator for 12 hours. The cells were fixed and permeabilised before blocking with either 
5% BSA or Dako Protein Block Serum-Free. ECs were then incubated with rabbit anti-ITGA5 primary antibody overnight in 
a humidified chamber at 4 °C. Following two washes to remove the unreacted primary antibody, the cells were incubated 
with donkey anti-rabbit Alexa 488 secondary antibody. The coverslips were mounted with Prolong Gold with Dapi to stain 
the nucleus in blue, whereas ITGA5 was stained green. A) Representative ECs treated with Ctrl-siRNA. B) Representative 
NRP2-depleted ECs. Scale bar is shown as 10 µm. 
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A) 
 
B) 
 
Figure 5.2 Measuring the elongated shape of the ITGA5 formed in the NRP2-depleted ECs compared to control cells. 
A) A representative EC (Top) treated with either Ctrl-siRNA or NRP2-siRNA. ImageJ™ software Plugin-(simple neurite 
tracer) was used to measure the length of ITGA5 in both siRNA-nucleofected conditions. B) The bar chart shows the 
average length of ITGA5 in both siRNA-nucleofected conditions; n>490, and (mean +SEM). Asterisks indicate statistical 
significance: **** P<0.0001 
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5.2. Subcellular protein fractionation revealed NRP2 is localized in cellular 
membranes.  
Since the late 1980s (Bretscher 1989), (Sczekan and Juliano 1990), it has been known that 
integrin heterodimers are internalised from the plasma membrane, trafficked into endosomal 
compartments, and recycled back to the cell surface (Ramsay, Keppler et al. 2007). 
Because we were not able to visualise NRP2 in our mLMECs (see above), we decided to 
examine NRP2’s subcellular localisation biochemically. To this end, we employed a 
subcellular protein fractionation kit, which allows the extraction of subcellular proteins from 
five different cellular compartments sequentially (i.e., cytoplasm, cellular membranes, 
soluble nucleus, chromatin-bound nucleus and cytoskeleton) based on the addition of 
different extraction buffers for each compartment and different centrifugation speeds to 
separate the proteins residing in these different compartments from the same starting 
material. We reasoned that if NRP2 regulates ITGA5 trafficking, which may be the reason for 
the disruption of ITGA5 organisation in NRP2-depleted cells, as shown in Figure 5.1 and 
5.2, this assay might yield a general idea of which compartments display changes in ITGA5 
or NRP2 cellular distribution.  Prior to describing the findings from these studies, it is worth 
noting the following: 1) because of the sequential extraction of cellular compartments from 
the same cell pellet, there is some inevitable carry over between extraction steps (i.e. the 
method is not perfect in definitively isolating each examined compartment); 2) the membrane 
extraction buffer extracts proteins that reside in the plasma membrane, mitochondrial 
membrane, and ER and Golgi membranes; in other words, these distinct, and important, 
locations cannot be distinguished from one another using this method. 
Nonetheless, we explored the distribution of both NRP2 and ITGA5 in siRNA-treated cells 
using this method. Interestingly, NRP2 seemed to reside only in the cellular membrane 
compartments in Ctrl-siRNA treated cells (Figure 5.3 A). In contrast, although ITGA5 was 
detected in all subcellular compartments (noting the limitations mentioned above), most was 
localised in cellular membranes. Taken together, this suggests that ITGA5 and NRP2 
normally co-localise in cellular membranes. Upon NRP2 knockdown, only small changes 
were observed in ITGA5 localisation: we noted increased levels of ITGA5 in the cytoplasm 
and in cellular membranes, and a reduction in the cytoskeleton compartment (Figure 5.3 B).  
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Given the noted changes in ITGA5 expression and organisation upon NRP2-depletion e.g. 
upregulation of total cellular expression (see Figure 4.8 A-B), changes in what look to be 
fibrillar adhesions (see Figure 5.1 and 5.2), and potential changes in subcellular distribution 
(see Figure 5.3), coupled with observed physical interactions between NRP2 and ITGA5 (see 
Figure 4.9), we decided to further explore whether NRP2 regulates ITGA5 trafficking. 
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Figure 5.3 NRP2 resides only in the cellular membranes in which only the compartment NRP2 was localised with 
ITGA5. A) 4x106 ECs were nucleofected with either Ctrl-siRNA or NRP2-siRNA and seeded in a T75 flask pre-coated with 
10 µg/ml FN and incubated at 37 °C in CO2. Twenty-four hours later, the cells were trypsinised and 3x10
6 cells from each 
siRNA-nucleofected condition were seeded in a new T75 flask pre-coated with 10 ug/ml FN and incubated at 37 °C in CO2 
incubator. After another 24 hours, the cells were detached with sodium saline buffer and then transferred to tubes that were 
centrifuged at 500 g for 4 minutes to obtain a visible pellet from each siRNA-nucleofected condition. The pellets were then 
subjected to the cellular fractionation assay to extract proteins from five subcellular compartments sequentially (i.e., 
cytoplasm, cellular membranes, soluble nucleus, chromatin-bound nucleus and finally cytoskeleton) based on different 
extraction buffers and different centrifugation speeds. B) Fractionated samples were then subjected to Western blot analysis, 
and the blot was quantified by ImageJ™ densitometric analysis. The controls were (1) cytoplasmic extract; (2) all cellular 
membranes extracts; (3) soluble nuclear extracts; (4) chromatin-bound extracts; (5) cytoskeletal extracts. ITGA5 level in 
each compartment was normalised to the control detected in that compartment. The bar charts represent the ITGA5 levels in 
different compartments normalised to the indicated protein control of that compartment. 
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5.3. NRP2 seems to regulate ITGA5 turnover 
Seven different large ribosomal 60S subunits (Rpl3a, Rpl7, Rpl8, Rpl9, Rpl22, Rpl35 and 
Rpl37a) and three different small ribosomal 40S subunits (Rps5, Rps24 and Rps26) were 
detected as partner proteins of NRP2 in MS (see Table 4.1). These interactions, in addition to 
the upregulation of ITGA5 in the cytoplasm upon NRP2 knockdown in the fractionation 
study (see Figure 5.3 B), suggested that NRP2 may regulate the translation of ITGA5. 
Therefore, we decided to examine this potential mechanism by treating cells with 
cycloheximide, which inhibits protein synthesis by binding to the E-site of the large 
ribosomal 60S subunit and subsequently blocking translational elongation (Schneider-
Poetsch, Ju et al. 2010), (Klinge, Voigts-Hoffmann et al. 2011).  
ECs were transfected with either Ctrl-siRNA or NRP2-siRNA and treated with 10 µg/ml of 
cycloheximide for eight hours as described previously (Sampieri, Nuttall et al. 2008). The 
lysates then were subjected to a Western blot to analyse the half-life of ITGA5 (Figure 5.4 
A-B). Cycloheximide successfully inhibited the synthesis of both ITGA5 and NRP2 
compared to the untreated ECs (levels of both were decreased after cycloheximide treatment). 
However, after cycloheximide treatment, there was no significant difference in the level of 
ITGA5 in the NRP2-depleted ECs compared to the Ctrl-siRNA treated ECs; the normally 
increased expression of ITGA5 observed upon NRP2 knockdown was gone. This suggested 
to us that either NRP2 regulates ITGA5 translation, or ITGA5 is turned-over faster in the 
absence of NRP2.  
5.4. NRP2 knockdown does not change ITGA5 levels on the cell surface  
Integrins are the main ECM receptors, and the number of these receptors expressed on the 
plasma membrane is believed to be proportional to the efficacy of the spreading and adhesion 
of cells on ECM (Ginsberg, Partridge et al. 2005), (Serini, Valdembri et al. 2006). Because 
we also detected a slight increase in ITGA5 level in the NRP2-depleted membrane extracted 
proteins, which could be any of the cellular membranes, we decided to start with the plasma 
membrane and examine the expression of ITGA5 on the cell surface using flow cytometry. 
However, no significant difference was observed in the amount of total ITGA5 on the plasma 
membrane compared to the Ctrl-siRNA treated cells (Figure 5.5).  
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A)                                                               B) 
 
        
Figure 5.4 NRP2 regulates ITGA5’s turnover. 4x106 ECs were nucleofected with either Ctrl-siRNA or NRP2-siRNA, 
seeded in a T75 flask pre-coated with 10 µg/ml FN and then incubated at 37 °C in CO2. Twenty-four hours later, the cells 
were trypsinised and seeded at a density of 3x106 cells serum-free OptiMEM® in new T75 flasks pre-coated with 10 µg/ml 
FN to starve the cells for 12 hours. Then 10 µg/ml of cycloheximide was added to half of the dishes for eight hours. 
Following lysing, the cells were subjected to DC protein quantification assay. A) The lysates were subjected to a Western 
blot to examine the levels of ITGA5 and NRP2 with or without the cycloheximide treatment. B) The graph shows the level 
of ITGA5 analysed by ImageJTM densitometric quantification; n = 4, and (mean +SEM). The asterisks indicate statistical 
significance: * = 0.029; nsd means not significantly different. Unpaired two-tailed t-test. 
 
 
 
---------------------------------------------------------------------------------------------------------------- 
 
 
Figure 5.5 NRP2 does not change the mount of ITGA5 on the plasma membrane. The nucleofected ECs with either 
Ctrl-siRNA or NRP2-siRNA were seeded in 10-cm dishes pre-coated with10 µg/ml FN and incubated at 37 °C in CO2. After 
48 hours, the cells were detached with sodium saline buffer, centrifuged, and resuspended in FACS buffer. 1x105 ECs from 
each siRNA-nucleofected condition were untreated with antibody, labelled with ITGA5 BE-conjugated antibody or labelled 
with isotype BE-conjugated antibody control in a dark room. Flowing two washes with FACS to remove the unbound 
conjugated antibodies, the cells were subjected to flow cytometry to measure ITGA5 expression on the plasm membrane. 
The histogram was generated using FlowJo™ software to analyse the expression on INTA5 in NRP2-depleated ECs 
compared to the Ctrl-siRNA-transfected ECs.  
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5.5. NRP2 does not regulate the total ITGA5 subunit internalization. 
Dynamic membrane trafficking (i.e., endocytosis and recycling) regulates integrin-ECM 
adhesion turnover and the assembly of actin cytoskeleton during cell migration (Huttenlocher 
and Horwitz 2011), (De Franceschi, Hamidi et al. 2015), (Ata and Antonescu 2017). In 
general, integrins are internalised from the plasma membrane at the base of the protrusion 
and retracting edge, trafficked into endosomal compartments, and then recycled back to the 
cell surface at the leading edge to form new adhesions. The disassembly of FAs at the cell 
posterior and the polymerisation of actin cytoskeletal within the lamellipodium then allows 
for retracting the rear of the migrating cell (Caswell and Norman 2006), (Caswell and 
Norman 2008), (Chao and Kunz 2009), (Ata and Antonescu 2017). 
Activated integrins can be internalised through clathrin-dependent endocytosis (Ramsay, 
Keppler et al. 2007), (Ezratty, Bertaux et al. 2009), clathrin-independent endocytosis 
(Bridgewater, Norman et al. 2012), (Lakshminarayan, Wunder et al. 2014) or circular dorsal 
ruffles during phagocytosis (Gu, Noss et al. 2011) and then recycled back to the plasma 
membrane in a Ras-related family proteins (Rab)-dependent fashion (see chapter 1; 
subsection 1.2.3.2.4) (Roberts, Barry et al. 2001), (Powelka, Sun et al. 2004), (Yoon, Shin et 
al. 2005), (Caswell, Vadrevu et al. 2009), (Morgan, Byron et al. 2009). For example, the 
active α5β1-NRP1 interaction forms a complex with the GIPC1 adaptor protein, which then 
regulates the endocytosis of this integrin through the Rab5 pathway (Valdembri, Caswell et 
al. 2009) (see chapter 1; Figure 1.18 B). The non-ECM-engaged integrin can also be 
endocytosed through the clathrin-independent pathway or the caveolin-dependent pathway 
(Fabbri, Di Meglio et al. 2005), (Echarri and Pozo 2006). However, several lines of evidence 
support the idea that inactive integrins can also be endocytosed by a clathrin-adaptor 
mechanism (Teckchandani, Toida et al. 2009). For example, a quantitative proteomic analysis 
showed that depletion of the endocytic Dab2 adaptor protein in human immortalised HeLa 
cells slowed the endocytosis of ITGA1, ITGA2, ITGA3 and ITGB1 (but not ITGA5 or 
ITGAV) that were not attached to the cytoskeleton whether they were bound to ECM or not. 
Moreover, the same study showed that ITGA5 and ITGB1 were more dependent on AP-2 
complex adaptor, or clathrin-dependent endocytosis, than on Dab2, suggesting that clathrin 
and the AP-2 complex adaptor regulate freely diffusing ITGA5 and ITGB1 endocytosis 
(Teckchandani, Toida et al. 2009). Interestingly, other studies reported that AP-2 complex 
(Chao and Kunz 2009) and clathrin (Ezratty, Bertaux et al. 2009) were involved in FA 
disassembly and regulated α5β1 integrin endocytosis in a clathrin-dependent fashion (Ezratty, 
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Bertaux et al. 2009). MS results (shown in Table 4.1) identified NRP2 interactions with the 
clathrin-dependent endocytosis protein clathrin heavy chain and its classical AP-2 complex 
adaptor proteins, which bind to the cytoplasmic tail of cell surface proteins and recruit 
clathrin to form clathrin-coated pits (Chao and Kunz 2009), (Ezratty, Bertaux et al. 2009), 
(Ezratty, Bertaux et al. 2009). We therefore decided to study the endo-exocytosis of ITGA5 
in NRP2-depleted cells. 
To this end, we used cell surface biotinylation assays in which cell surface proteins are first 
labelled with biotin and then incubated for different times at 37°C to allow the biotin-labelled 
proteins to internalise before remaining biotin is stripped off the cell surfaces using a 
membrane-impermeable reducing agent. The lysates were then subjected to 
immunoprecipitation for biotin before analysing the amount of the internalised protein of 
interest by Western blot. However, the Robinson lab previously failed to strip off the 
remaining biotin using two different membrane-impermeable reducing agents (Mesna and 
TCEP) from mLMECs (Ellison, Atkinson et al. 2015). Therefore, we first optimised the 
protocol by testing different concentrations of reducing agents, times of incubation and lysis 
buffers. After performing multiple rounds of troubleshooting, we successfully achieved the 
complete stripping of biotin from the cell surfaces of immortalised ECs using both reducing 
agents (Mesna and TCEP). In short, we found that dissolving the reducing reagents in Tris 
buffer (Valdembri, Caswell et al. 2009) while increasing both their concentration and the 
incubation period, resulted in enhancing the biotin stripping efficacy compared to dissolving 
the reducing agents in SBS (Remacle, Murphy et al. 2003). 
Given this success, we conducted a cell surface biotinylation assay to investigate the 
internalisation of ITGA5 in NRP2-depleted ECs compared to Ctrl-siRNA treated cells at 
different incubation times. A schematic representation of the internalisation assay is shown in 
Figure 5.6 A. No change was detected in the amount of the internalised ITGA5 in the NRP2-
depleted ECs compared to control cells (Figure 5.6 B-D). This result suggests that NRP2 
does not regulate internalisation of total ITGA5. Similarly, Serini’s group (Valdembri, 
Caswell et al. 2009) reported that human NRP1 does not regulate total  ITGA5 internalisation 
in HUVECs. However, because they were using human cells, Valdembri et al. were able to 
examine active α5β1 internalisation using the SNAKA51 antibody. They found that NRP1 
regulates the internalisation of the active α5β1. Because no commercially available antibody 
detects mouse active α5β1, we are unable to comment further.  
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A) 
 
 
B) 
 
 
C)                                                                D) 
                       
Figure 5.6 NRP2 doesn’t regulate the total ITGA5 internalization. 2x106 of ECs nucleofected with either Ctrl-siRNA or 
NRP2-siRNA were seeded in each 10-cm dish (12 dishes in total) that were pre-coated with 10 µg/ml FN for 48 hours and 
In
te
r
n
a
li
z
e
d
 I
T
G
A
5
 (
%
)
0
 m
in
2
 m
in
4
 m
in
1
0
 m
in
2
0
 m
in
0
5 0
1 0 0
1 5 0
2 0 0
C trl-s iR N A
N R P 2 -s iR N A
 187 
incubated at 37 °C in a CO2 incubator. The cells were starved in a serum-free OptiMEM
® for three hours before placing all 
the dishes on ice. A) Internalisation assay schematic, in which all steps were performed at 4 °C unless otherwise indicated. 
EC surface proteins were labelled with biotin before quenching the non-reacted biotin with glycine. The plates were 
incubated in a pre-warmed serum-free OptiMEM® for different times at 37 °C to allow the cell surface biotin-labelled 
proteins to internalise, whereas (-/+) control dishes were left at 4 °C. Then the incubated plates were immediately placed on 
ice to stop the internalisation process. The remaining biotin on the cell surfaces in the incubated plates, including the (+) 
control plates, was stripped off by Mesna before quenching the Mesna with iodoacetamide. The cells in all the plates were 
lysed at the same time. The lysates were subjected to a DC protein assay and then immunoprecipitated for biotin. B) Western 
blot of biotin-pulldowns shows the internalisation level of ITGA5 over the indicated time. C) Western blot shows the 
efficiency of NRP2 knockdown. The blot in B) was quantified by a densitometric analysis. D) The graph shows the 
internalisation of ITGA5 in percentages at different times normalised to their total level (in cells not incubated and not 
stripped off). The data are representative of two independent experiments. 
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5.6. NRP2 knockdown supresses ITGA5 subunit recycling. 
Because NRP2 did not regulate the internalisation of ITGA5 (see Figure 5.6), but the MS 
data analysis identified an interaction between NRP2 and other trafficking and recycling 
molecules (see Table 4.1), including Lamtor1, Scamp1, Scamp3, COPl, α-SNAP and 
Annexin-A1, we conducted a recycling assay to investigate whether NRP2 regulates ITGA5 
recycling to the plasma membrane.  
A recycling assay was performed in a manner that was similar to the internalisation assay but 
with eight more plates than were used in the internalisation assay. The schematic 
representation of the recycling assay is shown in Figure 5.7 A. In this assay, the biotin-
labelled cell surface proteins were allowed to internalise before stripping off the remaining 
biotin from the cell surfaces. The cells then were incubated at different time points before 
stripping off or not the recycled biotin-labelled proteins. The level of biotinylated ITGA5 was 
then compared between these two samples. Comparing Ctrl-siRNA cells to NRP2-depleted 
cells, we found that ITGA5 is recycled to the plasma membrane more slowly in the latter 
(Figure 5.7 B-D).  
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B) 
 
 
C)                                                                   D)                         
                   
Figure 5.7 NRP2 knockdown supresses total ITGA5 Recycling.  2x106 of ECs nucleofected with either Ctrl-siRNA or 
NRP2-siRNA were seeded in each 10-cm dish (20 dishes in total) that were pre-coated with 10 µg/ml FN and incubated for 
48 hours at 37 °C in CO2. A) Recycling assay schematic, in which all steps were performed at 4 °C unless otherwise 
indicated. Following cell starvation and biotinylation, the cells in two plates from each siRNA-nucleofected condition (Lanes 
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1 to 4) were kept at 4 °C, and the rest were incubated in pre-warmed serum-free Opti-MEM® for 20 minutes at 37 °C in a 
CO2 incubator to allow the biotin-labelled cell surface proteins to internalise. Then incubated plates were immediately placed 
on ice to stop the internalisation process. The un-internalised biotin-labelled proteins were stripped off by Mesna. Two plates 
from each condition (Lanes 5 to 20) were incubated for different periods at 37 °C in a CO2 incubator to allow the 
internalised biotin-labelled proteins to recycle to the cell surfaces. Then the plates were immediately placed on ice to stop the 
recycling process. One plate from each condition (Lanes 5 to 20) was kept at 4 °C, and the rest were subjected to Mesna to 
strip off the recycled biotin-labelled proteins. The cells in the all the plates (Lane 1 to 20) were lysed at the same time. The 
lysates were subjected to the DC protein assay and then immunoprecipitated for biotin. B) Western blot of biotin-pulldowns 
shows the level of ITGA5 inside the cells (i.e. the ITGA5-biotin labelled that didn’t recycle back to the cell surface) over the 
indicated periods. C) Western blot shows the efficiency of NRP2 knockdown. The blot in B) was quantified by a 
densitometric analysis. D) The graph shows the percentage of the recycled ITGA5 in which the amount of ITGA5 in each 
siRNA-nucleofected condition was normalised to the total amount of ITGA5 on the surface of the untreated cells with 
Mesna in the same period of incubation. For example, lane 18 was normalised to lane 17, and lane 20 was normalised to lane 
19. The control lanes (1 to 4) were used to show the efficiency of stripping biotin from the plasma membranes by Mesna. 
The data are representative of two independent experiments. 
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5.7. Discussion 
 Laukaikis et al. showed that the initial adhesive complex formation of a migrated cell begins 
when paxillin enters nascent adhesions and turns-over rapidly at the adhesion regions in the 
newly forming protrusion at the leading edge (Laukaitis, Webb et al. 2001). This process is 
followed by the appearance of α-actinin along the cell border in the membrane protrusion and 
in the fibrous-like structure that slides toward the cell body. Subsequently, the ITGA5 subunit 
appears to stabilise the FAs as well as to translocate paxillin and α-actinin-containing 
cytoskeletal complexes to the cell rear (Laukaitis, Webb et al. 2001). With respect to the 
function of NRP in this context, Goel et al. showed that NRP2 co-localised with the ITGA6 
subunit at the leading edge of laminin-dependent matrices and regulated α6β1 signalling to 
promote the robust association between α6β1 and laminin required for the spread of breast 
cancer cells during the migration process (Goel, Pursell et al. 2012). In the following year, 
Cao et al. showed that NRP2 expressed on renal cell carcinoma promoted vascular adhesion, 
extravasation and tumour metastasis via trans-binding with the ITGA5 subunit expressed on 
ECs (Cao, Hoeppner et al. 2013). Furthermore, Valdembri et al. showed that NRP1 promoted 
HUVEC adhesion to FN matrices via its cytoplasmic tail, which binds to the active ITGA5 
subunit mediated by the GIPCI/Myo6 complex to ensure the recycling of vesicles containing 
active α5β1 to the new adhesion sites required for the spread of ECs on FN matrixes 
(Valdembri, Caswell et al. 2009). Based on the findings of these studies and our findings that 
NRP2 was a binding partner with the ITGA5 subunit in ECs (see Figure 4.7 C and Figure 
4.9) and that NRP2 knockdown upregulated the expression of the ITGA5 subunit (see Figure 
4.8), we investigated the mechanism by which NRP2 regulates the ITGA5 subunit in 
mLMECs, which could explain our finding of the significant reduction in migration (see 
Figure 4.3), adhesion (see Figure 4.5 F) and FA turnover (see Figure 4.6 B-C) upon NRP2 
knockdown.  
We first attempted to visualise the effect of NRP2 knockdown on the movement of the 
ITGA5 subunit in living mLMECs. However, the ITGA5-GFP construct signal after cell 
nucleofection was too weak to track using the available inverted Axiovert microscope. 
Alternatively, we investigated this effect on fixed cells. Unfortunately, by using three 
different commercial anti-NRP2 antibodies, we were unable to confirm that these antibodies 
worked in immunocytochemistry (ICC). Therefore, we were not able to co-localise the two 
molecules in this context. However, by examining the effect of NRP2 knockdown on ITGA5 
organisation in fixed mLMECs, we showed that NRP2-siRNA-treated ECs exhibited a 
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significant disruption of ITGA5 organisation on FN matrices, which appeared in elongated 
fibrillar structures, compared to the Ctrl-siRNA-treated cells (see Figure 5.1 and 5.2). 
Because we were unable to localise NRP2 in fixed cells, we then used the subcellular protein 
fractionation kit to study the distribution of the two molecules in different cellular 
compartments. Interestingly, NRP2 was localised only in the cellular membrane 
compartments, and a majority of ITGA5 was localised in the same compartments, which 
suggested that the two molecules were co-localised in the cellular membranes. Overall, the 
localisation of NRP2 on the cellular membranes and the biochemical interaction between 
NRP2 and ITGA5 subunit, as well as the upregulation of ITGA5, the disruption of ITGA5 
organisation in FN, and the potential changes in ITGA5 levels in the subcellular 
compartments upon NRP2 knockdown led us to investigate the possibility that NRP2 could 
regulate ITGA5 turnover/trafficking. Additionally, the detection of small and large ribosomal 
subunits as a binding partner of NRP2 in MS (see Table 4.1) suggested that NRP2 may also 
regulate the transcription of ITGA5 expression. To investigate these two possibilities, we first 
employed cycloheximide to inhibit protein synthesis in NRP2-depleted cells and in Ctrl-
siRNA treated cells. Interestingly, compared to the cycloheximide-untreated cells, the 
upregulation of ITGA5 level in the NRP2-depleted cells was absent. This finding suggests 
that the ITGA5 subunit was degraded faster in the NRP2-depleted cells and that 
simultaneously, the translation of ITGA5 was increased to compensate the degraded ITGA5. 
Because the number of integrins expressed on the plasma membrane is believed to be 
proportional to cell adhesion on ECM (Ginsberg, Partridge et al. 2005), (Serini, Valdembri et 
al. 2006), we also examined whether NRP2 knockdown would change ITGA5 expression on 
the plasma membranes using flow cytometry. However, the NRP2 knockdown exhibited no 
difference in the total ITGA5 level on the cell surface compared to the control conditions, 
which supported our suggestion that the rate of ITGA5 translation is also rapid in the NRP2-
depleted cells to compensate for increased degradation of ITGA5.  
In general, it has been shown that activated integrins are endocytosed from the plasma 
membrane through different mechanisms: clathrin-dependent endocytosis (Ramsay, Keppler 
et al. 2007), (Ezratty, Bertaux et al. 2009), clathrin-independent endocytosis (Bridgewater, 
Norman et al. 2012), (Lakshminarayan, Wunder et al. 2014) or circular dorsal ruffles during 
phagocytosis (Gu, Noss et al. 2011). With respect to clathrin-dependent endocytosis, most 
integrins recruit endocytic adaptor proteins, such as Dab-2 and AP-2 complex adaptor 
proteins, at or near FAs shortly before the integrins disassemble to form the clathrin-coated 
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pits required for integrin endocytosis (Margadant, Monsuur et al. 2011). Previous studies 
showed that the silencing of clathrin, Dab-2, or AP-2 complex adaptor resulted in reductions 
in FA disassembly and cell migration (Ezratty, Bertaux et al. 2009), (Chao and Kunz 2009), 
(Teckchandani, Toida et al. 2009) (see chapter 1; subsection 1.2.3.2.4). With respect to α5β1, 
Teckandani et al. suggested that both ITGB1 and ITGA5 endocytosis were regulated by 
clathrin and AP-2 complex adaptor complex (Teckchandani, Toida et al. 2009). In agreement 
with Teckandani, two studies published in the same year showed that clathrin (Ezratty, 
Bertaux et al. 2009) and AP-2 adaptor complex (Chao and Kunz 2009) were involved in the 
induction of FA disassembly and in α5β1 endocytosis in a clathrin-dependent manner 
(Ezratty, Bertaux et al. 2009). Interestingly, the clathrin heavy chain and its classical AP-2 
complex adaptor proteins were identified in MS results (see Table 4.1) as NRP2 binding 
partners.  
The MS analysis also identified ITGA5, ITGB1 and ITGAV but not ITGB3 or ITGB5, which 
are binding partners of ITGAV, which suggested that, similar to NRP1 (Valdembri, Caswell 
et al. 2009), NRP2 may also regulate the trafficking of active α5β1 during the cell migration 
on FN matrices. Additionally, this suggestion was supported by the identification of EH 
domain-containing protein 2 (EHD2) as a binding partner protein in MS, which is 
functionally localised to the neck of the invaginated caveolae to form oligomeric rings around 
lipid membranes to limit the scission and subsequent endocytosis of these membrane pits 
(Morén, Shah et al. 2012), (Stoeber, Stoeck et al. 2012), (Mohan, Morén et al. 2015), 
(Hoernke, Mohan et al. 2017). In addition to EHD2, other molecules involved in the 
endocytosis and trafficking processes were also identified in the MS analysis, including the 
regulator complex protein LAMTOR1 (Lamtor1) (Mu, Wang et al. 2017), (Malek, 
Guillaumot et al. 2012), the secretory carrier-associated membrane protein 1 (Scamp1) (Lam, 
Siu et al. 2007), (Cai, Jia et al. 2011), (Zhang and Castle 2011), (Vadakekolathu, Al-Juboori 
et al. 2018), the secretory carrier-associated membrane protein 3 (Scamp3) (Falguières, 
Castle et al. 2012), (Naboulsi, Bracht et al. 2016), the epsilon-coatomer subunit (COPl) 
(Lippincott-Schwartz, Roberts et al. 2000), (Ward, Polishchuk et al. 2001), (Wang, Wang et 
al. 2010) (Benyair, Ogen-Shtern et al. 2015), the alpha-soluble NSF attachment protein (α-
SNAP) (Stenbeck 1998), (Shah, Colbert et al. 2015) and Annexin-A1 (Lizarbe, Barrasa et al. 
2013) as well as other cytoskeletal binding proteins, such as β-actin and γ-actin, T-complex 
protein 1 subunit beta (TCP1) (Llorca, McCormack et al. 1999), (Gómez‐Puertas, Martín‐
Benito et al. 2004), α-catenin l and β-catenin 1 (Peng, Maiers et al. 2012), (Choi, Estarás et 
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al. 2013), alpha-centractin (Arp1) (Holleran, Tokito et al. 1996), (Cheong, Feng et al. 2014) β 
and γ-adducin (Yang, Sui et al. 2018), F-actin-capping protein subunit alpha-2 and 
tropomodulin-3 (Almenar-Queralt, Gregorio et al. 1999), (Fischer, Fritz-Six et al. 2003) (see 
Table 4.1).  
Using the cell-surface biotinylation assay, Valdemebri et al. showed that human NRP1 did 
not regulate total α5β1 endocytosis. However, they found that the NRP1-GIPC1-Myo6 
complex was bound to active α5β1, thus regulating the endocytosis of the active α5β1 via the 
Rab5-dependent pathway in HUVECs (see chapter 1; Figure 1.18 B) (Valdembri, Caswell et 
al. 2009). Using the same technique, we found that mouse NRP2, similar to human NRP1 
(Valdembri, Caswell et al. 2009), did not regulate total α5β1 endocytosis. Recently, Lilja et 
al. showed that the silencing of SHANK3 significantly increased the active ITGB1 levels on 
the cell surface without affecting the total ITGB1 expression on the cell surface (Lilja, 
Zacharchenko et al. 2017). Interestingly, the MS analysis showed that SHANK3 was a 
potential binding partner of NRP2; however, we could not investigate this possibility because 
there is no commercially available antibody against mouse active ITGA5.  
Based on this finding, as well as the identification of other trafficking, recycling and 
cytoskeletal adaptor molecules as binding partner adaptor proteins in the MS analysis, we 
sought to investigate the possibility that NRP2 regulates ITGA5 recycling. Interestingly, the 
cell-surface biotinylation assay showed that total ITGA5 in NRP2-depleted ECs was recycled 
to the cell surface slower than the total ITGA5 in the Ctrl-siRNA-treated cells, indicating that 
NRP2 expression regulates the total ITGA5 subunit recycling in mLMECs.  
5.8. Conclusion 
In this chapter, we have shown that: 
 NRP2 knockdown disrupts the structural formation of ITGA5 subunit on FN 
matrix. 
 NRP2 is mainly localized in cellular membranes; and ITGA5 is also highly 
expressed in the cellular membranes compartments. 
 
 NRP2 regulates ITGA5 subunit turnover.  
 NRP2 does not regulate total ITGA5 subunit internalisation. 
 NRP2 knockdown attenuates total ITGA5 subunit recycling.  
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Chapter 6: Investigating NRP2 silencing effect in the 
angiogenesis ex vivo aortic ring model  
___________________________________________________________________________ 
 
As mentioned in chapter 3, previous studies showed that NRP2 regulates VEGF-induced 
signalling (Favier, Alam et al. 2006) (Caunt, Mak et al. 2008) and angiogenesis (Dallas, Gray 
et al. 2008), (German, Mammoto et al. 2014). However, because when we knocked down 
NRP2 levels, we only detected marginal reductions in VEGFR2 and ERK phosphorylation 
(see Figure 4.2), and no VEGF-induced alterations in cell migration (see Figure 4.3), we 
decided to investigate the biological function of endothelial NRP2 in VEGF-induced 
sprouting by using a Cre-loxP model; a model that would allow us to control NRP2 gene 
activity in a time and tissue-specific manner (Feil, Valtcheva et al. 2009). We wanted to 
import NRP2 floxed mice, but because of the health status of the facility from which the mice 
were available, we were not allowed to import them into our animal research unit before the 
end of this project. Alternatively, we therefore decided to generate Cre-induced lentiviral-
mediated shRNAs. By transfecting these into aortic rings derived from animals carrying an 
endothelial, and Tamoxifen-inducible, Cre recombinase, we endeavoured to stably silence 
NRP2 expression specifically in endothelial cells to study the effects on ex vivo angiogenesis. 
The ex vivo aortic ring assay has been documented to provide a complete picture of 
angiogenic processes including: cellular proliferation, migration, tube formation, microvessel 
branching, perivascular recruitment and remodelling (Baker, Robinson et al. 2012). 
Therefore, it has become widely used as an angiogenesis model to investigate the effect of 
silencing a certain gene in the formation of microvessel sprouts in response to angiogenic 
stimuli (Nicosia 2009), (Yang and Proweller 2011), (Han, Yang et al. 2012), (Yakkundi, 
Bennett et al. 2015), (Ellison, Atkinson et al. 2015), (Mukai, Muramatsu et al. 2016). 
However, the aorta explants are composed of ECs as well as other cells including pericytes, 
fibroblasts, macrophages and dendritic cells (Nicosia 2009). In order to silence NRP2 
specifically in aortic ECs but not in other cells, we opted for the Plasmid for Stable 
Interference Condition system which has been widely used for conditional cell-type-specific 
gene-silencing based on the Cre-loxP system (Ventura, Meissner et al. 2004), (Susanto, Lin et 
al. 2008), (D'Amico, Robinson et al. 2010), (Heitz, Johansson et al. 2014), (Jung, Lee et al. 
2016). This was done by cloning different  oligonucleotides coding for NRP2-shRNA into the 
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pSico vector to generate lentiviruses carrying these pSico-shRNA constructs to silence 
endothelial NRP2 expression conditionally in aortic rings derived from a tamoxifen inducible 
(iCreER
T2
) system under the transcriptional control of endothelial-specific promoter (pdgfb) 
(Claxton, Kostourou et al. 2008). 
6.1. Selection of NRP2 targeting sequences, designing the short hairpin 
RNA (shRNA) oligonucleotides, and generating conditional lentiviral 
vectors. 
A schematic diagram showing an overview of the whole process used to generate lentiviruses 
for conditional silencing of NRP2 (Figure 6.1 A) using pSico (for conditional activation) and 
pSicoR (for conditional inactivation) vectors (Figure 6.1 B). We used 
PSICOLIGOMAKER1.5, a programme established by Tyler Jacks’s lab at MIT (Ventura, 
Meissner et al. 2004), to choose targeting sequences most likely to elicit efficient NRP2 
silencing. Because NRP2 is composed of five extracellular domains (Pellet-Many, Frankel et 
al. 2008), we selected three target sequences from different domains (Figure 6.1 C). We also 
included the NRP2-siRNA (#3) sequence GCUAUGACAUGGAGUAUCA that we used in 
previous chapters because it showed 90% knockdown in transient assays (see chapter 3; 
Figure 3.2 C-D) and it conforms to PSICOLIGOMAKER1.5 rules for a fourth target 
sequence (Table 6.1). Then, we used the same programme to design both the sense and anti-
sense shRNA oligonucleotides for cloning into pSico and pSicoR (Table 6.2). By using the 
Web Surfaces for RNA Secondary Structure Prediction (Reuter and Mathews 2010), we also 
checked the percentage probability of the designed shRNAs to form the hairpin structures 
required for efficient silencing (Figure 6.2). The NRP2-shRNAs were cloned in both vectors 
at HpaI-XhoI sites and the vectors were then digested with restriction enzymes (NotI & SacII 
for pSico; XbaI & Xho1 for pSicoR) as shown in Figure 6.1 B. Positive clones released a 
larger DNA sequence than the fragment released by empty vector: 701-bp vs 646-bp for 
pSico (Figure 6.3 A), and 375-bp vs 319-bp for pSicoR (Figure 6.3 B). The positive clones 
were Sanger sequenced by Source BioSience Ltd to confirm the correct cloned sequences. 
Finally, the pSico conditional lentivirus vectors were generated as described in the Virapower 
Lentiviral Expression System User Manual (Invitrogen). 
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A) 
 
B)                                                                                         C) 
                                               
Figure 6.1 Selection of NRP2 targets and cloning the shRNA oligonucleotides in conditional vectors. A) A schematic 
representation of generating a conditional lentiviral vectors. B) A schematic representation showing the sites of cloning the 
designed 55 shRNA oligonucleotides in the pSico or pSicoR vectors. Following digestion of the pSico or pSicoR vectors 
with HpaI and XhoI restriction enzymes, the designed shRNAs were annealed at HpaI-XhoI sites. After cloning the shRNA 
in the pSico vector, the two sites NotI and SacII were digested with their restriction enzymes and released 701-bp positive 
fragment compared to 646-bp negative cloning, whereas the shRNA cloned in the pSicoR were digested with the HpaI nad 
XhoI restriction enzymes and released 374-bp positive fragments compared to 315-bp negative fragments. C) A schematic 
representation showing the four selected NRP2 sequences and their target domains. Adapted from (Ventura, Meissner et al. 
2004) 
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Table 6.1: Selecting four different NRP2 targeting sequences starting with (G) and indicating 
the position, length, score, exon number and the targeting domain of each target. 
Target Position Sequence Length Score Exon Domain 
1 1071 GGATGGAGATCATCCTACA 19 7 4 CUP (a2) 
2 1588 GAAAGGCTACTACGTCAAA 19 7 7 FV/VIII (a1) 
3 2691 GCATGGAGTTCCAGTACCA 19 7 13 MAM (1) 
4 2837 GCTATGACATGGAGTATCA 19 7 13 MAM (2) = NRP2-
siRNA #3 
 
 
Table 6.2: Designing NRP2-shRNA (sense & anti-sense) oligonucleotides containing hairpin 
sequences. 
Target NRP2-shRNA 
 
1 
Sense 5’-TGGATGGAGATCATCCTACATTCAAGAGATGTAGGATGATCTCCATCCTTTTTTC 
Anti-sense 5’-TCGAGAAAAAAGGATGGAGATCATCCTACATCTCTTGAATGTAGGATGATCTCCATCCA 
 
2 
Sense 5’-TGAAAGGCTACTACGTCAAATTCAAGAGATTTGACGTAGTAGCCTTTCTTTTTTC 
Anti-sense 5’-TCGAGAAAAAAGAAAGGCTACTACGTCAAATCTCTTGAATTTGACGTAGTAGCCTTTCA 
 
3 
Sense 5’-TGCATGGAGTTCCAGTACCATTCAAGAGATGGTACTGGAACTCCATGCTTTTTTC 
Anti-sense 5’-TCGAGAAAAAAGCATGGAGTTCCAGTACCATCTCTTGAATGGTACTGGAACTCCATGCA 
 
4 
Sense 5’-TGCTATGACATGGAGTATCATTCAAGAGATGATACTCCATGTCATAGCTTTTTTC 
Anti-sense 5’-TCGAGAAAAAAGCTATGACATGGAGTATCATCTCTTGAATGATACTCCATGTCATAGCA 
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1) CUP (a2)                                                                   2) FV/VIII (a1) 
                                                 
 
3) MAM1                                                                         4) MAM2 = NRP2-siRNA (#3) 
       
Figure 6.2 The percentage prediction formation of the short hairpin structures of the four designed shRNAs 
oligonucleotides targeting different domains of NRP2. The Web Surfaces for RNA Secondary Structure Prediction 
(Reuter and Mathews 2010) was used to predict the percentage formation of the short hairpin RNA structure of four 
designed oligonucleotides that target different domains of NRP2 gene.  
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A)                                                                              
  
B) 
  
Figure 6.3 pSico and pSicoR constructs digestions with restriction enzymes to detect the positive cloned shRNAs. 
Following inserting the designed shRNA in either pSico or pSicoR plasmids and then transforming the vectors into E.coli for 
amplification, numbers of selected colonies were grown in LB media before purifying the plasmid DNA using plasmid DNA 
mini kit (OMEGA). A) pSico vectors carrying the designed shRNAs were digested with NotI & SacII and released 701-bp 
(positive cloning) and 646-bp (Negative cloning), whereas B) pSicoR vectors were digested with XbaI & XhoI and released 
374-bp (positive cloning) and 319-bp (negative cloning). Note that the red arrows are all the potential positive cloning 
samples that were then sent to the Source BioSience Ltd to confirm the correct cloned shRNAs sequences. 
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6.2. Inefficient mLMECs uptake of pSicoR constructs introduced by 
electroporation. 
pSicoR constructs allow for constitutive expression of the target shRNAs with no need for 
Tamoxifen. In fact, the addition of Tamoxifen will turn off the shRNAs expression by 
activating the Cre-loxP recombination which will, in turn, result in the excision of the target 
shRNAs (Figure 6.4 A).  
 
We showed that electroporation is a fairly efficient technique in delivering the paxillin-GFP 
constructs in mLMECs (see figure 4.6); therefore we decided to nucleofect our mLMECs 
with different amounts of the pSicoR constructs to examine their ability to silence NRP2.  
Forty-eight hours post nucleofection, the cells were checked for the intensity of the GFP 
expression (Figure 6.4 B), which reflects the efficacy of the shRNAs expression, before 
subjecting the lysed cells to Western blot and evaluating NRP2 knockdown. Unexpectedly, 
silencing NRP2 expression by NRP2-siRNA #3 (lane 2) showed 90% knockdown, whereas 
the shRNA (lane 11-14), which targets the same sequence as the siRNA, showed only 20% 
knockdown when it was compared to the scramble-shRNA condition (Figure 6.4 C-D).   
 
Two possibilities may explain the low number of cells transfected with pSicoR constructs 
compared with siRNA induced knockdown in Figure 6.4 B: 1) electroporation does not allow 
complete uptake of pSicoR constructs by mLMECs. The pSicoR construct is relatively large 
(7,271-bp) compared to NRP2-siRNA #3 (19-bp); 2) in this experiment, the nucleofected 
cells were seeded in complete IMMLEC medium, which contains phenol red. Previous 
studies indicated that phenol red can mimic the action of estrogen (Berthois, 
Katzenellenbogen et al. 1986), (Węsierska-Gądek, Schreiner et al. 2007). This may mean that 
even though Tamoxifen was not added, phenol red was able to bind to the estrogen receptor 
and thus turn off the shRNA by activating the Cre-loxP system leading to the excision of the 
cloned shRNA (see Figure 6.4 A). Another way to get better uptake of the pSicoR plasmid 
would be to treat mLMECs with lentiviral particles, but the Robinson lab has previously 
found these viral particles to be rather inefficient in these immortalised cells.  
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A) 
 
B) 
 
 
 
C) 
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D) 
 
Figure 6.4 Inefficient uptake of pSiocR constructs by electroporation. A) A schematic representation showing the active 
pSicoR and its inactivation. B) mLMECs were nucleofected with Ctrl-siRNA, NRP2-siRNA or different amount of pSicoR 
constructs and seeded on 6-well plates coated with 0.1% gelatin in a CO2 incubator. 48 hours later, only the cells that 
nucleofected with the constructs were fluorescence imaged as shown in B, and the cells were lysed. C) The lysates were 
protein quantified before being subjected to Western blot to check NRP2 knockdown. D) ImageJTM densitometric 
quantification of the blot shown in C). 
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6.3. Infecting primary ECs with pSico lentiviruses induced marginal NRP2 
knockdown. 
Because mLMECs do not uptake plasmids by lentiviral particles, we decided to infect 
primary ECs with lentivirus containing our pSico constructs. The lung ECs were isolated (as 
described in chapter 2; section 2.2) from the lungs of pdgfb-Cre mice. ECs were then 
infected with the four conditional lentiviruses that carry the pSico shRNA constructs to test 
their efficacy in silencing NRP2 (Figure 6.5 A). Four days after adding Tamoxifen, which 
mediates the inducible loxP-specific recombination event by sequestering the bound HSP90 
and translocating the active iCreER from the cytoplasm to the nucleus (Claxton, Kostourou et 
al. 2008), the ECs were lysed and subjected to Western blot analysis. Comparing the NRP2 
knockdown induced by the four shRNA constructs with the scrambled sample, the shRNA 
constructs that target FV/VIII and MAM domains of NRP2 seemed to be somewhat 
promising, eliciting knockdowns ranging from 25% – 40%.  The NRP2-shRNA targeting 
CUP (a2) domain showed no effect (Figure 6.5 B-C). Therefore, the three somewhat 
promising shRNA lentiviruses were taken forward to study NRP2 silencing in the ex vivo 
aortic ring angiogenesis assay.   
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A) 
 
 
 
B)  
                                   
 
C) 
   
Figure 6.5 Testing pSico lentivirus of primary ECs. A) A schematic representation of the pSico constructs activation. B) 
Following the isolation of the lung primary ECs from pdgfb-iCreER mice, the cells were infected with pSico lentivirus 
targeting different domain in NRP2 gene. The cells were lysed and subjected to Western blot to evaluate NRP2 expression. 
Scramble-shRNA was used as a negative control, whereas the NRP2-shRNA targeting the same sequence as NRP2-siRNA 
#3 was used as a positive control. C) ImageJTM densitometric quantification of the blot shown in B). 
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6.4. Infecting aortic rings with the pSico lentivirus provided inconclusive 
results. 
To analyse the role of NRP2 in VEGF-induced neovascularisation responses, we used the 
aortic ring assay in which thoracic aortic rings from pdgfb-iCreER mice were infected with 
lentiviruses carrying pSico shRNAs constructs. These were a scrambled control shRNA, a 
VEGFR2 shRNA, or one of the shRNAs targeting NRP2 (see Table 6.1). These rings were 
embedded in collagen matrix in the presence of VEGF plus Tamoxifen to induce shRNA 
expression. Quantification of the number of endothelial microvessel sprouts after 6 days of 
treatment indicated that: 1) VEGF induced-sprouting was achieved (no VEGF showed very 
little sprouting, Figure 6.6 Lane 1-2). 2) VEGFR2-shRNA stopped VEGF-induced sprouting 
(positive control, Figure 6.6 Lane 3-4); 3) The NRP2-shRNAs did not significantly alter the 
micovessel sprouting compared to the scrambled shRNA condition (Figure 6.6 Lane 5-7), 
though there seemed to be a trend of reduced sprouting effect similar to NRP2 silencing trend 
seen in Figure 6.5 B-C. However, because the slight (insufficient) NRP2 knockdown 
introduced by pSicoR, which was tested on mLMECs, (see Figure 6.4 B-C) and pSico, 
which was tested on primary ECs, (see Figure 6.5 B-C), the NRP2 role in VEGF-induced 
neovascularisation remained inconclusive.  
To overcome this problem in the future we would need to generate Tamoxifen-dependent 
(inducible) NRP2 knockout mice. This will allow studying the role of NRP2 in VEGF-
induced neovascularisation responses and other in vivo studies without needing lentivirus.  
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Figure 6.6 Infecting aortic rings with the pSico lentivirus provided inconclusive results. Thoracic aortae were isolated 
from pdgfb-iCreER mice, cut into rings, before transfecting 20–25 rings with the indicated lentivirus (Lane 3-7) in serum-
free OptiMEM® in a 24-well plate overnight. No lentivirus transfection controls were included (Lane 1-2). The rings were 
then impeded in collagen type-1 supplemented with 30ng/mL VEGF plus 1 μM OHT for 6 days. Following fixation with 4% 
PFA, the rings were stained with FITC-conjugated BS1-Lectin overnight. The endothelial Microvessel sprouting of aortic 
rings were then counted.  The bar chart shows the total number of sprouts per aortic ring (mean +SEM from 3 independent 
experiments; n≥25 rings per condition). Asterisks indicate statistical significance: ***, P<0,001; ****, P<0.0001; nsd = not 
significantly different. Unpaired two-tailed t-test. 
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6.5. Discussion 
In 1982, the aortic ring assay was first described by Nicosia et al. as a model for studying 
angiogenesis in vitro that produces microvessels in 3-dimensional matrix in a less complex 
setting than the live animal models, such as the rabbit ear chamber, the rat cornea, the dorsal 
air sac of the rat, and the chorioallantoic membrane of the chick embryo, which provides 
invaluable information on the growth of blood vessels (Nicosia, Tchao et al. 1982), (Nicosia 
2009). Briefly, in response to angiogenic stimuli, the aortic ring in culture is composed of a 
mixed population of cells that appear at different time points. After two days in culture, 
fibroblasts and macrophages, which originate in the aortic ring adventitia, are the first cells 
that migrate beyond the aortic ring. After three days, endothelial tip cells start to appear and 
migrate without dividing, whereas the trailing endothelial cells actively proliferate to extend 
filopodia-like processes that elongate and develop a vessel with a visible lumen surrounded 
by pericytes and dendritic cells. After one week of spouting and branching, the vessels stop 
growing. Subsequently, they regress and eventually dissociate from the aortic ring (Nicosia 
2009). Because this model provides a complete view of angiogenic processes and has many 
other advantages, including reproducibility, cost effectiveness, ease of use, and bridging the 
gap between in vitro and in vivo angiogenesis assays, it has become a widely used model in 
studying angiogenesis (Nicosia 2009), (Baker, Robinson et al. 2012).  
Because the purpose of our study was to investigate the role of NRP2 in ECs in a VEGF-
induced aortic ring micro vessel sprouting model, and that previous studies showed that 
NRP2 was also expressed on the surfaces of fibroblast (Zimmermann-Geller, Köppert et al. 
2016) and dendritic cells (Curreli, Arany et al. 2007), (Rey-Gallardo, Escribano et al. 2010) 
we therefore used pSico, a widely used technique for silencing a gene of interest in time- and 
tissue-specific contexts. We selected NRP2 target sequences, designed shRNA 
oligonucleotides, cloned the selected oligonucleotides coding for NRP2-shRNA in both pSico 
and pSicoR vectors, and generated lentiviral vector-mediated NRP2-shRNA.  
To investigate the ability of the selected target to silence NRP2, we first tested different 
concentrations of the pSicoR constructs in silencing of NRP2 expression on mLMECs by 
electroporation. However, all pSicoR constructs exhibited a low number of transfected cells, 
and thus failed to induce NRP2 knockdown compared to NRP2-siRNA, which showed a 
knockdown of 90% (see Figure 6.4 C lane 1-2). We reasoned that this failure was due to 
either the large size of pSicoR (7,271-bp) constructs compared to NRP2-siRNA (19-bp) or 
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the presence of phenol red in the IMMLEC cultural medium. As mentioned earlier, the 
Robinson group previously found that the transfection of lentiviral particles was inefficient in 
mLMECs, we tested the selected NRP2 target sequences in primary ECs isolated form pdgfb-
iCreER mice. Unfortunately, by infecting the generated lentiviral vector-mediated NRP2-
shRNA in primary ECs, the NRP2-shRNA constructs that targeted the CUP domain failed to 
induce NRP2 knockdown. In contrast, the constructs that targeted the FV/VIII and MAM 
domains of NRP2-induced low knockdowns ranging from 25–40% (see Figure 6.5). Though 
it could be argued that this low knockdown was insufficient, we used these NRP2-shRNA 
lentiviruses to study the biological function of NRP2 in VEGF-induced aortic ring 
microvessel sprouting. The quantification analysis showed that the NRP2-shRNA lentiviruses 
induced a slight, but insignificant, reduction in the number of endothelial microvessel sprouts 
compared to the scrambled-shRNA lentiviruses (see Figure 6.6). This trend suggested that 
NRP2 may regulate VEGF-induced angiogenesis in ECs. However, because we did not 
achieve sufficient NRP2 silencing by using the pSico technique, we need to generate a 
tamoxifen-dependent (inducible) NRP2 knockout mouse model. This model would allow the 
study of the role of NRP2 in VEGF-induced neovascularisation responses and other in vivo 
studies without the need for the lentivirus. 
6.6. Conclusion 
In this chapter, we generating conditional lentiviral vectors-mediated NRP2-shRNA to 
investigate the biological function of endothelial NRP2 in VEGF-induced sprouting by using 
a Cre-loxP model and showed that: 
 mLMECs do not uptake pSicoR constructs efficiently by electroporation. 
 Infecting primary ECs isolated from PDFGb-iCreER mice with pSico 
lentiviruses carrying NRP2-shRNA induced only marginal NRP2 knockdown. 
 Infecting aortic rings isolated from PDFGb-iCreER mice with pSico lentiviruses 
carrying NRP2-shRNA did not significantly alter the microvesselas sprouting, 
thus providing inconclusive results as to the angiogenic role of EC NRP2 in vivo.  
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Chapter 7: Summary and Conclusion 
___________________________________________________________________________ 
 
7.1. Novelty and Significance 
Does this thesis contribute to the field of angiogenesis? 
Several studies have reported the upregulation of NRP2 levels in cancers, including prostate 
cancer, bladder cancer, breast cancer, lung cancer, liver cancer, pancreatic cancer, colorectal 
cancer and oral cancer. They found that NRP2 expression was consistently correlated with 
cancer progression and aggressiveness, suggesting that NRP2 may serve as a potential target 
in treating cancers (see subsection 1.2.3.1.4.2.2.1.). Favier et el. imitated this upregulation of 
NRP2 observed in cancer cells by overexpressing NRP2 in hMVECs and found that cell 
survival in these ECs was significantly increased with VEGF-A- or VEGF-C-induced 
stimulation, whereas NRP2 knockdown significantly inhibited both VEGF-A- or VEGF-C-
induced migration. Therefore, Favier suggested that NRP2 is an interesting pharmacological 
target. Additionally, Favier pointed out that it is important to understand the cross-talk 
between NRP2 and other receptors (mainly VEGF, integrins and plexins) in ECs to 
understand the mechanisms underlying angiogenesis and lymph-angiogenesis, which would 
help in designing new drugs to better control these phenomena in autoimmune diseases and 
tumour development (Favier, Alam et al. 2006). In 2014, in an interview, Ian Zachary said, 
“the cellular function of NRP2 is less well studied than for NRP1, and it is unclear what its 
primary functions are in endothelial, lymphatic or cancer cells” (Zachary 2014). My study is 
the first to investigate the biological function underlying the interaction between integrins and 
NRP2 within ECs. 
7.2. Summary of the Findings and discussion 
Previous research conducted in our laboratory showed that NRP1 expression is upregulated in 
β3HET ECs, and that migration is only sensitive to NRP1 perturbations when ITGB3 levels 
are reduced (Ellison, Atkinson et al. 2015). We began this project by investigating the 
potential interaction between the ITGB3 subunit and NRP2 in mLMECs. We found that 
similar to NRP1, NRP2 expression was upregulated in β3HET ECs (see Figure 4.1 A). 
Additionally, we showed that the upregulation of NRP2 was not a response to the long-term 
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depletion of ITGB3 (see Figure 4.1 B). Based on these findings, we carried out signalling 
and migration studies, and we investigated the potential cross-talk between the two 
molecules. However, whilst NRP2 silencing modestly reduced VEGFR2 and ERK1/2 
phosphorylation, it did so in both WT and β3HET ECs (see Figure 4.2 A-B), which 
suggested the absence of a link between NRP2 and ITGB3 in VEGF-induced signalling. 
NRP2 knockdown significantly reduced EC migration on FN matrices, but this effect was 
also independent of ITGB3 expression (see Figure 4.3). 
The adhesion of ECs to ECM deposition is a requisite stage in EC migration, proliferation 
and invasion during angiogenesis (Somanath, Razorenova et al. 2006), (Matsunaga, Iyoda et 
al. 2014). This process is mainly mediated through integrins that connect the ECM to the 
actin filaments, which is mediated by more than 150 intracellular adaptor molecules 
(Somanath, Razorenova et al. 2006), (Reinhart‐King 2008). Mechanistically, these adaptor 
molecules bind to the cytoplasmic tail of integrins and recruit other integrins to cluster at the 
sites of adhesion to assemble stable FA complexes, which act as hand grips to tether the cell 
fronts during migration (Small, Rottner et al. 1998), (Webb, Parsons et al. 2002), (Li, Guan et 
al. 2005), (Valdembri and Serini 2012), (De Pascalis and Etienne-Manneville 2017). 
Therefore, we sought to determine whether the significant reduction in EC migration on FN 
upon NRP2 silencing was the result of the disruption of EC adhesion on FN. Our findings 
(see Figure 4.5 F) suggest that EC adhesion on FN substratum is also dependent on NRP2 
expression. This finding led us to further investigate whether NRP2 expression regulated the 
formation of FAs. By using paxillin as a marker of FAs, we showed that NRP2 silencing 
significantly reduced both the assembly and disassembly of FAs on FN substratum (see 
Figure 4.6). Our findings are the first to show that EC migration is dependent on NRP2 
expression by regulating FA turnover.  
To understand the molecular mechanism underlying the effects of NRP2 silencing on EC 
migration, adhesion and FA turnover on FN matrixes, we employed MS analysis to identify 
the potential binding partners of NRP2, which could help us to understand the mechanism of 
this regulation. We were able to identify translational, endocytic, trafficking and cytoskeletal 
proteins as binding partner proteins of NRP2 (see Table 4.1). Importantly, the ITGA5 and 
ITGB1 subunits, which are the main FN receptors in ECs (Serini, Valdembri et al. 2006), 
(Hynes 2007), (Valdembri, Caswell et al. 2009), (Mana, Clapero et al. 2016), were among the 
binding partner proteins of NRP2. We showed that the siRNA-depletion of NRP2 
significantly upregulated ITGA5 subunit expression (see Figure 4.8), which suggests that 
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NRP2 may regulate the biological function of the endothelial ITGA5 subunit. Importantly, 
we showed that NRP2-depleted ECs exhibited a significant disruption of ITGA5 organisation 
on FN, ITGA5 appearing as elongated fibrillar structures after NRP2 silencing (see Figure 
5.1 and 5.2). Using the subcellular fractionation kit, we localised NRP2 specifically in the 
cellular membrane compartments (see Figure 5.3). This finding and the upregulation of 
ITGA5 levels upon NRP2 knockdown as well as the identification of translational, endocytic, 
trafficking and cytoskeletal proteins as binding partner proteins of NRP2 led us to investigate 
the possibility that NRP2 regulates the translation and/or turnover of the ITGA5 subunit. The 
data we obtained following the inhibition of protein synthesis using cycloheximide reagent 
(see Figure 5.4) suggested that ITGA5 was degraded faster when NRP2 expression was 
absent, whereas the translation of ITGA5 was simultaneously increased to (possibly) 
compensate for increased ITGA5 degradation. By using flow cytometry and a cell-surface 
biotinylation assay to determine whether these effects would change the total cellular 
membrane level of ITGA5 subunit or ITGA5 endocytosis, respectively, we found that NRP2 
knockdown changed neither the cellular membrane level (see Figure 5.5) nor endocytosis 
(see Figure 5.6) of the “total” ITGA5 subunit. However, these data are inconclusive because 
we cannot comment on the “active” ITGA5 subunit. Interestingly, by investigating ITGA5 
recycling, we showed that the total ITGA5 in the NRP2-depleted cells was recycled to the 
cell surface more slowly than that in the Ctrl-siRNA-treated cells (see Figure 5.7), indicating 
that NRP2 regulates the ITGA5 subunit recycling in mLMECs (Figure 7.1).  
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Figure 7.6 Model mechanism. Schematic representation of how neuropilin-2 (NRP2) regulates integrin-α5 (ITGA5) in 
microvascular endothelial cells (ECs). Microvascular ECs migration, adhesion and FAs turnover were significantly reduced 
when NRP2 expression was knocked down (not drawn). The structural organisation of endothelial ITGA5 on fibronectin 
(FN) were disrupted in NRP2-depleted ECs (not drawn), whereas the effect of NRP2 silencing on FN organisation (FN 
fibrillogenesis) is still unknown (???). The total level of the ITGA5 subunit was upregulated in the intracellular region when 
NRP2 expression was silenced, whereas the total level of ITGA5 on the plasma membrane and the rate of ITGA5 
endocytosis in NRP2-depleted ECs remained unchanged in these two parameters compared to that in the WT ECs. However, 
the recycling rate of “total” ITGA5 to the plasma membrane became slower in the NRP2-depleted ECs compared to the WT 
ECs. The blocking of protein synthesis by the cycloheximide reagent suggests that ITGA5 degradation is faster when NRP2 
expression is knocked down, but whether NRP2 controls the translational rate of ITGA5 expression or not is still unknown 
(???). 
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7.3. Final Conclusion 
Overall, we highlight two main findings of this thesis that will contribute to the field of 
angiogenesis: 
 EC migration is dependent on NRP2 expression by regulating EC adhesion and FA 
turnover on FN. 
 NRP2 expression regulates the biological function of the ITGA5 subunit within ECs. 
7.4. Priority future work 
The data presented in this thesis suggested that NRP2 controls microvascular EC migration, 
adhesion and FA turnover by regulating ITGA5 biological function. At this time, we want to 
answer two questions to understand the molecular mechanism through which NRP2 regulates 
the biological function of ITGA5 in ECs. First, does NRP2 regulate FN organisation (i.e. FN 
fibrillogenesis)? Second, does NRP2 control ITGA5 protein synthesis in ECs? These 
questions must be answered to validate the findings reported in this thesis before its 
publication (see Figure 7.1). 
First, as shown in Figure 5.1 and Figure 5.2, compared to the control condition, the NRP2 
siRNA-depleted ECs exhibited a significant disruption of ITGA5 organisation on FN. Based 
on the prior knowledge that ECM remodelling involves numerous cellular processes, 
including cell signalling, proliferation, migration, differentiation, survival, morphogenesis, 
angiogenesis etc. (Iivanainen, Kähäri et al. 2003) (Theocharis, Skandalis et al. 2016) 
(Hellewell, Rosini et al. 2017), and because α5β1 integrin is the main FN receptor in ECs to 
mediates the cell adhesion (Serini, Valdembri et al. 2006) (Hynes 2007) (Valdembri, Caswell 
et al. 2009) (Mana, Clapero et al. 2016), it is possible that the elongated structure of ITGA5 
observed in the NRP2 siRNA-depleted ECs could be the result of the disruption of FN 
assembly formation during ECs migration, which then caused the disruption of ITGA5 
organisation.  
To investigate whether NRP2-siRNA silencing regulates ECs-derived FN organisation, we 
will follow the protocol of a recent study in which a rapid method was described for 
detaching the cells adhered on cultured plates by using ammonium hydroxide, while the cell-
derived ECM will remain intact for use in further experiments (Hellewell, Rosini et al. 2017). 
In the experiment, WT and NRP2-siRNA ECs will be seeded on uncoated acid-washed/oven-
sterilised glass coverslips in two wells of a 6-well plate for 48 hours at 37 °C in a 5% CO2 
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incubator to achieve NRP2-siRNA knockdown and to allow the ECs enough time to deposit 
their own ECMs, including FN. Forty-eight hours post-nucleofection, the ECs from both 
conditions will be detached by 20 mM ammonium hydroxide. The intact EC-derived FN on 
the coverslips will be subjected to fluorescence microscopy using a mouse anti-FN antibody 
to investigate whether NRP2 knockdown would change the FN fibrillogenesis compared to 
the control condition. Additionally, we will determine whether the NRP2-depleted ECs 
seeded on the WT EC-derived FN exhibits the same significant disruption of ITGA5 
organisation shown in Figure 5.1 and Figure 5.2. This will be done by performing the same 
protocol described above. However, after detaching the ECs from both conditions using 20 
mM ammonium hydroxide, the WT ECs will be seeded on the coverslips containing the ECs-
derived FN from both conditions for 24 hours at 37 °C in a 5% CO2 incubator. The ECs then 
will be sequentially fixed with 4% PFA, permeabilised with PBS 0.25% Triton X-100, and 
blocked with 5% BSA before the cells are subjected to immuno-labelling for ITGA5 to 
examine the organisation of ITGA5 in the NRP2-depleted ECs compared with the WT ECs.  
Second, Dutta et al. described a molecular mechanism by which NRP2 expression in PC3 
prostate cancer cells controlled the synthesis of the vesicle trafficking protein WDFY1 
(Dutta, Roy et al. 2016). These authors showed that NRP2 knockdown increased the 
transcriptional activity of WDFY1 in both mRNA and protein levels by shifting the 
localisation of the transcriptional repressor protein FAC1 from the nucleus to the cytosol. In 
the absence of NRP2 expression, this translocation resulted in the reduction of the repressor 
protein FAC1 binding to WDFY1 in the nucleus, which caused the continual synthesis of 
WDFY1 (Dutta, Roy et al. 2016). The results of treating the ECs with cycloheximide (see 
Figure 5.4) suggested that the ITGA5 subunit degraded faster in the NRP2-depleted ECs. 
Simultaneously, the translation of ITGA5 in these depleted cells increased to compensate for 
the fast degradation of ITGA5, thus maintaining the total level of ITGA5 on the plasma 
membrane similar to that in the control condition (see Figure 7.1). Importantly, 
cycloheximide assay is not an assay that allows measuring the rate of protein synthesis. In 
fact, cycloheximide reagent binds to the E-site of the large ribosomal 60S subunit and 
subsequently inhibit protein synthesis by blocking the translational elongation (Schneider-
Poetsch, Ju et al. 2010), (Klinge, Voigts-Hoffmann et al. 2011). This assay allowed us to 
measure the half-life of the remaining ITGA5 in NRP2-depleted cells compare to that in the 
cycloheximide-untreated cells. 
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As we mentioned previously, MS analysis identified numbers of the large 60S and small 40S 
ribosomal subunits as partner proteins of NRP2 and because NRP2 knockdown increases the 
protein level of ITGA5 subunit (see Figure 4.8), it is possible that NRP2 may use a 
mechanism similar to that described by Dutta et al. to regulate ITGA5 synthesis in ECs. To 
investigate this hypothesis, we need to use an assay that measures the translational rate of 
ITGA5 (i.e. how fast is ITGA5 is synthesised) in NRP2-depleted cells compare to control 
condition. This will be done by using polysome profiling assay which measures the 
association between mRNA and ribosomes by separating the mRNA-ribosome complex in 
five layers of sucrose gradients (10%, 20%, 30%, 40% and 50%) using ultracentrifuigation 
and RTqPCR analysis. 
7.5. Other future work 
In this thesis, there were research limitations and number of results need to be also considered 
in the future. First, our findings showed that similar to NRP1 (Ellison, Atkinson et al. 2015), 
NRP2 expression was upregulated in β3HET ECs, which is not a response to the long-term 
depletion of the Itgb3 gene because it can be replicated by ITGB3-siRNA knockdown. We 
therefore suggest that a mechanism for cross-talk exists between the NRP2 and ITGB3 
subunits in ECs. However, we did not observe a link between the two molecules in EC 
migration or in VEGF-induced signalling. Thus, further investigation is required to 
understand the mechanism of the cross-talk between NRP2 and ITGB3 within ECs. Second, 
we successfully showed that EC migration on FN is dependent on NRP2 in a VEGF-
independent manner. However, we were not able to demonstrate a VEGF-induced increase in 
the speed of cell migration using the time-lapse CRM assay. Thus, we could not comment on 
the role of NRP2 in VEGF-induced EC migration. Favier et al. previously showed that 
human NRP2 interacted with VEGFR2 and enhanced its phosphorylation threshold as 
induced by VEGF165 (Favier, Alam et al. 2006). These authors also showed that NRP2 
knockdown inhibited VEGF165-induced migration using the BD BioCoat angiogenesis 
system-endothelial cell migration, a version of the transwell migration assay that facilitates 
investigation of the effects on endothelial cell invasion, migration, and tube formation 
(Favier, Alam et al. 2006). Therefore, we suggest using this system or another in vitro 3D 
migration assay (Kramer, Walzl et al. 2013) to investigate the role of NRP2 in VEGF-
induced EC migration. Third, similar to others (Cao, Hoeppner et al. 2013), we showed that 
NRP2 is trypsin sensitive. To overcome this limitation, we tested different cell-dissociation 
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reagents and buffers that were reported to be less aggressive in cleaving cell surface proteins, 
including dispase, TrypLE, citric saline buffer and EDTA. However, these reagents and 
buffers either failed to detach our mLMECs (dispase and EDTA), were more aggressive than 
trypsin (TrypLE), or it was impossible to count cells after cell-dissociation (citric saline 
buffer). Therefore, we recovered NRP2 expression in a suspension state before seeding the 
cells. Because the citric saline buffer successfully detached mLMECs without affecting the 
cell-surface receptors, we suggest that this buffer should be developed by including other 
chemicals such as chelators to help detach the cells singly rather than in sheets of attached 
cells. Fourth, using the MS analysis, we were able to identify 87 binding partner proteins of 
NRP2. For example, the ITGAV subunit and four EC specific markers were identified: 
Pecam1, Mcam, endoglin and PLVAP. Furthermore, other translational, endocytic, 
trafficking, and cytoskeletal proteins were also identified as binding partners of NRP2. These 
proteins require further research to better understand the cellular mechanisms that are 
regulated by NRP2 expression in ECs. Fifth, because our attempts to visualise the movement 
of ITGA5 in living cells using the ITGA5-GFP constructs as well as the localising of NRP2 
and ITGA5 in fixed cells were unsuccessful, these experiments remain a priority for better 
understanding their functions in living ECs. To localise or visualise the movement of ITGA5 
and NRP2 separately in living cells, we suggest using the fluorescent labelling technique and 
generating new tagged ITGA5 and NRP2 constructs, whereas biomolecular fluorescence 
complementation (BiFC) could be used to validate NRP2-ITGA5 interaction in living cells. 
The BiFC technique is based on genetically attaching nonfluorescent, unfolded and 
complementary fragments of differently coloured fluorescent proteins (FP) to NRP2 and 
ITGA5. When NRP2-ITGA5 interacts with a living cell, the fluorescent fragments are 
attracted, and they generate fluorescent signals that can be detected using an inverted 
fluorescent microscope. Furthermore, this technique utilises the visualisation and analysis of 
the intensity and the distribution of the interaction between the two molecules in living cells 
(Zal 2008). Sixth, we showed that NRP2 did not regulate total ITGA5 internalisation similar 
to human NRP1 in HUVECs (Valdembri, Caswell et al. 2009). However, by using the 
available SNAKA51 antibody, Valdembri et al. showed that human NRP1 regulated active 
α5β1 internalisation in HUVECs. As previously mentioned, because no commercially 
available antibody detects mouse active α5β1, it remains a priority for us to investigate 
whether NRP2 regulates active α5β1 internalisation in mouse ECs. A recent study showed 
that the silencing of SHANK3 significantly increased the active ITGB1 levels on the cell 
surface without affecting the total ITGB1 expression on the cell surface (Lilja, Zacharchenko 
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et al. 2017). Because SHANK3 is one of the 87 binding partner proteins of NRP2, it would be 
interesting to investigate whether the silencing of SHANK3 changes the active ITGA5 or 
NRP2 levels on the plasma membrane. Seventh, because the applications of the pSico and 
pSicoR techniques were unsuccessful in our study of NRP2 in VEGF-induced ex vivo 
angiogenesis, we strongly suggest that NRP2 knockout mice should be ordered, which we 
have already done. When these mice arrive in the laboratory, we will generate an EC-
specific, tamoxifen-dependent (inducible) NRP2 knockout mice model. This model can (and 
will) be intercrossed with ITGA5 floxed mice, so that we can better investigate both the in 
vivo role of NRP2, and interactions between the two molecules. 
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Abbreviations: 
ITGA5 Integrin-α5 
ITGAV Integrin-αv 
ITGA6 Integrin-α6 
ITGB1 Integrin-β1 
ITGB3 Integrin-β3 
ITGB5 Integrin-β5 
αvβ3 alpha-v-beta-3-integrin 
α5β1 alpha-5-beta-1-integrin 
Nuropilin 1 NRP1 
Nuropilin 2 NRP2 
HSC70 Heat shock cognate 70 kDa protein 8 
GAPDH Glyceraldehyde 3-phosphate dehydrogenase   
ECs Endothelial cells 
ECM Extracellular matrix 
HUAECs Human umbilical artery endothelial cells 
HUVECs Human umbilical vain endothelial cells 
HDMECs Human dermal microvascular endothelial cells 
HLDMVECs Human lymphatic dermal microvascular endothelial cells  
HBDMVECs Human blood dermal microvascular endothelial cells  
PAE Porcine aortic endothelial cell 
HEK293 Human embryonic kidney 293 cells expressing the SV40 large T 
antigen 
EPCs Endothelial progenitor cells 
SMCs Smooth muscle cells 
BMDCs bone marrow-derived dendritic cells  
vSMCs Vascular smooth muscle cells 
TSAd Nuclear factor of activated T-cells  
BM Basement membrane 
OPP Oxygen partial pressure 
VE-cadherin Vascular endothelial cadherin 
JAM-A Junctional adhesion molecules A 
MCAM Melanoma cell-associated molecules  
ICAM Intercellular adhesion molecule  
VCAM 1 Vascular cell adhesion molecule 1  
PECAM Platelet endothelial cell adhesion molecule 
CD99 Cluster of differentiation 99 
TJ Tight junctions 
GJ Gap junctions 
AJ Adhesion junctions 
HSPGs Heparan sulphate proteoglycans  
FN fibronectin  
MMPs matrix metalloproteases  
NSCLC nonsmall cell lung carcinoma  
HCC Hepatocellular carcinoma  
OSCC Oral squamous cell carcinoma  
RCC Renal cancer cell carcinoma  
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VEGFs Vascular endothelial growth factors 
CHO Chinese hamster ovary cells 
VEGF-A or VEGF Vascular endothelial growth factor A 
VEGF-B or VRF Vascular endothelial growth factor B 
VEGF-C Vascular endothelial growth factor C 
VEGF-D Vascular endothelial growth factor D 
VEGF-E Vascular endothelial growth factor E 
VEGF-F Vascular endothelial growth factor F 
VEGFR Vascular endothelial growth factor receptor 
VEGFR1 or flt-1 Vascular endothelial growth factor receptor 1 
VEGFR2 or flk-1 Vascular endothelial growth factor receptor 2 
VEGFR3 or flt-4 Vascular endothelial growth factor receptor 3 
FGFR1 Fibroblast growth factor receptors  
PDGFR Platelet-derived growth factor receptor 
TGFR-β1 transforming growth factor-β1  
HGFR Hepatocyte growth factor receptor 
FGFR Fibroblast growth factor receptor 
PGF-B Placental growth factor-B receptor 
IGF-1R Insulin-like growth factor-1 receptor  
PAR-1 Protease-activated receptors-1 
GPCR G protein coupled receptor 
CXCR4 Chemokine receptor 4 
RTKs Receptor tyrosine kinases  
ANG-1 Angiopietin 1  
ANG-2 Angiopietin 2  
GRB2 growth factor receptor-bound protein 2  
HIF-2α Hypoxia-inducible factor-2α  
PlGF, PLGF, PGF Placental growth factor  
TGF-β1 Transforming growth factor-β1  
GEF Guanine nucleotide-exchange factors  
PDGF-B Platelet-derived growth factor B 
PDGF-BB Platelet derived growth factor-BB  
FGF Fibroblast growth factor  
FGF-1 Fibroblast growth factor-1 
bFGF Basic fibroblast growth factor 
EGF Epidermal growth factor  
bEGF Basic epidermal growth factor 
TNFa Tumour necrosis factor alpha  
DLL4 Delta like ligand 4 
TIMPs Tissue inhibitors of metalloproteinases  
PAI-1 Plasminogen activator inhibitor-1  
Rac1 Ras-related C3 botulinum toxin substrate 1  
NO Nitric oxide 
eNOS Endothelial nitric oxide synthase  
Akt or PKB Protein kinase B  
ERK1/2 Extracellular-signal-regulated kinase  
PLCγ Phospholipase Cγ  
PKC Protein kinase C  
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WDFY1 WD Repeat and FYVE domain containing 1  
LAMP2 Lysosome-associated membrane protein 2  
Spry4 Sprouty4  
Tyr Tyrosine 
VRAP VEGF receptor associated protein (VRAP) 
PI 3-kinase Phosphatidylinositol 3-kinase  
FAs Focal adhesions 
FAK Focal adhesion kinase  
SOS Nucleotide-exchange factor Son of sevenless  
SHC Src homology collagen homology  
ER Endoplasmic reticulum  
PIP2 Phospholipid phosphatidylinositol (4, 5)-bisphosphate  
PIP3 Phosphatidylinositol-3,4,5-trisphosphate  
IP3 Inositol 1,3,5-triphosphate  
DAG Diacylglycerol  
PAK2 p21-activated protein kinase-2  
MAPK  Mitogen activated protein kinase 
CDC42 cell division cycle 42  
p38-MAPK P38 mitogen-activated protein kinases 
MAPKAPK2 MAPK-activated protein kinase 2 
HSP27 Heat shock protein 27 
ILK Integrin linked kinase  
PDK-1 Phosphoinositide-dependent kinase-1  
PDK-2 Phosphoinositide-dependent kinase-2 
FOXO1 Forkhead box protein O1  
GSK-3β Glycogen synthase kinase 3 beta 
Anxa2 Annexin A2  
Sema-3 Semaphorin 3 
C-terminal Carboxyl-terminal domain 
N-terminus amino-terminus  
CUB doamin Complement C1r/C1s, Uegf, Bmp1 domain 
MAM domain Meprin, A-5 protein domain, and a receptor protein-tyrosine 
phosphatase mu domain 
V/VIII domain Coagulation factor V/VIII homology domain 
TMD Transmembrane domain  
FAT focal adhesion targeting domain  
PTB phosphotyrosine binding domain 
PHD2 Prolyl hydroxylase domain 2  
GAG Glycosaminoglycan  
GIPC RGS-GAIP interacting protein C-terminus  
NIP-1 neuropilin-interacting protein-1  
GIK GlyIsoLys  
sNRP1 Soluble NRP1 
sNRP2 Soluble NRP2 
sFN Soluble FN  
F-actin  Filamentous actin   
TURBT Transurethral resection  
RCT Radio-chemotherapy 
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ZEB-1 Zinc finger E-box-binding homeobox-1  
RGD Arginine-glycine-aspartic acid tripeptide  
LDV Leucine-aspartic acid-valine  
Src Src family kinase  
PP2A Protein phosphatase 2A  
Dok1 Docking protein 1  
RIAM Rap1-GTP-interacting adaptor molecule  
P38 or p38 MAPK P38 mitogen-activated protein kinases  
SAPK2/p38 Stress-activated protein kinase-2/p38  
Rac1 Ras-related C3 botulinum toxin substrate 1 
Rcc2 Telophase disk protein  
β3HET ITGB3-heterozyous  
α5HET ITGA5-heterozyous 
-NULL mice Knockout mice  
-EC-KO Endothelial-specific knockout mice 
CNS Central nervous system  
Arf ADP-ribosylation factor GTPase 
GAP GTPase-activating proteins  
ARL ARF-like proteins 
COPI Cytosolic coatomer complex I  
TGN trans-Golgi network  
Dab-2 Disabled-2  
AP-2 Adaptor protein-2  
EE Early endosomes  
PKD1 Protein kinase D1  
PNRC Perinuclear recycling compartment  
FBS Foetal bovine serum  
PFA Paraformaldehyde 
PBS Phosphate buffered saline 
PBS/T Phosphate buffered saline supplemented with Tween-20 
P/S penicillin/streptomycin  
EtOH Ethanol  
MACS Magnetic activated cell sorting  
PyMT polyoma-middle-T-antigen retrovirus 
dH2O Distilled water  
SDS Sodium dodecyl sulphate  
APS ammonium persulfate  
BSA Bovine serum albumin  
HRP Horseradish peroxidase  
Caspase-8 Cysteine-aspartic proteases-8 
Caspase-9 Cysteine-aspartic proteases-9 
GFP Green florescent proteins 
TCL Total cell lysate  
Mesna 2-mercaptoethane sulfonate Na 
TCEP Tris-(2-carboxyethyl)phosphine 
Oligo Oligonucleotides  
mRNA Messenger RNA  
siRNAs Short interference Ribonucleic acids (RNA)  
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shRNAs Short hairpin RNAs 
Ctrl-siRNA Control-short interference RNA 
NRP2-siRNA Neuropilin-short interference RNA 
pSico Plasmid for Stable Interference Condition 
pSicoR Plasmid for Stable Interference Condition Reverse 
OHT 4-hydroxytamoxifen  
PLVAP Plasmalemma vesicle-associated protein  
ICC immunocytochemistry  
EHD2 EH domain-containing protein 2  
Lamtor1 Regulator complex protein LAMTOR1 
Scamp1 Secretory carrier-associated membrane protein 1  
Scamp3 Secretory carrier-associated membrane protein 3 
α-SNAP Alpha-soluble NSF attachment protein  
TCP1 T-complex protein 1 subunit beta  
Arp1 Alpha-centractin  
BiFC Biomolecular fluorescence complementation  
bp Base pair 
E Embryonic day 
EMT Epithelial-mesenchymal transition 
neo  Neomycin 
p Phosphorylated 
Ig Immunoglobulin 
IP Immunoprecipitation 
p130Cas p130 CRK-associated substrate 
PDZ  PSD-95/DIg/ZO-1 
PMSF  Phenylmethanesulfonylfluoride 
SDS-PAGE Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
CRM assay Cell random motility assays  
WH assays Wound healing assays 
BAE assay Bovine aortic endothelial assay 
LFQ Label-Free quantitative  
MS Mass spectrometry 
DMEM Dulbecco’s modified eagle medium 
FACS Fluorescence activated cell sorting  
CEB Cytoplasmic extraction buffer 
MEB Membrane extraction buffer  
NEB Nuclear extraction buffer  
PEB Pellet extraction buffer  
SBS Soerensen buffer  
EDTA Ethylenediaminetetraacetic acid 
TAE Buffer containing Tris base, acetic acid, and EDTA 
TE Tris-EDTA 
EB Elution buffer  
LB Lysogeny broth medium 
DAPI 4',6-diamidino-2-phenylindole 
et.al er alia 
FITC Fluorescein-5-isothiocyanate  
PE Phycoerythrin 
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